{
  "drug_name": "baricitinib",
  "generic_name": "baricitinib",
  "mechanism": "Janus Kinase Inhibitor",
  "target": null,
  "approved_indications": [
    "adults with severe alopecia areata",
    "covid-19 in certain hospitalized adults",
    "adults with moderately-to-severely active rheumatoid arthritis",
    "moderately-to-severely active rheumatoid arthritis"
  ],
  "opportunities": [
    {
      "extraction": {
        "source": {
          "pmid": "39541169",
          "doi": "10.1172/JCI179436",
          "url": "https://pubmed.ncbi.nlm.nih.gov/39541169/",
          "title": "Rapid response of lichen planus to baricitinib associated with suppression of cytotoxic CXCL13+CD8+ T cells.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Cutaneous lichen planus",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 12,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "topical steroids",
            "oral steroids",
            "intramuscular steroids",
            "methotrexate",
            "topical calcineurin inhibitors"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "Mean age 63.6 years, 91.7% female, 75% White, mean disease duration 26.5 months, all with treatment-refractory LP, 41.7% with hypertrophic variant"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "2 mg daily (with dose escalation to 4 mg daily in some patients)",
          "frequency": null,
          "duration": "16 weeks (with additional 12 weeks at higher dose for some patients)",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "10/12 (83.3%)",
          "responders_n": 10,
          "responders_pct": 83.3,
          "time_to_response": "as early as week 1 in 37.5% of patients, 100% by week 12",
          "duration_of_response": "sustained at week 20 (4 weeks off therapy)",
          "effect_size_description": "Large effect size with dramatic improvements: mean total lesion count decreased from 151.9 to 17.1, pruritus NRS from 7.2 to 1.8, pain NRS from 7.7 to 1.9",
          "primary_endpoint": "Physician Global Assessment (PGA) scores 0-3 with \u226550% score reduction at week 16",
          "endpoint_result": "83.3% of patients achieved primary endpoint",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib demonstrated rapid and sustained efficacy in treatment-refractory cutaneous lichen planus with 83.3% response rate. Clinical improvement was seen as early as week 1, with dramatic reductions in lesion counts, pruritus, and pain scores. Response was sustained 4 weeks after discontinuation."
        },
        "safety": {
          "adverse_events": [
            "neutropenia"
          ],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Baricitinib was well tolerated with 12 total adverse events, mostly mild to moderate. Only one mild neutropenia was deemed probably related to study drug. No serious adverse events or treatment discontinuations occurred.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "20 weeks (including 4 weeks off therapy)",
        "key_findings": "First-in-human trial demonstrating rapid, sustained response to baricitinib in treatment-refractory cutaneous lichen planus with suppression of cytotoxic CXCL13+CD8+ T cells and interferon signaling.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "Physician Global Assessment (PGA) 0-3 with \u226550% improvement",
            "endpoint_category": "Primary",
            "timepoint": "Week 16",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 10,
            "responders_pct": 83.3,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "95% CI: 51.6%-97.9%, primary endpoint"
          },
          {
            "endpoint_name": "PGA Grade 0 (completely clear)",
            "endpoint_category": "Secondary",
            "timepoint": "Week 16",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 5,
            "responders_pct": 41.7,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "5 of 10 treatment-responsive patients"
          },
          {
            "endpoint_name": "PGA Grade 1 (almost clear)",
            "endpoint_category": "Secondary",
            "timepoint": "Week 16",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 5,
            "responders_pct": 41.7,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "5 of 10 treatment-responsive patients"
          },
          {
            "endpoint_name": "Total body lesion count",
            "endpoint_category": "Secondary",
            "timepoint": "Week 16",
            "measurement_type": "Change from baseline",
            "value": 17.1,
            "unit": "lesions",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 151.9,
            "change_from_baseline": -134.8,
            "change_pct": null,
            "p_value": "0.002",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Mean value, SD 33.5 at week 16"
          },
          {
            "endpoint_name": "Body Surface Area (BSA) affected",
            "endpoint_category": "Secondary",
            "timepoint": "Week 16",
            "measurement_type": "Change from baseline",
            "value": 1.0,
            "unit": "%",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 4.9,
            "change_from_baseline": -3.9,
            "change_pct": null,
            "p_value": "0.002",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Mean value, SD 2.5 at week 16"
          },
          {
            "endpoint_name": "Pruritus Numeric Rating Scale (NRS)",
            "endpoint_category": "Secondary",
            "timepoint": "Week 16",
            "measurement_type": "Change from baseline",
            "value": 1.8,
            "unit": "NRS score",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 7.2,
            "change_from_baseline": -5.4,
            "change_pct": null,
            "p_value": "0.003",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Mean value, SD 3.2 at week 16"
          },
          {
            "endpoint_name": "Pruritus Visual Analog Scale (VAS)",
            "endpoint_category": "Secondary",
            "timepoint": "Week 16",
            "measurement_type": "Change from baseline",
            "value": 1.7,
            "unit": "VAS score",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 6.6,
            "change_from_baseline": -4.9,
            "change_pct": null,
            "p_value": "0.003",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Mean value, SD 3.0 at week 16"
          },
          {
            "endpoint_name": "Pain Numeric Rating Scale (NRS)",
            "endpoint_category": "Secondary",
            "timepoint": "Week 16",
            "measurement_type": "Change from baseline",
            "value": 1.9,
            "unit": "NRS score",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 7.7,
            "change_from_baseline": -5.8,
            "change_pct": null,
            "p_value": "0.005",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Mean value, SD 3.2 at week 16"
          },
          {
            "endpoint_name": "Skindex-16 overall score",
            "endpoint_category": "Secondary",
            "timepoint": "Week 16",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "Skindex-16 score",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 59.0,
            "change_from_baseline": -37.3,
            "change_pct": null,
            "p_value": "0.008",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Mean decrease, SD 18.3"
          },
          {
            "endpoint_name": "Skindex-16 symptom subscore",
            "endpoint_category": "Secondary",
            "timepoint": "Week 16",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "Skindex-16 subscore",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": -12.4,
            "change_pct": null,
            "p_value": "0.005",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Mean decrease, SD 5.8"
          },
          {
            "endpoint_name": "Skindex-16 emotional subscore",
            "endpoint_category": "Secondary",
            "timepoint": "Week 16",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "Skindex-16 subscore",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": -20.9,
            "change_pct": null,
            "p_value": "0.003",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Mean decrease, SD 9.4"
          },
          {
            "endpoint_name": "Skindex-16 functional subscore",
            "endpoint_category": "Secondary",
            "timepoint": "Week 16",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "Skindex-16 subscore",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": -5.5,
            "change_pct": null,
            "p_value": "0.012",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Mean decrease, SD 5.6"
          },
          {
            "endpoint_name": "Pruritus NRS4 improvement",
            "endpoint_category": "Secondary",
            "timepoint": "Week 16",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 9,
            "responders_pct": 75.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "\u22654 point improvement from baseline"
          },
          {
            "endpoint_name": "Pain NRS4 improvement",
            "endpoint_category": "Secondary",
            "timepoint": "Week 16",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 8,
            "responders_pct": 66.7,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "\u22654 point improvement from baseline"
          },
          {
            "endpoint_name": "PGA improvement - Early response",
            "endpoint_category": "Exploratory",
            "timepoint": "Week 1",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": null,
            "responders_pct": 37.5,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Early improvement observed"
          },
          {
            "endpoint_name": "PGA improvement - Complete early response",
            "endpoint_category": "Exploratory",
            "timepoint": "Week 12",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 12,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "All patients showed improvement by week 12"
          },
          {
            "endpoint_name": "Sustained response off therapy",
            "endpoint_category": "Secondary",
            "timepoint": "Week 20",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 12,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "4 weeks off therapy, all patients demonstrated continued response"
          },
          {
            "endpoint_name": "PGA Grade 0 - Dose escalation group",
            "endpoint_category": "Secondary",
            "timepoint": "Week 28",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 3,
            "responders_pct": 60.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "After 12 weeks of 4mg baricitinib daily in dose-escalation group"
          },
          {
            "endpoint_name": "PGA Grade 1 - Dose escalation group",
            "endpoint_category": "Secondary",
            "timepoint": "Week 28",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 20.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "After 12 weeks of 4mg baricitinib daily in dose-escalation group"
          },
          {
            "endpoint_name": "PGA Grade 4 - Dose escalation group",
            "endpoint_category": "Secondary",
            "timepoint": "Week 28",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 20.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "After 12 weeks of 4mg baricitinib daily in dose-escalation group"
          },
          {
            "endpoint_name": "Post-treatment sustained response",
            "endpoint_category": "Secondary",
            "timepoint": "Week 32",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 20.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Only one patient remained treatment responsive after 4 weeks off therapy in dose-escalation group"
          },
          {
            "endpoint_name": "mCAILS score",
            "endpoint_category": "Secondary",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": 12.3,
            "unit": "mCAILS score",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 12.3,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Mean baseline value, SD 3.2"
          },
          {
            "endpoint_name": "Pruritus Verbal Rating Scale - Moderate/Severe",
            "endpoint_category": "Secondary",
            "timepoint": "Baseline",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 11,
            "responders_pct": 91.7,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Baseline moderate/severe itch rating"
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "Neutropenia",
            "event_category": "Lab abnormality",
            "severity_grade": "Mild",
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": 1,
            "relatedness": "Possibly related",
            "outcome": null,
            "action_taken": "None",
            "notes": "Absolute neutrophil count 0.78 \u00d7 10(9)/L, did not result in treatment discontinuation"
          },
          {
            "event_name": "Adverse events (mild)",
            "event_category": "AE",
            "severity_grade": "Mild",
            "patients_affected_n": null,
            "patients_affected_pct": 58.3,
            "events_total": 7,
            "relatedness": null,
            "outcome": null,
            "action_taken": "None",
            "notes": "7 of 12 total AEs were mild"
          },
          {
            "event_name": "Adverse events (moderate)",
            "event_category": "AE",
            "severity_grade": "Moderate",
            "patients_affected_n": null,
            "patients_affected_pct": 25.0,
            "events_total": 3,
            "relatedness": null,
            "outcome": null,
            "action_taken": "None",
            "notes": "3 of 12 total AEs were moderate"
          },
          {
            "event_name": "Adverse events (severe)",
            "event_category": "AE",
            "severity_grade": "Severe",
            "patients_affected_n": null,
            "patients_affected_pct": 16.7,
            "events_total": 2,
            "relatedness": null,
            "outcome": null,
            "action_taken": "None",
            "notes": "2 of 12 total AEs were severe (calculated from remaining percentage)"
          },
          {
            "event_name": "Serious adverse events",
            "event_category": "SAE",
            "severity_grade": null,
            "patients_affected_n": 0,
            "patients_affected_pct": null,
            "events_total": 0,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "No serious AEs occurred with baricitinib"
          }
        ],
        "extraction_timestamp": "2025-12-07T17:23:08.339815",
        "extraction_confidence": 0.6,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [
            "Table 1: Demographics and outcomes on individual patient level",
            "Table 2: Baseline characteristics including affected BSA, total body lesions, mCAILS scores, Skindex-16 scores, pruritus and pain ratings"
          ],
          "efficacy_tables": [
            "Table 2: Secondary efficacy measures at week 16 including lesion counts, BSA, pruritus scores, pain scores, Skindex-16 improvements",
            "Table 3: Dose escalation outcomes showing PGA grades after 12 weeks of 4mg baricitinib",
            "Supplemental Table 2: Per-protocol analysis results",
            "Supplemental Table 3: Post-treatment evaluation after 4 weeks off therapy"
          ],
          "safety_tables": [
            "Supplemental Table 4: Adverse events summary showing 12 total AEs with one mild AE probably related to study drug"
          ],
          "efficacy_figures": [
            "Figure 1: Treatment response and PGA scores with 83.3% achieving response at week 16",
            "Supplemental Figure 2: Individual PGA scores",
            "Supplemental Figure 3: Pruritus NRS improvement",
            "Supplemental Figure 4: Pain NRS improvement"
          ],
          "results_sections": [
            "Patients section with demographics and baseline characteristics",
            "Efficacy section showing primary and secondary outcomes",
            "Dose escalation section with 4mg results",
            "Safety section with adverse events",
            "Molecular profiling of lesional and nonlesional tissue",
            "Molecular profiling of peripheral blood"
          ],
          "patient_count": 12,
          "study_type": "Case Series",
          "has_quantitative_outcomes": true,
          "notes": "This is actually a phase II clinical trial with comprehensive molecular profiling, not just a traditional case series. Includes detailed single-cell and spatial RNA sequencing analysis alongside clinical outcomes."
        }
      },
      "market_intelligence": {
        "disease": "Cutaneous lichen planus",
        "epidemiology": {
          "us_prevalence_estimate": "0.15% to 0.19%",
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": 569500,
          "prevalence_source": "ScienceDirect",
          "prevalence_source_url": "https://www.sciencedirect.com/science/article/abs/pii/S0190962224032365",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Opzelura (ruxolitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": null,
              "notes": "Currently in clinical trials, shows promise but not yet FDA approved for cutaneous lichen planus"
            },
            {
              "drug_name": "Clobetasol propionate",
              "drug_class": "Topical corticosteroid",
              "is_branded_innovative": false,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "Generic topical steroid, first-line treatment but not FDA approved for this specific indication"
            },
            {
              "drug_name": "Protopic (tacrolimus)",
              "drug_class": "Calcineurin inhibitor",
              "is_branded_innovative": false,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Used off-label as second-line therapy, not FDA approved for cutaneous lichen planus"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 3,
          "pipeline_therapies": [
            {
              "drug_name": "Ruxolitinib cream",
              "company": "Incyte Corporation",
              "mechanism": "JAK1/JAK2 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT05593432",
              "expected_completion": null
            },
            {
              "drug_name": "Secukinumab",
              "company": "Novartis",
              "mechanism": "IL-17A inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT04300296",
              "expected_completion": null
            },
            {
              "drug_name": "Baricitinib",
              "company": "Eli Lilly",
              "mechanism": "JAK1/JAK2 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT05188521",
              "expected_completion": null
            }
          ],
          "pipeline_details": "The cutaneous lichen planus pipeline consists of three Phase 2 trials testing JAK inhibitors (ruxolitinib cream and baricitinib) and an IL-17A inhibitor (secukinumab). All trials are evaluating systemic or topical therapies for this inflammatory skin condition.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "High-potency topical corticosteroids are first-line therapy, followed by systemic corticosteroids or topical calcineurin inhibitors for recalcitrant cases.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved treatments exist specifically for cutaneous lichen planus, with all current therapies being used off-label despite 25.6% of dermatologists believing FDA-approved treatments exist",
          "competitive_landscape": "The treatment landscape consists entirely of off-label therapies including topical and systemic corticosteroids, calcineurin inhibitors, and phototherapy. Ruxolitinib cream represents the most promising investigational treatment currently in development.",
          "soc_source": "Medscape Medical News and clinical guidelines from AAFP"
        },
        "market_size_estimate": "$14.2B",
        "market_size_usd": 14237500000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 171000000.0,
        "tam_estimate": "$171M",
        "tam_rationale": "Of ~570K global patients with cutaneous lichen planus, ~60% are diagnosed (342K), ~40% receive treatment beyond topical corticosteroids (137K), ~20% fail first-line therapy and need systemic treatment (27.4K). With 0 approved drugs and high unmet need, a new drug could capture 35-40% market share (~10K patients). At $17K/yr pricing (specialty dermatology treatment), TAM = $171M. Strong positioning opportunity given no approved competitors.",
        "tam_sources": [
          "https://www.openpr.com/news/3972605/lichen-planus-market-trends-technologies-global-forecast",
          "https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2021.737813/full",
          "https://www.mdpi.com/2075-4418/14/7/692"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov/study/NCT03697460",
          "https://cdn.clinicaltrials.gov/large-docs/96/NCT04300296/Prot_000.pdf",
          "https://cdn.clinicaltrials.gov/large-docs/32/NCT05593432/Prot_000.pdf"
        ],
        "attributed_sources": [
          {
            "url": "https://www.dermatologyadvisor.com/news/patients-with-lichen-planus-may-undertreated-dermatologists/",
            "title": "Patients With Lichen Planus May be Undertreated by Dermatologists",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.jaad.org/article/S0190-9622(21)02974-1/fulltext",
            "title": "Prevalence of lichen planus in the United States: A cross-sectional ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.medscape.com/viewarticle/survey-identifies-gaps-lichen-planus-management-2025a1000a90",
            "title": "Survey Identifies Gaps in Lichen Planus Management",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.medscape.com/viewarticle/ruxolitinib-cream-shows-promise-treating-lichen-planus-2024a1000j36",
            "title": "Ruxolitinib Cream Shows Promise in Treating Lichen Planus",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://onlinelibrary.wiley.com/doi/10.1111/ddg.14565",
            "title": "Lichen planus \u2013 a clinical guide - Solimani - Wiley Online Library",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT03697460",
            "title": "NCT03697460 | Topical Ruxolitinib Lichen Planus",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/96/NCT04300296/Prot_000.pdf",
            "title": "Clinical Trial Protocol CAIN457S12201 / NCT04300296",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.openpr.com/news/3972605/lichen-planus-market-trends-technologies-global-forecast",
            "title": "Lichen Planus Market Trends, Technologies & Global Forecast",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2021.737813/full",
            "title": "Frontiers | Lichen Planus",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 7.5,
        "evidence_quality": 7.5,
        "market_opportunity": 10.0,
        "overall_priority": 8.1,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 7.1,
          "endpoint_quality": 3.3,
          "organ_domain_breadth": 10.0,
          "safety_categories": [
            "cytopenia",
            "thromboembolic",
            "cardiovascular",
            "pulmonary"
          ],
          "regulatory_flags": [
            "cytopenia",
            "thromboembolic",
            "cardiovascular",
            "pulmonary"
          ]
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 7.1,
        "endpoint_quality_score": 3.3,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 6.0,
          "publication_venue": 10.0,
          "response_durability": 6.0,
          "extraction_completeness": 8.3
        },
        "sample_size_score": 6.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 6.0,
        "extraction_completeness_score": 8.3,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 10.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 10.0,
        "unmet_need_score": 10.0
      },
      "rank": 1
    },
    {
      "extraction": {
        "source": {
          "pmid": "38903518",
          "doi": "10.3389/fimmu.2024.1395288",
          "url": "https://pubmed.ncbi.nlm.nih.gov/38903518/",
          "title": "Case report: Sequential therapy with dupilumab and baricitinib for severe alopecia areata with atopic dermatitis in children.",
          "authors": "HF, FZ, WL, YJ, QL, DY",
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "severe alopecia areata with atopic dermatitis in children",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "minoxidil solution",
            "topical clobetasol"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "8-year-old female with severe alopecia areata (SALT score 70%) and atopic dermatitis since infancy"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "2mg daily",
          "frequency": null,
          "duration": "5 months",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": "5 months",
          "duration_of_response": "ongoing at end of treatment period",
          "effect_size_description": "SALT score improved from 20% (after dupilumab) to <10% after baricitinib",
          "primary_endpoint": "SALT score reduction",
          "endpoint_result": "SALT score reduced to <10%",
          "durability_signal": null,
          "efficacy_summary": "Sequential therapy with dupilumab followed by baricitinib resulted in significant hair regrowth with SALT score improving from initial 70% to <10%. Eyebrows and hair essentially fully recovered after baricitinib treatment."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No adverse drug reactions were observed during the treatment course. Regular monitoring of blood tests and liver/kidney function showed no abnormalities.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "11 months total treatment period",
        "key_findings": "Sequential dupilumab then baricitinib therapy achieved excellent hair regrowth in pediatric severe alopecia areata with no safety concerns observed.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "SALT score",
            "endpoint_category": "Primary",
            "timepoint": "Month 5",
            "measurement_type": "Absolute value",
            "value": 10.0,
            "unit": "percent",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 20.0,
            "change_from_baseline": -10.0,
            "change_pct": -50.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "SALT score decreased to less than 10% after 5 months of baricitinib treatment"
          },
          {
            "endpoint_name": "Hair regrowth - eyebrows and scalp",
            "endpoint_category": "Primary",
            "timepoint": "Month 5",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Eyebrows and hair essentially fully recovered after 5 months of baricitinib"
          },
          {
            "endpoint_name": "Alanine aminotransferase (ALT)",
            "endpoint_category": "Secondary",
            "timepoint": "Month 5",
            "measurement_type": "Change from baseline",
            "value": 6.0,
            "unit": "IU/L",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 5.0,
            "change_from_baseline": 1.0,
            "change_pct": 20.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Liver function monitoring during baricitinib treatment"
          },
          {
            "endpoint_name": "Aspartate aminotransferase (AST)",
            "endpoint_category": "Secondary",
            "timepoint": "Month 5",
            "measurement_type": "Change from baseline",
            "value": 26.0,
            "unit": "IU/L",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 21.0,
            "change_from_baseline": 5.0,
            "change_pct": 23.8,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Liver function monitoring during baricitinib treatment"
          },
          {
            "endpoint_name": "Total bilirubin",
            "endpoint_category": "Secondary",
            "timepoint": "Month 5",
            "measurement_type": "Change from baseline",
            "value": 7.09,
            "unit": "\u03bcmol/L",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 7.34,
            "change_from_baseline": -0.25,
            "change_pct": -3.4,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Liver function monitoring during baricitinib treatment"
          },
          {
            "endpoint_name": "Direct bilirubin",
            "endpoint_category": "Secondary",
            "timepoint": "Month 5",
            "measurement_type": "Change from baseline",
            "value": 2.24,
            "unit": "\u03bcmol/L",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 0.87,
            "change_from_baseline": 1.37,
            "change_pct": 157.5,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Liver function monitoring during baricitinib treatment"
          },
          {
            "endpoint_name": "Serum total bile acids",
            "endpoint_category": "Secondary",
            "timepoint": "Month 5",
            "measurement_type": "Change from baseline",
            "value": 4.9,
            "unit": "\u03bcmol/L",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 6.3,
            "change_from_baseline": -1.4,
            "change_pct": -22.2,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Liver function monitoring during baricitinib treatment"
          },
          {
            "endpoint_name": "Uric acid",
            "endpoint_category": "Secondary",
            "timepoint": "Month 5",
            "measurement_type": "Change from baseline",
            "value": 274.0,
            "unit": "\u03bcmol/L",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 277.0,
            "change_from_baseline": -3.0,
            "change_pct": -1.1,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Kidney function monitoring during baricitinib treatment"
          },
          {
            "endpoint_name": "Creatinine",
            "endpoint_category": "Secondary",
            "timepoint": "Month 5",
            "measurement_type": "Change from baseline",
            "value": 45.0,
            "unit": "\u03bcmol/L",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 48.0,
            "change_from_baseline": -3.0,
            "change_pct": -6.3,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Kidney function monitoring during baricitinib treatment"
          },
          {
            "endpoint_name": "White blood cell count",
            "endpoint_category": "Secondary",
            "timepoint": "Month 5",
            "measurement_type": "Change from baseline",
            "value": 9.1,
            "unit": "x 10^9/L",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 9.1,
            "change_from_baseline": 0.0,
            "change_pct": 0.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Hematological monitoring during baricitinib treatment - no change"
          },
          {
            "endpoint_name": "Neutrophil percentage",
            "endpoint_category": "Secondary",
            "timepoint": "Month 5",
            "measurement_type": "Change from baseline",
            "value": 44.6,
            "unit": "percent",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 44.6,
            "change_from_baseline": 0.0,
            "change_pct": 0.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Hematological monitoring during baricitinib treatment - no change"
          },
          {
            "endpoint_name": "Lymphocyte percentage",
            "endpoint_category": "Secondary",
            "timepoint": "Month 5",
            "measurement_type": "Change from baseline",
            "value": 45.7,
            "unit": "percent",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 45.7,
            "change_from_baseline": 0.0,
            "change_pct": 0.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Hematological monitoring during baricitinib treatment - no change"
          },
          {
            "endpoint_name": "Red blood cell count",
            "endpoint_category": "Secondary",
            "timepoint": "Month 5",
            "measurement_type": "Change from baseline",
            "value": 5.02,
            "unit": "x 10^9/L",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 5.02,
            "change_from_baseline": 0.0,
            "change_pct": 0.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Hematological monitoring during baricitinib treatment - no change"
          },
          {
            "endpoint_name": "Hemoglobin level",
            "endpoint_category": "Secondary",
            "timepoint": "Month 5",
            "measurement_type": "Change from baseline",
            "value": 137.0,
            "unit": "g/L",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 137.0,
            "change_from_baseline": 0.0,
            "change_pct": 0.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Hematological monitoring during baricitinib treatment - no change"
          },
          {
            "endpoint_name": "Platelet count",
            "endpoint_category": "Secondary",
            "timepoint": "Month 5",
            "measurement_type": "Change from baseline",
            "value": 261.0,
            "unit": "x 10^9/L",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 261.0,
            "change_from_baseline": 0.0,
            "change_pct": 0.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Hematological monitoring during baricitinib treatment - no change"
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "No adverse drug reactions observed",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 0,
            "patients_affected_pct": null,
            "events_total": 0,
            "relatedness": null,
            "outcome": null,
            "action_taken": "None",
            "notes": "Explicitly stated that no adverse drug reactions were observed during baricitinib treatment period of 5 months in 8-year-old patient"
          },
          {
            "event_name": "Normal liver function maintained",
            "event_category": "Lab abnormality",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": "None",
            "notes": "ALT, AST, total bilirubin, direct bilirubin, and serum bile acids remained within normal ranges during baricitinib treatment"
          },
          {
            "event_name": "Normal kidney function maintained",
            "event_category": "Lab abnormality",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": "None",
            "notes": "Creatinine and uric acid remained within normal ranges during baricitinib treatment"
          },
          {
            "event_name": "Normal hematological parameters maintained",
            "event_category": "Lab abnormality",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": "None",
            "notes": "White blood cell count, neutrophil percentage, lymphocyte percentage, red blood cell count, hemoglobin level, and platelet count remained unchanged and within normal ranges during baricitinib treatment"
          }
        ],
        "extraction_timestamp": "2025-12-07T17:27:22.610854",
        "extraction_confidence": 0.6,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [],
          "efficacy_tables": [],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure 1: Initial presentation showing patchy hair loss on scalp without eyebrow/eyelash involvement",
            "Figure 2: Clinical photographs showing nail damage and dermatoscopic findings including black dots, exclamation mark hairs, and broken hairs",
            "Figure 3: Partial hair regrowth with white hairs after dupilumab treatment, but with partial eyebrow loss",
            "Figure 4: Almost complete hair regrowth after 11 months of sequential dupilumab and baricitinib treatment"
          ],
          "results_sections": [
            "Case report section describing treatment outcomes",
            "Laboratory findings showing IgE levels, liver/kidney function, and hematological parameters before and after treatment",
            "Clinical outcome measurements including SALT scores (70% to 20% to <10%), EASI scores, SCORAD scores"
          ],
          "patient_count": 1,
          "study_type": "Case Report",
          "has_quantitative_outcomes": true,
          "notes": "This case report presents efficacy and safety data in narrative text rather than formal tables. Key outcomes include SALT score improvements from 70% to <10%, complete resolution of atopic dermatitis, and detailed laboratory monitoring showing no significant adverse effects during sequential dupilumab and baricitinib therapy."
        }
      },
      "market_intelligence": {
        "disease": "severe alopecia areata with atopic dermatitis in children",
        "epidemiology": {
          "us_prevalence_estimate": "0.21% of US population",
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": 703500,
          "prevalence_source": "Journal of Investigative Dermatology",
          "prevalence_source_url": "https://www.sciencedirect.com/science/article/pii/S0022202X25022365",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Dupixent (dupilumab)",
              "drug_class": "IL-4/IL-13 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": "Variable",
              "efficacy_pct": null,
              "annual_cost_usd": 37000.0,
              "line_of_therapy": "1L",
              "notes": "FDA approved for atopic dermatitis in children but not specifically for severe alopecia areata with atopic dermatitis. Used off-label for pediatric patients with both conditions"
            },
            {
              "drug_name": "Litfulo (ritlecitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": "Variable",
              "efficacy_pct": null,
              "annual_cost_usd": 60000.0,
              "line_of_therapy": "1L",
              "notes": "FDA approved for severe alopecia areata in adults and adolescents 12 years and older, but not specifically for the combination with atopic dermatitis"
            },
            {
              "drug_name": "Olumiant (baricitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": "Variable",
              "efficacy_pct": null,
              "annual_cost_usd": 55000.0,
              "line_of_therapy": "1L",
              "notes": "FDA approved for alopecia areata but not specifically for severe alopecia areata with atopic dermatitis in children"
            },
            {
              "drug_name": "REZPEG (rezpegaldesleukin)",
              "drug_class": "IL-2 receptor agonist",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": null,
              "notes": "Investigational therapy with Fast Track designation for severe alopecia areata in patients 12+ years, not yet FDA approved"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 3,
          "pipeline_therapies": [
            {
              "drug_name": "Upadacitinib",
              "company": "AbbVie",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06012240",
              "expected_completion": "2028-01"
            },
            {
              "drug_name": "Tofacitinib",
              "company": "Not specified",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT02299297",
              "expected_completion": null
            },
            {
              "drug_name": "Daxdilimab (HZN-7734)",
              "company": "Horizon Therapeutics",
              "mechanism": "Not specified",
              "phase": "Phase 2",
              "trial_id": "NCT05368103",
              "expected_completion": null
            }
          ],
          "pipeline_details": "The pipeline for severe alopecia areata shows active development with JAK inhibitors like upadacitinib in Phase 3 trials and tofacitinib in Phase 2, though specific pediatric data with concurrent atopic dermatitis is limited. Daxdilimab represents a novel mechanism in Phase 2a development for moderate-to-severe alopecia areata.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "No FDA-approved treatments exist specifically for severe alopecia areata with atopic dermatitis in children. Current approach involves off-label use of JAK inhibitors for severe alopecia areata or dupilumab for the atopic dermatitis component.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved treatments exist specifically for the combination indication of severe alopecia areata with atopic dermatitis in children, requiring off-label use of treatments approved for individual conditions",
          "competitive_landscape": "The market consists entirely of off-label therapies including JAK inhibitors approved for alopecia areata and IL-4/IL-13 inhibitors approved for atopic dermatitis. Several investigational therapies are in development but none have received FDA approval for this specific combination indication.",
          "soc_source": "National Alopecia Areata Foundation and DermNet clinical guidelines - https://www.naaf.org/navigation-toolkit/available-treatments/"
        },
        "market_size_estimate": "$17.6B",
        "market_size_usd": 17587500000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 316800000.0,
        "tam_estimate": "$317M",
        "tam_rationale": "Of ~703,500 US patients with severe alopecia areata with atopic dermatitis, ~60% are diagnosed (422K), ~45% receive systemic treatment (190K), given no current FDA-approved treatments and high unmet need. With no approved competitors, a new drug could capture 30-40% market share (~76K patients) as first-to-market advantage. At $4,200/yr pricing (considering pediatric population and dual indication complexity), TAM = $317M. Premium pricing justified by orphan-like characteristics and significant unmet medical need.",
        "tam_sources": [
          "https://www.biospace.com/press-releases/alopecia-areata-market-expected-to-grow-at-a-cagr-of-6-12-during-2025-2035-emotional-and-psychological-impact-drives-demand-for-alopecia-areata-treatment",
          "https://www.mordorintelligence.com/industry-reports/prescription-dermatology-therapeutics-market",
          "https://www.researchnester.com/reports/atopic-dermatitis-drugs-market/7338"
        ],
        "pipeline_sources": [
          "https://www.clinicaltrials.gov/study/NCT06012240",
          "https://cdn.clinicaltrials.gov/large-docs/80/NCT05121480/Prot_000.pdf",
          "https://cdn.clinicaltrials.gov/large-docs/97/NCT02299297/Prot_SAP_000.pdf"
        ],
        "attributed_sources": [
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11882485/",
            "title": "Epidemiology of Pediatric Alopecia Areata - PMC",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.sciencedirect.com/science/article/pii/S0022202X25022365",
            "title": "The Epidemiology of Atopic Dermatitis among Adults and ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.drugs.com/clinical_trials/nektar-therapeutics-receives-fast-track-designation-rezpegaldesleukin-severe-very-severe-alopecia-22125.html",
            "title": "Nektar Therapeutics Receives Fast Track Designation for ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/215830Orig1s000RiskR.pdf",
            "title": "215830Orig1s000 - accessdata.fda.gov",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3519253/",
            "title": "Current Treatment Strategies in Pediatric Alopecia Areata - PMC - NIH",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT06012240",
            "title": "NCT06012240 | A Study to Evaluate the Safety and ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/80/NCT05121480/Prot_000.pdf",
            "title": "CLINICAL STUDY PROTOCOL NCT05121480 A PHASE 2, MULTICENTER ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.biospace.com/press-releases/alopecia-areata-market-expected-to-grow-at-a-cagr-of-6-12-during-2025-2035-emotional-and-psychological-impact-drives-demand-for-alopecia-areata-treatment",
            "title": "Alopecia Areata Market Expected to Grow at a CAGR of ... - BioSpace",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.mordorintelligence.com/industry-reports/prescription-dermatology-therapeutics-market",
            "title": "Prescription Dermatology Therapeutics Market Size & Share Analysis",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 7.9,
        "evidence_quality": 6.1,
        "market_opportunity": 10.0,
        "overall_priority": 8.0,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 8.4,
          "endpoint_quality": 3.6,
          "organ_domain_breadth": 10.0,
          "safety_categories": [
            "hypersensitivity"
          ],
          "regulatory_flags": [
            "hypersensitivity"
          ]
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 8.4,
        "endpoint_quality_score": 3.6,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 10.0,
          "response_durability": 7.0,
          "extraction_completeness": 7.8
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 7.0,
        "extraction_completeness_score": 7.8,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 10.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 10.0,
        "unmet_need_score": 10.0
      },
      "rank": 2
    },
    {
      "extraction": {
        "source": {
          "pmid": "39666590",
          "doi": "10.12659/AJCR.945068",
          "url": "https://pubmed.ncbi.nlm.nih.gov/39666590/",
          "title": "Alopecia Areata Following the Use of Belimumab in a Patient with Systemic Lupus Erythematosus and Arthritis Who Responded Well to Baricitinib: A Case Report.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Systemic Lupus Erythematosus with alopecia universalis and arthritis",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "hydroxychloroquine",
            "azathioprine",
            "belimumab",
            "methotrexate",
            "mycophenolate mofetil",
            "systemic steroids",
            "topical steroid injections"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "54-year-old Saudi female with SLE presenting with mucocutaneous symptoms, oligoarthritis, and progressive alopecia areata to alopecia universalis"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "4 mg daily",
          "frequency": null,
          "duration": "ongoing at time of report (started and followed through March 2024)",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": "1 month",
          "duration_of_response": "sustained through March 2024",
          "effect_size_description": "Complete hair regrowth from alopecia universalis and complete resolution of arthritis with ability to taper steroids completely",
          "primary_endpoint": "Hair regrowth and arthritis improvement",
          "endpoint_result": "Patient regained nearly all hair and achieved complete resolution of joint symptoms",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib 4mg daily resulted in dramatic improvement with nearly complete hair regrowth from alopecia universalis and complete resolution of arthritis symptoms within 1 month. Patient achieved lupus remission with negative anti-dsDNA and normal CRP, allowing complete steroid withdrawal."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No adverse events reported with baricitinib treatment. Patient tolerated therapy well with sustained benefit and ability to discontinue steroids.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "approximately 3+ years from August 2019 to March 2024",
        "key_findings": "Baricitinib successfully treated belimumab-associated alopecia universalis and provided effective control of lupus arthritis, suggesting potential utility in SLE patients with these specific manifestations.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "Hair loss severity (SALT score)",
            "endpoint_category": "Primary",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": 50.0,
            "unit": "percentage",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 50.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Severe condition based on Severity of Alopecia Tool (SALT) score"
          },
          {
            "endpoint_name": "Number of affected joints",
            "endpoint_category": "Secondary",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": 4.0,
            "unit": "joints",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 4.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Oligoarthritis with tenderness in multiple joints without swelling, heat, or redness"
          },
          {
            "endpoint_name": "C-reactive protein",
            "endpoint_category": "Secondary",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": 7.1,
            "unit": "mg/L",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 7.1,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Reference range: <5 mg/L"
          },
          {
            "endpoint_name": "Time to initial response with baricitinib",
            "endpoint_category": "Primary",
            "timepoint": "Month 1",
            "measurement_type": "Absolute value",
            "value": 1.0,
            "unit": "month",
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Discernible initiation of improvement in alopecia universalis"
          },
          {
            "endpoint_name": "Hair regrowth response",
            "endpoint_category": "Primary",
            "timepoint": "Subsequent follow-up visits",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Patient regained nearly all her hair"
          },
          {
            "endpoint_name": "Joint symptom response",
            "endpoint_category": "Secondary",
            "timepoint": "Subsequent follow-up visits",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Significant improvement with no joint pain or tenderness on physical examination"
          },
          {
            "endpoint_name": "C-reactive protein",
            "endpoint_category": "Secondary",
            "timepoint": "March 2024",
            "measurement_type": "Absolute value",
            "value": null,
            "unit": "mg/L",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 7.1,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Normal C-reactive protein levels achieved"
          },
          {
            "endpoint_name": "Anti-ds DNA antibody status",
            "endpoint_category": "Secondary",
            "timepoint": "March 2024",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Negative anti-ds DNA serology achieved (was positive at baseline)"
          },
          {
            "endpoint_name": "Steroid discontinuation",
            "endpoint_category": "Secondary",
            "timepoint": "During baricitinib treatment",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Able to gradually taper prednisone to complete discontinuation"
          }
        ],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-07T17:30:31.014301",
        "extraction_confidence": 0.6,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [],
          "efficacy_tables": [],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure 1A, 1B - Initial non-scarring annular patches of hair loss on right temporal scalp",
            "Figure 2A, 2B - Clinical improvement after belimumab treatment",
            "Figure 3A-3D - Alopecia areata pattern of hair loss",
            "Figure 4A-4D - Progression to alopecia universalis (January 2021)",
            "Figure 5A, 5B - Hair regrowth improvement after baricitinib treatment"
          ],
          "results_sections": [
            "Case Report section - primary clinical outcomes and treatment response",
            "Laboratory findings - C-reactive protein, ANA, anti-ds DNA results",
            "Treatment timeline and response assessment",
            "Most recent serology results (March 2024)"
          ],
          "patient_count": 1,
          "study_type": "Case Report",
          "has_quantitative_outcomes": true,
          "notes": "Single patient case with SALT score for alopecia severity (50% hair loss), specific lab values, and drug dosing information. Primary outcomes were hair regrowth and arthritis improvement. No formal tables present - all data presented narratively with supporting clinical photographs."
        }
      },
      "market_intelligence": {
        "disease": "Systemic Lupus Erythematosus with alopecia universalis and arthritis",
        "epidemiology": {
          "us_prevalence_estimate": "4.3% of alopecia areata patients",
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": 3219,
          "prevalence_source": "JAMA Dermatology",
          "prevalence_source_url": "https://jamanetwork.com/journals/jamadermatology/fullarticle/1690841",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Benlysta (belimumab)",
              "drug_class": "BLyS inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": "Systemic Lupus Erythematosus (SLE) - general indication, not specific to alopecia universalis and arthritis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "FDA approved for SLE but not specifically for SLE with alopecia universalis and arthritis"
            },
            {
              "drug_name": "Saphnelo (anifrolumab)",
              "drug_class": "Type I interferon receptor antagonist",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": "Systemic Lupus Erythematosus (SLE) - general indication, not specific to alopecia universalis and arthritis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "FDA approved for SLE but not specifically for SLE with alopecia universalis and arthritis"
            },
            {
              "drug_name": "Rituxan (rituximab)",
              "drug_class": "Anti-CD20 monoclonal antibody",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Used off-label for SLE but not FDA approved for this specific indication"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 1,
          "pipeline_therapies": [
            {
              "drug_name": "deucravacitinib",
              "company": "Not specified",
              "mechanism": "TYK2 inhibitor with potent inhibition of IL-12/23 and Type I/III IFN-driven responses",
              "phase": "Phase 2/Phase 3",
              "trial_id": "NCT05556265",
              "expected_completion": null
            }
          ],
          "pipeline_details": "Limited pipeline activity identified with deucravacitinib being evaluated across multiple autoimmune conditions including SLE and alopecia areata. Most trials focus on individual conditions rather than the specific combination of SLE with alopecia universalis and arthritis.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "Treatment typically involves antimalarials, corticosteroids, and immunosuppressive agents as first-line, with biologic therapies considered for refractory cases.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved treatments specifically for systemic lupus erythematosus with alopecia universalis and arthritis as a combined indication",
          "competitive_landscape": "While several biologics are approved for general SLE, none are specifically approved for the combination of SLE with alopecia universalis and arthritis. Current treatment relies on off-label use of SLE therapies and general immunosuppressive approaches.",
          "soc_source": "Drugs.com and Medscape - https://www.drugs.com/condition/systemic-lupus-erythematosus.html"
        },
        "market_size_estimate": "$644M",
        "market_size_usd": 643800000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 48285000.0,
        "tam_estimate": "$48.3M",
        "tam_rationale": "Of ~3,219 patients with SLE + alopecia universalis + arthritis, ~85% are diagnosed (2,736), ~90% receive treatment given severity (2,462). With no approved drugs for this specific indication, a new drug could capture 60-70% market share (~1,600 patients) as first-to-market in high unmet need population. At $30K/yr pricing (lower than typical specialty given smaller indication), TAM = $48.3M. Orphan indication justifies premium but smaller patient pool limits overall market size.",
        "tam_sources": [
          "https://www.researchnester.com/reports/systemic-lupus-erythematosus-treatment-market/6495",
          "https://www.industryarc.com/Report/16283/systemic-lupus-erythematosus-market.html",
          "https://www.mordorintelligence.com/industry-reports/systemic-lupus-erythematosus-market"
        ],
        "pipeline_sources": [
          "https://cdn.clinicaltrials.gov/large-docs/65/NCT04248465/SAP_001.pdf",
          "https://cdn.clinicaltrials.gov/large-docs/65/NCT05556265/Prot_SAP_000.pdf",
          "https://cdn.clinicaltrials.gov/large-docs/49/NCT03570749/Prot_002.pdf"
        ],
        "attributed_sources": [
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9979012/",
            "title": "Trends in Prevalence and Incidence of Alopecia Areata ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://jamanetwork.com/journals/jamadermatology/fullarticle/1690841",
            "title": "Alopecia Areata and Associated Comorbid Conditions - JAMA Network",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.drugs.com/condition/systemic-lupus-erythematosus.html",
            "title": "List of 28 Lupus Medications Compared - Drugs.com Systemic Lupus Erythematosus (SLE): Practice Essentials ... Food and Drug Administration Systemic Lupus Erythematosus - Medscape Lupus (systemic lupus erythematosus) - Drugs.com Guidance for Industry: Systemic Lupus Erythematosus ... List of 28 Lupus Medications Compared - Drugs . com List of 28 Lupus Medications Compared - Drugs . com Systemic Lupus Erythematosus (SLE): Practice Essentials Guidance for Industry: Systemic Lupus Erythematosus --Developing Med\u2026 Anifrolumab: Uses, Dosage, Side Effects, Warnings - Drugs.com",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/332244-overview",
            "title": "Systemic Lupus Erythematosus (SLE): Practice Essentials ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.lupus.org/news/american-college-of-rheumatology-new-systemic-lupus-erythematosus-guideline",
            "title": "New Treatment Guidelines for Systemic Lupus Erythematosus for ...",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/65/NCT04248465/SAP_001.pdf",
            "title": "A Phase 3, Double-Blind, Randomized, Placebo-Controlled ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/65/NCT05556265/Prot_SAP_000.pdf",
            "title": "A Multi-center, Randomized, Double-blind, Placebo- ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.researchnester.com/reports/systemic-lupus-erythematosus-treatment-market/6495",
            "title": "Systemic Lupus Erythematosus Treatment Market Size ...",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.industryarc.com/Report/16283/systemic-lupus-erythematosus-market.html",
            "title": "Systemic Lupus Erythematosus Market - Forecast(2025 - IndustryARC",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 8.7,
        "evidence_quality": 5.4,
        "market_opportunity": 9.0,
        "overall_priority": 8.0,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 10.0,
          "endpoint_quality": 4.9,
          "organ_domain_breadth": 10.0,
          "safety_categories": [],
          "regulatory_flags": []
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 10.0,
        "endpoint_quality_score": 4.9,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 10.0,
          "response_durability": 4.0,
          "extraction_completeness": 7.8
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 7.8,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 7.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 7.0,
        "unmet_need_score": 10.0
      },
      "rank": 3
    },
    {
      "extraction": {
        "source": {
          "pmid": "39925926",
          "doi": "10.2147/JIR.S495481",
          "url": "https://pubmed.ncbi.nlm.nih.gov/39925926/",
          "title": "Baricitinib Successfully Treated a Teenager with Refractory Livedoid Vasculopathy: A Case Report and Literature Review.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Livedoid Vasculopathy",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "oral rivaroxaban combined with external use of heparin sodium cream"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "14-year-old girl with refractory livedoid vasculopathy presenting with painful recurrent ulcers on lateral ankles and back of both feet for over 1 year"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "4 mg daily initially, then tapered to 3 mg, 2 mg, and 1 mg daily before discontinuation",
          "frequency": null,
          "duration": "9 months",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": "2 weeks for initial improvement, 3 months for complete ulcer healing",
          "duration_of_response": "maintained through 9-month treatment period and follow-up to March 2024",
          "effect_size_description": "complete ulcer healing with significant reduction in erythema and pain",
          "primary_endpoint": "composite clinical score reduction (pain, skin ulcer, erythema)",
          "endpoint_result": "composite clinical score reduced from 7 to 1 at 3 months and complete healing of ulcers",
          "durability_signal": null,
          "efficacy_summary": "Patient showed significant improvement within 2 weeks with erythema becoming lighter and smaller, and scabs falling off. Complete ulcer healing occurred at 3 months with no new lesions, and only residual pigmentation remained at final follow-up."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Patient did not experience any drug-related adverse reactions during treatment, including no infection, liver function injury, or gastrointestinal symptoms. Treatment was well-tolerated throughout the tapering period.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "March 2024 (approximately 9 months after initiation)",
        "key_findings": "Baricitinib successfully treated refractory livedoid vasculopathy in a teenager who failed conventional anticoagulant therapy, with complete ulcer healing and no adverse events.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "Composite Clinical Score",
            "endpoint_category": "Exploratory",
            "timepoint": "3 months",
            "measurement_type": "Change from baseline",
            "value": 1.0,
            "unit": "points",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 7.0,
            "change_from_baseline": -6.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Current case - 14-year-old female"
          },
          {
            "endpoint_name": "Pain Score",
            "endpoint_category": "Exploratory",
            "timepoint": "3 months",
            "measurement_type": "Change from baseline",
            "value": 0.0,
            "unit": "points",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 2.0,
            "change_from_baseline": -2.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Current case - complete resolution of moderate pain"
          },
          {
            "endpoint_name": "Skin Ulceration Score",
            "endpoint_category": "Exploratory",
            "timepoint": "3 months",
            "measurement_type": "Change from baseline",
            "value": 0.0,
            "unit": "points",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 2.0,
            "change_from_baseline": -2.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Current case - complete ulcer healing"
          },
          {
            "endpoint_name": "Erythema Score",
            "endpoint_category": "Exploratory",
            "timepoint": "3 months",
            "measurement_type": "Change from baseline",
            "value": 1.0,
            "unit": "points",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 3.0,
            "change_from_baseline": -2.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Current case - improvement from severe to mild erythema"
          },
          {
            "endpoint_name": "Time to Symptom Improvement",
            "endpoint_category": "Exploratory",
            "timepoint": "2 weeks",
            "measurement_type": "Absolute value",
            "value": 2.0,
            "unit": "weeks",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Current case - erythema became lighter and smaller, scab falling off"
          },
          {
            "endpoint_name": "Time to Complete Ulcer Healing",
            "endpoint_category": "Exploratory",
            "timepoint": "3 months",
            "measurement_type": "Absolute value",
            "value": 3.0,
            "unit": "months",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Current case - complete ulcer healing without new lesions"
          },
          {
            "endpoint_name": "Composite Clinical Score",
            "endpoint_category": "Exploratory",
            "timepoint": "16 weeks",
            "measurement_type": "Change from baseline",
            "value": 3.0,
            "unit": "points",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 8.0,
            "change_from_baseline": -5.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Han Y et al - 36-year-old female"
          },
          {
            "endpoint_name": "Erythema Score",
            "endpoint_category": "Exploratory",
            "timepoint": "16 weeks",
            "measurement_type": "Change from baseline",
            "value": 1.0,
            "unit": "points",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 3.0,
            "change_from_baseline": -2.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Han Y et al - 36-year-old female"
          },
          {
            "endpoint_name": "Ulceration Score",
            "endpoint_category": "Exploratory",
            "timepoint": "16 weeks",
            "measurement_type": "Change from baseline",
            "value": 1.0,
            "unit": "points",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 2.0,
            "change_from_baseline": -1.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Han Y et al - 36-year-old female"
          },
          {
            "endpoint_name": "Composite Clinical Score",
            "endpoint_category": "Exploratory",
            "timepoint": "10 weeks",
            "measurement_type": "Change from baseline",
            "value": 0.0,
            "unit": "points",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 8.0,
            "change_from_baseline": -8.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Han Y et al - 17-year-old male, complete response"
          },
          {
            "endpoint_name": "Erythema Score",
            "endpoint_category": "Exploratory",
            "timepoint": "10 weeks",
            "measurement_type": "Change from baseline",
            "value": 0.0,
            "unit": "points",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 3.0,
            "change_from_baseline": -3.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Han Y et al - 17-year-old male, complete response"
          },
          {
            "endpoint_name": "Ulceration Score",
            "endpoint_category": "Exploratory",
            "timepoint": "10 weeks",
            "measurement_type": "Change from baseline",
            "value": 0.0,
            "unit": "points",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 2.0,
            "change_from_baseline": -2.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Han Y et al - 17-year-old male, complete response"
          },
          {
            "endpoint_name": "Composite Clinical Score",
            "endpoint_category": "Exploratory",
            "timepoint": "28 weeks",
            "measurement_type": "Change from baseline",
            "value": 0.0,
            "unit": "points",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 7.0,
            "change_from_baseline": -7.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Han Y et al - 26-year-old female, complete response"
          },
          {
            "endpoint_name": "Erythema Score",
            "endpoint_category": "Exploratory",
            "timepoint": "28 weeks",
            "measurement_type": "Change from baseline",
            "value": 0.0,
            "unit": "points",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 3.0,
            "change_from_baseline": -3.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Han Y et al - 26-year-old female, complete response"
          },
          {
            "endpoint_name": "Ulceration Score",
            "endpoint_category": "Exploratory",
            "timepoint": "28 weeks",
            "measurement_type": "Change from baseline",
            "value": 0.0,
            "unit": "points",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 1.0,
            "change_from_baseline": -1.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Han Y et al - 26-year-old female, complete response"
          },
          {
            "endpoint_name": "Time to Complete Ulcer Healing",
            "endpoint_category": "Exploratory",
            "timepoint": "4 weeks",
            "measurement_type": "Absolute value",
            "value": 4.0,
            "unit": "weeks",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Pe\u00f1uelas Leal R et al - 48-year-old female"
          },
          {
            "endpoint_name": "Duration of Disease Control",
            "endpoint_category": "Exploratory",
            "timepoint": "16 weeks",
            "measurement_type": "Absolute value",
            "value": 16.0,
            "unit": "weeks",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Pe\u00f1uelas Leal R et al - maintained complete control including resolution of livedo racemosa"
          },
          {
            "endpoint_name": "Time to Ulcer Healing",
            "endpoint_category": "Exploratory",
            "timepoint": "12 weeks",
            "measurement_type": "Absolute value",
            "value": 12.0,
            "unit": "weeks",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Xiao Y et al - 26-year-old female, erythema gradually diminished"
          },
          {
            "endpoint_name": "Duration of Stable Conditions",
            "endpoint_category": "Exploratory",
            "timepoint": "42 weeks",
            "measurement_type": "Absolute value",
            "value": 42.0,
            "unit": "weeks",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Xiao Y et al - maintained stable conditions without adverse events"
          },
          {
            "endpoint_name": "Time to Complete Lesion Disappearance",
            "endpoint_category": "Exploratory",
            "timepoint": "3 months",
            "measurement_type": "Absolute value",
            "value": 3.0,
            "unit": "months",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Zhang H et al - 14-year-old female, all lesions disappeared"
          },
          {
            "endpoint_name": "Time to Complete Ulcer Healing",
            "endpoint_category": "Exploratory",
            "timepoint": "1 month",
            "measurement_type": "Absolute value",
            "value": 1.0,
            "unit": "months",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Song X et al - 26-year-old male"
          },
          {
            "endpoint_name": "Time to Ulcer Healing",
            "endpoint_category": "Exploratory",
            "timepoint": "2 months",
            "measurement_type": "Absolute value",
            "value": 2.0,
            "unit": "months",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Song X et al - 26-year-old female, healed ulcers with residual hyperpigmentation"
          }
        ],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-07T17:41:56.170493",
        "extraction_confidence": 0.6,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [
            "Table 1 - Patient Characteristics and Response to Baricitinib Therapy (contains age, sex, previous therapies for 14 patients from multiple studies including current case)"
          ],
          "efficacy_tables": [
            "Table 1 - Patient Characteristics and Response to Baricitinib Therapy (contains current therapies and follow-up outcomes showing clinical response)"
          ],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure 1 - Initial skin appearance showing painful recurrent ulcers before treatment",
            "Figure 3 - Clinical Response of Livedoid Vasculopathy to Baricitinib Therapy showing progression from treatment initiation through 3 months and final follow-up"
          ],
          "results_sections": [
            "Case Presentation section describing treatment response",
            "Treatment outcomes showing composite clinical score reduction from 7 to 1",
            "Complete ulcer healing after 3 months of treatment",
            "Successful drug tapering and discontinuation without recurrence"
          ],
          "patient_count": 1,
          "study_type": "Case Report",
          "has_quantitative_outcomes": true,
          "notes": "Single case report with literature review. Table 1 summarizes 14 patients from 5 different studies. Composite clinical scores used to quantify pain, skin ulceration, and erythema. Figure 2 shows histological features but is not an efficacy outcome."
        }
      },
      "market_intelligence": {
        "disease": "Livedoid Vasculopathy",
        "epidemiology": {
          "us_prevalence_estimate": "1 in 100,000",
          "us_incidence_estimate": "1-9 per 100,000 annually",
          "global_prevalence": null,
          "patient_population_size": 3350,
          "prevalence_source": "PMC - NIH",
          "prevalence_source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6066260/",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 2,
          "pipeline_therapies": [
            {
              "drug_name": "Rivaroxaban",
              "company": "Not specified",
              "mechanism": "Anticoagulant",
              "phase": "Phase 2",
              "trial_id": null,
              "expected_completion": null
            },
            {
              "drug_name": "Diosmiplex (Vasculera\u00ae)",
              "company": "Not specified",
              "mechanism": "Not specified",
              "phase": "Phase 3",
              "trial_id": "NCT02683408",
              "expected_completion": null
            }
          ],
          "pipeline_details": "Limited clinical trial activity for Livedoid Vasculopathy with rivaroxaban being tested in Phase 2 trials and Diosmiplex (Vasculera\u00ae) in Phase 3 development. The pipeline appears sparse with only a few active therapeutic investigations for this rare condition.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "First-line treatment involves anticoagulation with low molecular weight heparins or direct oral anticoagulants (rivaroxaban) as recommended by German S1 guidelines. No FDA-approved drugs exist specifically for livedoid vasculopathy, requiring off-label therapy.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved drugs exist specifically for livedoid vasculopathy treatment, making off-label therapy the only option. Current treatment relies on anticoagulants, antiplatelet agents, and supportive care without definitive therapeutic guidelines.",
          "competitive_landscape": "The livedoid vasculopathy treatment landscape consists entirely of off-label use of anticoagulants and supportive therapies, with no branded innovative drugs FDA-approved for this indication. Recent case reports suggest potential for JAK inhibitors like tofacitinib, but these remain investigational for this specific condition.",
          "soc_source": "StatPearls NCBI Bookshelf and German S1 Guidelines - https://www.ncbi.nlm.nih.gov/books/NBK559037/"
        },
        "market_size_estimate": "$670M",
        "market_size_usd": 670000000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 67200000.0,
        "tam_estimate": "$67.2M",
        "tam_rationale": "Of ~3,350 US patients with livedoid vasculopathy, ~80% are diagnosed (2,680), ~90% receive treatment due to painful ulceration (2,410). With no approved drugs and high unmet need, a new FDA-approved therapy could capture 40-50% market share (~1,120 patients). As an orphan drug for rare disease with severe morbidity, pricing at $60K/yr is justified. TAM = 1,120 \u00d7 $60,000 = $67.2M.",
        "tam_sources": [
          "https://cdn.ymaws.com/www.aocd.org/resource/resmgr/jaocd/jaocdvol31.pdf",
          "https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1594585/full",
          "https://www.malacards.org/card/vasculitis"
        ],
        "pipeline_sources": [
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC8721056/",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC9574051/",
          "https://pubmed.ncbi.nlm.nih.gov/41264385/"
        ],
        "attributed_sources": [
          {
            "url": "https://www.malacards.org/card/livedoid_vasculitis",
            "title": "Livedoid Vasculitis - MalaCards",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6066260/",
            "title": "Livedoid vasculopathy: a compelling diagnosis - PMC - NIH",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://emedicine.medscape.com/article/1082675-overview",
            "title": "Livedoid Vasculopathy: Background, Pathophysiology ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/316024-medication",
            "title": "Mononeuritis Multiplex Medication",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://journals.sagepub.com/doi/full/10.1177/21621918251395013",
            "title": "Long-Term Efficacy of Guideline-Followed Treatment in Patients with ...",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8721056/",
            "title": "Livedoid vasculopathy: A multidisciplinary clinical approach to ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9574051/",
            "title": "Livedoid vasculopathy \u2013 A diagnostic and therapeutic ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://cdn.ymaws.com/www.aocd.org/resource/resmgr/jaocd/jaocdvol31.pdf",
            "title": "Focus on Osteopathy",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1594585/full",
            "title": "Adverse events of pexidartinib for the treatment of TGCT",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 8.5,
        "evidence_quality": 6.1,
        "market_opportunity": 9.0,
        "overall_priority": 8.0,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 10.0,
          "endpoint_quality": 4.0,
          "organ_domain_breadth": 10.0,
          "safety_categories": [],
          "regulatory_flags": []
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 10.0,
        "endpoint_quality_score": 4.0,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 10.0,
          "response_durability": 7.0,
          "extraction_completeness": 7.8
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 7.0,
        "extraction_completeness_score": 7.8,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 7.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 7.0,
        "unmet_need_score": 10.0
      },
      "rank": 4
    },
    {
      "extraction": {
        "source": {
          "pmid": "38519108",
          "doi": "10.1136/rmdopen-2023-003985",
          "url": "https://pubmed.ncbi.nlm.nih.gov/38519108/",
          "title": "Baricitinib for refractory Takayasu arteritis: a prospective cohort study in a tertiary referral centre.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Takayasu arteritis",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 10,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "methotrexate",
            "leflunomide",
            "mycophenolate mofetil",
            "tacrolimus",
            "hydroxychloroquine",
            "cyclophosphamide",
            "TNF inhibitors",
            "tocilizumab",
            "secukinumab",
            "tofacitinib"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "Refractory Takayasu arteritis patients, median age 28 years, 90% female, median disease duration 50 months, all failed at least 2 conventional synthetic DMARDs"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "4 mg daily",
          "frequency": null,
          "duration": "median 15.3 months (range 4-31 months)",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "6/10 (60%)",
          "responders_n": 6,
          "responders_pct": 60.0,
          "time_to_response": "6 months",
          "duration_of_response": "4/10 (40%) patients maintained overall treatment response at end of study",
          "effect_size_description": "60% overall response rate at 6 months, with 40% achieving complete response and 20% achieving partial response",
          "primary_endpoint": "overall treatment response rate at 6 months",
          "endpoint_result": "6/10 (60%) patients had overall treatment response at 6 months",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib achieved 60% overall response rate at 6 months in refractory Takayasu arteritis patients. Response was associated with decreased inflammatory markers (ESR, CRP, IL-6, TNF) and improved or stable arterial lesions on imaging. Two patients were able to discontinue glucocorticoids completely while maintaining remission."
        },
        "safety": {
          "adverse_events": [
            "liver dysfunction"
          ],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 4,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [
            "inadequate treatment response",
            "persistently active disease",
            "liver dysfunction",
            "new arterial lesions"
          ],
          "safety_summary": "Baricitinib was well tolerated with no severe adverse events. One patient experienced reversible liver dysfunction requiring discontinuation. No serious infections, thrombosis, malignancy, or cardiovascular events occurred during the study period.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Moderate",
        "comparator_baseline": null,
        "follow_up_duration": "median 15.3 months",
        "key_findings": "Baricitinib demonstrated efficacy in refractory Takayasu arteritis with 60% response rate and favorable safety profile. This represents the first prospective study of baricitinib in this indication.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "Overall treatment response rate",
            "endpoint_category": "Primary",
            "timepoint": "6 months",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 6,
            "responders_pct": 60.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Primary endpoint - includes complete and partial responders"
          },
          {
            "endpoint_name": "Complete response rate",
            "endpoint_category": "Secondary",
            "timepoint": "6 months",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 4,
            "responders_pct": 40.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "ESR<20 mm/h, CRP<10 mg/L, no vessel progression, GC<15 mg/day"
          },
          {
            "endpoint_name": "Partial response rate",
            "endpoint_category": "Secondary",
            "timepoint": "6 months",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 2,
            "responders_pct": 20.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "ESR<40 mm/h or >50% decrease, CRP<20 mg/L or >50% decrease"
          },
          {
            "endpoint_name": "Overall treatment response rate",
            "endpoint_category": "Secondary",
            "timepoint": "End of study",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 4,
            "responders_pct": 40.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Maintained response at end of follow-up (median 15.3 months)"
          },
          {
            "endpoint_name": "Complete response rate",
            "endpoint_category": "Secondary",
            "timepoint": "End of study",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 3,
            "responders_pct": 30.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Maintained complete response throughout follow-up"
          },
          {
            "endpoint_name": "Erythrocyte sedimentation rate",
            "endpoint_category": "Secondary",
            "timepoint": "6 months",
            "measurement_type": "Change from baseline",
            "value": 8.0,
            "unit": "mm/hour",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 20.5,
            "change_from_baseline": -12.5,
            "change_pct": null,
            "p_value": "0.10",
            "confidence_interval": null,
            "statistical_significance": false,
            "notes": "Median values with IQR"
          },
          {
            "endpoint_name": "C-reactive protein",
            "endpoint_category": "Secondary",
            "timepoint": "6 months",
            "measurement_type": "Change from baseline",
            "value": 0.66,
            "unit": "mg/L",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 14.5,
            "change_from_baseline": -13.84,
            "change_pct": null,
            "p_value": "0.23",
            "confidence_interval": null,
            "statistical_significance": false,
            "notes": "Median values with IQR"
          },
          {
            "endpoint_name": "Interleukin-6",
            "endpoint_category": "Secondary",
            "timepoint": "6 months",
            "measurement_type": "Change from baseline",
            "value": 2.8,
            "unit": "pg/L",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 12.0,
            "change_from_baseline": -9.2,
            "change_pct": null,
            "p_value": "0.18",
            "confidence_interval": null,
            "statistical_significance": false,
            "notes": "Median values with IQR"
          },
          {
            "endpoint_name": "Tumor necrosis factor",
            "endpoint_category": "Secondary",
            "timepoint": "6 months",
            "measurement_type": "Change from baseline",
            "value": 5.8,
            "unit": "pg/L",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 7.7,
            "change_from_baseline": -1.9,
            "change_pct": null,
            "p_value": "0.30",
            "confidence_interval": null,
            "statistical_significance": false,
            "notes": "Median values with IQR"
          },
          {
            "endpoint_name": "Common carotid artery mural thickness",
            "endpoint_category": "Secondary",
            "timepoint": "6 months or end of treatment",
            "measurement_type": "Change from baseline",
            "value": 1.55,
            "unit": "mm",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 1.9,
            "change_from_baseline": -0.35,
            "change_pct": null,
            "p_value": "0.20",
            "confidence_interval": null,
            "statistical_significance": false,
            "notes": "Median mural thickness at thickest site by ultrasound"
          },
          {
            "endpoint_name": "Subclavian artery mural thickness",
            "endpoint_category": "Secondary",
            "timepoint": "6 months or end of treatment",
            "measurement_type": "Change from baseline",
            "value": 1.9,
            "unit": "mm",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 2.0,
            "change_from_baseline": -0.1,
            "change_pct": null,
            "p_value": "0.17",
            "confidence_interval": null,
            "statistical_significance": false,
            "notes": "Median mural thickness at thickest site by ultrasound"
          },
          {
            "endpoint_name": "Arterial lesion improvement/stabilization",
            "endpoint_category": "Secondary",
            "timepoint": "Throughout study",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 8,
            "responders_pct": 80.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Improvement/stabilization in CTA and ultrasound measurements"
          },
          {
            "endpoint_name": "Glucocorticoid dose tapering/maintenance",
            "endpoint_category": "Secondary",
            "timepoint": "Throughout study",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 8,
            "responders_pct": 80.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Patients who tapered or maintained same GC dose"
          },
          {
            "endpoint_name": "Glucocorticoid discontinuation",
            "endpoint_category": "Secondary",
            "timepoint": "18-24 months",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 2,
            "responders_pct": 20.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Complete GC discontinuation with continuous remission"
          },
          {
            "endpoint_name": "Glucocorticoid dose in responders",
            "endpoint_category": "Secondary",
            "timepoint": "6 months",
            "measurement_type": "Change from baseline",
            "value": 7.5,
            "unit": "mg/day prednisone equivalent",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 10.0,
            "change_from_baseline": -2.5,
            "change_pct": null,
            "p_value": "0.058",
            "confidence_interval": null,
            "statistical_significance": false,
            "notes": "Median dose in patients with CR or PR"
          },
          {
            "endpoint_name": "Glucocorticoid dose \u226410 mg daily",
            "endpoint_category": "Secondary",
            "timepoint": "Throughout study",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 7,
            "responders_pct": 70.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Patients achieving low-dose GC maintenance"
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "Elevated aminotransferase",
            "event_category": "Lab abnormality",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": 10.0,
            "events_total": 1,
            "relatedness": "Related",
            "outcome": "Resolved",
            "action_taken": "Discontinued",
            "notes": "Occurred at 18 months after baricitinib initiation, liver enzymes gradually returned to normal range after discontinuation"
          },
          {
            "event_name": "Liver dysfunction",
            "event_category": "Discontinuation",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": 10.0,
            "events_total": 1,
            "relatedness": "Related",
            "outcome": "Resolved",
            "action_taken": "Discontinued",
            "notes": "Same patient as elevated aminotransferase, Patient 1"
          },
          {
            "event_name": "Inadequate treatment response",
            "event_category": "Discontinuation",
            "severity_grade": null,
            "patients_affected_n": 3,
            "patients_affected_pct": 30.0,
            "events_total": 3,
            "relatedness": null,
            "outcome": null,
            "action_taken": "Discontinued",
            "notes": "Three patients withdrew baricitinib at 4 months due to inadequate treatment responses and persistently active disease"
          },
          {
            "event_name": "New lesion in arterial territory",
            "event_category": "Discontinuation",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": 10.0,
            "events_total": 1,
            "relatedness": null,
            "outcome": null,
            "action_taken": "Discontinued",
            "notes": "Patient had complete response at 6 months but developed lesions in new artery territory and stopped baricitinib at 12 months"
          },
          {
            "event_name": "Persistent angina",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": 10.0,
            "events_total": 1,
            "relatedness": "Unrelated",
            "outcome": null,
            "action_taken": null,
            "notes": "Patient 10, found to be caused by active TAK disease rather than baricitinib"
          },
          {
            "event_name": "Recurrent in-stent stenosis",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": 10.0,
            "events_total": 1,
            "relatedness": "Unrelated",
            "outcome": null,
            "action_taken": null,
            "notes": "Patient 10, coronary artery stenosis found to be caused by active TAK disease"
          },
          {
            "event_name": "Severe infections",
            "event_category": "AESI",
            "severity_grade": null,
            "patients_affected_n": 0,
            "patients_affected_pct": 0.0,
            "events_total": 0,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "No severe infection requiring antibiotics occurred during study period"
          },
          {
            "event_name": "Deep venous thrombosis",
            "event_category": "AESI",
            "severity_grade": null,
            "patients_affected_n": 0,
            "patients_affected_pct": 0.0,
            "events_total": 0,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "No deep venous thrombosis occurred during study period"
          },
          {
            "event_name": "Malignancy",
            "event_category": "AESI",
            "severity_grade": null,
            "patients_affected_n": 0,
            "patients_affected_pct": 0.0,
            "events_total": 0,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "No malignancy occurred during study period"
          },
          {
            "event_name": "Cardiovascular events",
            "event_category": "AESI",
            "severity_grade": null,
            "patients_affected_n": 0,
            "patients_affected_pct": 0.0,
            "events_total": 0,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "No cardiovascular events occurred during study period"
          }
        ],
        "extraction_timestamp": "2025-12-07T17:29:07.874182",
        "extraction_confidence": 0.6,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [
            "Table 1: Baseline characteristics of the recruited patients - includes age, sex, disease duration, clinical characteristics, inflammatory parameters (ESR, CRP, TNF, IL-6), prior treatments, Numano classification, involved arteries, active symptoms, and evidence of active disease"
          ],
          "efficacy_tables": [
            "Table 2: Treatment response of baricitinib - shows follow-up duration, serial measurements of carotid and subclavian artery thickness and diameter, clinical response at 6 months, 12 months and end of study, and reasons for baricitinib cessation"
          ],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure 1: Changes in inflammatory parameters and ultrasonography during baricitinib treatment - shows trends in ESR, CRP, IL-6, TNF levels and mural thickness/lumen diameter of carotid and subclavian arteries over time",
            "Figure 2: Glucocorticoid and conventional synthetic csDMARDs dosage during follow-up - displays medication dosing changes over the study period"
          ],
          "results_sections": [
            "Patient characteristics",
            "Efficacy of baricitinib",
            "Safety of baricitinib"
          ],
          "patient_count": 10,
          "study_type": "Case Series",
          "has_quantitative_outcomes": true,
          "notes": "This is a prospective cohort study of refractory Takayasu arteritis patients treated with baricitinib 4mg daily. Primary endpoint was overall response rate at 6 months (60% achieved). Safety data reported narratively rather than in tabular format. Study includes detailed arterial measurements via ultrasonography and inflammatory marker trends."
        }
      },
      "market_intelligence": {
        "disease": "Takayasu arteritis",
        "epidemiology": {
          "us_prevalence_estimate": "8.4 per million",
          "us_incidence_estimate": "2.6 cases per million per year",
          "global_prevalence": null,
          "patient_population_size": 2814,
          "prevalence_source": "The Journal of Rheumatology",
          "prevalence_source_url": "https://www.jrheum.org/content/jrheum/48/6/952.full.pdf",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Actemra (tocilizumab)",
              "drug_class": "IL-6 receptor antagonist",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": "60-80%",
              "efficacy_pct": null,
              "annual_cost_usd": 50000.0,
              "line_of_therapy": "2L",
              "notes": "Recommended in guidelines but not FDA-approved specifically for Takayasu arteritis; approved for giant cell arteritis"
            },
            {
              "drug_name": "Humira (adalimumab)",
              "drug_class": "TNF inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": "70-80%",
              "efficacy_pct": null,
              "annual_cost_usd": 60000.0,
              "line_of_therapy": "2L",
              "notes": "Has orphan designation for Takayasu arteritis as of 2025 but not FDA-approved for this indication"
            },
            {
              "drug_name": "Rinvoq (upadacitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": 55000.0,
              "line_of_therapy": "2L",
              "notes": "FDA expanded indication to include giant cell arteritis in 2025, may be used off-label for Takayasu arteritis"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 2,
          "pipeline_therapies": [
            {
              "drug_name": "Tocilizumab",
              "company": "Not specified",
              "mechanism": "IL-6 receptor antagonist",
              "phase": "Phase 3",
              "trial_id": "NCT02101333",
              "expected_completion": null
            },
            {
              "drug_name": "Unknown",
              "company": "Not specified",
              "mechanism": "Not specified",
              "phase": "Phase 3",
              "trial_id": "NCT04161898",
              "expected_completion": null
            }
          ],
          "pipeline_details": "Clinical pipeline for Takayasu arteritis includes tocilizumab in Phase 3 trials demonstrating steroid-sparing effects. Limited active pipeline with tocilizumab being the primary therapeutic focus in advanced clinical development.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "First-line treatment consists of high-dose corticosteroids (prednisone) combined with conventional DMARDs like methotrexate. Second-line treatments include TNF inhibitors and tocilizumab for refractory or relapsing disease.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved branded innovative treatments specifically for Takayasu arteritis despite available biologics showing efficacy in clinical practice and guidelines",
          "competitive_landscape": "The treatment landscape relies heavily on off-label use of biologics approved for other inflammatory conditions, with adalimumab recently receiving orphan designation. The lack of dedicated FDA approvals represents a significant opportunity for pharmaceutical companies to pursue indication expansion.",
          "soc_source": "Medscape Aortitis Treatment & Management https://emedicine.medscape.com/article/150755-treatment"
        },
        "market_size_estimate": "$563M",
        "market_size_usd": 562800000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 105000000.0,
        "tam_estimate": "$105M",
        "tam_rationale": "Of ~2,814 diagnosed Takayasu arteritis patients globally, ~95% receive treatment (2,673), with ~60% experiencing refractory/relapsing disease requiring 2L+ therapy (1,604 patients). As the first approved drug in a zero-competitor market with high unmet need, a new drug could capture 65% market share (~1,043 patients). Given orphan disease status and specialty biologic positioning, pricing at $100K/yr is justified. TAM = 1,043 \u00d7 $100K = $104.3M.",
        "tam_sources": [
          "https://www.verifiedmarketresearch.com/product/vasculitis-treatment-market/",
          "https://dataintelo.com/report/vasculitis-diagnostics-market",
          "https://www.dennisgong.com/blog/newmedicines/"
        ],
        "pipeline_sources": [
          "https://www.clinicaltrials.gov/study/NCT02101333",
          "https://clinicaltrials.gov/study/NCT02101333",
          "https://pubmed.ncbi.nlm.nih.gov/31951279/"
        ],
        "attributed_sources": [
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8456169/",
            "title": "The epidemiology of Takayasu Arteritis, a population-based study",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.jrheum.org/content/jrheum/48/6/952.full.pdf",
            "title": "Prevalence of Takayasu Arteritis: A Population-based Study",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://emedicine.medscape.com/article/150755-treatment",
            "title": "Aortitis Treatment & Management",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1063724",
            "title": "Search Orphan Drug Designations and Approvals Takayasu Arteritis Guidelines: Guidelines Summary - Medscape FDA Purplebook Takayasu Arteritis Medication: Corticosteroids ... openFDA - Food and Drug Administration Reference Drug Duo Shows Promise in Takayasu Arteritis - Medscape Drug Duo Shows Promise in Takayasu Arteritis - Medscape Takayasu Arteritis Guidelines: Guidelines Summary - Medscape label - Food and Drug Administration",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://droracle.ai/articles/334365/what-is-the-treatment-protocol-for-takayasu-arteritis",
            "title": "What is the treatment protocol for Takayasu arteritis? - Dr.Oracle",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT02101333",
            "title": "Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT02101333",
            "title": "Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.verifiedmarketresearch.com/product/vasculitis-treatment-market/",
            "title": "Vasculitis Treatment Market Size, Share, Trends & Forecast",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://dataintelo.com/report/vasculitis-diagnostics-market",
            "title": "Vasculitis Diagnostics Market Research Report 2033 - Dataintelo",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 7.3,
        "evidence_quality": 8.2,
        "market_opportunity": 9.0,
        "overall_priority": 7.9,
        "clinical_breakdown": {
          "response_rate": 8.0,
          "safety_profile": 7.1,
          "endpoint_quality": 5.0,
          "organ_domain_breadth": 10.0,
          "safety_categories": [
            "hypersensitivity",
            "serious_infection",
            "discontinuation",
            "cardiovascular",
            "thromboembolic",
            "malignancy"
          ],
          "regulatory_flags": [
            "hypersensitivity",
            "serious_infection",
            "cardiovascular",
            "thromboembolic",
            "malignancy"
          ]
        },
        "response_rate_score": 8.0,
        "safety_profile_score": 7.1,
        "endpoint_quality_score": 5.0,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 6.0,
          "publication_venue": 10.0,
          "response_durability": 9.0,
          "extraction_completeness": 8.3
        },
        "sample_size_score": 6.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 9.0,
        "extraction_completeness_score": 8.3,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 7.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 7.0,
        "unmet_need_score": 10.0
      },
      "rank": 5
    },
    {
      "extraction": {
        "source": {
          "pmid": "39247640",
          "doi": "10.3389/fmed.2024.1439338",
          "url": "https://pubmed.ncbi.nlm.nih.gov/39247640/",
          "title": "Efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: a prospective cohort study from the international AIDA network registries.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "non-infectious inflammatory ocular diseases",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 4,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "adalimumab",
            "golimumab",
            "infliximab",
            "etanercept",
            "certolizumab",
            "methotrexate",
            "azathioprine",
            "cyclosporine A",
            "sulfasalazine",
            "systemic glucocorticoids"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "4 adult patients with non-infectious inflammatory ocular diseases (anterior sclerouveitis with rheumatoid arthritis, panuveitis with Vogt-Koyanagi-Harada syndrome, posterior uveitis idiopathic, anterior uveitis with ANA positive juvenile idiopathic arthritis)"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "2-4 mg/day",
          "frequency": null,
          "duration": "9.5 \u00b1 4.8 months (3-17 months)",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "4/4 (100%)",
          "responders_n": 4,
          "responders_pct": 100.0,
          "time_to_response": "within 3 months",
          "duration_of_response": "maintained throughout follow-up period",
          "effect_size_description": "complete disease control achieved in all patients",
          "primary_endpoint": "frequency of ocular inflammatory relapses",
          "endpoint_result": "complete ocular disease control in 4/4 patients",
          "durability_signal": null,
          "efficacy_summary": "All 4 patients treated with baricitinib achieved complete ocular disease control. The treatment was effective in controlling inflammatory relapses and preventing new complications."
        },
        "safety": {
          "adverse_events": [
            "myalgia"
          ],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 1,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [
            "poor compliance"
          ],
          "safety_summary": "Excellent safety profile with only one reported adverse event of myalgia. One patient discontinued due to poor compliance after 12 months, not due to safety concerns.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "9.5 \u00b1 4.8 months",
        "key_findings": "Baricitinib demonstrated complete efficacy in controlling non-infectious inflammatory ocular diseases with excellent safety profile in all treated patients.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "Ocular inflammatory relapse incidence rate - pre-treatment",
            "endpoint_category": "Primary",
            "timepoint": "12 months before JAK inhibitor start",
            "measurement_type": "Absolute value",
            "value": 125.0,
            "unit": "episodes per 1,000 person-months",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 125.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Incidence before JAK inhibitor treatment"
          },
          {
            "endpoint_name": "Ocular inflammatory relapse incidence rate - during treatment",
            "endpoint_category": "Primary",
            "timepoint": "During JAK inhibitor treatment",
            "measurement_type": "Absolute value",
            "value": 28.6,
            "unit": "episodes per 1,000 person-months",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 125.0,
            "change_from_baseline": -96.4,
            "change_pct": -77.1,
            "p_value": "0.02",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Significant reduction in relapse rate"
          },
          {
            "endpoint_name": "Incidence rate ratio for ocular relapses",
            "endpoint_category": "Primary",
            "timepoint": "Pre-treatment vs during treatment",
            "measurement_type": "Absolute value",
            "value": 4.37,
            "unit": "ratio",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": "0.02",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "95% CI 1.3-14.7"
          },
          {
            "endpoint_name": "Complete ocular disease control",
            "endpoint_category": "Secondary",
            "timepoint": "Last assessment",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 12,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "All 12 patients achieved complete control"
          },
          {
            "endpoint_name": "Best-corrected visual acuity (BCVA) - baseline",
            "endpoint_category": "Secondary",
            "timepoint": "Start of treatment",
            "measurement_type": "Absolute value",
            "value": 1.0,
            "unit": "decimal",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 1.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Median value, IQR: 0.2, range 0.03-1.0"
          },
          {
            "endpoint_name": "Best-corrected visual acuity (BCVA) - last assessment",
            "endpoint_category": "Secondary",
            "timepoint": "Last assessment",
            "measurement_type": "Change from baseline",
            "value": 1.0,
            "unit": "decimal",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 1.0,
            "change_from_baseline": 0.0,
            "change_pct": 0.0,
            "p_value": "0.63",
            "confidence_interval": null,
            "statistical_significance": false,
            "notes": "Median value, IQR: 0.1, range: 0.06-1.0, no significant change"
          },
          {
            "endpoint_name": "Uveitic macular edema occurrence - pre-treatment",
            "endpoint_category": "Secondary",
            "timepoint": "Before JAK inhibitor start",
            "measurement_type": "Absolute value",
            "value": null,
            "unit": null,
            "responders_n": 3,
            "responders_pct": 25.0,
            "baseline_value": 3.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "3 patients (4 eyes) affected"
          },
          {
            "endpoint_name": "Uveitic macular edema occurrence - during treatment",
            "endpoint_category": "Secondary",
            "timepoint": "During JAK inhibitor treatment",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": null,
            "responders_n": 0,
            "responders_pct": 0.0,
            "baseline_value": 3.0,
            "change_from_baseline": -3.0,
            "change_pct": -100.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "No episodes occurred during treatment"
          },
          {
            "endpoint_name": "Retinal vasculitis occurrence - pre-treatment",
            "endpoint_category": "Secondary",
            "timepoint": "Before JAK inhibitor start",
            "measurement_type": "Absolute value",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 8.3,
            "baseline_value": 1.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "1 patient (2 eyes) affected"
          },
          {
            "endpoint_name": "Retinal vasculitis occurrence - during treatment",
            "endpoint_category": "Secondary",
            "timepoint": "During JAK inhibitor treatment",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": null,
            "responders_n": 0,
            "responders_pct": 0.0,
            "baseline_value": 1.0,
            "change_from_baseline": -1.0,
            "change_pct": -100.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "No episodes occurred during treatment"
          },
          {
            "endpoint_name": "Glucocorticoid dose - baseline",
            "endpoint_category": "Secondary",
            "timepoint": "Start of JAK inhibitor therapy",
            "measurement_type": "Absolute value",
            "value": 28.4,
            "unit": "mg/day PDN equivalent",
            "responders_n": 4,
            "responders_pct": 33.3,
            "baseline_value": 28.4,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "\u00b115.7 mg, 4 patients on systemic GCs"
          },
          {
            "endpoint_name": "Glucocorticoid dose - 3 months",
            "endpoint_category": "Secondary",
            "timepoint": "3 months",
            "measurement_type": "Change from baseline",
            "value": 9.4,
            "unit": "mg/day PDN equivalent",
            "responders_n": 2,
            "responders_pct": 16.7,
            "baseline_value": 28.4,
            "change_from_baseline": -19.0,
            "change_pct": -66.9,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "\u00b18 mg, 2 patients still on systemic GCs"
          },
          {
            "endpoint_name": "Number needed to treat for ocular flares",
            "endpoint_category": "Secondary",
            "timepoint": "Overall treatment period",
            "measurement_type": "Absolute value",
            "value": 10.4,
            "unit": "patients",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Number needed to treat to prevent one ocular flare"
          },
          {
            "endpoint_name": "Treatment duration - baricitinib",
            "endpoint_category": "Secondary",
            "timepoint": "Overall treatment period",
            "measurement_type": "Absolute value",
            "value": 9.5,
            "unit": "months",
            "responders_n": 4,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "\u00b14.8 months for baricitinib patients"
          },
          {
            "endpoint_name": "New ocular complications during treatment",
            "endpoint_category": "Secondary",
            "timepoint": "During JAK inhibitor treatment",
            "measurement_type": "Absolute value",
            "value": null,
            "unit": null,
            "responders_n": 0,
            "responders_pct": 0.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "No further ocular complications developed"
          },
          {
            "endpoint_name": "Treatment relapses during JAK inhibitor therapy",
            "endpoint_category": "Secondary",
            "timepoint": "During treatment period",
            "measurement_type": "Absolute value",
            "value": null,
            "unit": null,
            "responders_n": 2,
            "responders_pct": 16.7,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "3 eyes (2 patients) experienced single relapse each within first 3 months"
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "Myalgia",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": "Possibly related",
            "outcome": null,
            "action_taken": null,
            "notes": "Episodes of myalgia that the patient attributed to drug intake during JAK inhibitor treatment"
          },
          {
            "event_name": "Treatment discontinuation due to poor compliance",
            "event_category": "Discontinuation",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": 1,
            "relatedness": null,
            "outcome": null,
            "action_taken": "Discontinued",
            "notes": "One patient discontinued baricitinib due to poor compliance after a 12-month relapse-free period"
          }
        ],
        "extraction_timestamp": "2025-12-07T17:36:37.322439",
        "extraction_confidence": 0.6,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [
            "Table 1: Demographic, clinical and therapeutic features describing the twelve patients enrolled - includes sex, age at onset/diagnosis, ocular diagnosis, systemic diagnosis, treatment details, and glucocorticoid dosing"
          ],
          "efficacy_tables": [
            "Table 2: Treatment preceding the start of Janus kinases (JAK) inhibitors - shows prior conventional and biologic treatments used before JAK inhibitor initiation"
          ],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure 1: Flow-chart explaining the selection of patients included in this study from the AIDA Network registries - patient selection diagram, not clinical outcomes"
          ],
          "results_sections": [
            "Treatment details section - describes JAK inhibitor usage, treatment duration, and reasons for initiation",
            "Efficacy outcomes in text - ocular flare incidence rates, IRR calculations, BCVA measurements, UME and retinal vasculitis data",
            "Safety profile in text - reports single adverse event of myalgia",
            "Disease control outcomes - complete ocular disease control achieved in 12/12 patients"
          ],
          "patient_count": 12,
          "study_type": "Retrospective Study",
          "has_quantitative_outcomes": true,
          "notes": "Study reports significant reduction in ocular flare incidence (IRR 4.37, p=0.02). No dedicated safety table despite safety being a stated endpoint. Most efficacy and safety data presented in text rather than tables. One patient discontinued due to poor compliance after 12 months."
        }
      },
      "market_intelligence": {
        "disease": "non-infectious inflammatory ocular diseases",
        "epidemiology": {
          "us_prevalence_estimate": "121 per 100,000",
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": 405350,
          "prevalence_source": "JAMA Ophthalmology",
          "prevalence_source_url": "https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2551695",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Humira (adalimumab)",
              "drug_class": "TNF-alpha inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "non-infectious uveitis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": 60000.0,
              "line_of_therapy": "2L",
              "notes": "FDA approved TNF-alpha inhibitor for uveitis, used as second-line biologic therapy"
            },
            {
              "drug_name": "Xiidra (lifitegrast)",
              "drug_class": "LFA-1/ICAM-1 antagonist",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": "dry eye disease",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": 4000.0,
              "line_of_therapy": null,
              "notes": "FDA approved for dry eye disease, not specifically for non-infectious inflammatory ocular diseases"
            },
            {
              "drug_name": "Miebo (perfluorohexyloctane)",
              "drug_class": "Semi-fluorinated alkane",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": "dry eye disease",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": null,
              "notes": "FDA approved for dry eye disease, not specifically for non-infectious inflammatory ocular diseases"
            }
          ],
          "approved_drug_names": [
            "Humira (adalimumab)"
          ],
          "num_approved_drugs": 1,
          "num_pipeline_therapies": 4,
          "pipeline_therapies": [
            {
              "drug_name": "filgotinib",
              "company": "Gilead Sciences",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT03207815",
              "expected_completion": null
            },
            {
              "drug_name": "baricitinib",
              "company": null,
              "mechanism": "JAK inhibitor",
              "phase": "Phase 3",
              "trial_id": null,
              "expected_completion": null
            },
            {
              "drug_name": "brepocitinib",
              "company": null,
              "mechanism": "JAK inhibitor",
              "phase": "Phase 2/Phase 3",
              "trial_id": null,
              "expected_completion": null
            },
            {
              "drug_name": "NORFLO ORO",
              "company": null,
              "mechanism": null,
              "phase": "Phase 2",
              "trial_id": "NCT03584724",
              "expected_completion": null
            }
          ],
          "pipeline_details": "The pipeline for non-infectious inflammatory ocular diseases is dominated by JAK inhibitors, with filgotinib completing Phase 2 trials and baricitinib advancing to Phase 3. Multiple JAK inhibitors including brepocitinib are in various phases of development for uveitis treatment.",
          "avg_annual_cost_usd": 60000.0,
          "treatment_paradigm": "First-line treatment uses corticosteroids followed by conventional immunosuppressants (methotrexate, mycophenolate mofetil, azathioprine). Second-line therapy employs TNF-alpha inhibitors like adalimumab, with third-line biologics targeting other cytokines.",
          "unmet_need": true,
          "unmet_need_description": "Limited FDA-approved branded innovative treatments specifically for non-infectious inflammatory ocular diseases, with most therapy relying on off-label use of systemically approved biologics and conventional immunosuppressants",
          "competitive_landscape": "The treatment landscape is dominated by generic immunosuppressants and off-label use of systemic biologics. There is significant opportunity for ocular-specific innovative therapies given the limited number of FDA-approved branded treatments for this indication.",
          "soc_source": "L'Oculista Italiano and PMC articles on non-infectious uveitis treatment guidelines"
        },
        "market_size_estimate": "$24.3B",
        "market_size_usd": 24321000000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 486540000.0,
        "tam_estimate": "$487M",
        "tam_rationale": "Of ~405,350 US patients with non-infectious inflammatory ocular diseases, ~85% are diagnosed (344,548), ~75% receive treatment beyond topical therapy (258,411), ~40% fail first-line corticosteroids and require second-line therapy (103,364). With only 1 approved drug and high unmet need, a new second-line drug could capture 35-40% market share (~37,800 patients). At $12,870/yr average treatment cost (mix of chronic immunosuppressants and biologics), TAM = $487M.",
        "tam_sources": [
          "http://acta.bibl.u-szeged.hu/74139/1/syrptbrs_2022.pdf",
          "https://www.malacards.org/card/psoriatic_arthritis"
        ],
        "pipeline_sources": [
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC12330259/",
          "https://cdn.clinicaltrials.gov/large-docs/15/NCT03207815/Prot_000.pdf",
          "https://cdn.clinicaltrials.gov/large-docs/79/NCT02247479/Prot_001.pdf"
        ],
        "attributed_sources": [
          {
            "url": "https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2021.695904/full",
            "title": "Epidemiology and Risk Factors in Non-infectious Uveitis - Frontiers",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2551695",
            "title": "Prevalence of Noninfectious Uveitis in the United States",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.drugs.com/drug-class/ophthalmic-anti-inflammatory-agents.html",
            "title": "List of Ophthalmic anti-inflammatory agents - Drugs.com Biosimilars Basics for Patients | FDA What are biologic drugs and how do they work? Nonclinical Evaluation of the Immunotoxic Potential of ... What Are \"Biologics\" Questions and Answers | FDA List of Ophthalmic anti- inflammatory agents - Drugs . com Search Orphan Drug Designations and Approvals What are biologic drugs and how do they work? Biosimilars vs Biologics: What are they and how do they compare?",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.drugs.com/medical-answers/what-biologic-drug-3565613/",
            "title": "What are biologic drugs and how do they work?",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.oculistaitaliano.it/en/articles/non-infectious-uveitis-classification-and-treatment/",
            "title": "Non-infectious uveitis: classification and treatment - L'Oculista Italiano",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12330259/",
            "title": "Janus kinase inhibitors: another potential for uveitis ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/15/NCT03207815/Prot_000.pdf",
            "title": "(rJ GILEAU - cdn.clinicaltrials.gov",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "http://acta.bibl.u-szeged.hu/74139/1/syrptbrs_2022.pdf",
            "title": "[PDF] IV. Symposium of Young Researchers on Pharmaceutical ...",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.malacards.org/card/psoriatic_arthritis",
            "title": "Psoriatic Arthritis - MalaCards",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 8.4,
        "evidence_quality": 6.0,
        "market_opportunity": 9.0,
        "overall_priority": 7.9,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 10.0,
          "endpoint_quality": 3.5,
          "organ_domain_breadth": 10.0,
          "safety_categories": [
            "discontinuation"
          ],
          "regulatory_flags": []
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 10.0,
        "endpoint_quality_score": 3.5,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 2.0,
          "publication_venue": 10.0,
          "response_durability": 5.0,
          "extraction_completeness": 8.3
        },
        "sample_size_score": 2.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 5.0,
        "extraction_completeness_score": 8.3,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 10.0,
          "unmet_need": 10.0
        },
        "competitors_score": 7.0,
        "market_size_score": 10.0,
        "unmet_need_score": 10.0
      },
      "rank": 6
    },
    {
      "extraction": {
        "source": {
          "pmid": "36286617",
          "doi": "10.1111/dth.15960",
          "url": "https://pubmed.ncbi.nlm.nih.gov/36286617/",
          "title": "Juvenile dermatomyositis-associated calcinosis successfully treated with combined immunosuppressive, bisphosphonate, oral baricitinib and physical therapy.",
          "authors": "Manuel Agud-Dios, Jorge Arroyo-Andres, Carmen Rubio-Mu\u00f1iz, Carlos Zarco-Olivo, Alba Calleja-Algarra, Sara Isabel Palencia Perez, Jaime de Inocencio",
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Juvenile dermatomyositis-associated calcinosis",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "corticosteroids",
            "methotrexate",
            "immunoglobulins",
            "hydroxychloroquine",
            "mycophenolate",
            "IV cyclophosphamide",
            "tacrolimus"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "5-year-old Romanian boy with juvenile dermatomyositis who developed severe calcinosis with exoskeleton formation after treatment interruption"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "2 mg per day",
          "frequency": null,
          "duration": "7 months",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": "5 months to see evident clinical benefit",
          "duration_of_response": "ongoing at 7 months",
          "effect_size_description": "Marked improvement in general condition, autonomy, and muscle strength; normalization of creatinine kinase levels from >600 U/L",
          "primary_endpoint": "Calcinosis improvement and functional recovery",
          "endpoint_result": "Calcium deposits progressively softened, articular balance increased significantly, patient able to ride bicycle again",
          "durability_signal": null,
          "efficacy_summary": "Patient showed marked improvement in general condition, muscle strength, and autonomy after 5 months of baricitinib treatment. Calcium deposits progressively softened and articular balance increased significantly, enabling functional recovery including ability to ride bicycle again."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No adverse events were reported during 7 months of baricitinib treatment. The authors noted that JAK inhibitors appear safe in pediatric population.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "7 months",
        "key_findings": "Baricitinib combined with immunosuppressive therapy successfully treated severe dermatomyositis-associated calcinosis in a pediatric patient who had failed multiple prior treatments.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "Treatment safety",
            "endpoint_category": "Exploratory",
            "timepoint": "Month 7",
            "measurement_type": "Absolute value",
            "value": null,
            "unit": null,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "After 7 months, continues treatment with no adverse events"
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "No adverse events",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": 0,
            "relatedness": null,
            "outcome": null,
            "action_taken": "None",
            "notes": "After 7 months of treatment with immunoglobulins, pamidronate, hydroxychloroquine, methotrexate and baricitinib, no adverse events were reported"
          }
        ],
        "extraction_timestamp": "2025-12-07T17:46:11.759664",
        "extraction_confidence": 0.6,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [],
          "efficacy_tables": [],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure 1: Seven\u2010year old boy with dermatomyositis showing heliotrope erythema, periungual telangiectasia and extensive calcium deposition with exoskeleton formation (A, C) confirmed with X\u2010ray imaging (B). Clinical improvement with calcium softening and improvement of articular balance (D)"
          ],
          "results_sections": [
            "Clinical narrative describing treatment response",
            "Creatinine kinase normalization after 6 months",
            "Progressive softening of calcium deposits",
            "Improvement in muscle strength and autonomy"
          ],
          "patient_count": 1,
          "study_type": "Case Report",
          "has_quantitative_outcomes": true,
          "notes": "Single case report of severe JDM-associated calcinosis. Quantitative outcomes include CK levels (>600 U/L baseline, normalized at 6 months) and treatment timeline (5 months to evident clinical benefit). No formal tables present - outcomes described narratively. Safety reported as 'no adverse events' after 7 months of combination therapy including baricitinib."
        }
      },
      "market_intelligence": {
        "disease": "Juvenile dermatomyositis-associated calcinosis",
        "epidemiology": {
          "us_prevalence_estimate": "20% to 40% of juvenile dermatomyositis patients develop calcinosis",
          "us_incidence_estimate": "varies by study: 2-5% at diagnosis, 13-40% overall",
          "global_prevalence": null,
          "patient_population_size": 268,
          "prevalence_source": "Frontiers in Medicine",
          "prevalence_source_url": "https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1155839/full",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Octagam 10% (immune globulin intravenous)",
              "drug_class": "Intravenous immunoglobulin",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "FDA approved for dermatomyositis in adults but not specifically for juvenile dermatomyositis-associated calcinosis"
            },
            {
              "drug_name": "Rituximab (rituximab)",
              "drug_class": "Anti-CD20 monoclonal antibody",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Used off-label for refractory juvenile dermatomyositis but not FDA approved for calcinosis indication"
            },
            {
              "drug_name": "Diltiazem (diltiazem)",
              "drug_class": "Calcium channel blocker",
              "is_branded_innovative": false,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": null,
              "notes": "Generic drug used off-label with varying success rates for calcinosis"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 1,
          "pipeline_therapies": [
            {
              "drug_name": "Abatacept",
              "company": "George Washington University",
              "mechanism": "T-cell costimulation inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT02594735",
              "expected_completion": null
            }
          ],
          "pipeline_details": "Limited pipeline activity with one Phase 2 trial investigating abatacept for refractory juvenile dermatomyositis. Most clinical evidence comes from case reports of JAK inhibitors like tofacitinib and baricitinib showing efficacy for calcinosis, but these appear to be off-label use rather than formal trials.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "No FDA-approved branded innovative treatments exist specifically for juvenile dermatomyositis-associated calcinosis. Treatment is primarily off-label use of immunosuppressive agents and calcium channel blockers.",
          "unmet_need": true,
          "unmet_need_description": "Complete absence of FDA-approved branded innovative treatments for juvenile dermatomyositis-associated calcinosis, with current therapy relying on off-label use of generic medications with inconsistent responses",
          "competitive_landscape": "The treatment landscape is characterized by significant unmet need with no approved branded therapies. Current approaches use off-label immunomodulatory agents and calcium channel blockers with limited evidence base.",
          "soc_source": "Medscape Juvenile Dermatomyositis Treatment & Management - https://emedicine.medscape.com/article/1417215-treatment"
        },
        "market_size_estimate": "$54M",
        "market_size_usd": 53600000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 6700000.0,
        "tam_estimate": "$6.7M",
        "tam_rationale": "Of 268 US JDM patients, ~30% develop calcinosis over disease course (80 patients), with ~90% diagnosed and receiving treatment (72 patients). Given zero FDA-approved drugs and high unmet need, a new drug positioned as 1L therapy could capture 60-80% market share (~50 patients). At $134K/yr orphan drug pricing reflecting severe rare disease status, TAM = $6.7M. Premium pricing justified by lack of approved alternatives and debilitating nature of calcinosis.",
        "tam_sources": [
          "https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1155839/pdf",
          "https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1155839/full",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC5118224/"
        ],
        "pipeline_sources": [
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC12185052/",
          "https://cdn.clinicaltrials.gov/large-docs/81/NCT05612581/SAP_003.pdf",
          "https://cdn.clinicaltrials.gov/large-docs/35/NCT02594735/Prot_SAP_000.pdf"
        ],
        "attributed_sources": [
          {
            "url": "https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1155839/full",
            "title": "Calcinosis in juvenile dermatomyositis: Updates on pathogenesis ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12312478/",
            "title": "Calcinosis Universalis: An Atypical Presentation of Mi-2 Positive ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://emedicine.medscape.com/article/332783-medication",
            "title": "Dermatomyositis Medication: Disease-Modifying ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/1417215-treatment",
            "title": "Juvenile Dermatomyositis Treatment & Management",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.jrd.or.kr/journal/view.html?doi=10.4078/jrd.2022.29.1.14",
            "title": "Juvenile Dermatomyositis - Journal of Rheumatic Diseases",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12185052/",
            "title": "Current Evidence for Janus Kinase Inhibitors in Adult and ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/81/NCT05612581/SAP_003.pdf",
            "title": "cdn.clinicaltrials.gov",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1155839/pdf",
            "title": "Calcinosis in juvenile dermatomyositis: Updates on ...",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1155839/full",
            "title": "Frontiers | Calcinosis in juvenile dermatomyositis : Updates on...",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 8.5,
        "evidence_quality": 6.1,
        "market_opportunity": 8.3,
        "overall_priority": 7.9,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 10.0,
          "endpoint_quality": 4.0,
          "organ_domain_breadth": 10.0,
          "safety_categories": [],
          "regulatory_flags": []
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 10.0,
        "endpoint_quality_score": 4.0,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 10.0,
          "response_durability": 7.0,
          "extraction_completeness": 7.8
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 7.0,
        "extraction_completeness_score": 7.8,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 5.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 5.0,
        "unmet_need_score": 10.0
      },
      "rank": 7
    },
    {
      "extraction": {
        "source": {
          "pmid": "40411764",
          "doi": "10.1093/rheumatology/keaf286",
          "url": "https://pubmed.ncbi.nlm.nih.gov/40411764/",
          "title": "Baricitinib for Takayasu arteritis refractory to TNF-\u03b1 inhibitors: a multicentre, single-arm trial.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Takayasu arteritis refractory to TNF-\u03b1 inhibitors",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 10,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "TNF-\u03b1 inhibitors",
            "glucocorticoids",
            "conventional immunosuppressants",
            "adalimumab",
            "etanercept",
            "infliximab"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "10 patients (9 female, 1 male) with median age 29 years and median disease duration 56.5 months with TAK refractory to TNF-\u03b1 inhibitors"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "4 mg daily",
          "frequency": null,
          "duration": "up to 48 weeks",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "8/10 (80%)",
          "responders_n": 8,
          "responders_pct": 80.0,
          "time_to_response": "24 weeks",
          "duration_of_response": "no relapses observed in responders during 48-week follow-up",
          "effect_size_description": "Significant reduction in NIH score (3.0 vs 0), ITAS (5.0 vs 0), ITAS-A (6.5 vs 0), ESR (26.5 vs 3.5), CRP (34.4 vs 3.3), and glucocorticoid dose (20.0 vs 6.3 mg/day)",
          "primary_endpoint": "overall response rate (complete response plus partial response) at 24 weeks",
          "endpoint_result": "80% overall response rate at 24 weeks (6 patients achieved complete response, 2 achieved partial response)",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib demonstrated strong efficacy with 80% overall response rate at 24 weeks in TNF-\u03b1 inhibitor-refractory TAK patients. Significant improvements were observed in disease activity scores, inflammatory markers, and glucocorticoid dose reduction with sustained response through 48 weeks."
        },
        "safety": {
          "adverse_events": [
            "upper respiratory tract infection",
            "diarrhea"
          ],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Baricitinib showed a favorable safety profile with only mild adverse events including upper respiratory tract infections in 2 patients and diarrhea in 1 patient. No serious adverse events, cardiovascular events, thromboembolism, or opportunistic infections were reported.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "48 weeks",
        "key_findings": "Baricitinib achieved 80% response rate in TNF-\u03b1 inhibitor-refractory TAK with significant steroid-sparing effect and sustained remission without serious adverse events.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "Overall Response Rate (Complete Response + Partial Response)",
            "endpoint_category": "Primary",
            "timepoint": "Week 24",
            "measurement_type": "Responder",
            "value": 80.0,
            "unit": "%",
            "responders_n": 8,
            "responders_pct": 80.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "8 out of 10 patients achieved remission (6 CR + 2 PR)"
          },
          {
            "endpoint_name": "Complete Response Rate",
            "endpoint_category": "Secondary",
            "timepoint": "Week 24",
            "measurement_type": "Responder",
            "value": 60.0,
            "unit": "%",
            "responders_n": 6,
            "responders_pct": 60.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "6 out of 10 patients achieved complete response"
          },
          {
            "endpoint_name": "Partial Response Rate",
            "endpoint_category": "Secondary",
            "timepoint": "Week 24",
            "measurement_type": "Responder",
            "value": 20.0,
            "unit": "%",
            "responders_n": 2,
            "responders_pct": 20.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "2 out of 10 patients achieved partial response"
          },
          {
            "endpoint_name": "NIH Score",
            "endpoint_category": "Secondary",
            "timepoint": "Week 24",
            "measurement_type": "Change from baseline",
            "value": 0.0,
            "unit": "score",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 3.0,
            "change_from_baseline": -3.0,
            "change_pct": null,
            "p_value": "< 0.001",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Median baseline: 3.0 [3.0, 4.0], Week 24: 0 [0, 2.3]"
          },
          {
            "endpoint_name": "ITAS Score",
            "endpoint_category": "Secondary",
            "timepoint": "Week 24",
            "measurement_type": "Change from baseline",
            "value": 0.0,
            "unit": "score",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 5.0,
            "change_from_baseline": -5.0,
            "change_pct": null,
            "p_value": "0.008",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Median baseline: 5.0 [3.0, 6.0], Week 24: 0 [0, 3.0]"
          },
          {
            "endpoint_name": "ITAS-A Score",
            "endpoint_category": "Secondary",
            "timepoint": "Week 24",
            "measurement_type": "Change from baseline",
            "value": 0.0,
            "unit": "score",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 6.5,
            "change_from_baseline": -6.5,
            "change_pct": null,
            "p_value": "0.006",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Median baseline: 6.5 [5.8, 8.3], Week 24: 0 [0, 4.3]"
          },
          {
            "endpoint_name": "ESR",
            "endpoint_category": "Secondary",
            "timepoint": "Week 24",
            "measurement_type": "Change from baseline",
            "value": 3.5,
            "unit": "mm/hr",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 26.5,
            "change_from_baseline": -23.0,
            "change_pct": null,
            "p_value": "0.019",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Median baseline: 26.5 [19.0, 73.0], Week 24: 3.5 [2.0, 10.0]"
          },
          {
            "endpoint_name": "CRP",
            "endpoint_category": "Secondary",
            "timepoint": "Week 24",
            "measurement_type": "Change from baseline",
            "value": 3.3,
            "unit": "mg/L",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 34.4,
            "change_from_baseline": -31.1,
            "change_pct": null,
            "p_value": "0.002",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Median baseline: 34.4 [27.8, 46.2], Week 24: 3.3 [0.7, 12.1]"
          },
          {
            "endpoint_name": "Glucocorticoid Daily Dose",
            "endpoint_category": "Secondary",
            "timepoint": "Week 24",
            "measurement_type": "Change from baseline",
            "value": 6.3,
            "unit": "mg/day",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 20.0,
            "change_from_baseline": -13.7,
            "change_pct": null,
            "p_value": "< 0.001",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Median baseline: 20.0 [15.0, 26.3], Week 24: 6.3 [4.4, 10.6]"
          },
          {
            "endpoint_name": "Relapse Rate Among Responders",
            "endpoint_category": "Secondary",
            "timepoint": "Week 48",
            "measurement_type": "Responder",
            "value": 0.0,
            "unit": "%",
            "responders_n": 0,
            "responders_pct": 0.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "No relapse among 8 patients who achieved remission by week 24"
          },
          {
            "endpoint_name": "Imaging Improvement Rate",
            "endpoint_category": "Exploratory",
            "timepoint": "Week 24",
            "measurement_type": "Responder",
            "value": 20.0,
            "unit": "%",
            "responders_n": 2,
            "responders_pct": 20.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "2 patients showed improvement (1 subclavian artery, 1 carotid artery)"
          },
          {
            "endpoint_name": "Imaging Stable Disease Rate",
            "endpoint_category": "Exploratory",
            "timepoint": "Week 24",
            "measurement_type": "Responder",
            "value": 60.0,
            "unit": "%",
            "responders_n": 6,
            "responders_pct": 60.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "6 patients showed no progression of vascular lesions"
          },
          {
            "endpoint_name": "Disease Progression Rate",
            "endpoint_category": "Secondary",
            "timepoint": "Week 24",
            "measurement_type": "Responder",
            "value": 20.0,
            "unit": "%",
            "responders_n": 2,
            "responders_pct": 20.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "2 patients showed disease progression (non-responders)"
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "Upper respiratory tract infection",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 2,
            "patients_affected_pct": 20.0,
            "events_total": 2,
            "relatedness": null,
            "outcome": "Resolved",
            "action_taken": "None",
            "notes": "Improved following anti-infective therapy"
          },
          {
            "event_name": "Diarrhoea",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": 10.0,
            "events_total": 1,
            "relatedness": null,
            "outcome": "Resolved",
            "action_taken": "None",
            "notes": "Improved following symptomatic therapy"
          },
          {
            "event_name": "Major cardiovascular events",
            "event_category": "SAE",
            "severity_grade": null,
            "patients_affected_n": 0,
            "patients_affected_pct": 0.0,
            "events_total": 0,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "No events observed"
          },
          {
            "event_name": "Thromboembolism",
            "event_category": "SAE",
            "severity_grade": null,
            "patients_affected_n": 0,
            "patients_affected_pct": 0.0,
            "events_total": 0,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "No events observed"
          },
          {
            "event_name": "Opportunistic infections",
            "event_category": "SAE",
            "severity_grade": null,
            "patients_affected_n": 0,
            "patients_affected_pct": 0.0,
            "events_total": 0,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "No events observed"
          },
          {
            "event_name": "Severe allergic reactions",
            "event_category": "SAE",
            "severity_grade": null,
            "patients_affected_n": 0,
            "patients_affected_pct": 0.0,
            "events_total": 0,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "No events observed"
          },
          {
            "event_name": "Serious infections",
            "event_category": "SAE",
            "severity_grade": null,
            "patients_affected_n": 0,
            "patients_affected_pct": 0.0,
            "events_total": 0,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "No events observed"
          },
          {
            "event_name": "Malignancy",
            "event_category": "SAE",
            "severity_grade": null,
            "patients_affected_n": 0,
            "patients_affected_pct": 0.0,
            "events_total": 0,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "No events observed"
          }
        ],
        "extraction_timestamp": "2025-12-07T17:44:18.206523",
        "extraction_confidence": 0.6,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [
            "Table 1: Information of 10 patients with TAK refractory to TNF-\u03b1 inhibitors - contains patient demographics, disease duration, clinical manifestations, arterial lesions at enrollment, baseline scores (NIH, ITAS, ITAS-A), inflammatory markers, and previous therapies"
          ],
          "efficacy_tables": [
            "Table 1 also contains efficacy data including NIH scores at 24 weeks, ITAS scores at 24 weeks, imaging changes at 24 weeks, treatment evaluation (CR/PR/Non-remission), and concomitant treatments at 24 weeks"
          ],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure 1: Changes in ESR, CRP, daily glucocorticoid dose, NIH scores, ITAS and ITAS-A in 10 patients from baseline to week 24",
            "Figure 2: Changes in ESR, CRP, daily glucocorticoid dose, NIH scores, ITAS and ITAS-A in 10 patients from baseline to week 24 and 48"
          ],
          "results_sections": [
            "Patients' characteristics",
            "Efficacy of baricitinib",
            "Safety of baricitinib"
          ],
          "patient_count": 10,
          "study_type": "Case Series",
          "has_quantitative_outcomes": true,
          "notes": "Single-arm clinical trial with 10 TAK patients refractory to TNF-\u03b1 inhibitors. Primary endpoint was overall response rate (ORR) at 24 weeks, which was 80%. Safety data reported in text only with no separate table - AEs included upper respiratory tract infections (n=2) and diarrhea (n=1), with no serious AEs. Table 1 serves dual purpose containing both baseline characteristics and efficacy outcomes."
        }
      },
      "market_intelligence": {
        "disease": "Takayasu arteritis refractory to TNF-\u03b1 inhibitors",
        "epidemiology": {
          "us_prevalence_estimate": "2.6-8.4 per million population",
          "us_incidence_estimate": "2.6 cases per million per year",
          "global_prevalence": null,
          "patient_population_size": 1845,
          "prevalence_source": "Mayo Clinic Proceedings and PMC studies",
          "prevalence_source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8456169/",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Actemra (tocilizumab)",
              "drug_class": "IL-6 receptor antagonist",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": "80%+",
              "efficacy_pct": null,
              "annual_cost_usd": 39000.0,
              "line_of_therapy": "2L",
              "notes": "Not FDA approved for this specific indication but shows efficacy in refractory cases including TNF-inhibitor failures"
            },
            {
              "drug_name": "Rinvoq (upadacitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": "70-80%",
              "efficacy_pct": null,
              "annual_cost_usd": 79000.0,
              "line_of_therapy": "2L",
              "notes": "FDA approved for giant cell arteritis but not specifically for Takayasu arteritis refractory to TNF inhibitors"
            },
            {
              "drug_name": "Olumiant (baricitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": "70-80%",
              "efficacy_pct": null,
              "annual_cost_usd": 65000.0,
              "line_of_therapy": "2L",
              "notes": "Promising results in prospective cohort studies for refractory Takayasu arteritis but no FDA approval for this indication"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 1,
          "pipeline_therapies": [
            {
              "drug_name": "Tocilizumab",
              "company": "Not specified",
              "mechanism": "IL-6 receptor antagonist",
              "phase": "Phase 3",
              "trial_id": "NCT02101333",
              "expected_completion": null
            }
          ],
          "pipeline_details": "Limited pipeline activity for Takayasu arteritis refractory to TNF-\u03b1 inhibitors, with tocilizumab being evaluated in Phase 3 trials as an alternative biologic therapy.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "No FDA-approved treatments specifically for Takayasu arteritis refractory to TNF-\u03b1 inhibitors. Treatment relies on off-label use of IL-6 inhibitors and JAK inhibitors as second-line therapy.",
          "unmet_need": true,
          "unmet_need_description": "Significant unmet need exists as there are no FDA-approved branded innovative treatments specifically for Takayasu arteritis refractory to TNF-\u03b1 inhibitors, forcing reliance on off-label therapies",
          "competitive_landscape": "The treatment landscape consists entirely of off-label use of biologics and targeted small molecules. IL-6 receptor antagonists like tocilizumab and JAK inhibitors show promise but lack specific FDA approval for this indication.",
          "soc_source": "Medscape Takayasu Arteritis Treatment Guidelines and PMC Novel Therapies Review"
        },
        "market_size_estimate": "$369M",
        "market_size_usd": 369000000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 92250000.0,
        "tam_estimate": "$92.3M",
        "tam_rationale": "Of ~1,845 US patients with Takayasu arteritis, ~80% are diagnosed (1,476), ~90% receive treatment (1,328), ~40% fail first-line TNF-\u03b1 inhibitors and become refractory candidates (531). A new drug targeting TNF-\u03b1 refractory patients could capture 35% market share (~186 patients) given zero approved competitors and high unmet need. At $125K/yr orphan drug pricing for chronic treatment, TAM = $23.3M. However, including global markets (US represents ~25% of developed market), global TAM reaches ~$92.3M.",
        "tam_sources": [
          "https://pubmed.ncbi.nlm.nih.gov/22328491/",
          "https://emedicine.medscape.com/article/332378-treatment",
          "https://pubmed.ncbi.nlm.nih.gov/40411764/"
        ],
        "pipeline_sources": [
          "https://www.clinicaltrials.gov/study/NCT02101333",
          "https://cdn.clinicaltrials.gov/large-docs/75/NCT05168475/Prot_000.pdf",
          "https://cdn.clinicaltrials.gov/large-docs/66/NCT00799266/Prot_000.pdf"
        ],
        "attributed_sources": [
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8456169/",
            "title": "The epidemiology of Takayasu Arteritis, a population-based study",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://journals.sagepub.com/doi/10.1177/1759720X211020917",
            "title": "Tocilizumab in refractory Caucasian Takayasu's arteritis",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://emedicine.medscape.com/article/150755-treatment",
            "title": "Aortitis Treatment & Management",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/332378-overview",
            "title": "Takayasu Arteritis: Practice Essentials, Background, ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8790042/",
            "title": "Novel Therapies in Takayasu Arteritis - PMC - PubMed Central",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT02101333",
            "title": "Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/75/NCT05168475/Prot_000.pdf",
            "title": "Clinical Trial Protocol",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://pubmed.ncbi.nlm.nih.gov/22328491/",
            "title": "Tumor necrosis factor inhibitors in patients with Takayasu arteritis",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://emedicine.medscape.com/article/332378-treatment",
            "title": "Takayasu Arteritis Treatment & Management - Medscape Reference",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 7.4,
        "evidence_quality": 7.7,
        "market_opportunity": 8.7,
        "overall_priority": 7.8,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 7.2,
          "endpoint_quality": 3.2,
          "organ_domain_breadth": 10.0,
          "safety_categories": [
            "hypersensitivity",
            "non_serious_infection",
            "serious_infection",
            "cardiovascular",
            "thromboembolic",
            "malignancy"
          ],
          "regulatory_flags": [
            "hypersensitivity",
            "serious_infection",
            "cardiovascular",
            "thromboembolic",
            "malignancy"
          ]
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 7.2,
        "endpoint_quality_score": 3.2,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 6.0,
          "publication_venue": 10.0,
          "response_durability": 7.0,
          "extraction_completeness": 8.3
        },
        "sample_size_score": 6.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 7.0,
        "extraction_completeness_score": 8.3,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 6.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 6.0,
        "unmet_need_score": 10.0
      },
      "rank": 8
    },
    {
      "extraction": {
        "source": {
          "pmid": "37249471",
          "doi": "10.1093/mrcr/rxad012",
          "url": "https://pubmed.ncbi.nlm.nih.gov/37249471/",
          "title": "A case in which baricitinib was effective for both rheumatoid arthritis and essential thrombocythemia.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "essential thrombocythemia",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "hydroxycarbamide",
            "antiplatelet drug"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "72-year-old male with rheumatoid arthritis and JAK2V617F mutation-positive essential thrombocythemia"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": "substantial reduction in platelet count with improvement in inflammatory markers",
          "primary_endpoint": "platelet count reduction",
          "endpoint_result": "platelet count decreased from 700,000-1,000,000/\u03bcl to 400,000-600,000/\u03bcl",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib effectively reduced platelet count from 700,000-1,000,000/\u03bcl to 400,000-600,000/\u03bcl in a patient with essential thrombocythemia. Additionally, C-reactive protein levels decreased and arthritis symptoms improved, demonstrating dual efficacy for both conditions."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No adverse events were reported in this case report. The patient tolerated baricitinib well with effective control of both thrombocythemia and rheumatoid arthritis.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Moderate",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "Baricitinib demonstrated dual efficacy in treating both rheumatoid arthritis and essential thrombocythemia in a patient with JAK2V617F mutation, suggesting potential off-label use for myeloproliferative neoplasms.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-07T17:26:07.144645",
        "extraction_confidence": 0.5,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "essential thrombocythemia",
        "epidemiology": {
          "us_prevalence_estimate": "24 cases per 100,000",
          "us_incidence_estimate": "2.5 cases per 100,000 annually",
          "global_prevalence": null,
          "patient_population_size": 80400,
          "prevalence_source": "PMC article PMC7780200",
          "prevalence_source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7780200/",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Agrylin (anagrelide)",
              "drug_class": "platelet-reducing agent",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "essential thrombocythemia",
              "efficacy_range": "70-80%",
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "FDA approved for essential thrombocythemia with clinical studies showing effectiveness in reducing platelet counts"
            },
            {
              "drug_name": "Ojjaara (momelotinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": "myelofibrosis including post-essential thrombocythemia",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": null,
              "notes": "FDA approved for secondary myelofibrosis post-ET, not for essential thrombocythemia itself"
            },
            {
              "drug_name": "Vonjo (pacritinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": "myelofibrosis including post-essential thrombocythemia",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": null,
              "notes": "FDA approved for secondary myelofibrosis post-ET, not for essential thrombocythemia itself"
            },
            {
              "drug_name": "Hydroxyurea",
              "drug_class": "antimetabolite",
              "is_branded_innovative": false,
              "fda_approved": true,
              "fda_approved_indication": "essential thrombocythemia",
              "efficacy_range": "80-90%",
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "Generic drug considered first-line therapy but not branded innovative"
            }
          ],
          "approved_drug_names": [
            "Agrylin (anagrelide)"
          ],
          "num_approved_drugs": 1,
          "num_pipeline_therapies": 0,
          "pipeline_therapies": [],
          "pipeline_details": null,
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "First-line therapy typically uses hydroxyurea with second-line options including anagrelide, interferon alfa, and busulfan for cytoreductive therapy in high-risk patients.",
          "unmet_need": true,
          "unmet_need_description": "Limited branded innovative treatment options with only one FDA-approved branded drug specifically for essential thrombocythemia, with most treatments being generic agents",
          "competitive_landscape": "The treatment landscape is dominated by generic agents like hydroxyurea as first-line therapy. Anagrelide (Agrylin) remains the primary branded innovative option, while newer JAK inhibitors are approved only for secondary myelofibrosis progression.",
          "soc_source": "Medscape Essential Thrombocytosis Treatment & Management - https://emedicine.medscape.com/article/206697-treatment"
        },
        "market_size_estimate": "$4.0B",
        "market_size_usd": 4020000000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 432000000.0,
        "tam_estimate": "$432M",
        "tam_rationale": "Of ~80,400 US patients with essential thrombocythemia, ~85% are diagnosed (68K), ~70% receive treatment (48K), with high-risk patients requiring cytoreductive therapy (~60% of treated, 29K patients). A new drug positioned as 1L/2L could capture 15-20% market share (~5,400 patients) given only one approved drug and high unmet need. At $80K/yr for this rare hematologic malignancy, TAM = $432M.",
        "tam_sources": [
          "https://www.futuremarketinsights.com/reports/essential-thrombocythemia-market",
          "https://www.wissenresearch.com/essential-thrombocythemia-market-report/",
          "https://www.jubilantpharmova.com/Uploads/image/2674imguf_Investor_Presentation_Nov_25_vf(1).pdf"
        ],
        "pipeline_sources": [
          "https://www.merck.com/news/merck-announces-phase-3-trial-initiation-for-bomedemstat-an-investigational-candidate-for-the-treatment-of-certain-patients-with-essential-thrombocythemia/",
          "https://www.clinicaltrials.gov/study/NCT04644211",
          "https://www.clinicaltrials.gov/study/NCT06351631"
        ],
        "attributed_sources": [
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7780200/",
            "title": "The Essential Thrombocythemia in 2020: What We Know and Where ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://mpnresearchfoundation.org/new-prevalence-data-for-mpns/",
            "title": "NEW PREVALENCE DATA FOR MPNS - MPN Research Foundation",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://emedicine.medscape.com/article/206697-treatment",
            "title": "Essential Thrombocytosis Treatment & Management",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.fda.gov/news-events/press-announcements/fda-roundup-september-19-2023",
            "title": "FDA Roundup: September 19, 2023",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://pcnconnectmd.com/wp-content/uploads/2022/07/Essential-Thrombocythemia-Guidelines.pdf",
            "title": "[PDF] Essential Thrombocythemia | ConnectMD",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://www.merck.com/news/merck-announces-phase-3-trial-initiation-for-bomedemstat-an-investigational-candidate-for-the-treatment-of-certain-patients-with-essential-thrombocythemia/",
            "title": "Merck Announces Phase 3 Trial Initiation for Bomedemstat, ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT04644211",
            "title": "Ruxolitinib in Thrombocythemia and Polycythemia Vera",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.futuremarketinsights.com/reports/essential-thrombocythemia-market",
            "title": "Essential Thrombocythemia Market Outlook 2025 to 2035",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.wissenresearch.com/essential-thrombocythemia-market-report/",
            "title": "Essential Thrombocythemia Treatment Market Report",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 8.8,
        "evidence_quality": 4.9,
        "market_opportunity": 8.3,
        "overall_priority": 7.7,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 10.0,
          "endpoint_quality": 5.0,
          "organ_domain_breadth": 10.0,
          "safety_categories": [],
          "regulatory_flags": []
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 10.0,
        "endpoint_quality_score": 5.0,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 10.0,
          "response_durability": 4.0,
          "extraction_completeness": 5.5
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 5.5,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 8.0,
          "unmet_need": 10.0
        },
        "competitors_score": 7.0,
        "market_size_score": 8.0,
        "unmet_need_score": 10.0
      },
      "rank": 9
    },
    {
      "extraction": {
        "source": {
          "pmid": "38887110",
          "doi": "10.1111/ajd.14335",
          "url": "https://pubmed.ncbi.nlm.nih.gov/38887110/",
          "title": "JAK inhibitors in refractory dermatomyositis: A case series.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "refractory dermatomyositis",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 14,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [],
          "disease_severity": null,
          "comorbidities": null,
          "description": "patients with refractory dermatomyositis"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": null,
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": null,
          "responders_pct": null,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": "76% reduction in CDASI scores with median decrease of 21 points",
          "primary_endpoint": "CDASI score reduction",
          "endpoint_result": "median decrease of 21 points and 76% reduction in CDASI scores",
          "durability_signal": null,
          "efficacy_summary": "JAK inhibitors showed significant efficacy in refractory dermatomyositis with a 76% reduction in CDASI scores and complete resolution of muscular symptoms in 64% of patients. Treatment was effective across various dermatomyositis subtypes."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "JAK inhibitors were well-tolerated with mild and manageable adverse events reported. No specific adverse events were detailed in the abstract.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "JAK inhibitors including baricitinib demonstrated significant efficacy in refractory dermatomyositis with 76% reduction in disease severity and complete muscular symptom resolution in most patients.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-07T17:27:36.319195",
        "extraction_confidence": 0.5,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "refractory dermatomyositis",
        "epidemiology": {
          "us_prevalence_estimate": "21.4 per 100,000 people",
          "us_incidence_estimate": "15.2 per million person-years",
          "global_prevalence": null,
          "patient_population_size": 71690,
          "prevalence_source": "PMC",
          "prevalence_source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10924937/",
          "trend": "increasing"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Octagam 10% (immune globulin intravenous)",
              "drug_class": "Intravenous immunoglobulin (IVIG)",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "dermatomyositis in adults",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "FDA approved in July 2021 for dermatomyositis in adults based on ProDERM trial showing minimal improvement without deterioration"
            },
            {
              "drug_name": "Hizentra (immune globulin subcutaneous)",
              "drug_class": "Subcutaneous immunoglobulin (SCIG)",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Has orphan designation for dermatomyositis but no FDA approval for this indication"
            },
            {
              "drug_name": "Rituximab (rituximab)",
              "drug_class": "CD20 monoclonal antibody",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Used off-label for refractory cases but no FDA approval for dermatomyositis"
            }
          ],
          "approved_drug_names": [
            "Octagam 10% (immune globulin intravenous)"
          ],
          "num_approved_drugs": 1,
          "num_pipeline_therapies": 5,
          "pipeline_therapies": [
            {
              "drug_name": "Tofacitinib",
              "company": "Not specified",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT03002649",
              "expected_completion": null
            },
            {
              "drug_name": "KZR-616",
              "company": "Not specified",
              "mechanism": "Immunoproteasome inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT04033926",
              "expected_completion": null
            },
            {
              "drug_name": "Dazukibart (PF-06823859)",
              "company": "Pfizer",
              "mechanism": "Anti-IFN-\u03b2 neutralizing antibody",
              "phase": "Phase 2",
              "trial_id": "NCT03181893",
              "expected_completion": null
            },
            {
              "drug_name": "Brepocitinib",
              "company": "Not specified",
              "mechanism": "TYK2 and JAK1 inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT05437263",
              "expected_completion": null
            },
            {
              "drug_name": "Topical Ruxolitinib",
              "company": "Not specified",
              "mechanism": "JAK1/2 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT06857240",
              "expected_completion": null
            }
          ],
          "pipeline_details": "The refractory dermatomyositis pipeline is focused primarily on JAK inhibitors and immune modulators, with multiple Phase 2 and Phase 3 trials ongoing. Key therapies include systemic JAK inhibitors (tofacitinib, brepocitinib), topical treatments (ruxolitinib cream), and novel mechanisms like immunoproteasome inhibition and interferon-\u03b2 neutralization.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "First-line treatment consists of high-dose corticosteroids with or without immunosuppressants like methotrexate or azathioprine. Second-line options for refractory cases include IVIG (Octagam 10%), rituximab, mycophenolate mofetil, and calcineurin inhibitors.",
          "unmet_need": true,
          "unmet_need_description": "Only one FDA-approved treatment specifically for dermatomyositis (Octagam 10%) despite 30-40% of patients failing first-line therapy and requiring multiple off-label agents",
          "competitive_landscape": "Octagam 10% is the only FDA-approved branded innovative treatment for dermatomyositis, representing the first new treatment in 30 years. Most other therapies used are off-label generic immunosuppressants or biologics approved for other autoimmune conditions.",
          "soc_source": "Medscape Dermatomyositis Treatment Guidelines - https://emedicine.medscape.com/article/332783-treatment"
        },
        "market_size_estimate": "$3.6B",
        "market_size_usd": 3584500000.0,
        "growth_rate": "5-10% CAGR (increasing prevalence)",
        "tam_usd": 430200000.0,
        "tam_estimate": "$430M",
        "tam_rationale": "Of ~72K global dermatomyositis patients, ~80% are diagnosed (57K), ~70% receive treatment (40K), ~35% become refractory to first-line corticosteroids/immunosuppressants (14K). A new drug would likely be positioned as 2L+ therapy for refractory cases. With only 1 approved drug and high unmet need, a new entrant could capture 35-40% market share (~5K patients). At $86K/yr pricing (typical for rare autoimmune indications), TAM = $430M.",
        "tam_sources": [
          "https://www.emjreviews.com/wp-content/uploads/2025/05/EMJ-2.4-2017.pdf",
          "https://thedermdigest.com/wp-content/uploads/2022/05/TDD_April-2022.pdf",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC7102062/"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov/study/NCT03002649",
          "https://clinicaltrials.gov/study/NCT06568783",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC11034924/"
        ],
        "attributed_sources": [
          {
            "url": "https://www.delveinsight.com/report-store/dermatomyositis-market",
            "title": "Dermatomyositis Market Summary - DelveInsight",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.healio.com/clinical-guidance/dermatomyositis/epidemiology-of-dm",
            "title": "Dermatomyositis Epidemiology | Clinical Guidance",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.drugs.com/adalimumab.html",
            "title": "Adalimumab: Uses, Dosage, Side Effects, Warnings - Drugs.com Approved Drug Products with Therapeutic Equivalence ... Dermatomyositis: Practice Essentials, Background, Pathophysiology FDA Purplebook Drugs@FDA - Food and Drug Administration",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/332783-medication",
            "title": "Dermatomyositis Medication: Disease-Modifying ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.delveinsight.com/blog/dermatomyositis-treatment-outlook",
            "title": "Navigating the Challenges in Dermatomyositis Treatment",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT03002649",
            "title": "Study of Tofacitinib in Refractory Dermatomyositis",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT06568783",
            "title": "Evaluation of Patients With Refractory Dermatomyositis ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.emjreviews.com/wp-content/uploads/2025/05/EMJ-2.4-2017.pdf",
            "title": "EUROPEAN MEDICAL JOURNAL",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://thedermdigest.com/wp-content/uploads/2022/05/TDD_April-2022.pdf",
            "title": "The JAK Inhibitor Experience in Rheumatology",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 8.1,
        "evidence_quality": 6.2,
        "market_opportunity": 8.3,
        "overall_priority": 7.7,
        "clinical_breakdown": {
          "response_rate": 9.0,
          "safety_profile": 9.0,
          "endpoint_quality": 5.0,
          "organ_domain_breadth": 10.0,
          "safety_categories": [],
          "regulatory_flags": []
        },
        "response_rate_score": 9.0,
        "safety_profile_score": 9.0,
        "endpoint_quality_score": 5.0,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 6.0,
          "publication_venue": 10.0,
          "response_durability": 4.0,
          "extraction_completeness": 4.4
        },
        "sample_size_score": 6.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 4.4,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 8.0,
          "unmet_need": 10.0
        },
        "competitors_score": 7.0,
        "market_size_score": 8.0,
        "unmet_need_score": 10.0
      },
      "rank": 10
    },
    {
      "extraction": {
        "source": {
          "pmid": "39031307",
          "doi": "10.1111/1346-8138.17354",
          "url": "https://pubmed.ncbi.nlm.nih.gov/39031307/",
          "title": "A double-blind pilot study of oral baricitinib in adult patients with lupus erythematosus panniculitis.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Lupus erythematosus panniculitis",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Retrospective Study",
        "patient_population": {
          "n_patients": 5,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "conventional therapies"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "Adults aged \u226518 years with active lupus erythematosus panniculitis with RCLASI-active score \u22654, recalcitrant or intolerant to conventional therapies"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "4 mg",
          "frequency": null,
          "duration": "20-24 weeks",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "2/3 (67%)",
          "responders_n": 2,
          "responders_pct": 67.0,
          "time_to_response": "12 weeks",
          "duration_of_response": "maintained through week 24",
          "effect_size_description": "Significant decrease in RCLASI-A score in responders",
          "primary_endpoint": "Proportion of patients with RCLASI-A score decreased by 20% at week 12",
          "endpoint_result": "2/3 patients (67%) in baricitinib group showed significant RCLASI-A decrease at week 12",
          "durability_signal": null,
          "efficacy_summary": "Two of three patients treated with baricitinib showed significant improvement in RCLASI-A scores at week 12, with response maintained through week 24. Placebo patients showed no improvement at week 12 but demonstrated significant improvement after switching to baricitinib at week 24."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No new safety events were observed during the study period. Treatment with baricitinib was well tolerated in all patients with lupus erythematosus panniculitis.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Moderate",
        "comparator_baseline": null,
        "follow_up_duration": "24 weeks",
        "key_findings": "Baricitinib was effective and well tolerated in patients with lupus erythematosus panniculitis, with 67% response rate and no safety concerns observed.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-07T17:25:56.684090",
        "extraction_confidence": 0.5,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Lupus erythematosus panniculitis",
        "epidemiology": {
          "us_prevalence_estimate": null,
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": null,
          "prevalence_source": null,
          "prevalence_source_url": null,
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Hydroxychloroquine (antimalarial)",
              "drug_class": "antimalarial",
              "is_branded_innovative": false,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "First-line treatment but not FDA approved for lupus panniculitis specifically"
            },
            {
              "drug_name": "Rituximab",
              "drug_class": "anti-CD20 monoclonal antibody",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": 30000.0,
              "line_of_therapy": "3L",
              "notes": "Case reports show efficacy for refractory lupus panniculitis but not FDA approved for this indication"
            },
            {
              "drug_name": "Prednisone (corticosteroid)",
              "drug_class": "corticosteroid",
              "is_branded_innovative": false,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Second-line treatment after antimalarials but not FDA approved for lupus panniculitis specifically"
            },
            {
              "drug_name": "Methotrexate",
              "drug_class": "immunosuppressive",
              "is_branded_innovative": false,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "3L",
              "notes": "Third-line immunosuppressive option but not FDA approved for lupus panniculitis"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 5,
          "pipeline_therapies": [
            {
              "drug_name": "Telitacicept",
              "company": "Not specified",
              "mechanism": "B-cell activating factor inhibitor",
              "phase": "Phase 3",
              "trial_id": null,
              "expected_completion": null
            },
            {
              "drug_name": "SAR443122",
              "company": "Sanofi",
              "mechanism": "Not specified",
              "phase": "Phase 2",
              "trial_id": "NCT04781816",
              "expected_completion": null
            },
            {
              "drug_name": "Anifrolumab",
              "company": "Not specified",
              "mechanism": "Type I interferon receptor antagonist",
              "phase": "Phase 3",
              "trial_id": null,
              "expected_completion": null
            },
            {
              "drug_name": "VIB7734",
              "company": "Not specified",
              "mechanism": "Not specified",
              "phase": "Phase 2",
              "trial_id": null,
              "expected_completion": null
            },
            {
              "drug_name": "GDC-0853",
              "company": "Genentech",
              "mechanism": "BTK inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT02908100",
              "expected_completion": null
            }
          ],
          "pipeline_details": "The lupus erythematosus panniculitis pipeline includes several therapies in Phase 2-3 trials targeting different mechanisms including B-cell inhibition, interferon signaling, and BTK inhibition. Most development appears focused on cutaneous lupus manifestations with some agents showing promising efficacy signals.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "No FDA-approved drugs exist specifically for lupus erythematosus panniculitis. Treatment follows off-label use starting with antimalarials (hydroxychloroquine), followed by systemic corticosteroids, then immunosuppressives like methotrexate or biologics like rituximab for refractory cases.",
          "unmet_need": true,
          "unmet_need_description": "Significant unmet need with no FDA-approved drugs specifically for lupus erythematosus panniculitis. Current treatment relies entirely on off-label use of drugs approved for other indications, with limited evidence and variable outcomes.",
          "competitive_landscape": "No competitive landscape exists as there are no FDA-approved branded innovative drugs for this specific indication. All current treatments are off-label use of generics or biologics approved for other autoimmune conditions.",
          "soc_source": "PMC articles PMC7694699 and PMC9537468"
        },
        "market_size_estimate": null,
        "market_size_usd": null,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 112500000.0,
        "tam_estimate": "$112.5M",
        "tam_rationale": "Lupus erythematosus panniculitis affects an estimated 1,500-2,000 US patients (rare subset of lupus), with ~80% diagnosed (1,600), ~75% receiving treatment (1,200), targeting 2L+ therapy after antimalarial failure (~900 patients). As the first FDA-approved drug, could capture 50% market share (~450 patients) given zero approved competitors and high unmet need. At $250K/yr orphan drug pricing, TAM = $112.5M.",
        "tam_sources": [
          "https://www.science.gov/topicpages/p/panniculitis+nodular+nonsuppurative",
          "http://iranianra.ir/files/site1/files/awt_thumbnails/Nature%20Reviews%20Rheumatology%202019%209.pdf",
          "https://www.odermatol.com/odermatology/20174/issue20174.pdf"
        ],
        "pipeline_sources": [
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC12515005/",
          "https://cdn.clinicaltrials.gov/large-docs/16/NCT04781816/Prot_000.pdf",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC9537468/"
        ],
        "attributed_sources": [
          {
            "url": "https://www.rheumatologyadvisor.com/ddi/systemic-lupus-erythematosus/",
            "title": "Systemic Lupus Erythematosus - Rheumatology Advisor",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://emedicine.medscape.com/article/1065529-overview",
            "title": "Discoid Lupus Erythematosus: Background, Etiology, Epidemiology",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.fda.gov/media/71150/download",
            "title": "Guidance for Industry: Systemic Lupus Erythematosus ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761029Orig1s000MedR.pdf",
            "title": "761029Orig1s000 - accessdata.fda.gov",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7694699/",
            "title": "Refractory Lupus Panniculitis Treated Successfully with Rituximab",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12515005/",
            "title": "The Potential of Telitacicept in Treating Lupus erythematosus ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/16/NCT04781816/Prot_000.pdf",
            "title": "AMENDED CLINICAL TRIAL PROTOCOL 02",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.science.gov/topicpages/p/panniculitis+nodular+nonsuppurative",
            "title": "panniculitis nodular nonsuppurative: Topics by Science.gov",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "http://iranianra.ir/files/site1/files/awt_thumbnails/Nature%20Reviews%20Rheumatology%202019%209.pdf",
            "title": "HIGHLIGHTS",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 7.9,
        "evidence_quality": 6.4,
        "market_opportunity": 8.3,
        "overall_priority": 7.6,
        "clinical_breakdown": {
          "response_rate": 8.0,
          "safety_profile": 10.0,
          "endpoint_quality": 5.0,
          "organ_domain_breadth": 8.0,
          "safety_categories": [],
          "regulatory_flags": []
        },
        "response_rate_score": 8.0,
        "safety_profile_score": 10.0,
        "endpoint_quality_score": 5.0,
        "organ_domain_score": 8.0,
        "evidence_breakdown": {
          "sample_size": 4.0,
          "publication_venue": 10.0,
          "response_durability": 5.0,
          "extraction_completeness": 7.2
        },
        "sample_size_score": 4.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 5.0,
        "extraction_completeness_score": 7.2,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 5.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 5.0,
        "unmet_need_score": 10.0
      },
      "rank": 11
    },
    {
      "extraction": {
        "source": {
          "pmid": "30673078",
          "doi": "10.1001/jamadermatol.2018.5077",
          "url": "https://pubmed.ncbi.nlm.nih.gov/30673078/",
          "title": "Assessment of Clinical Response to Janus Kinase Inhibition in Patients With Familial Chilblain Lupus and TREX1 Mutation.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Familial chilblain lupus with TREX1 mutation",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 3,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [],
          "disease_severity": null,
          "comorbidities": null,
          "description": "2 women and 1 man; mean age 51 years with familial chilblain lupus due to TREX1 mutation"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "4 mg daily",
          "frequency": null,
          "duration": "3 months",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "3/3 (100%)",
          "responders_n": 3,
          "responders_pct": 100.0,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": "Significant improvement in cutaneous lesions with suppression of systemic type I interferon activation",
          "primary_endpoint": "Reduction of cutaneous lupus lesions measured by revised cutaneous lupus area and severity index (rCLASI)",
          "endpoint_result": "Significant improvement of cutaneous lupus lesions in all patients",
          "durability_signal": null,
          "efficacy_summary": "All 3 patients showed significant improvement of cutaneous lupus lesions with suppression of systemic type I interferon activation. One patient achieved complete remission regarding pain, and 2 patients had partial reduction in joint inflammation-associated pain."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No severe adverse reactions were reported during the 3-month treatment period. Treatment was well tolerated in all patients.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "3 months",
        "key_findings": "JAK inhibition with baricitinib demonstrated therapeutic efficacy in monogenic familial chilblain lupus, providing mechanistic insight into cold-induced disease exacerbation in TREX1-deficient cells.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "Cutaneous lupus lesions (revised cutaneous lupus area and severity index)",
            "endpoint_category": "Primary",
            "timepoint": "3 months",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "rCLASI score",
            "responders_n": 3,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "All 3 patients showed significant improvement of cutaneous lupus lesions"
          },
          {
            "endpoint_name": "Pain due to skin and joint involvement (visual analog scale)",
            "endpoint_category": "Primary",
            "timepoint": "3 months",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "VAS score",
            "responders_n": 3,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "One patient had complete remission regarding pain, in 2 patients pain associated with joint inflammation was partially reduced"
          },
          {
            "endpoint_name": "Complete pain remission",
            "endpoint_category": "Secondary",
            "timepoint": "3 months",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 33.3,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "One patient achieved complete remission regarding pain"
          },
          {
            "endpoint_name": "Partial pain reduction (joint inflammation)",
            "endpoint_category": "Secondary",
            "timepoint": "3 months",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 2,
            "responders_pct": 66.7,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Two patients had partial reduction in pain associated with joint inflammation"
          },
          {
            "endpoint_name": "Type I interferon signature in blood",
            "endpoint_category": "Primary",
            "timepoint": "3 months",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "PCR measurement",
            "responders_n": 3,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Suppression of systemic type I IFN activation in all patients"
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "No severe adverse reactions",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 0,
            "patients_affected_pct": 0.0,
            "events_total": 0,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "Explicitly stated that no severe adverse reactions were reported during 3-month treatment period"
          }
        ],
        "extraction_timestamp": "2025-12-07T17:45:09.097946",
        "extraction_confidence": 0.6,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [],
          "efficacy_tables": [],
          "safety_tables": [],
          "efficacy_figures": [],
          "results_sections": [],
          "patient_count": 3,
          "study_type": "Case Series",
          "has_quantitative_outcomes": true,
          "notes": "Full text content not provided - only abstract available. Based on abstract, study involved 3 patients with TREX1 mutation-related familial chilblain lupus treated with baricitinib 4mg daily for 3 months. Outcomes measured included revised cutaneous lupus area and severity index, pain visual analog scale, and type I IFN signature. All patients showed significant improvement with no severe adverse reactions reported."
        }
      },
      "market_intelligence": {
        "disease": "Familial chilblain lupus with TREX1 mutation",
        "epidemiology": {
          "us_prevalence_estimate": null,
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": 50,
          "prevalence_source": "Pediatric Rheumatology",
          "prevalence_source_url": "https://ped-rheum.biomedcentral.com/articles/10.1186/s12969-020-00423-y",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 1,
          "pipeline_therapies": [
            {
              "drug_name": "Baricitinib",
              "company": "Not specified",
              "mechanism": "Janus Kinase Inhibitor",
              "phase": "Phase 2/3",
              "trial_id": "NCT04517253",
              "expected_completion": null
            }
          ],
          "pipeline_details": "Limited pipeline activity for familial chilblain lupus with TREX1 mutation, with one JAK inhibitor (baricitinib) being studied in a Phase 2/3 trial for related interferonopathy conditions including familial chilblain lupus.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "No FDA-approved treatments exist specifically for familial chilblain lupus with TREX1 mutation; treatment is primarily supportive care and off-label use of immunosuppressants.",
          "unmet_need": true,
          "unmet_need_description": "There are currently no FDA-approved branded innovative treatments specifically for familial chilblain lupus with TREX1 mutation, representing a significant unmet medical need for this rare monogenic interferonopathy.",
          "competitive_landscape": "The treatment landscape consists entirely of off-label use of drugs approved for other lupus conditions such as SLE or lupus nephritis, including belimumab and rituximab. This rare genetic condition lacks targeted therapies, creating an opportunity for drug development in the interferonopathy space.",
          "soc_source": "Journal of Rheumatology and multiple dermatology sources describing familial chilblain lupus"
        },
        "market_size_estimate": "$10M",
        "market_size_usd": 10000000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 7500000.0,
        "tam_estimate": "$7.5M",
        "tam_rationale": "With only ~50 global patients with familial chilblain lupus with TREX1 mutation, approximately 80% are diagnosed (40 patients) and 90% of diagnosed patients receive treatment (36 patients) given severity of symptoms. As no approved therapies exist, a first-in-class drug could capture 60-70% market share (~25 patients). At $300K/yr reflecting orphan drug pricing for ultra-rare genetic conditions, TAM = $7.5M. Limited by extremely small patient population despite high unmet need.",
        "tam_sources": [
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC7694882/",
          "http://iranianra.ir/files/Journal2022/Arthritis%20&%20Rheumatology%202022%205.pdf",
          "https://en.wiktionary.org/wiki/familial"
        ],
        "pipeline_sources": [
          "https://cdn.clinicaltrials.gov/large-docs/53/NCT04517253/Prot_000.pdf",
          "https://www.jrheum.org/content/52/8/840",
          "https://clinicaltrials.gov/"
        ],
        "attributed_sources": [
          {
            "url": "https://ped-rheum.biomedcentral.com/articles/10.1186/s12969-020-00423-y",
            "title": "Familial chilblain lupus due to a novel mutation in TREX1 ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7158086/",
            "title": "Familial chilblain lupus due to a novel mutation in TREX1 ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.drugs.com/condition/systemic-lupus-erythematosus.html",
            "title": "List of 28 Lupus Medications Compared - Drugs.com Systemic Lupus Erythematosus (SLE) Treatment & Management Trexall Uses, Side Effects & Warnings - Drugs.com Systemic Lupus Erythematosus - Medscape CNS Lupus Treatment & Management - Medscape List of Lupus Erythematosus Medications - Drugs.com List of 28 Lupus Medications Compared - Drugs . com CNS Lupus Treatment & Management: Approach Considerations List of 28 Lupus Medications Compared - Drugs . com Systemic Lupus Erythematosus (SLE) Treatment & Management Systemic Lupus Erythematosus (SLE) Medication - Medscape",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/332244-treatment",
            "title": "Systemic Lupus Erythematosus (SLE) Treatment & Management",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.jrheum.org/content/52/8/840",
            "title": "TREX1-Associated Familial Chilblain Lupus With Cerebral ...",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/53/NCT04517253/Prot_000.pdf",
            "title": "Protocol I4V-JE-JAJE (d) A Phase 2/3, Multicenter, Open- ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.jrheum.org/content/52/8/840",
            "title": "TREX1-Associated Familial Chilblain Lupus With Cerebral ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7694882/",
            "title": "The role of cutaneous type I interferons in autoimmune and ...",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "http://iranianra.ir/files/Journal2022/Arthritis%20&%20Rheumatology%202022%205.pdf",
            "title": "[PDF] Arthritis & Rheumatology",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 8.3,
        "evidence_quality": 5.9,
        "market_opportunity": 8.0,
        "overall_priority": 7.6,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 10.0,
          "endpoint_quality": 3.1,
          "organ_domain_breadth": 10.0,
          "safety_categories": [],
          "regulatory_flags": []
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 10.0,
        "endpoint_quality_score": 3.1,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 2.0,
          "publication_venue": 10.0,
          "response_durability": 5.0,
          "extraction_completeness": 7.8
        },
        "sample_size_score": 2.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 5.0,
        "extraction_completeness_score": 7.8,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 4.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 4.0,
        "unmet_need_score": 10.0
      },
      "rank": 12
    },
    {
      "extraction": {
        "source": {
          "pmid": "35190385",
          "doi": "10.1136/annrheumdis-2021-221961",
          "url": "https://pubmed.ncbi.nlm.nih.gov/35190385/",
          "title": "Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Giant Cell Arteritis",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 15,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "glucocorticoids"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "15 patients with relapsing GCA (11 female, 73%), mean age 72.4 years, median GCA duration 9 months, median 1 prior relapse"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "4 mg/day",
          "frequency": null,
          "duration": "52 weeks",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "13/14 (93%)",
          "responders_n": 13,
          "responders_pct": 93.0,
          "time_to_response": null,
          "duration_of_response": "52 weeks",
          "effect_size_description": "93% achieved steroid-free remission with only 7% relapse rate",
          "primary_endpoint": "glucocorticoid discontinuation and disease remission",
          "endpoint_result": "13/14 patients achieved steroid discontinuation and remained in remission",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib allowed glucocorticoid discontinuation in 13 of 14 patients who completed the study. Only 1 of 14 patients relapsed during the 52-week treatment period, with the remaining patients maintaining disease remission."
        },
        "safety": {
          "adverse_events": [
            "infection not requiring antibiotics",
            "infection requiring antibiotics",
            "nausea",
            "leg swelling",
            "fatigue",
            "diarrhea"
          ],
          "serious_adverse_events": [
            "one serious adverse event recorded"
          ],
          "sae_count": 1,
          "sae_percentage": 7.0,
          "discontinuations_n": 1,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [
            "adverse event"
          ],
          "safety_summary": "14 of 15 patients had at least one adverse event, most commonly infections and gastrointestinal symptoms. One patient discontinued due to adverse events and one serious adverse event was recorded.",
          "safety_profile": "Acceptable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "52 weeks",
        "key_findings": "Baricitinib demonstrated strong efficacy in relapsing GCA with 93% achieving steroid-free remission and only 7% relapsing during 52 weeks of treatment.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-07T17:49:12.085543",
        "extraction_confidence": 0.5,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Giant Cell Arteritis",
        "epidemiology": {
          "us_prevalence_estimate": "228,000 adults in the US",
          "us_incidence_estimate": "6.42-10.00 per 100,000 people over 50 years",
          "global_prevalence": null,
          "patient_population_size": 228000,
          "prevalence_source": "Genentech",
          "prevalence_source_url": "https://www.gene.com/stories/understanding-giant-cell-arteritis",
          "trend": "decreasing"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Actemra (tocilizumab)",
              "drug_class": "IL-6 receptor inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Giant Cell Arteritis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L/2L",
              "notes": "First biologic FDA approved for GCA in May 2017 based on phase 3 GiACTA trial, used with corticosteroid tapering"
            },
            {
              "drug_name": "Rinvoq (upadacitinib)",
              "drug_class": "JAK1 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Giant Cell Arteritis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "FDA approved in May 2025 for adults with GCA based on phase 3 SELECT-GCA study with corticosteroid tapering regimen"
            },
            {
              "drug_name": "Tyenne (tocilizumab)",
              "drug_class": "IL-6 receptor inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Giant Cell Arteritis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L/2L",
              "notes": "FDA approved March 7, 2024 for Giant Cell Arteritis, alternative tocilizumab formulation"
            },
            {
              "drug_name": "Avtozma (tocilizumab)",
              "drug_class": "IL-6 receptor inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Giant Cell Arteritis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L/2L",
              "notes": "FDA approved January 30, 2025 for Giant Cell Arteritis, biosimilar tocilizumab formulation"
            }
          ],
          "approved_drug_names": [
            "Actemra (tocilizumab)",
            "Rinvoq (upadacitinib)",
            "Tyenne (tocilizumab)",
            "Avtozma (tocilizumab)"
          ],
          "num_approved_drugs": 4,
          "num_pipeline_therapies": 3,
          "pipeline_therapies": [
            {
              "drug_name": "Upadacitinib",
              "company": "AbbVie",
              "mechanism": "Selective JAK inhibitor blocking IL-6 and interferon-\u03b3 signaling",
              "phase": "Phase 3",
              "trial_id": "NCT03725202",
              "expected_completion": null
            },
            {
              "drug_name": "Anakinra",
              "company": "Unknown",
              "mechanism": "IL-1 receptor antagonist",
              "phase": "Phase 3",
              "trial_id": null,
              "expected_completion": null
            },
            {
              "drug_name": "Tocilizumab",
              "company": "Unknown",
              "mechanism": "IL-6 receptor antagonist",
              "phase": "Phase 3",
              "trial_id": "NCT06037460",
              "expected_completion": null
            }
          ],
          "pipeline_details": "Giant cell arteritis pipeline includes JAK inhibitors like upadacitinib in Phase 3 trials, along with IL-1 and IL-6 pathway inhibitors. Multiple Phase 3 studies are evaluating targeted immunomodulatory approaches as glucocorticoid-sparing treatments.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "First-line treatment remains high-dose corticosteroids (40-60mg prednisone daily) with ACR now conditionally recommending tocilizumab with glucocorticoids as first-line therapy, while EULAR recommends biologics as second-line for relapsing disease or corticosteroid toxicity.",
          "unmet_need": false,
          "unmet_need_description": "Multiple FDA-approved biologics now available including tocilizumab (first approved 2017) and upadacitinib (2025) providing steroid-sparing options for this previously corticosteroid-dependent condition",
          "competitive_landscape": "Tocilizumab dominates with multiple formulations (Actemra, Tyenne, Avtozma) approved for GCA, establishing IL-6 inhibition as key mechanism. Upadacitinib represents newer JAK inhibitor approach expanding treatment options beyond IL-6 pathway.",
          "soc_source": "Medscape Giant Cell Arteritis Treatment & Management https://emedicine.medscape.com/article/332483-treatment"
        },
        "market_size_estimate": "$5.7B",
        "market_size_usd": 5700000000.0,
        "growth_rate": "0-2% CAGR (decreasing prevalence)",
        "tam_usd": 410000000.0,
        "tam_estimate": "$410M",
        "tam_rationale": "Of ~228,000 US GCA patients, ~80% are diagnosed (182K), ~85% receive treatment (155K). With ACR recommending tocilizumab as first-line, ~40% are candidates for biologics/advanced therapies (62K patients). A new drug positioned as 1L alternative or 2L option could capture 15-20% market share (~11K patients) in this aging-driven growing market. At $75K/yr average pricing for specialty biologics, TAM = $825M globally, with US representing ~50% = $410M.",
        "tam_sources": [
          "https://www.mordorintelligence.com/industry-reports/vasculitis-treatment-market",
          "https://www.dennisgong.com/blog/newmedicines/",
          "https://www.sec.gov/Archives/edgar/data/1114448/000137036822000077/a221025-99_2.htm"
        ],
        "pipeline_sources": [
          "https://pubmed.ncbi.nlm.nih.gov/40174237/",
          "https://clinicaltrials.gov/study/NCT03725202",
          "https://pubmed.ncbi.nlm.nih.gov/38180809"
        ],
        "attributed_sources": [
          {
            "url": "https://acrabstracts.org/abstract/prevalence-and-incidence-of-giant-cell-arteritis-among-medicare-fee-for-service-beneficiaries-united-states-2014-2019/",
            "title": "Prevalence and Incidence of Giant Cell Arteritis Among Medicare ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7948334/",
            "title": "A meta-analysis of the epidemiology of giant cell arteritis across time ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://emedicine.medscape.com/article/332483-medication",
            "title": "Giant Cell Arteritis (Temporal Arteritis) Medication",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.drugs.com/health-guide/giant-cell-arteritis-temporal-arteritis.html",
            "title": "Giant cell arteritis (temporal arteritis) Guide",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.rmmj.org.il/issues/57/1623/manuscript",
            "title": "Giant Cell Arteritis: State of the Art in Diagnosis, Monitoring, and ...",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://pubmed.ncbi.nlm.nih.gov/40174237/",
            "title": "A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT03725202",
            "title": "NCT03725202 | A Study to Evaluate the Safety and ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.mordorintelligence.com/industry-reports/vasculitis-treatment-market",
            "title": "Vasculitis Treatment Market Size, Share & 2030 Growth Trends Report",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.dennisgong.com/blog/newmedicines/",
            "title": "Developing new medicines (Part I) - Dennis Gong",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 7.5,
        "evidence_quality": 8.1,
        "market_opportunity": 7.3,
        "overall_priority": 7.6,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 6.0,
          "endpoint_quality": 5.0,
          "organ_domain_breadth": 10.0,
          "safety_categories": [],
          "regulatory_flags": []
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 6.0,
        "endpoint_quality_score": 5.0,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 6.0,
          "publication_venue": 10.0,
          "response_durability": 9.0,
          "extraction_completeness": 7.8
        },
        "sample_size_score": 6.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 9.0,
        "extraction_completeness_score": 7.8,
        "market_breakdown": {
          "competitors": 5.0,
          "market_size": 9.0,
          "unmet_need": 8.0
        },
        "competitors_score": 5.0,
        "market_size_score": 9.0,
        "unmet_need_score": 8.0
      },
      "rank": 13
    },
    {
      "extraction": {
        "source": {
          "pmid": "35462572",
          "doi": "10.1007/s10787-022-00936-w",
          "url": "https://pubmed.ncbi.nlm.nih.gov/35462572/",
          "title": "A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Rheumatoid arthritis-associated interstitial lung disease",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Retrospective Study",
        "patient_population": {
          "n_patients": 18,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "bDMARDs"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "Adults with RA-ILD receiving baricitinib, 69.3% women, mean age 59.5 years, mean disease duration 7.44 years"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "4 mg daily",
          "frequency": null,
          "duration": "18 months",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "15/18 (83.9%)",
          "responders_n": 15,
          "responders_pct": 83.9,
          "time_to_response": null,
          "duration_of_response": "18 months",
          "effect_size_description": "19.4% showed improvement, 64.5% remained stable, 16.1% worsened",
          "primary_endpoint": "Change in HRCT fibrosis percentage using computer-aided method",
          "endpoint_result": "83.9% of patients showed stability or improvement in RA-ILD",
          "durability_signal": null,
          "efficacy_summary": "Treatment with baricitinib was associated with stability or improvement of RA-ILD in 83.9% of patients over 18 months. Only disease duration was significantly associated with RA-ILD progression in JAK inhibitor-treated patients."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Safety data were not available in this retrospective study. The authors noted they were unable to study safety data due to lack of available information.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Moderate",
        "comparator_baseline": null,
        "follow_up_duration": "18 months",
        "key_findings": "Baricitinib showed efficacy in preventing RA-ILD progression, with similar outcomes to abatacept treatment in this retrospective comparison.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "HRCT fibrosis worsening (\u226515% progression)",
            "endpoint_category": "Primary",
            "timepoint": "18 months",
            "measurement_type": "Responder",
            "value": 16.1,
            "unit": "percent",
            "responders_n": 5,
            "responders_pct": 16.1,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "JAKis group - patients with \u226515% progression of pulmonary fibrosis"
          },
          {
            "endpoint_name": "HRCT fibrosis stability (<15% change)",
            "endpoint_category": "Primary",
            "timepoint": "18 months",
            "measurement_type": "Responder",
            "value": 64.5,
            "unit": "percent",
            "responders_n": 20,
            "responders_pct": 64.5,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "JAKis group - patients with progression or reduction of fibrosis <15%"
          },
          {
            "endpoint_name": "HRCT fibrosis improvement (\u226515% reduction)",
            "endpoint_category": "Primary",
            "timepoint": "18 months",
            "measurement_type": "Responder",
            "value": 19.4,
            "unit": "percent",
            "responders_n": 6,
            "responders_pct": 19.4,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "JAKis group - patients with \u226515% reduction of pulmonary fibrosis"
          },
          {
            "endpoint_name": "HRCT fibrosis stability or improvement combined",
            "endpoint_category": "Primary",
            "timepoint": "18 months",
            "measurement_type": "Responder",
            "value": 83.9,
            "unit": "percent",
            "responders_n": 26,
            "responders_pct": 83.9,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "JAKis group - patients with stability or improvement of RA-ILD"
          },
          {
            "endpoint_name": "HRCT-CaM fibrosis percentage",
            "endpoint_category": "Primary",
            "timepoint": "18 months",
            "measurement_type": "Change from baseline",
            "value": 17.52,
            "unit": "percent",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 18.54,
            "change_from_baseline": -1.02,
            "change_pct": null,
            "p_value": "0.53",
            "confidence_interval": null,
            "statistical_significance": false,
            "notes": "JAKis group - computer-aided method assessment of lung fibrosis"
          },
          {
            "endpoint_name": "Clinical Disease Activity Index (CDAI)",
            "endpoint_category": "Secondary",
            "timepoint": "18 months",
            "measurement_type": "Change from baseline",
            "value": 8.77,
            "unit": "score",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 38.56,
            "change_from_baseline": -29.79,
            "change_pct": null,
            "p_value": "<0.001",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "JAKis group - disease activity measurement"
          },
          {
            "endpoint_name": "Health Assessment Questionnaire Disability Index (HAQ-DI)",
            "endpoint_category": "Secondary",
            "timepoint": "18 months",
            "measurement_type": "Change from baseline",
            "value": 0.71,
            "unit": "score",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 1.54,
            "change_from_baseline": -0.83,
            "change_pct": null,
            "p_value": "<0.001",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "JAKis group - functional disability measure"
          },
          {
            "endpoint_name": "Borg Dyspnea Index",
            "endpoint_category": "Secondary",
            "timepoint": "18 months",
            "measurement_type": "Change from baseline",
            "value": 1.87,
            "unit": "score",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 2.51,
            "change_from_baseline": -0.64,
            "change_pct": null,
            "p_value": "0.03",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "JAKis group - dyspnea assessment"
          },
          {
            "endpoint_name": "DLco (% predicted)",
            "endpoint_category": "Secondary",
            "timepoint": "18 months",
            "measurement_type": "Change from baseline",
            "value": 62.75,
            "unit": "percent predicted",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 59.72,
            "change_from_baseline": 3.03,
            "change_pct": null,
            "p_value": "0.28",
            "confidence_interval": null,
            "statistical_significance": false,
            "notes": "JAKis group - diffusion lung capacity of carbon monoxide"
          },
          {
            "endpoint_name": "FVC (% predicted)",
            "endpoint_category": "Secondary",
            "timepoint": "18 months",
            "measurement_type": "Change from baseline",
            "value": 79.59,
            "unit": "percent predicted",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 81.18,
            "change_from_baseline": -1.59,
            "change_pct": null,
            "p_value": "0.55",
            "confidence_interval": null,
            "statistical_significance": false,
            "notes": "JAKis group - forced vital capacity"
          },
          {
            "endpoint_name": "HRCT fibrosis worsening (\u226515% progression)",
            "endpoint_category": "Primary",
            "timepoint": "18 months",
            "measurement_type": "Responder",
            "value": 11.3,
            "unit": "percent",
            "responders_n": 5,
            "responders_pct": 11.3,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "ABA group - patients with \u226515% progression of pulmonary fibrosis"
          },
          {
            "endpoint_name": "HRCT fibrosis stability (<15% change)",
            "endpoint_category": "Primary",
            "timepoint": "18 months",
            "measurement_type": "Responder",
            "value": 72.7,
            "unit": "percent",
            "responders_n": 32,
            "responders_pct": 72.7,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "ABA group - patients with progression or reduction of fibrosis <15%"
          },
          {
            "endpoint_name": "HRCT fibrosis improvement (\u226515% reduction)",
            "endpoint_category": "Primary",
            "timepoint": "18 months",
            "measurement_type": "Responder",
            "value": 16.0,
            "unit": "percent",
            "responders_n": 7,
            "responders_pct": 16.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "ABA group - patients with \u226515% reduction of pulmonary fibrosis"
          },
          {
            "endpoint_name": "HRCT fibrosis stability or improvement combined",
            "endpoint_category": "Primary",
            "timepoint": "18 months",
            "measurement_type": "Responder",
            "value": 88.6,
            "unit": "percent",
            "responders_n": 39,
            "responders_pct": 88.6,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "ABA group - patients with stability or improvement of RA-ILD"
          },
          {
            "endpoint_name": "HRCT-CaM fibrosis percentage",
            "endpoint_category": "Primary",
            "timepoint": "18 months",
            "measurement_type": "Change from baseline",
            "value": 18.94,
            "unit": "percent",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 19.41,
            "change_from_baseline": -0.47,
            "change_pct": null,
            "p_value": "0.71",
            "confidence_interval": null,
            "statistical_significance": false,
            "notes": "ABA group - computer-aided method assessment of lung fibrosis"
          },
          {
            "endpoint_name": "Clinical Disease Activity Index (CDAI)",
            "endpoint_category": "Secondary",
            "timepoint": "18 months",
            "measurement_type": "Change from baseline",
            "value": 10.11,
            "unit": "score",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 34.66,
            "change_from_baseline": -24.55,
            "change_pct": null,
            "p_value": "<0.001",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "ABA group - disease activity measurement"
          },
          {
            "endpoint_name": "Health Assessment Questionnaire Disability Index (HAQ-DI)",
            "endpoint_category": "Secondary",
            "timepoint": "18 months",
            "measurement_type": "Change from baseline",
            "value": 0.75,
            "unit": "score",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 1.45,
            "change_from_baseline": -0.7,
            "change_pct": null,
            "p_value": "<0.001",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "ABA group - functional disability measure"
          },
          {
            "endpoint_name": "Borg Dyspnea Index",
            "endpoint_category": "Secondary",
            "timepoint": "18 months",
            "measurement_type": "Change from baseline",
            "value": 1.9,
            "unit": "score",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 2.54,
            "change_from_baseline": -0.64,
            "change_pct": null,
            "p_value": "0.01",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "ABA group - dyspnea assessment"
          },
          {
            "endpoint_name": "DLco (% predicted)",
            "endpoint_category": "Secondary",
            "timepoint": "18 months",
            "measurement_type": "Change from baseline",
            "value": 61.26,
            "unit": "percent predicted",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 58.69,
            "change_from_baseline": 2.57,
            "change_pct": null,
            "p_value": "0.22",
            "confidence_interval": null,
            "statistical_significance": false,
            "notes": "ABA group - diffusion lung capacity of carbon monoxide"
          },
          {
            "endpoint_name": "FVC (% predicted)",
            "endpoint_category": "Secondary",
            "timepoint": "18 months",
            "measurement_type": "Change from baseline",
            "value": 81.24,
            "unit": "percent predicted",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 82.29,
            "change_from_baseline": -1.05,
            "change_pct": null,
            "p_value": "0.59",
            "confidence_interval": null,
            "statistical_significance": false,
            "notes": "ABA group - forced vital capacity"
          }
        ],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-07T17:50:54.849937",
        "extraction_confidence": 0.6,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [
            "Table 1: Clinical and lung functional data at abatacept and JAKis beginning (Time 0) and after 18 months of treatment, including age, disease duration, CDAI, HAQ-DI, Borg Dyspnea Index, DLco, FVC, and HRCT-CaM fibrosis percentages"
          ],
          "efficacy_tables": [
            "Table 1: Clinical and lung functional data showing changes from baseline to 18 months for both treatment groups",
            "Table 2: Multivariate regression analysis of variables predictive of pulmonary fibrosis evaluated at HRCT by computer-aided method in JAK inhibitor-treated patients"
          ],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure 1: Trend in disease activity (Clinical Disease Activity Index) after 18 months of treatment with Janus-kinase inhibitors or abatacept",
            "Figure 2: Trend in lung fibrosis rate (estimated by OsiriX, computer-aided method) after 18 months of treatment with Janus-kinase inhibitors or abatacept"
          ],
          "results_sections": [
            "Patient demographics and baseline characteristics",
            "Treatment outcomes at 18 months showing RA-ILD progression, stability, and improvement rates",
            "Multivariate regression analysis identifying predictors of RA-ILD progression",
            "Comparison of JAKi vs abatacept efficacy"
          ],
          "patient_count": 75,
          "study_type": "Retrospective Study",
          "has_quantitative_outcomes": true,
          "notes": "Study compares JAK inhibitors (n=31, including 18 baricitinib and 13 tofacitinib patients) vs abatacept (n=44) in RA-ILD patients. Primary outcome was HRCT fibrosis progression assessed by computer-aided method. No safety data tables available due to insufficient data. Study shows 83.9% of JAKi patients and 88.6% of abatacept patients had stable or improved RA-ILD."
        }
      },
      "market_intelligence": {
        "disease": "Rheumatoid arthritis-associated interstitial lung disease",
        "epidemiology": {
          "us_prevalence_estimate": "3.2 to 6.0 cases per 100,000 people",
          "us_incidence_estimate": "2.7 to 3.8 cases per 100,000 people annually",
          "global_prevalence": null,
          "patient_population_size": 15542,
          "prevalence_source": "Journal of Rheumatology",
          "prevalence_source_url": "https://www.jrheum.org/content/early/2018/12/07/jrheum.171315",
          "trend": "increasing"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Rituximab (rituximab)",
              "drug_class": "CD20 monoclonal antibody",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": 25000.0,
              "line_of_therapy": "1L",
              "notes": "Conditionally recommended as first-line treatment for SARD-ILD but no specific FDA approval for RA-ILD indication"
            },
            {
              "drug_name": "Tocilizumab (tocilizumab)",
              "drug_class": "IL-6 receptor antagonist",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": 40000.0,
              "line_of_therapy": "2L",
              "notes": "Mentioned in guidelines as therapy to consider for RA-ILD progression but no specific FDA approval for RA-ILD indication"
            },
            {
              "drug_name": "Abatacept (abatacept)",
              "drug_class": "CTLA-4 fusion protein",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": 35000.0,
              "line_of_therapy": "1L",
              "notes": "Strong evidence for role in RA-ILD treatment but conditional recommendation against as first-line and no specific FDA approval for RA-ILD indication"
            },
            {
              "drug_name": "Nintedanib (nintedanib)",
              "drug_class": "Tyrosine kinase inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": 180000.0,
              "line_of_therapy": "2L",
              "notes": "Conditionally recommended for SARD-ILD progression despite first treatment but no specific FDA approval for RA-ILD indication"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 2,
          "pipeline_therapies": [
            {
              "drug_name": "pirfenidone",
              "company": "Not specified",
              "mechanism": "Anti-fibrotic agent",
              "phase": "Phase 2",
              "trial_id": "NCT02808871",
              "expected_completion": null
            },
            {
              "drug_name": "BI compound",
              "company": "Boehringer Ingelheim",
              "mechanism": "Not specified",
              "phase": "Not specified",
              "trial_id": "NCT04093024",
              "expected_completion": null
            }
          ],
          "pipeline_details": "The RA-ILD pipeline includes pirfenidone in Phase 2 testing (TRAIL1 study) and a Boehringer Ingelheim compound in development. Pirfenidone showed promising safety and tolerability results in the completed Phase 2 trial for RA-ILD patients.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "No FDA-approved branded innovative therapies exist specifically for RA-ILD. Current treatment relies on off-label use of immunosuppressants with mycophenolate, rituximab, and cyclophosphamide as conditionally recommended first-line options.",
          "unmet_need": true,
          "unmet_need_description": "Significant unmet need exists as no branded innovative drugs have FDA approval specifically for rheumatoid arthritis-associated interstitial lung disease, requiring reliance on off-label use of drugs approved for other indications",
          "competitive_landscape": "The RA-ILD treatment landscape lacks FDA-approved branded innovative therapies, creating opportunities for drug development. Current management relies on conventional immunosuppressants and off-label use of biologics approved for other rheumatic conditions.",
          "soc_source": "ACR and CHEST Guidelines via The Rheumatologist https://www.the-rheumatologist.org/article/the-acr-and-chest-release-2-new-ild-guidelines/"
        },
        "market_size_estimate": "$1.6B",
        "market_size_usd": 1554200000.0,
        "growth_rate": "5-10% CAGR (increasing prevalence)",
        "tam_usd": 186000000.0,
        "tam_estimate": "$186M",
        "tam_rationale": "Of ~15,542 US RA-ILD patients, ~85% are diagnosed (13,211), ~70% receive systemic treatment (9,248), with no current FDA-approved options positioning a new drug as 1L therapy. A first-to-market innovative therapy could capture 40-50% market share (~4,200 patients) given high unmet need and lack of approved competitors. At $44K/yr pricing (reflecting severe rare disease positioning between specialty and orphan pricing), TAM = $186M. Zero approved branded therapies and reliance on off-label immunosuppressants supports premium positioning for purpose-built RA-ILD therapy.",
        "tam_sources": [
          "https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1542400/full",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC12149157/",
          "https://www.ser.es/wp-content/uploads/2020/04/Clinical-Practice-Guidelines-for-the-Management-of-Patients-with-Rheumatoid-Arthritis.pdf"
        ],
        "pipeline_sources": [
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC12331258/",
          "https://pubmed.ncbi.nlm.nih.gov/36075242/",
          "https://cdn.clinicaltrials.gov/large-docs/71/NCT02808871/SAP_001.pdf"
        ],
        "attributed_sources": [
          {
            "url": "https://www.nature.com/articles/s41598-023-37452-y",
            "title": "Epidemiology and clinical characteristics of interstitial lung disease ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.resmedjournal.com/article/S0954-6111(23)00170-1/abstract",
            "title": "Rheumatoid arthritis associated interstitial lung disease",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.medscape.com/index/list_973_462",
            "title": "Medscape Today News - Index Page 463",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.medscape.com/viewarticle/998453",
            "title": "TNF Inhibitors May Be OK for Treating RA-ILD",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.mdpi.com/2077-0383/12/20/6657",
            "title": "Targeted Therapy in Rheumatoid-Arthritis-Related Interstitial Lung ...",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12331258/",
            "title": "Rheumatoid Arthritis-Associated Interstitial Lung Disease",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://pubmed.ncbi.nlm.nih.gov/36075242/",
            "title": "Safety, tolerability, and efficacy of pirfenidone in patients ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1542400/full",
            "title": "Frontiers | Navigating interstitial lung disease associated with...",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12149157/",
            "title": "Research progress on complications of rheumatoid arthritis - PMC",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 6.6,
        "evidence_quality": 8.0,
        "market_opportunity": 9.3,
        "overall_priority": 7.6,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 5.0,
          "endpoint_quality": 2.4,
          "organ_domain_breadth": 10.0,
          "safety_categories": [],
          "regulatory_flags": []
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": 2.4,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 6.0,
          "publication_venue": 10.0,
          "response_durability": 9.0,
          "extraction_completeness": 7.2
        },
        "sample_size_score": 6.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 9.0,
        "extraction_completeness_score": 7.2,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 8.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 8.0,
        "unmet_need_score": 10.0
      },
      "rank": 14
    },
    {
      "extraction": {
        "source": {
          "pmid": "33984091",
          "doi": "10.14740/jmc3629",
          "url": "https://pubmed.ncbi.nlm.nih.gov/33984091/",
          "title": "A Novel Report on the Compassionate Use of Baricitinib in Treating a Pediatric Patient With Severe Symptoms of COVID-19 Infection.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Severe COVID-19 in pediatric patient",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "hydroxychloroquine",
            "azithromycin",
            "vitamin C",
            "zinc",
            "high-flow nasal cannula",
            "CPAP"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "17-year-old obese female with severe COVID-19 symptoms and acute hypoxic respiratory failure"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "4 mg",
          "frequency": null,
          "duration": "5 days",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": "Day 3 after starting baricitinib (marked improvement noted)",
          "duration_of_response": "Sustained through discharge on day 8",
          "effect_size_description": "Rapid and marked improvement with weaning from CPAP to ambient air and radiographic clearing",
          "primary_endpoint": "Clinical improvement and reduction in oxygen requirements",
          "endpoint_result": "Marked improvement in respiratory status, weaned from CPAP to ambient air by day 6",
          "durability_signal": null,
          "efficacy_summary": "Patient showed rapid clinical improvement starting day 3 of baricitinib treatment, with successful weaning from CPAP to ambient air by day 6. Inflammatory markers decreased significantly and chest X-ray opacities resolved markedly."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No adverse events reported during the 5-day treatment course. Patient tolerated baricitinib well with no safety concerns noted.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "Through discharge on day 8",
        "key_findings": "First reported case of baricitinib use in pediatric severe COVID-19 showing rapid clinical improvement and successful avoidance of intubation. Inflammatory markers decreased significantly with treatment.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "C-reactive protein (CRP)",
            "endpoint_category": "Secondary",
            "timepoint": "Day 6",
            "measurement_type": "Change from baseline",
            "value": 0.638,
            "unit": "mg/mL",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 14.1,
            "change_from_baseline": -13.462,
            "change_pct": -95.5,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Inflammatory marker showing dramatic improvement"
          },
          {
            "endpoint_name": "Erythrocyte sedimentation rate (ESR)",
            "endpoint_category": "Secondary",
            "timepoint": "Day 6",
            "measurement_type": "Change from baseline",
            "value": 55.0,
            "unit": "mm/h",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 67.0,
            "change_from_baseline": -12.0,
            "change_pct": -17.9,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Inflammatory marker improvement, peaked at day 2 (126 mm/h)"
          },
          {
            "endpoint_name": "Ferritin",
            "endpoint_category": "Secondary",
            "timepoint": "Day 5",
            "measurement_type": "Change from baseline",
            "value": 179.7,
            "unit": "ng/mL",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 251.2,
            "change_from_baseline": -71.5,
            "change_pct": -28.5,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Inflammatory marker showing steady decline from day 2"
          },
          {
            "endpoint_name": "Oxygen saturation on ambient air",
            "endpoint_category": "Primary",
            "timepoint": "Day 6",
            "measurement_type": "Absolute value",
            "value": 98.0,
            "unit": "%",
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": 98.0,
            "change_from_baseline": 0.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Patient weaned off supplemental oxygen completely by day 6"
          },
          {
            "endpoint_name": "Respiratory rate",
            "endpoint_category": "Primary",
            "timepoint": "Day 3",
            "measurement_type": "Change from baseline",
            "value": 20.0,
            "unit": "breaths/min",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 30.0,
            "change_from_baseline": -10.0,
            "change_pct": -33.3,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Range 18-22, marked clinical improvement noted"
          },
          {
            "endpoint_name": "Time to clinical improvement",
            "endpoint_category": "Primary",
            "timepoint": "Day 3",
            "measurement_type": "Absolute value",
            "value": 3.0,
            "unit": "days",
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Marked improvement after first dose of baricitinib"
          },
          {
            "endpoint_name": "Hospital length of stay",
            "endpoint_category": "Primary",
            "timepoint": "Discharge",
            "measurement_type": "Absolute value",
            "value": 8.0,
            "unit": "days",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Discharged home on day 8 of admission"
          },
          {
            "endpoint_name": "Body temperature normalization",
            "endpoint_category": "Secondary",
            "timepoint": "Day 3",
            "measurement_type": "Change from baseline",
            "value": 37.1,
            "unit": "\u00b0C",
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": 38.4,
            "change_from_baseline": -1.3,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Temperature normalized by day 3"
          },
          {
            "endpoint_name": "Heart rate normalization",
            "endpoint_category": "Secondary",
            "timepoint": "Day 3",
            "measurement_type": "Change from baseline",
            "value": 97.0,
            "unit": "beats/min",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 140.0,
            "change_from_baseline": -43.0,
            "change_pct": -30.7,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Heart rate improvement noted on day 3"
          },
          {
            "endpoint_name": "Chest X-ray improvement",
            "endpoint_category": "Secondary",
            "timepoint": "Day 3",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Marked improvement in opacities by day 3, significant resolution by day 6"
          },
          {
            "endpoint_name": "Oxygen support weaning success",
            "endpoint_category": "Primary",
            "timepoint": "Day 6",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Successfully weaned from CPAP \u2192 HFNC \u2192 Venturi mask \u2192 nasal cannula \u2192 ambient air"
          }
        ],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-07T17:35:09.132895",
        "extraction_confidence": 0.6,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [],
          "efficacy_tables": [
            "Table 1: Markers of Inflammation Measured Daily From Admission to Discharge - showing CRP, ESR, and Ferritin values demonstrating improvement over 6 days"
          ],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure 1: Series of chest X-ray images from the day of admission to the last day of admission - showing radiographic improvement from bilateral patchy infiltrates to clear lungs"
          ],
          "results_sections": [
            "Case Report section describing clinical course and outcomes",
            "Table 1 showing inflammatory marker trends",
            "Clinical improvement described from day 3 onwards with deescalation of oxygen support"
          ],
          "patient_count": 1,
          "study_type": "Case Report",
          "has_quantitative_outcomes": true,
          "notes": "Single pediatric case with detailed tracking of inflammatory markers and radiographic changes. Figure 2 is mechanistic diagram, not clinical outcome data. No formal baseline characteristics table but demographics provided in case description."
        }
      },
      "market_intelligence": {
        "disease": "Severe COVID-19 in pediatric patient",
        "epidemiology": {
          "us_prevalence_estimate": null,
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": 13555,
          "prevalence_source": "COVID-NET surveillance",
          "prevalence_source_url": "https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2836413",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Veklury (remdesivir)",
              "drug_class": "RNA polymerase inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Treatment of COVID-19 in adults and pediatric patients (birth to <18 years weighing \u22651.5 kg) who are hospitalized or not hospitalized with mild-to-moderate COVID-19 at high risk for progression to severe COVID-19",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved for pediatric patients from birth to <18 years weighing at least 1.5 kg, including severe COVID-19 when hospitalized"
            },
            {
              "drug_name": "Dexamethasone",
              "drug_class": "Corticosteroid",
              "is_branded_innovative": false,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "Generic corticosteroid used off-label in severe COVID-19 for patients \u226512 years requiring oxygen"
            }
          ],
          "approved_drug_names": [
            "Veklury (remdesivir)"
          ],
          "num_approved_drugs": 1,
          "num_pipeline_therapies": 4,
          "pipeline_therapies": [
            {
              "drug_name": "COVID-19 vaccine candidate",
              "company": "Not specified",
              "mechanism": "Vaccination/immunization",
              "phase": "Phase 2/3",
              "trial_id": "NCT04672395",
              "expected_completion": null
            },
            {
              "drug_name": "COVID-19 vaccine candidate",
              "company": "Not specified",
              "mechanism": "Vaccination/immunization",
              "phase": "Phase 3",
              "trial_id": "NCT05468736",
              "expected_completion": null
            },
            {
              "drug_name": "Antiviral therapy",
              "company": "Not specified",
              "mechanism": "Antiviral activity",
              "phase": "Phase 3",
              "trial_id": "NCT04292899",
              "expected_completion": null
            },
            {
              "drug_name": "Investigational therapy",
              "company": "Not specified",
              "mechanism": "Not specified",
              "phase": "Phase 1/2/3",
              "trial_id": "NCT04816643",
              "expected_completion": null
            }
          ],
          "pipeline_details": "Several COVID-19 clinical trials include pediatric populations aged 12 and above, primarily focusing on vaccine candidates and antiviral therapies in Phase 2/3 stages. The pipeline shows active development of both preventive and therapeutic approaches for severe COVID-19 in pediatric patients.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "First-line treatment for severe COVID-19 in pediatric patients primarily involves Veklury (remdesivir) for hospitalized patients, often combined with supportive care and corticosteroids for patients \u226512 years requiring oxygen.",
          "unmet_need": true,
          "unmet_need_description": "Limited FDA-approved branded innovative treatments specifically for severe COVID-19 in pediatric patients, with most therapy relying on generic supportive care and off-label use of medications",
          "competitive_landscape": "Veklury (remdesivir) is the primary FDA-approved branded treatment for COVID-19 in pediatric patients including severe cases. The treatment landscape relies heavily on supportive care and generic medications like corticosteroids.",
          "soc_source": "FDA drug labeling and pediatric treatment guidelines from UC Davis Health and CDC"
        },
        "market_size_estimate": "$1.4B",
        "market_size_usd": 1355500000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 50000000.0,
        "tam_estimate": "$50M",
        "tam_rationale": "Of 13,555 severe COVID-19 pediatric patients, ~95% are hospitalized and diagnosed (12,877), ~80% receive antiviral treatment (10,302). With only 1 approved drug (remdesivir), a new entrant could capture 30-40% market share (~3,600 patients) given high unmet need. At acute treatment cost of ~$14K per course (similar to adult remdesivir pricing for severe cases), TAM = $50M. Limited competition and severe indication support premium acute care pricing.",
        "tam_sources": [
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC8403523/",
          "https://www.cdc.gov/covid/hcp/clinical-care/for-pediatric-hcp.html",
          "https://alphatalon.substack.com/p/novo-nordisk-from-insulin-giant-to"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov/study/NCT04672395",
          "https://www.clinicaltrials.gov/study/NCT05468736",
          "https://cdn.clinicaltrials.gov/large-docs/70/NCT04963270/Prot_000.pdf"
        ],
        "attributed_sources": [
          {
            "url": "https://www.cdc.gov/acip/downloads/slides-2025-06-25-26/02-MacNeil-COVID-508.pdf",
            "title": "[PDF] COVID-19\u2013Associated Hospitalizations Update - CDC",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2836413",
            "title": "Pediatric COVID-19 Hospitalization Trends by Race and Ethnicity",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.fda.gov/media/145808/download",
            "title": "Frequently Asked Questions on the Emergency Use ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214787Orig1s011.pdf",
            "title": "214787Orig1s011 - accessdata.fda.gov",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8403523/",
            "title": "COVID-19: potential therapeutics for pediatric patients - PMC",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT04672395",
            "title": "Study Details | NCT04672395 | A Controlled Phase 2/3 ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT05468736",
            "title": "Study to Evaluate Safety and Immunogenicity of COVID-19 ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8403523/",
            "title": "COVID-19: potential therapeutics for pediatric patients - PMC",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.cdc.gov/covid/hcp/clinical-care/for-pediatric-hcp.html",
            "title": "Information for Pediatric Healthcare Providers | COVID-19 - CDC",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 8.2,
        "evidence_quality": 5.4,
        "market_opportunity": 8.3,
        "overall_priority": 7.5,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 10.0,
          "endpoint_quality": 2.6,
          "organ_domain_breadth": 10.0,
          "safety_categories": [],
          "regulatory_flags": []
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 10.0,
        "endpoint_quality_score": 2.6,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 10.0,
          "response_durability": 4.0,
          "extraction_completeness": 7.8
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 7.8,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 8.0,
          "unmet_need": 10.0
        },
        "competitors_score": 7.0,
        "market_size_score": 8.0,
        "unmet_need_score": 10.0
      },
      "rank": 15
    },
    {
      "extraction": {
        "source": {
          "pmid": "40428884",
          "doi": "10.3390/medicina61050926",
          "url": "https://pubmed.ncbi.nlm.nih.gov/40428884/",
          "title": "Clinical Effectiveness, Clinical Stability, and Effects on Serum Galectin-7 Levels of Dupilumab and JAK Inhibitors in Moderate-to-Severe Atopic Dermatitis: A Real-World, Single-Center Analysis.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "moderate-to-severe atopic dermatitis",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Retrospective Study",
        "patient_population": {
          "n_patients": 5,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "topical therapies"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "patients with moderate-to-severe atopic dermatitis (EASI >16, IGA \u22653, BSA >10%)"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "4 mg daily",
          "frequency": null,
          "duration": "52 weeks",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": null,
          "responders_pct": null,
          "time_to_response": "rapid improvement by 4 weeks",
          "duration_of_response": "52 weeks",
          "effect_size_description": "substantial reduction in disease severity with EASI score improvement of approximately 70%",
          "primary_endpoint": "EASI score reduction",
          "endpoint_result": "69.63% reduction at 16 weeks for JAK inhibitor group",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib showed high effectiveness comparable to dupilumab for treating moderate-to-severe atopic dermatitis with rapid onset of action. JAK inhibitors improved patient-reported outcomes more quickly than dupilumab but showed higher instability of effectiveness between 16-52 weeks."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [
            "inadequate response",
            "patient preference"
          ],
          "safety_summary": "No specific safety data reported for baricitinib group. Some patients discontinued between 16-52 weeks due to inadequate response or patient preference.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "52 weeks",
        "key_findings": "Baricitinib demonstrated comparable efficacy to dupilumab in atopic dermatitis with faster onset but potentially less stable long-term effectiveness.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "EASI percentage reduction",
            "endpoint_category": "Primary",
            "timepoint": "Week 4",
            "measurement_type": "Change from baseline",
            "value": 58.36,
            "unit": "percent",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": 58.36,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "All patients, standard deviation \u00b1 22.09"
          },
          {
            "endpoint_name": "EASI percentage reduction",
            "endpoint_category": "Primary",
            "timepoint": "Week 8",
            "measurement_type": "Change from baseline",
            "value": 69.59,
            "unit": "percent",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": 69.59,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "All patients, standard deviation \u00b1 20.96"
          },
          {
            "endpoint_name": "EASI percentage reduction",
            "endpoint_category": "Primary",
            "timepoint": "Week 16",
            "measurement_type": "Change from baseline",
            "value": 75.98,
            "unit": "percent",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": 75.98,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "All patients, standard deviation \u00b1 19.70"
          },
          {
            "endpoint_name": "EASI percentage reduction",
            "endpoint_category": "Primary",
            "timepoint": "Week 4",
            "measurement_type": "Change from baseline",
            "value": 59.69,
            "unit": "percent",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": 59.69,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "JAK inhibitors only, standard deviation \u00b1 32.33"
          },
          {
            "endpoint_name": "EASI percentage reduction",
            "endpoint_category": "Primary",
            "timepoint": "Week 8",
            "measurement_type": "Change from baseline",
            "value": 53.98,
            "unit": "percent",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": 53.98,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "JAK inhibitors only, standard deviation \u00b1 34.69"
          },
          {
            "endpoint_name": "EASI percentage reduction",
            "endpoint_category": "Primary",
            "timepoint": "Week 16",
            "measurement_type": "Change from baseline",
            "value": 69.63,
            "unit": "percent",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": 69.63,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "JAK inhibitors only, standard deviation \u00b1 20.82"
          },
          {
            "endpoint_name": "EASI50 response rate",
            "endpoint_category": "Secondary",
            "timepoint": "Week 4",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percent",
            "responders_n": null,
            "responders_pct": 68.29,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Entire population"
          },
          {
            "endpoint_name": "EASI50 response rate",
            "endpoint_category": "Secondary",
            "timepoint": "Week 8",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percent",
            "responders_n": null,
            "responders_pct": 82.35,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Entire population"
          },
          {
            "endpoint_name": "EASI50 response rate",
            "endpoint_category": "Secondary",
            "timepoint": "Week 16",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percent",
            "responders_n": null,
            "responders_pct": 87.18,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Entire population"
          },
          {
            "endpoint_name": "EASI75 response rate",
            "endpoint_category": "Secondary",
            "timepoint": "Week 4",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percent",
            "responders_n": null,
            "responders_pct": 31.7,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Entire population"
          },
          {
            "endpoint_name": "EASI75 response rate",
            "endpoint_category": "Secondary",
            "timepoint": "Week 8",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percent",
            "responders_n": null,
            "responders_pct": 47.06,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Entire population"
          },
          {
            "endpoint_name": "EASI75 response rate",
            "endpoint_category": "Secondary",
            "timepoint": "Week 16",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percent",
            "responders_n": null,
            "responders_pct": 71.79,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Entire population"
          },
          {
            "endpoint_name": "EASI90 response rate",
            "endpoint_category": "Secondary",
            "timepoint": "Week 4",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percent",
            "responders_n": null,
            "responders_pct": 2.44,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Entire population"
          },
          {
            "endpoint_name": "EASI90 response rate",
            "endpoint_category": "Secondary",
            "timepoint": "Week 8",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percent",
            "responders_n": null,
            "responders_pct": 5.88,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Entire population"
          },
          {
            "endpoint_name": "EASI90 response rate",
            "endpoint_category": "Secondary",
            "timepoint": "Week 16",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percent",
            "responders_n": null,
            "responders_pct": 23.08,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Entire population"
          },
          {
            "endpoint_name": "EASI score",
            "endpoint_category": "Primary",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": 25.6,
            "unit": "points",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 25.6,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Standard deviation \u00b1 7.03"
          },
          {
            "endpoint_name": "DLQI score",
            "endpoint_category": "Secondary",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": 12.28,
            "unit": "points",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 12.28,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Standard deviation \u00b1 7.03"
          },
          {
            "endpoint_name": "POEM score",
            "endpoint_category": "Secondary",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": 17.74,
            "unit": "points",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 17.74,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Standard deviation \u00b1 6.99"
          },
          {
            "endpoint_name": "Serum galectin-7 levels",
            "endpoint_category": "Exploratory",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": 284.9,
            "unit": "pg/mL",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 284.9,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "AD patients, standard deviation \u00b1 197.2"
          },
          {
            "endpoint_name": "Serum galectin-7 levels",
            "endpoint_category": "Exploratory",
            "timepoint": "Week 4",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "pg/mL",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Significantly reduced after treatment"
          },
          {
            "endpoint_name": "Serum galectin-7 levels",
            "endpoint_category": "Exploratory",
            "timepoint": "Week 16",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "pg/mL",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Significantly reduced after treatment"
          },
          {
            "endpoint_name": "DLQI score improvement",
            "endpoint_category": "Secondary",
            "timepoint": "Week 4",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "points",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Significantly and rapidly reduced"
          },
          {
            "endpoint_name": "POEM score improvement",
            "endpoint_category": "Secondary",
            "timepoint": "Week 4",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "points",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Significantly and rapidly reduced"
          },
          {
            "endpoint_name": "Visits with unstable effectiveness",
            "endpoint_category": "Exploratory",
            "timepoint": "Week 28-52",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percent",
            "responders_n": 9,
            "responders_pct": 40.9,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "JAK inhibitors, 9 out of 22 visits"
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "Treatment discontinuation due to inadequate response",
            "event_category": "Discontinuation",
            "severity_grade": null,
            "patients_affected_n": 7,
            "patients_affected_pct": null,
            "events_total": 7,
            "relatedness": null,
            "outcome": null,
            "action_taken": "Discontinued",
            "notes": "Between 16 and 52 weeks, 7 patients stopped or changed systemic therapies due to inadequate response"
          },
          {
            "event_name": "Treatment discontinuation due to patient preference",
            "event_category": "Discontinuation",
            "severity_grade": null,
            "patients_affected_n": 2,
            "patients_affected_pct": null,
            "events_total": 2,
            "relatedness": null,
            "outcome": null,
            "action_taken": "Discontinued",
            "notes": "Between 16 and 52 weeks, 2 patients stopped or changed systemic therapies due to patient preference"
          },
          {
            "event_name": "Treatment discontinuation due to significant response",
            "event_category": "Discontinuation",
            "severity_grade": null,
            "patients_affected_n": 2,
            "patients_affected_pct": null,
            "events_total": 2,
            "relatedness": null,
            "outcome": null,
            "action_taken": "Discontinued",
            "notes": "Between 16 and 52 weeks, 2 patients stopped or changed systemic therapies due to significant response"
          }
        ],
        "extraction_timestamp": "2025-12-07T17:55:54.226208",
        "extraction_confidence": 0.6,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [
            "Table 1: Patient characteristics including age, sex, baseline EASI, DLQI, and POEM scores"
          ],
          "efficacy_tables": [
            "Table 2: Visits with unstable effectiveness comparing dupilumab vs JAK inhibitors at 28, 40, and 52 weeks"
          ],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure 1: EASI score percentage reductions and achievement rates (EASI50/75/90) at 4, 8, and 16 weeks",
            "Figure 2: Serum galectin-7 levels in AD patients vs healthy controls and correlations with disease severity markers",
            "Figure 3: DLQI scores over 52 weeks comparing dupilumab vs JAK inhibitors",
            "Figure 4: POEM scores over 52 weeks comparing dupilumab vs JAK inhibitors"
          ],
          "results_sections": [
            "3.1. Patient Characteristics",
            "3.2. Short-Term Effectiveness of Dupilumab and JAK Inhibitors Based on the EASI Score",
            "3.3. Serum Galectin-7 Levels in AD Patients Treated with Dupilumab or JAK Inhibitors",
            "3.4. One-Year Effectiveness of Dupilumab and JAK Inhibitors Based on Patient-Oriented Outcomes",
            "3.5. One-Year Stability of Dupilumab and JAK Inhibitors Based on the POEM Score"
          ],
          "patient_count": 55,
          "study_type": "Retrospective Study",
          "has_quantitative_outcomes": true,
          "notes": "Study includes 5 baricitinib patients and 5 upadacitinib patients in JAK inhibitor group. Novel biomarker galectin-7 measured. Focus on effectiveness stability over 52 weeks with JAK inhibitors showing more instability than dupilumab."
        }
      },
      "market_intelligence": {
        "disease": "moderate-to-severe atopic dermatitis",
        "epidemiology": {
          "us_prevalence_estimate": "6.6 million adults have moderate-to-severe atopic dermatitis",
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": 6600000,
          "prevalence_source": "Atopic Dermatitis in America Study",
          "prevalence_source_url": "https://www.jidonline.org/article/S0022-202X%2818%2932678-2/fulltext",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Dupixent (dupilumab)",
              "drug_class": "IL-4/IL-13 receptor antagonist",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "moderate-to-severe atopic dermatitis",
              "efficacy_range": "75%",
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved for moderate-to-severe atopic dermatitis in patients 6 months and older. First-line systemic therapy with strong recommendation."
            },
            {
              "drug_name": "Adbry (tralokinumab)",
              "drug_class": "IL-13 antagonist",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "moderate-to-severe atopic dermatitis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved for moderate-to-severe atopic dermatitis in patients aged 12 years and older. First FDA-approved biologic specifically targeting IL-13."
            },
            {
              "drug_name": "Rinvoq (upadacitinib)",
              "drug_class": "JAK1 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "refractory moderate-to-severe atopic dermatitis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "FDA approved for refractory moderate-to-severe atopic dermatitis in patients 12 years and older whose disease is not adequately controlled with other systemic drugs, including biologics."
            },
            {
              "drug_name": "Cibinqo (abrocitinib)",
              "drug_class": "JAK1 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "refractory moderate-to-severe atopic dermatitis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "FDA approved for refractory moderate-to-severe atopic dermatitis in patients 12 years and older who failed other systemic therapies including biologics."
            },
            {
              "drug_name": "Nemluvio (nemolizumab)",
              "drug_class": "IL-31 receptor antagonist",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "moderate-to-severe atopic dermatitis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved for moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years and older in conjunction with topical corticosteroids or calcineurin inhibitors."
            }
          ],
          "approved_drug_names": [
            "Dupixent (dupilumab)",
            "Adbry (tralokinumab)",
            "Rinvoq (upadacitinib)",
            "Cibinqo (abrocitinib)",
            "Nemluvio (nemolizumab)"
          ],
          "num_approved_drugs": 5,
          "num_pipeline_therapies": 4,
          "pipeline_therapies": [
            {
              "drug_name": "LW402",
              "company": "Unknown",
              "mechanism": "Unknown",
              "phase": "Phase 3",
              "trial_id": "NCT07186387",
              "expected_completion": null
            },
            {
              "drug_name": "Lebrikizumab",
              "company": "Dermira",
              "mechanism": "IL-13 inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT04146363",
              "expected_completion": null
            },
            {
              "drug_name": "Upadacitinib",
              "company": "Unknown",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT03569293",
              "expected_completion": null
            },
            {
              "drug_name": "LY3454738",
              "company": "Unknown",
              "mechanism": "Unknown",
              "phase": "Phase 3",
              "trial_id": "NCT07020351",
              "expected_completion": null
            }
          ],
          "pipeline_details": "The moderate-to-severe atopic dermatitis pipeline shows robust Phase 3 activity with multiple advanced therapies including JAK inhibitors and IL-13 targeted biologics. Several trials are evaluating long-term efficacy and safety data for oral and injectable treatment options.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "First-line systemic therapy typically begins with biologics like Dupixent or Adbry for moderate-to-severe atopic dermatitis not controlled by topical therapies. JAK inhibitors like Rinvoq and Cibinqo are reserved as second-line options for refractory disease after biologics have failed or are inadvisable.",
          "unmet_need": false,
          "unmet_need_description": null,
          "competitive_landscape": "The moderate-to-severe atopic dermatitis market is well-served with multiple FDA-approved biologics and JAK inhibitors offering different mechanisms of action. Dupilumab dominates as the first-line choice with the broadest age indication and strong efficacy data, while newer agents provide alternatives for patients who fail initial therapy.",
          "soc_source": "American Academy of Dermatology Guidelines and FDA drug approval documents"
        },
        "market_size_estimate": "$165.0B",
        "market_size_usd": 165000000000.0,
        "growth_rate": "4-7% CAGR (active pipeline)",
        "tam_usd": 3960000000.0,
        "tam_estimate": "$3.96B",
        "tam_rationale": "Of 6.6M US adults with moderate-to-severe atopic dermatitis, ~85% are diagnosed (5.6M), ~60% receive systemic treatment (3.36M). With 5 approved drugs already competing, a new entrant positioned as 1L biologic could capture 15-20% market share (~600K patients). At average biologics pricing of $66K/yr (competitive with Dupixent), TAM = $3.96B. Market growth driven by expanding treatment adoption and physician comfort with biologics.",
        "tam_sources": [
          "https://2025.igem.wiki/sjtu-biox-shanghai/entrepreneurship",
          "https://www.biospace.com/atopic-dermatitis-market-estimated-to-reach-usd-37213-7-million-by-2034-impelled-by-widespread-adoption-of-novel-biologics",
          "https://www.databridgemarketresearch.com/reports/global-atopic-dermatitis-treatment-market?srsltid=AfmBOopvDKDEfEVUw399cNz3UKTFAuRf1M86tWlax-EL8OgSAfskKKZK"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov/study/NCT07186387",
          "https://pubmed.ncbi.nlm.nih.gov/36920778/",
          "https://pubmed.ncbi.nlm.nih.gov/40900410/"
        ],
        "attributed_sources": [
          {
            "url": "https://www.sciencedirect.com/science/article/pii/S0022202X25022365",
            "title": "The Epidemiology of Atopic Dermatitis among Adults and ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.jidonline.org/article/S0022-202X%2818%2932678-2/fulltext",
            "title": "Atopic Dermatitis in America Study: A Cross-Sectional Study ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.drugs.com/history/adbry.html",
            "title": "Adbry (tralokinumab-ldrm) FDA Approval History",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/1049085-treatment",
            "title": "Atopic Dermatitis Treatment & Management",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11627575/",
            "title": "Atopic Dermatitis: A Review of Diagnosis and Treatment - PMC",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT07186387",
            "title": "Study of LW402 in Moderate-to-Severe Atopic Dermatitis",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://pubmed.ncbi.nlm.nih.gov/36920778/",
            "title": "Two Phase 3 Trials of Lebrikizumab for Moderate-to- ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://2025.igem.wiki/sjtu-biox-shanghai/entrepreneurship",
            "title": "Entrepreneurship | SJTU-BioX-Shanghai - iGEM 2025",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.biospace.com/atopic-dermatitis-market-estimated-to-reach-usd-37213-7-million-by-2034-impelled-by-widespread-adoption-of-novel-biologics",
            "title": "Atopic Dermatitis Market Estimated to Reach USD 37213.7 ...",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 7.6,
        "evidence_quality": 7.3,
        "market_opportunity": 7.7,
        "overall_priority": 7.5,
        "clinical_breakdown": {
          "response_rate": 9.0,
          "safety_profile": 5.0,
          "endpoint_quality": 7.4,
          "organ_domain_breadth": 10.0,
          "safety_categories": [
            "discontinuation"
          ],
          "regulatory_flags": []
        },
        "response_rate_score": 9.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": 7.4,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 4.0,
          "publication_venue": 10.0,
          "response_durability": 9.0,
          "extraction_completeness": 6.6
        },
        "sample_size_score": 4.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 9.0,
        "extraction_completeness_score": 6.6,
        "market_breakdown": {
          "competitors": 5.0,
          "market_size": 10.0,
          "unmet_need": 8.0
        },
        "competitors_score": 5.0,
        "market_size_score": 10.0,
        "unmet_need_score": 8.0
      },
      "rank": 16
    },
    {
      "extraction": {
        "source": {
          "pmid": "35096866",
          "doi": "10.3389/fmed.2021.764067",
          "url": "https://www.semanticscholar.org/paper/8eb489dd88a10d89629139d8d8798aae6258d47c",
          "title": "Effectiveness of Baricitinib in Refractory Seronegative Rheumatoid Arthritis and Uveitis: A Case Report",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "Uveitis associated with rheumatoid arthritis",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "betamethasone ophthalmic solution",
            "prednisolone",
            "methotrexate",
            "salazosulfapyridine",
            "adalimumab",
            "infliximab"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "35-year-old man with seronegative rheumatoid arthritis and bilateral severe non-granulomatous panuveitis"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "8 mg/day",
          "frequency": null,
          "duration": "2 years and 7 months",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": "3 months",
          "duration_of_response": "2 years and 7 months with no relapse",
          "effect_size_description": "CRP decreased from 11.03 mg/dL to 0.26 mg/dL; complete resolution of serous retinal detachment; improvement in vitreous opacity and anterior chamber cells",
          "primary_endpoint": "Improvement in uveitis inflammatory activity and systemic arthritis",
          "endpoint_result": "Improvement in vitreous opacity, serous retinal detachment, anterior chamber cells, and arthritis symptoms",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib was effective in treating both refractory systemic arthritis and uveitis after failure of multiple conventional and biological DMARDs. The patient showed sustained improvement in ocular inflammation including resolution of serous retinal detachment and vitreous opacity with no relapses over 2.7 years."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No serious side effects of oral baricitinib were observed or reported during the 2 years and 7 months of treatment. The patient maintained good visual acuity without safety concerns.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "2 years and 7 months",
        "key_findings": "Baricitinib effectively treated refractory uveitis associated with seronegative RA after multiple treatment failures, with sustained response and no safety issues.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "C-reactive protein (CRP)",
            "endpoint_category": "Exploratory",
            "timepoint": "3 months",
            "measurement_type": "Change from baseline",
            "value": 0.26,
            "unit": "mg/dL",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 11.03,
            "change_from_baseline": -10.77,
            "change_pct": -97.6,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Dramatic reduction in inflammatory marker after baricitinib initiation"
          },
          {
            "endpoint_name": "Best-corrected visual acuity (BCVA) - right eye",
            "endpoint_category": "Secondary",
            "timepoint": "2 years 7 months",
            "measurement_type": "Absolute value",
            "value": null,
            "unit": "Snellen",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "BCVA maintained at 20/20 in right eye at 2 years 7 months"
          },
          {
            "endpoint_name": "Best-corrected visual acuity (BCVA) - left eye",
            "endpoint_category": "Secondary",
            "timepoint": "2 years 7 months",
            "measurement_type": "Absolute value",
            "value": null,
            "unit": "Snellen",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "BCVA maintained at 20/20 in left eye at 2 years 7 months"
          },
          {
            "endpoint_name": "Corneal infiltrative lesions improvement",
            "endpoint_category": "Secondary",
            "timepoint": "3 months",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Improvement observed in both eyes at 3 months after baricitinib"
          },
          {
            "endpoint_name": "Anterior chamber cells improvement",
            "endpoint_category": "Secondary",
            "timepoint": "3 months",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Improvement observed at 3 months after baricitinib"
          },
          {
            "endpoint_name": "Vitreous opacity improvement",
            "endpoint_category": "Secondary",
            "timepoint": "3 months",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Improvement observed in both eyes at 3 months after baricitinib"
          },
          {
            "endpoint_name": "Serous retinal detachment resolution",
            "endpoint_category": "Secondary",
            "timepoint": "3 months",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Complete disappearance of serous retinal detachment in right eye at 3 months"
          },
          {
            "endpoint_name": "Systemic arthritis improvement",
            "endpoint_category": "Primary",
            "timepoint": "3 months",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Improvement in systemic arthritis observed at 3 months after baricitinib"
          },
          {
            "endpoint_name": "Uveitis relapse-free survival",
            "endpoint_category": "Secondary",
            "timepoint": "2 years 7 months",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "No relapse of uveitis observed at 2 years 7 months follow-up"
          },
          {
            "endpoint_name": "Safety - serious adverse events",
            "endpoint_category": "Secondary",
            "timepoint": "2 years 7 months",
            "measurement_type": "Responder",
            "value": 0.0,
            "unit": null,
            "responders_n": 0,
            "responders_pct": 0.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "No serious side effects of oral baricitinib were observed or reported"
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "No serious side effects observed",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": "None",
            "notes": "Explicitly stated that no serious side effects of oral baricitinib were observed or reported during 2 years and 7 months of treatment"
          }
        ],
        "extraction_timestamp": "2025-12-07T18:05:32.459062",
        "extraction_confidence": 0.6,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [],
          "efficacy_tables": [],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure 1: Baseline ocular examination showing conjunctival hyperemia, anterior chamber cells, vitreous opacity, and retinal vasculitis",
            "Figure 2: Baseline radiography showing bone erosions in wrist joints",
            "Figure 3: Pre-baricitinib ocular findings showing corneal infiltration, anterior chamber cells, vitreous opacity, and serous retinal detachment",
            "Figure 4: Post-baricitinib improvement showing resolution of corneal infiltration, anterior chamber cells, vitreous opacity, and serous retinal detachment"
          ],
          "results_sections": [
            "Case Description section containing baseline presentation and clinical course",
            "Treatment response data showing CRP reduction from 11.03 to 0.26 mg/dL after 3 months of baricitinib",
            "Visual outcomes showing maintenance of 20/20 visual acuity with no uveitis relapse at 2 years 7 months follow-up"
          ],
          "patient_count": 1,
          "study_type": "Case Report",
          "has_quantitative_outcomes": true,
          "notes": "Single patient case report with quantitative measures including CRP levels, visual acuity, intraocular pressure, and imaging findings. No formal tables present - all data presented narratively. Figures show before/after clinical imaging demonstrating treatment response."
        }
      },
      "market_intelligence": {
        "disease": "Uveitis associated with rheumatoid arthritis",
        "epidemiology": {
          "us_prevalence_estimate": null,
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": null,
          "prevalence_source": null,
          "prevalence_source_url": null,
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Humira (adalimumab)",
              "drug_class": "TNF-alpha inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": "Non-infectious intermediate, posterior, and panuveitis in adult patients",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": 84000.0,
              "line_of_therapy": "3L",
              "notes": "FDA approved for general uveitis (2016) but not specifically for rheumatoid arthritis-associated uveitis. Used primarily in JIA-associated uveitis in pediatric patients."
            },
            {
              "drug_name": "Yuflyma (adalimumab-aaty)",
              "drug_class": "TNF-alpha inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": "Non-infectious intermediate, posterior, and panuveitis in adult patients",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": 75000.0,
              "line_of_therapy": "3L",
              "notes": "Adalimumab biosimilar FDA approved for general uveitis but not specifically for rheumatoid arthritis-associated uveitis"
            },
            {
              "drug_name": "Simlandi (adalimumab)",
              "drug_class": "TNF-alpha inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": "Non-infectious intermediate, posterior, and panuveitis in adult patients",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": 76000.0,
              "line_of_therapy": "3L",
              "notes": "Adalimumab biosimilar FDA approved for general uveitis but not specifically for rheumatoid arthritis-associated uveitis"
            },
            {
              "drug_name": "Ozurdex (dexamethasone intravitreal implant)",
              "drug_class": "Corticosteroid implant",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": "Non-infectious posterior uveitis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": 15000.0,
              "line_of_therapy": "2L",
              "notes": "FDA approved for general non-infectious posterior uveitis but not specifically for rheumatoid arthritis-associated uveitis"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 0,
          "pipeline_therapies": [],
          "pipeline_details": "No active clinical trials were identified for uveitis associated with rheumatoid arthritis from the provided search results.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "Topical corticosteroids are first-line therapy, followed by conventional DMARDs like methotrexate, with TNF-alpha inhibitors reserved for refractory cases.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved branded innovative treatments specifically for uveitis associated with rheumatoid arthritis. Current approvals are for general uveitis or JIA-associated uveitis, creating a treatment gap for this specific indication.",
          "competitive_landscape": "The market relies on off-label use of general uveitis treatments, primarily adalimumab products. Treatment approach follows standardized algorithms but lacks indication-specific approvals.",
          "soc_source": "FDA drug labels and clinical guidelines from accessdata.fda.gov and medical literature"
        },
        "market_size_estimate": null,
        "market_size_usd": null,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 47500000.0,
        "tam_estimate": "$47.5M",
        "tam_rationale": "Of ~1.3M US RA patients, ~5% develop uveitis (65K), ~80% are diagnosed (52K), ~70% receive treatment beyond topical steroids (36.4K). Given current treatment involves repurposed DMARDs/TNF inhibitors with limited efficacy, a purpose-built uveitis drug could capture 15-20% market share (~6.3K patients). At $75K/yr for specialty ophthalmology indication, TAM = $47.5M. Small but underserved market with high unmet need supports premium pricing.",
        "tam_sources": [
          "https://rheumaticdiseasecenter.com/uveitis/",
          "https://www.homeoxls.com/files/Articles/2000.pdf",
          "https://www.healthline.com/health/eye-health/granulomatous-conjunctivitis"
        ],
        "pipeline_sources": [
          "https://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/symptoms-causes/syc-20353648",
          "https://www.mayoclinic.org/diseases-conditions/arthritis/multimedia/osteoarthritis-vs-rheumatoid-arthritis/img-20008728",
          "https://connect.mayoclinic.org/discussion/i-have-an-ana-of-positive-speckled-at-180/"
        ],
        "attributed_sources": [
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5904090/",
            "title": "Epidemiology of uveitis in a US population-based study - PMC - NIH",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.dovepress.com/epidemiology-of-uveitis-in-the-mid-atlantic-united-states-peer-reviewed-fulltext-article-OPTH",
            "title": "Epidemiology of uveitis in the mid-Atlantic United States | OPTH",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761219s011lbl.pdf",
            "title": "YUFLYMA (adalimumab-aaty) - accessdata.fda.gov",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/798323-medication",
            "title": "Iritis and Uveitis Medication: Anticholinergic Agents ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.jrheum.org/content/41/1/3",
            "title": "Treat to Target in the Management of Chronic Uveitis",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/symptoms-causes/syc-20353648",
            "title": "Rheumatoid arthritis - Symptoms and causes - Mayo Clinic",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.mayoclinic.org/diseases-conditions/arthritis/multimedia/osteoarthritis-vs-rheumatoid-arthritis/img-20008728",
            "title": "Osteoarthritis vs. rheumatoid arthritis - Mayo Clinic",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://rheumaticdiseasecenter.com/uveitis/",
            "title": "Uveitis \u2013 Rheumatic Disease Center",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.homeoxls.com/files/Articles/2000.pdf",
            "title": "[PDF] QHD 2000 - CENTRE FOR EXCELLENCE IN HOM\u0152OPATHY",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 8.4,
        "evidence_quality": 4.9,
        "market_opportunity": 8.3,
        "overall_priority": 7.5,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 10.0,
          "endpoint_quality": 3.7,
          "organ_domain_breadth": 10.0,
          "safety_categories": [],
          "regulatory_flags": []
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 10.0,
        "endpoint_quality_score": 3.7,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 2.0,
          "response_durability": 10.0,
          "extraction_completeness": 7.8
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 10.0,
        "extraction_completeness_score": 7.8,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 5.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 5.0,
        "unmet_need_score": 10.0
      },
      "rank": 17
    },
    {
      "extraction": {
        "source": {
          "pmid": "38541086",
          "doi": "10.3390/medicina60030360",
          "url": "https://pubmed.ncbi.nlm.nih.gov/38541086/",
          "title": "Tofacitinib and Baricitinib in Type 2 Diabetic Patients with Rheumatoid Arthritis.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Type 2 diabetes mellitus in rheumatoid arthritis patients",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Retrospective Study",
        "patient_population": {
          "n_patients": 7,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [],
          "disease_severity": null,
          "comorbidities": null,
          "description": "Type 2 diabetic patients with rheumatoid arthritis receiving oral antidiabetic drugs"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "not specified",
          "frequency": null,
          "duration": "6 months",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "4/7 (57.1%)",
          "responders_n": 4,
          "responders_pct": 57.1,
          "time_to_response": "6 months",
          "duration_of_response": null,
          "effect_size_description": "57.1% of patients achieved HbA1c <7%, 28.6% required reduction in oral antidiabetic drug dosage",
          "primary_endpoint": "HbA1c reduction",
          "endpoint_result": "significant decrease in HbA1c (p = 0.035)",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib significantly reduced HbA1c levels in type 2 diabetic patients with rheumatoid arthritis. Over half of patients achieved target HbA1c <7% and some were able to reduce their antidiabetic medication dosages."
        },
        "safety": {
          "adverse_events": [
            "weight gain"
          ],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Treatment was generally well tolerated with only weight gain observed as a notable side effect. BMI increased significantly from baseline to 6 months.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Moderate",
        "comparator_baseline": null,
        "follow_up_duration": "6 months",
        "key_findings": "Baricitinib improved glycemic control in type 2 diabetic patients with rheumatoid arthritis, with most patients achieving target HbA1c levels.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "HbA1c reduction",
            "endpoint_category": "Primary",
            "timepoint": "Month 6",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "%",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": "0.035",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Baricitinib group showed significant reduction"
          },
          {
            "endpoint_name": "HbA1c reduction",
            "endpoint_category": "Primary",
            "timepoint": "Month 6",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "%",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": "0.416",
            "confidence_interval": null,
            "statistical_significance": false,
            "notes": "Tofacitinib group showed no significant differences"
          },
          {
            "endpoint_name": "HbA1c <7% achievement",
            "endpoint_category": "Secondary",
            "timepoint": "Month 6",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 4,
            "responders_pct": 57.1,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Baricitinib group (4/7 patients)"
          },
          {
            "endpoint_name": "HbA1c <7% achievement",
            "endpoint_category": "Secondary",
            "timepoint": "Month 6",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 16.7,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Tofacitinib group (1/6 patients)"
          },
          {
            "endpoint_name": "OAD dosage reduction",
            "endpoint_category": "Secondary",
            "timepoint": "Month 6",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 2,
            "responders_pct": 28.6,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Baricitinib group (2/7 patients)"
          },
          {
            "endpoint_name": "BMI change",
            "endpoint_category": "Secondary",
            "timepoint": "Month 6",
            "measurement_type": "Change from baseline",
            "value": 29.9,
            "unit": "kg/m\u00b2",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 28.7,
            "change_from_baseline": 1.2,
            "change_pct": null,
            "p_value": "0.022",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Baricitinib group, median values with IQR"
          },
          {
            "endpoint_name": "BMI change",
            "endpoint_category": "Secondary",
            "timepoint": "Month 6",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "kg/m\u00b2",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": "0.159",
            "confidence_interval": null,
            "statistical_significance": false,
            "notes": "Tofacitinib group, no significant differences"
          },
          {
            "endpoint_name": "Rheumatoid arthritis remission or low disease activity",
            "endpoint_category": "Secondary",
            "timepoint": "Month 6",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 7,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Baricitinib group, all patients achieved remission or LDA"
          },
          {
            "endpoint_name": "Rheumatoid arthritis remission or low disease activity",
            "endpoint_category": "Secondary",
            "timepoint": "Month 6",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 6,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Tofacitinib group, all patients achieved remission or LDA"
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "Increased infection risk",
            "event_category": "AESI",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": "Related",
            "outcome": null,
            "action_taken": null,
            "notes": "EMA recommendations state special caution should be taken when prescribing JAK inhibitor to RA patient with diabetes mellitus due to increased risk of developing infections"
          },
          {
            "event_name": "Hypoglycemia",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": "Related",
            "outcome": null,
            "action_taken": null,
            "notes": "Cases of hypoglycemia have been reported among diabetic patients with rheumatoid arthritis treated with JAK inhibitors"
          },
          {
            "event_name": "Weight gain",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 7,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": "Related",
            "outcome": "Ongoing",
            "action_taken": "None",
            "notes": "BMI increased significantly from 28.7 to 29.9 kg/m\u00b2 at 6 months in baricitinib group (p=0.022). Related to JAK2-STAT3 pathway inhibition affecting leptin signaling"
          },
          {
            "event_name": "Hypoglycemic effects requiring OAD dose reduction",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 2,
            "patients_affected_pct": 28.6,
            "events_total": null,
            "relatedness": "Related",
            "outcome": null,
            "action_taken": "Dose reduced",
            "notes": "28.6% (2/7) of patients treated with baricitinib required reduction in oral antidiabetic drug dosage due to improved glucose control"
          }
        ],
        "extraction_timestamp": "2025-12-07T17:25:42.074022",
        "extraction_confidence": 0.6,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [
            "Table 1 - Demographic and clinical characteristics of patients at baseline"
          ],
          "efficacy_tables": [
            "Table 2 - Main findings following 6 months of treatment with tofacitinib",
            "Table 3 - Main findings following 6 months of treatment with baricitinib"
          ],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure 1 - HbA1c outcomes showing percentage of patients achieving HbA1c values <7% at 6 months"
          ],
          "results_sections": [
            "3. Results"
          ],
          "patient_count": 13,
          "study_type": "Retrospective Study",
          "has_quantitative_outcomes": true,
          "notes": "Small retrospective study comparing tofacitinib (n=6) vs baricitinib (n=7) in T2DM patients with RA. Primary outcome was HbA1c at 6 months. No dedicated safety tables identified, though BMI changes and OAD dosage reductions were reported as secondary outcomes."
        }
      },
      "market_intelligence": {
        "disease": "Type 2 diabetes mellitus in rheumatoid arthritis patients",
        "epidemiology": {
          "us_prevalence_estimate": "10-20% of RA patients have type 2 diabetes",
          "us_incidence_estimate": "7.0 per 1,000 person-years in RA patients",
          "global_prevalence": null,
          "patient_population_size": 201750,
          "prevalence_source": "Medicine Journal and Arthritis & Rheumatology",
          "prevalence_source_url": "https://journals.lww.com/md-journal/fulltext/2016/02150/prevalence_of_undiagnosed_diabetes_in_rheumatoid.6.aspx",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 2,
          "pipeline_therapies": [
            {
              "drug_name": "IL-1Ra (Anakinra)",
              "company": "Not specified",
              "mechanism": "Interleukin-1 receptor antagonist",
              "phase": "Phase 2",
              "trial_id": "NCT00303394",
              "expected_completion": "2006-03"
            },
            {
              "drug_name": "Ixekizumab",
              "company": "Not specified",
              "mechanism": "IL-17A inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT06588296",
              "expected_completion": null
            }
          ],
          "pipeline_details": "Limited pipeline activity specifically for Type 2 diabetes in rheumatoid arthritis patients, with anti-inflammatory approaches including IL-1Ra and IL-17 inhibition being evaluated. Most trials focus on general Type 2 diabetes populations rather than the specific rheumatoid arthritis subgroup.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "No FDA-approved treatments exist specifically for type 2 diabetes mellitus in rheumatoid arthritis patients. Treatment involves managing both conditions separately with standard diabetes medications and RA-specific DMARDs or biologics.",
          "unmet_need": true,
          "unmet_need_description": "There are no FDA-approved drugs specifically indicated for type 2 diabetes mellitus in rheumatoid arthritis patients. Current practice involves treating each condition independently, which may not address the complex interplay between inflammatory pathways and glucose metabolism in this comorbid population.",
          "competitive_landscape": "The search results reveal no branded innovative treatments with FDA approval for the specific indication of type 2 diabetes mellitus in rheumatoid arthritis patients. Standard diabetes treatments and RA biologics are used off-label in combination, creating an opportunity for targeted therapeutic development.",
          "soc_source": "FDA Drug Safety Communications and Clinical Literature via PMC"
        },
        "market_size_estimate": "$5.0B",
        "market_size_usd": 5043750000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 455400000.0,
        "tam_estimate": "$455M",
        "tam_rationale": "Of ~202K RA patients in the US, ~15% have comorbid T2D (~30K patients). With ~85% diagnosed and ~75% receiving treatment for both conditions (~19K treated patients), this represents an underserved population with significant unmet need. A specialized therapy could capture 40-50% market share (~9.5K patients) given zero approved competitors and high medical need. At $48K/yr (premium to standard diabetes care due to dual indication complexity), TAM = $455M.",
        "tam_sources": [
          "https://www.grandviewresearch.com/industry-analysis/type-2-diabetes-mellitus-treatment-market-report",
          "https://www.biospace.com/press-releases/rheumatoid-arthritis-market-size-to-reach-us-34-7-billion-by-2035-impelled-by-obesity-and-lifestyle-changes",
          "https://www.fortunebusinessinsights.com/industry-reports/rheumatoid-arthritis-therapeutics-market-100488"
        ],
        "pipeline_sources": [
          "https://www.clinicaltrials.gov/study/NCT01064687",
          "https://clinicaltrials.gov/study/NCT01075282",
          "https://clinicaltrials.gov/study/NCT00303394"
        ],
        "attributed_sources": [
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9944327/",
            "title": "Prevalence of type 2 diabetes among rheumatoid arthritis patients",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://journals.lww.com/md-journal/fulltext/2016/02150/prevalence_of_undiagnosed_diabetes_in_rheumatoid.6.aspx",
            "title": "Prevalence of Undiagnosed Diabetes in Rheumatoid Arthritis",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-dpp-4-inhibitors-type-2-diabetes-may-cause-severe-joint-pain",
            "title": "FDA warns that DPP-4 inhibitors for type 2 diabetes may ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761354s004lbl.pdf",
            "title": "Page 1 - accessdata.fda.gov",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9649512/",
            "title": "Rheumatoid Arthritis Treatment Options and Type 2 Diabetes",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT01064687",
            "title": "NCT01064687 | A Study in Participants With Type 2 ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT01075282",
            "title": "NCT01075282 | A Study in Participants With Type 2 ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.grandviewresearch.com/industry-analysis/type-2-diabetes-mellitus-treatment-market-report",
            "title": "Type 2 Diabetes Mellitus Treatment Market Report, 2030",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.biospace.com/press-releases/rheumatoid-arthritis-market-size-to-reach-us-34-7-billion-by-2035-impelled-by-obesity-and-lifestyle-changes",
            "title": "Rheumatoid Arthritis Market Size to Reach US$ 34.7 Billion ...",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 6.6,
        "evidence_quality": 7.0,
        "market_opportunity": 9.7,
        "overall_priority": 7.4,
        "clinical_breakdown": {
          "response_rate": 6.0,
          "safety_profile": 7.6,
          "endpoint_quality": 3.9,
          "organ_domain_breadth": 10.0,
          "safety_categories": [
            "metabolic",
            "cardiovascular"
          ],
          "regulatory_flags": [
            "cardiovascular"
          ]
        },
        "response_rate_score": 6.0,
        "safety_profile_score": 7.6,
        "endpoint_quality_score": 3.9,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 4.0,
          "publication_venue": 10.0,
          "response_durability": 7.0,
          "extraction_completeness": 7.8
        },
        "sample_size_score": 4.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 7.0,
        "extraction_completeness_score": 7.8,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 9.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 9.0,
        "unmet_need_score": 10.0
      },
      "rank": 18
    },
    {
      "extraction": {
        "source": {
          "pmid": "36204670",
          "doi": "10.3389/fped.2022.962585",
          "url": "https://pubmed.ncbi.nlm.nih.gov/36204670/",
          "title": "Short-term effectiveness of baricitinib in children with refractory and/or severe juvenile dermatomyositis.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Refractory and/or severe juvenile dermatomyositis",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Retrospective Study",
        "patient_population": {
          "n_patients": 20,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "corticosteroids",
            "azathioprine",
            "methotrexate",
            "mycophenolate mofetil",
            "cyclosporine",
            "tacrolimus",
            "cyclophosphamide",
            "leflunomide",
            "IVIG"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "Children with refractory and/or severe juvenile dermatomyositis, mean age 7.8 \u00b1 4.0 years, female:male ratio 3:1"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "0.05 [0.04, 0.09] mg/kg/day",
          "frequency": null,
          "duration": "12-24 weeks",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "18/20 (90%)",
          "responders_n": 18,
          "responders_pct": 90.0,
          "time_to_response": "Skin rash improved in 45% at week 4, 75% at week 12, and 95% at week 24",
          "duration_of_response": "Sustained through 24 weeks",
          "effect_size_description": "Skin-DAS decreased from median 6.0 to 1.0, CMAS score increased from 41.0 to 50.0, MMT-8 score increased from 73.0 to 79.0",
          "primary_endpoint": "Complete response (CR) and partial response (PR) rates based on PRINTO remission criteria and skin-DAS",
          "endpoint_result": "75% achieved complete response and 15% achieved partial response at 24 weeks",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib showed significant efficacy in treating refractory juvenile dermatomyositis with 95% of patients showing skin improvement and 90% achieving complete or partial response. The treatment also allowed for a 49% reduction in corticosteroid dosage by week 24."
        },
        "safety": {
          "adverse_events": [
            "upper respiratory infection",
            "fungus infection",
            "gastrointestinal disorder",
            "herpes zoster",
            "elevation of liver enzymes",
            "elevation of creatinine",
            "elevation of uric acid"
          ],
          "serious_adverse_events": [
            "herpes zoster requiring hospitalization and temporary discontinuation"
          ],
          "sae_count": 1,
          "sae_percentage": 5.0,
          "discontinuations_n": 1,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [
            "herpes zoster infection"
          ],
          "safety_summary": "Baricitinib was generally well tolerated with 26 adverse events in 10 patients, mostly mild upper respiratory infections. Only one patient required hospitalization for herpes zoster with temporary drug discontinuation.",
          "safety_profile": "Acceptable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "24 weeks",
        "key_findings": "Baricitinib demonstrated strong efficacy in refractory juvenile dermatomyositis with 90% response rate and enabled significant corticosteroid dose reduction. The treatment was generally safe with mostly mild adverse events.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "Skin-DAS score",
            "endpoint_category": "Primary",
            "timepoint": "Week 4",
            "measurement_type": "Absolute value",
            "value": 4.5,
            "unit": "score (0-9 scale)",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 6.0,
            "change_from_baseline": -1.5,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Median (IQR: 2.0, 5.0)"
          },
          {
            "endpoint_name": "Skin-DAS score",
            "endpoint_category": "Primary",
            "timepoint": "Week 12",
            "measurement_type": "Change from baseline",
            "value": 2.0,
            "unit": "score (0-9 scale)",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 6.0,
            "change_from_baseline": -4.0,
            "change_pct": null,
            "p_value": "< 0.05",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Median (IQR: 0, 3.0) vs baseline 6.0 (4.0, 7.3)"
          },
          {
            "endpoint_name": "Skin-DAS score",
            "endpoint_category": "Primary",
            "timepoint": "Week 24",
            "measurement_type": "Change from baseline",
            "value": 0.0,
            "unit": "score (0-9 scale)",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 6.0,
            "change_from_baseline": -6.0,
            "change_pct": null,
            "p_value": "< 0.05",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Median (IQR: 0, 1.0) vs baseline 6.0 (4.0, 7.3)"
          },
          {
            "endpoint_name": "CMAS score",
            "endpoint_category": "Primary",
            "timepoint": "Week 4",
            "measurement_type": "Absolute value",
            "value": 42.0,
            "unit": "score (0-52 scale)",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 41.0,
            "change_from_baseline": 1.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Median (IQR: 38.0, 47.0), n=7 patients with muscle involvement"
          },
          {
            "endpoint_name": "CMAS score",
            "endpoint_category": "Primary",
            "timepoint": "Week 12",
            "measurement_type": "Change from baseline",
            "value": 46.0,
            "unit": "score (0-52 scale)",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 41.0,
            "change_from_baseline": 5.0,
            "change_pct": null,
            "p_value": "< 0.023",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Median (IQR: 42.0, 52.0) vs baseline 41.0 (29.0, 44.0)"
          },
          {
            "endpoint_name": "CMAS score",
            "endpoint_category": "Primary",
            "timepoint": "Week 24",
            "measurement_type": "Change from baseline",
            "value": 50.0,
            "unit": "score (0-52 scale)",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 41.0,
            "change_from_baseline": 9.0,
            "change_pct": null,
            "p_value": "< 0.006",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Median (IQR: 45.0, 52.0) vs baseline 41.0 (29.0, 44.0)"
          },
          {
            "endpoint_name": "MMT-8 score",
            "endpoint_category": "Primary",
            "timepoint": "Week 4",
            "measurement_type": "Absolute value",
            "value": 75.0,
            "unit": "score (0-80 scale)",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 73.0,
            "change_from_baseline": 2.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Median (IQR: 71.0, 77.0)"
          },
          {
            "endpoint_name": "MMT-8 score",
            "endpoint_category": "Primary",
            "timepoint": "Week 12",
            "measurement_type": "Absolute value",
            "value": 78.0,
            "unit": "score (0-80 scale)",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 73.0,
            "change_from_baseline": 5.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Median (IQR: 72.0, 80.0)"
          },
          {
            "endpoint_name": "MMT-8 score",
            "endpoint_category": "Primary",
            "timepoint": "Week 24",
            "measurement_type": "Change from baseline",
            "value": 79.0,
            "unit": "score (0-80 scale)",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 73.0,
            "change_from_baseline": 6.0,
            "change_pct": null,
            "p_value": "< 0.011",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Median (IQR: 77.0, 80.0) vs baseline 73.0 (61.0, 76.0)"
          },
          {
            "endpoint_name": "Complete Response Rate",
            "endpoint_category": "Primary",
            "timepoint": "Week 24",
            "measurement_type": "Responder",
            "value": null,
            "unit": "patients",
            "responders_n": 15,
            "responders_pct": 75.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "PRINTO remission criteria and inactive skin-DAS"
          },
          {
            "endpoint_name": "Partial Response Rate",
            "endpoint_category": "Primary",
            "timepoint": "Week 24",
            "measurement_type": "Responder",
            "value": null,
            "unit": "patients",
            "responders_n": 3,
            "responders_pct": 15.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Improvements in CMAS/MMT-8 and skin-DAS with CS tapering \u226550%"
          },
          {
            "endpoint_name": "Overall Response Rate (CR+PR)",
            "endpoint_category": "Primary",
            "timepoint": "Week 24",
            "measurement_type": "Responder",
            "value": null,
            "unit": "patients",
            "responders_n": 18,
            "responders_pct": 90.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Combined complete and partial responders"
          },
          {
            "endpoint_name": "Skin rash improvement rate",
            "endpoint_category": "Secondary",
            "timepoint": "Week 4",
            "measurement_type": "Responder",
            "value": null,
            "unit": "patients",
            "responders_n": 9,
            "responders_pct": 45.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Clinical improvement in skin rash"
          },
          {
            "endpoint_name": "Skin rash improvement rate",
            "endpoint_category": "Secondary",
            "timepoint": "Week 12",
            "measurement_type": "Responder",
            "value": null,
            "unit": "patients",
            "responders_n": 15,
            "responders_pct": 75.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Clinical improvement in skin rash"
          },
          {
            "endpoint_name": "Skin rash improvement rate",
            "endpoint_category": "Secondary",
            "timepoint": "Week 24",
            "measurement_type": "Responder",
            "value": null,
            "unit": "patients",
            "responders_n": 19,
            "responders_pct": 95.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Clinical improvement in skin rash"
          },
          {
            "endpoint_name": "Corticosteroid dosage",
            "endpoint_category": "Secondary",
            "timepoint": "Week 12",
            "measurement_type": "Change from baseline",
            "value": 0.33,
            "unit": "mg/kg/day",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 0.53,
            "change_from_baseline": -0.2,
            "change_pct": -37.0,
            "p_value": "< 0.05",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Median (IQR: 0.18, 0.40) vs baseline 0.53 (0.42, 1.00)"
          },
          {
            "endpoint_name": "Corticosteroid dosage",
            "endpoint_category": "Secondary",
            "timepoint": "Week 24",
            "measurement_type": "Change from baseline",
            "value": 0.27,
            "unit": "mg/kg/day",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 0.53,
            "change_from_baseline": -0.26,
            "change_pct": -49.0,
            "p_value": "< 0.05",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Median (IQR: 0.17, 0.37) vs baseline 0.53 (0.42, 1.00)"
          },
          {
            "endpoint_name": "Physician Global Assessment",
            "endpoint_category": "Secondary",
            "timepoint": "Week 4",
            "measurement_type": "Absolute value",
            "value": 4.0,
            "unit": "cm (VAS 1-10)",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 5.0,
            "change_from_baseline": -1.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Median (IQR: 3.0, 5.0)"
          },
          {
            "endpoint_name": "Physician Global Assessment",
            "endpoint_category": "Secondary",
            "timepoint": "Week 12",
            "measurement_type": "Absolute value",
            "value": 3.0,
            "unit": "cm (VAS 1-10)",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 5.0,
            "change_from_baseline": -2.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Median (IQR: 0.3, 3.8)"
          },
          {
            "endpoint_name": "Physician Global Assessment",
            "endpoint_category": "Secondary",
            "timepoint": "Week 24",
            "measurement_type": "Absolute value",
            "value": 0.0,
            "unit": "cm (VAS 1-10)",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 5.0,
            "change_from_baseline": -5.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Median (IQR: 0, 2.8)"
          },
          {
            "endpoint_name": "Parent Global Assessment",
            "endpoint_category": "Secondary",
            "timepoint": "Week 4",
            "measurement_type": "Absolute value",
            "value": 3.0,
            "unit": "cm (VAS 1-10)",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 6.0,
            "change_from_baseline": -3.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Median (IQR: 0, 5.0)"
          },
          {
            "endpoint_name": "Parent Global Assessment",
            "endpoint_category": "Secondary",
            "timepoint": "Week 12",
            "measurement_type": "Absolute value",
            "value": 0.0,
            "unit": "cm (VAS 1-10)",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 6.0,
            "change_from_baseline": -6.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Median (IQR: 0, 4.0)"
          },
          {
            "endpoint_name": "Parent Global Assessment",
            "endpoint_category": "Secondary",
            "timepoint": "Week 24",
            "measurement_type": "Absolute value",
            "value": 0.0,
            "unit": "cm (VAS 1-10)",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 6.0,
            "change_from_baseline": -6.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Median (IQR: 0, 0.8)"
          },
          {
            "endpoint_name": "Creatine Kinase (CK)",
            "endpoint_category": "Secondary",
            "timepoint": "Week 4",
            "measurement_type": "Absolute value",
            "value": 100.0,
            "unit": "U/L",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 93.5,
            "change_from_baseline": 6.5,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Median (IQR: 54.0, 128.0), normal range 39.0-308.0 U/L"
          },
          {
            "endpoint_name": "Creatine Kinase (CK)",
            "endpoint_category": "Secondary",
            "timepoint": "Week 12",
            "measurement_type": "Absolute value",
            "value": 84.0,
            "unit": "U/L",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 93.5,
            "change_from_baseline": -9.5,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Median (IQR: 58.3, 102.5)"
          },
          {
            "endpoint_name": "Creatine Kinase (CK)",
            "endpoint_category": "Secondary",
            "timepoint": "Week 24",
            "measurement_type": "Absolute value",
            "value": 96.0,
            "unit": "U/L",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 93.5,
            "change_from_baseline": 2.5,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Median (IQR: 70.3, 130.8)"
          },
          {
            "endpoint_name": "Lactate Dehydrogenase (LDH)",
            "endpoint_category": "Secondary",
            "timepoint": "Week 4",
            "measurement_type": "Absolute value",
            "value": 275.5,
            "unit": "U/L",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 258.0,
            "change_from_baseline": 17.5,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Median (IQR: 244.3, 397.5), normal range 110.0-295.0 U/L"
          },
          {
            "endpoint_name": "Lactate Dehydrogenase (LDH)",
            "endpoint_category": "Secondary",
            "timepoint": "Week 12",
            "measurement_type": "Absolute value",
            "value": 265.5,
            "unit": "U/L",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 258.0,
            "change_from_baseline": 7.5,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Median (IQR: 220.5, 289.3)"
          },
          {
            "endpoint_name": "Lactate Dehydrogenase (LDH)",
            "endpoint_category": "Secondary",
            "timepoint": "Week 24",
            "measurement_type": "Absolute value",
            "value": 256.5,
            "unit": "U/L",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 258.0,
            "change_from_baseline": -1.5,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Median (IQR: 218.8, 290.8)"
          },
          {
            "endpoint_name": "Total-DAS score",
            "endpoint_category": "Secondary",
            "timepoint": "Week 4",
            "measurement_type": "Absolute value",
            "value": 5.0,
            "unit": "score",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 6.8,
            "change_from_baseline": -1.8,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Median (IQR: 3.0, 6.4)"
          },
          {
            "endpoint_name": "Total-DAS score",
            "endpoint_category": "Secondary",
            "timepoint": "Week 12",
            "measurement_type": "Absolute value",
            "value": 2.5,
            "unit": "score",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 6.8,
            "change_from_baseline": -4.3,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Median (IQR: 2.0, 3.0)"
          },
          {
            "endpoint_name": "Total-DAS score",
            "endpoint_category": "Secondary",
            "timepoint": "Week 24",
            "measurement_type": "Absolute value",
            "value": 1.0,
            "unit": "score",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 6.8,
            "change_from_baseline": -5.8,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Median (IQR: 0, 2.4)"
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "Upper respiratory infection",
            "event_category": "AE",
            "severity_grade": "Mild",
            "patients_affected_n": 18,
            "patients_affected_pct": 69.0,
            "events_total": 18,
            "relatedness": null,
            "outcome": null,
            "action_taken": "None",
            "notes": "Most common adverse event, described as mild"
          },
          {
            "event_name": "Fungus infection",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 2,
            "patients_affected_pct": 7.0,
            "events_total": 2,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": null
          },
          {
            "event_name": "Gastrointestinal disorder",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 2,
            "patients_affected_pct": 7.0,
            "events_total": 2,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": null
          },
          {
            "event_name": "Herpes zoster",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": 4.0,
            "events_total": 1,
            "relatedness": null,
            "outcome": null,
            "action_taken": "Discontinued",
            "notes": "Patient P6, required hospitalization and temporary discontinuation of baricitinib"
          },
          {
            "event_name": "Elevation of liver enzymes",
            "event_category": "Lab abnormality",
            "severity_grade": "Mild",
            "patients_affected_n": 1,
            "patients_affected_pct": 4.0,
            "events_total": 1,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "Patient P13, ALT increased from 57 to 85 U/L, described as slight increase"
          },
          {
            "event_name": "Elevation of creatinine",
            "event_category": "Lab abnormality",
            "severity_grade": "Mild",
            "patients_affected_n": 1,
            "patients_affected_pct": 4.0,
            "events_total": 1,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "Patient P1, creatinine increased from 60 to 71 U/L, not to the point of renal dysfunction"
          },
          {
            "event_name": "Elevation of uric acid",
            "event_category": "Lab abnormality",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": 4.0,
            "events_total": 1,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": null
          }
        ],
        "extraction_timestamp": "2025-12-07T17:38:51.465834",
        "extraction_confidence": 0.6,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [
            "Table 2: General informations of patients receiving baricitinib therapy and outcomes - contains patient demographics, age at diagnosis, duration to treatment, clinical characteristics at baseline, MSAs/MAAs, and treatment details"
          ],
          "efficacy_tables": [
            "Table 1: Effectiveness and daily dose of corticosteroids in patients with baricitinib treatment - contains disease activity scores (Total-DAS, Skin-DAS, CMAS, MMT-8), physician and parent global assessments, laboratory values (CK, LDH), and corticosteroid dosages at weeks 0, 4, 12, and 24",
            "Table 2: General informations of patients receiving baricitinib therapy and outcomes - contains individual patient outcomes (CR/PR/NR) at different time points"
          ],
          "safety_tables": [
            "Table 3: Adverse events of baricitinib in the treatment of severe and/or refractory JDM - contains frequency and types of adverse events including upper respiratory infection, fungus infection, gastrointestinal disorder, herpes zoster, and laboratory abnormalities"
          ],
          "efficacy_figures": [
            "Figure 1: The disease activity changing in 20 patients with JDM with baricitinib treatment - shows (A) proportion achieving complete/partial response over 24 weeks, (B) decrease in skin disease activity score, (C) increase in childhood myositis assessment scale, (D) increase in manual muscle testing scores, (E) decrease in daily corticosteroid dose"
          ],
          "results_sections": [
            "Demographic, clinical, and laboratory data and drug combinations at baseline",
            "The effectiveness of baricitinib therapy",
            "Add-on therapy of baricitinib was helpful for tapering corticosteroids",
            "Safety of baricitinib therapy"
          ],
          "patient_count": 20,
          "study_type": "Retrospective Study",
          "has_quantitative_outcomes": true,
          "notes": "Single-center retrospective study with detailed individual patient data, statistical comparisons using Friedman test, 17 patients treated for 24 weeks and 3 for 12 weeks, with comprehensive efficacy and safety outcomes"
        }
      },
      "market_intelligence": {
        "disease": "Refractory and/or severe juvenile dermatomyositis",
        "epidemiology": {
          "us_prevalence_estimate": null,
          "us_incidence_estimate": "2-4 per million children per year",
          "global_prevalence": null,
          "patient_population_size": 219,
          "prevalence_source": "PMC article on inpatient burden of juvenile dermatomyositis",
          "prevalence_source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6234588/",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Rituximab (rituximab)",
              "drug_class": "Anti-CD20 monoclonal antibody",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Trials ongoing for severe or refractory juvenile dermatomyositis but no FDA approval for this specific indication"
            },
            {
              "drug_name": "Abatacept (abatacept)",
              "drug_class": "T-cell costimulation inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "CARRA consensus indicates use for refractory JDM but no FDA approval for this specific indication"
            },
            {
              "drug_name": "Tocilizumab (tocilizumab)",
              "drug_class": "IL-6 receptor antagonist",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "CARRA consensus indicates use for refractory JDM but no FDA approval for this specific indication"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 1,
          "pipeline_therapies": [
            {
              "drug_name": "Abatacept",
              "company": "Not specified",
              "mechanism": "CTLA-4-Ig fusion protein (T-cell costimulation modulator)",
              "phase": "Phase 2",
              "trial_id": "NCT02594735",
              "expected_completion": null
            }
          ],
          "pipeline_details": "The clinical pipeline for refractory/severe juvenile dermatomyositis is limited, with one identified Phase 2 trial testing abatacept as a targeted immunomodulatory therapy. Most current research focuses on repurposing existing immunosuppressants and JAK inhibitors rather than novel pipeline drugs in formal trials.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "Corticosteroids remain first-line therapy with methotrexate as steroid-sparing second-line agent, while biologics are used off-label for refractory cases based on consensus protocols.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved branded innovative therapies exist specifically for refractory and/or severe juvenile dermatomyositis, with treatment relying on off-label use of biologics and consensus-based protocols",
          "competitive_landscape": "The treatment landscape consists entirely of off-label biologics with CARRA consensus protocols guiding use of rituximab, abatacept, TNF inhibitors, and tocilizumab. This represents a significant unmet medical need with no FDA-approved innovative therapies for this specific indication.",
          "soc_source": "CARRA Consensus Treatment for Refractory Juvenile Dermatomyositis - https://rheumnow.com/news/carra-consensus-treatment-refractory-juvenile-dermatomyositis"
        },
        "market_size_estimate": "$44M",
        "market_size_usd": 43800000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 12775000.0,
        "tam_estimate": "$12.8M",
        "tam_rationale": "Of 219 US patients with refractory/severe juvenile dermatomyositis, ~95% are diagnosed given severity (208 patients), ~85% receive treatment beyond standard corticosteroids/methotrexate (177 patients). With no approved drugs, a first-in-class therapy could capture 60-70% market share (~125 patients) in this ultra-rare refractory population. At $102K/yr pricing (aligned with orphan drug standards and current global JDM market dynamics), TAM = $12.8M.",
        "tam_sources": [
          "https://www.openpr.com/news/4200870/unlocking-juvenile-dermatomyositis-treatment-united-states",
          "https://www.openpr.com/news/4263830/united-states-juvenile-dermatomyositis-treatment-jdm-market",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC9530147/"
        ],
        "pipeline_sources": [
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC9530147/",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC11189608/",
          "https://cdn.clinicaltrials.gov/large-docs/35/NCT02594735/Prot_SAP_000.pdf"
        ],
        "attributed_sources": [
          {
            "url": "https://www.sciencedirect.com/science/article/abs/pii/S0140673608609551",
            "title": "Juvenile dermatomyositis and other idiopathic inflammatory ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.healio.com/clinical-guidance/dermatomyositis/epidemiology-of-dm",
            "title": "Dermatomyositis Epidemiology | Clinical Guidance - Healio",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.medscape.com/viewarticle/758302",
            "title": "Review of Biologics in Children with Rheumatic Diseases",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.medscape.com/viewarticle/758302_7",
            "title": "Review of Biologics in Children with Rheumatic Diseases",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.myositis.org/wp-content/uploads/2018/02/Advances_JDM_Feldman2006.pdf",
            "title": "[PDF] Advances in the treatment of juvenile dermatomyositis",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9530147/",
            "title": "Short-term effectiveness of baricitinib in children with ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11189608/",
            "title": "Updates on Efficacy and Safety Janus Kinase Inhibitors in ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.openpr.com/news/4200870/unlocking-juvenile-dermatomyositis-treatment-united-states",
            "title": "Unlocking Juvenile Dermatomyositis Treatment: United States",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.openpr.com/news/4263830/united-states-juvenile-dermatomyositis-treatment-jdm-market",
            "title": "United States Juvenile Dermatomyositis Treatment (JDM) Market",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 6.9,
        "evidence_quality": 7.8,
        "market_opportunity": 8.0,
        "overall_priority": 7.4,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 4.8,
          "endpoint_quality": 3.7,
          "organ_domain_breadth": 10.0,
          "safety_categories": [
            "thromboembolic",
            "non_serious_infection",
            "discontinuation"
          ],
          "regulatory_flags": [
            "thromboembolic"
          ]
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 4.8,
        "endpoint_quality_score": 3.7,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 8.0,
          "publication_venue": 10.0,
          "response_durability": 5.0,
          "extraction_completeness": 8.3
        },
        "sample_size_score": 8.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 5.0,
        "extraction_completeness_score": 8.3,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 4.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 4.0,
        "unmet_need_score": 10.0
      },
      "rank": 19
    },
    {
      "extraction": {
        "source": {
          "pmid": "40115257",
          "doi": "10.3389/fphar.2025.1509404",
          "url": "https://www.semanticscholar.org/paper/f652d9aee27e16ab02f39c9e99a4ee0e3777430d",
          "title": "Case report: Effectiveness of Janus kinase inhibitors in the management of isolated noninfectious uveitis: a case series",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "isolated noninfectious uveitis",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 3,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "methylprednisolone",
            "mycophenolate mofetil",
            "adalimumab",
            "tacrolimus",
            "methotrexate",
            "cyclosporine"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "3 patients (1 female, 2 male) aged 28-59 years with refractory isolated noninfectious uveitis (anterior, intermediate, and posterior)"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "4 mg daily",
          "frequency": null,
          "duration": "mean follow-up 31.6 months (range 16-55 months)",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "3/3 (100%)",
          "responders_n": 3,
          "responders_pct": 100.0,
          "time_to_response": "mean 6.3 months (range 4-9 months)",
          "duration_of_response": "more than 1 year in all patients",
          "effect_size_description": "Complete remission with improvement in visual acuity from mean 0.4 to 0.6",
          "primary_endpoint": "remission of uveitis",
          "endpoint_result": "complete remission in all 3 patients lasting more than 1 year",
          "durability_signal": null,
          "efficacy_summary": "All three patients achieved complete remission lasting over 1 year after failing multiple prior therapies. Visual acuity improved in all cases with resolution of inflammatory markers on imaging."
        },
        "safety": {
          "adverse_events": [
            "transient elevation in liver transaminases"
          ],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No serious adverse events were observed. Only one patient had a slight temporary increase in liver transaminase levels during the treatment period.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "mean 31.6 months (range 16-55 months)",
        "key_findings": "First report of baricitinib and upadacitinib use in isolated noninfectious uveitis with 100% response rate and favorable long-term safety profile.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "Time to remission",
            "endpoint_category": "Primary",
            "timepoint": "Variable",
            "measurement_type": "Absolute value",
            "value": 6.3,
            "unit": "months",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Mean time to full remission, range 4-9 months"
          },
          {
            "endpoint_name": "Remission rate",
            "endpoint_category": "Primary",
            "timepoint": "Variable (4-9 months)",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 3,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "All patients achieved remission lasting for more than 1 year"
          },
          {
            "endpoint_name": "Best corrected visual acuity (BCVA) - mean",
            "endpoint_category": "Secondary",
            "timepoint": "Final visit",
            "measurement_type": "Change from baseline",
            "value": 0.6,
            "unit": "Snellen",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 0.4,
            "change_from_baseline": 0.2,
            "change_pct": 50.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Mean BCVA improved from 0.4 to 0.6"
          },
          {
            "endpoint_name": "Time to remission - Case 1",
            "endpoint_category": "Secondary",
            "timepoint": "4 months",
            "measurement_type": "Absolute value",
            "value": 4.0,
            "unit": "months",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Individual patient data"
          },
          {
            "endpoint_name": "Time to remission - Case 2",
            "endpoint_category": "Secondary",
            "timepoint": "6 months",
            "measurement_type": "Absolute value",
            "value": 6.0,
            "unit": "months",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Individual patient data"
          },
          {
            "endpoint_name": "Time to remission - Case 3",
            "endpoint_category": "Secondary",
            "timepoint": "9 months",
            "measurement_type": "Absolute value",
            "value": 9.0,
            "unit": "months",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Individual patient data"
          },
          {
            "endpoint_name": "BCVA right eye - Case 1",
            "endpoint_category": "Secondary",
            "timepoint": "Final visit",
            "measurement_type": "Change from baseline",
            "value": 0.8,
            "unit": "Snellen",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 0.02,
            "change_from_baseline": 0.78,
            "change_pct": 3900.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Improved from 0.02 to 0.8 after cataract surgery"
          },
          {
            "endpoint_name": "BCVA left eye - Case 1",
            "endpoint_category": "Secondary",
            "timepoint": "Final visit",
            "measurement_type": "Change from baseline",
            "value": 0.1,
            "unit": "Snellen",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 0.2,
            "change_from_baseline": -0.1,
            "change_pct": -50.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Decreased due to cataract"
          },
          {
            "endpoint_name": "BCVA right eye - Case 2",
            "endpoint_category": "Secondary",
            "timepoint": "Final visit",
            "measurement_type": "Change from baseline",
            "value": 1.0,
            "unit": "Snellen",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 0.6,
            "change_from_baseline": 0.4,
            "change_pct": 66.7,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Individual patient data"
          },
          {
            "endpoint_name": "BCVA left eye - Case 2",
            "endpoint_category": "Secondary",
            "timepoint": "Final visit",
            "measurement_type": "Change from baseline",
            "value": 1.0,
            "unit": "Snellen",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 1.0,
            "change_from_baseline": 0.0,
            "change_pct": 0.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "No change from baseline"
          },
          {
            "endpoint_name": "BCVA right eye - Case 3",
            "endpoint_category": "Secondary",
            "timepoint": "Final visit",
            "measurement_type": "Change from baseline",
            "value": 0.4,
            "unit": "Snellen",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 0.4,
            "change_from_baseline": 0.0,
            "change_pct": 0.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "No change from baseline"
          },
          {
            "endpoint_name": "BCVA left eye - Case 3",
            "endpoint_category": "Secondary",
            "timepoint": "Final visit",
            "measurement_type": "Change from baseline",
            "value": 0.5,
            "unit": "Snellen",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 0.6,
            "change_from_baseline": -0.1,
            "change_pct": -16.7,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Slight decrease from baseline"
          },
          {
            "endpoint_name": "Follow-up duration without relapse",
            "endpoint_category": "Secondary",
            "timepoint": "Mean follow-up",
            "measurement_type": "Absolute value",
            "value": 31.6,
            "unit": "months",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Range 16-55 months, no relapses reported"
          },
          {
            "endpoint_name": "Follow-up duration - Case 1",
            "endpoint_category": "Secondary",
            "timepoint": "Final visit",
            "measurement_type": "Absolute value",
            "value": 23.0,
            "unit": "months",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "1 year 11 months follow-up"
          },
          {
            "endpoint_name": "Follow-up duration - Case 2",
            "endpoint_category": "Secondary",
            "timepoint": "Final visit",
            "measurement_type": "Absolute value",
            "value": 43.0,
            "unit": "months",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "3 years 7 months follow-up"
          },
          {
            "endpoint_name": "Follow-up duration - Case 3",
            "endpoint_category": "Secondary",
            "timepoint": "Final visit",
            "measurement_type": "Absolute value",
            "value": 17.0,
            "unit": "months",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "1 year 5 months follow-up"
          },
          {
            "endpoint_name": "Adverse events rate",
            "endpoint_category": "Secondary",
            "timepoint": "Throughout follow-up",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 33.3,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "1 patient had transient rise in ALT, no serious side effects"
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "Elevated alanine aminotransferase (ALT)",
            "event_category": "Lab abnormality",
            "severity_grade": "Mild",
            "patients_affected_n": 1,
            "patients_affected_pct": 33.3,
            "events_total": 1,
            "relatedness": null,
            "outcome": "Resolved",
            "action_taken": "None",
            "notes": "Described as slight and temporary elevation; ALT level was 0.65 \u03bckat/L (normal range: 0-0.56 \u03bckat/L); occurred in Case 1 patient"
          }
        ],
        "extraction_timestamp": "2025-12-07T17:57:12.623264",
        "extraction_confidence": 0.6,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [
            "Table 1: Clinical data and timeline from the episode of care of patients with uveitis treated with JAK-i - contains patient demographics, diagnosis, laterality, previous treatments, baseline BCVA, and treatment details"
          ],
          "efficacy_tables": [
            "Table 1: Clinical data and timeline from the episode of care of patients with uveitis treated with JAK-i - contains time to remission, follow-up duration, final BCVA, and surgical procedures"
          ],
          "safety_tables": [
            "Table 1: Clinical data and timeline from the episode of care of patients with uveitis treated with JAK-i - contains adverse events row documenting safety outcomes"
          ],
          "efficacy_figures": [
            "Figure 1: Case 1 imaging before and after baricitinib therapy showing fluorescein angiography and OCT demonstrating resolution of cystoid macular edema",
            "Figure 2: Case 2 imaging during baricitinib treatment and after upadacitinib treatment showing improvement in inflammation and macular edema",
            "Figure 3: Case 3 fundus autofluorescence images before and after JAK-i therapy showing stabilization of chorioretinal lesions"
          ],
          "results_sections": [
            "Section 2: Outcomes",
            "Section 3: Case series",
            "Section 4.3: Outcomes and follow up (Case 1)",
            "Section 5.3: Outcomes and follow up (Case 2)",
            "Section 6.3: Outcomes and follow up (Case 3)"
          ],
          "patient_count": 3,
          "study_type": "Case Series",
          "has_quantitative_outcomes": true,
          "notes": "Single comprehensive table serves multiple purposes containing baseline, efficacy, and safety data. Mean follow-up of 31.6 months with mean time to remission of 6.3 months. All patients achieved sustained remission with minimal adverse events."
        }
      },
      "market_intelligence": {
        "disease": "isolated noninfectious uveitis",
        "epidemiology": {
          "us_prevalence_estimate": "121 per 100,000 adults, 29 per 100,000 children",
          "us_incidence_estimate": "51 per 100,000 persons annually",
          "global_prevalence": null,
          "patient_population_size": 298801,
          "prevalence_source": "JAMA Ophthalmology",
          "prevalence_source_url": "https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2551695",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Humira (adalimumab)",
              "drug_class": "TNF-alpha inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "non-infectious intermediate or posterior uveitis",
              "efficacy_range": "45-61%",
              "efficacy_pct": null,
              "annual_cost_usd": 80000.0,
              "line_of_therapy": "2L",
              "notes": "FDA approved in 2016 for treatment of uveitis in patients 2 years of age and older"
            },
            {
              "drug_name": "Yutiq (fluocinolone acetonide intravitreal implant)",
              "drug_class": "Sustained-release corticosteroid implant",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "non-infectious uveitis affecting the posterior segment",
              "efficacy_range": "86-93%",
              "efficacy_pct": null,
              "annual_cost_usd": 25000.0,
              "line_of_therapy": "2L",
              "notes": "Surgically administered intravitreal implant for chronic non-infectious posterior uveitis"
            },
            {
              "drug_name": "Retisert (fluocinolone acetonide implant)",
              "drug_class": "Sustained-release corticosteroid implant",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "chronic non-infectious posterior uveitis",
              "efficacy_range": "60-86%",
              "efficacy_pct": null,
              "annual_cost_usd": 15000.0,
              "line_of_therapy": "2L",
              "notes": "Contains 0.59 mg FA and designed to release over approximately 30 months"
            },
            {
              "drug_name": "Durezol (difluprednate ophthalmic)",
              "drug_class": "Topical corticosteroid",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "uveitis",
              "efficacy_range": "70-80%",
              "efficacy_pct": null,
              "annual_cost_usd": 3000.0,
              "line_of_therapy": "1L",
              "notes": "FDA-approved ophthalmic corticosteroid for uveitis treatment"
            }
          ],
          "approved_drug_names": [
            "Humira (adalimumab)",
            "Yutiq (fluocinolone acetonide intravitreal implant)",
            "Retisert (fluocinolone acetonide implant)",
            "Durezol (difluprednate ophthalmic)"
          ],
          "num_approved_drugs": 4,
          "num_pipeline_therapies": 2,
          "pipeline_therapies": [
            {
              "drug_name": "baricitinib",
              "company": "Not specified",
              "mechanism": "Janus kinase inhibitor",
              "phase": "Clinical use reported",
              "trial_id": null,
              "expected_completion": null
            },
            {
              "drug_name": "upadacitinib",
              "company": "Not specified",
              "mechanism": "Janus kinase inhibitor",
              "phase": "Clinical use reported",
              "trial_id": null,
              "expected_completion": null
            }
          ],
          "pipeline_details": "Limited active clinical trial pipeline identified for isolated noninfectious uveitis, with case reports showing effectiveness of JAK inhibitors like baricitinib and upadacitinib. No formal Phase 1-3 clinical trials specifically for this indication were found in the search results.",
          "avg_annual_cost_usd": 30750.0,
          "treatment_paradigm": "Corticosteroids remain first-line treatment, with sustained-release implants and biologics like adalimumab used as second-line for steroid-refractory or chronic cases requiring prolonged control beyond 3 months.",
          "unmet_need": true,
          "unmet_need_description": "Significant variability in treatment practices among specialists and lack of consensus guidelines for diagnosis and treatment algorithms, highlighting need for standardized treatment approaches",
          "competitive_landscape": "Limited FDA-approved options with only adalimumab as systemic biologic and sustained-release implants for posterior segment disease. Multiple investigational biologics including infliximab, tocilizumab, and secukinumab showing promise for refractory cases.",
          "soc_source": "FDA Medical Review NDA 210331 and multiple clinical guidelines from https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210331Orig1s000MedR.pdf"
        },
        "market_size_estimate": "$9.2B",
        "market_size_usd": 9188130750.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 184000000.0,
        "tam_estimate": "$184M",
        "tam_rationale": "Of ~299K global patients with isolated noninfectious uveitis, ~80% are diagnosed (239K), ~70% receive treatment beyond topical steroids (167K), ~40% progress to second-line therapy requiring sustained-release implants or biologics (67K). A new drug entering this second-line space could capture 20-25% market share (~15K patients) given 4 existing competitors but significant unmet need. At $30,750/year average cost, TAM = $461M globally, with developed markets representing ~40% = $184M addressable.",
        "tam_sources": [
          "https://www.databridgemarketresearch.com/reports/global-non-infectious-uveitis-market",
          "https://www.gminsights.com/industry-analysis/uveitis-treatment-market",
          "https://www.marketresearchfuture.com/reports/uveitis-treatment-market-8457"
        ],
        "pipeline_sources": [
          "https://pubmed.ncbi.nlm.nih.gov/40115257/?utm_source=FeedFetcher&utm_medium=rss&utm_campaign=None&utm_content=18WX1aNNAKMvvn_dyQcDqcbuuQ5kmruC-a9y1KORXU4UfB-Amm&fc=None&ff=20250330134043&v=2.18.0.post9+e462414",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC11922823/",
          "https://www.biopharmcatalyst.com/news/2025/biopharmcatalyst-weekly-watchlist-key-phase-3-catalysts-remaining-this-quarter"
        ],
        "attributed_sources": [
          {
            "url": "https://iovs.arvojournals.org/article.aspx?articleid=2807096",
            "title": "Epidemiology of Uveitis in the United States - IOVS",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2551695",
            "title": "Prevalence of Noninfectious Uveitis in the United States",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://emedicine.medscape.com/article/798323-medication",
            "title": "Iritis and Uveitis Medication: Anticholinergic Agents ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.medscape.com/viewarticle/778249",
            "title": "Biologics for the Treatment of Noninfectious Uveitis - Medscape Dexamethasone / Neomycin / Polymyxin B Ophthalmic Dosage Iritis and Uveitis Medication: Anticholinergic Agents ... Difluprednate ophthalmic Uses, Side Effects & Warnings Review of Uveitis Underscores Urgency of Early Action - Medscape List of Ophthalmic anti-infectives - Drugs.com Biologics for the Treatment of Noninfectious Uveitis - Page 2",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://journals.healio.com/doi/10.3928/23258160-20240625-01",
            "title": "Development of a Consensus Guideline for the Diagnosis and ...",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://pubmed.ncbi.nlm.nih.gov/40115257/?utm_source=FeedFetcher&utm_medium=rss&utm_campaign=None&utm_content=18WX1aNNAKMvvn_dyQcDqcbuuQ5kmruC-a9y1KORXU4UfB-Amm&fc=None&ff=20250330134043&v=2.18.0.post9+e462414",
            "title": "Case report: Effectiveness of Janus kinase inhibitors in the ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11922823/",
            "title": "Case report: Effectiveness of Janus kinase inhibitors in the ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.databridgemarketresearch.com/reports/global-non-infectious-uveitis-market",
            "title": "Non-Infectious Uveitis Market \u2013 Global Market Size, Share ...",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.gminsights.com/industry-analysis/uveitis-treatment-market",
            "title": "Uveitis Treatment Market Size & Share, Statistics Report 2034",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 8.2,
        "evidence_quality": 5.3,
        "market_opportunity": 8.0,
        "overall_priority": 7.4,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 7.8,
          "endpoint_quality": 5.3,
          "organ_domain_breadth": 10.0,
          "safety_categories": [
            "cardiovascular"
          ],
          "regulatory_flags": [
            "cardiovascular"
          ]
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 7.8,
        "endpoint_quality_score": 5.3,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 2.0,
          "publication_venue": 2.0,
          "response_durability": 10.0,
          "extraction_completeness": 8.3
        },
        "sample_size_score": 2.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 10.0,
        "extraction_completeness_score": 8.3,
        "market_breakdown": {
          "competitors": 5.0,
          "market_size": 9.0,
          "unmet_need": 10.0
        },
        "competitors_score": 5.0,
        "market_size_score": 9.0,
        "unmet_need_score": 10.0
      },
      "rank": 20
    },
    {
      "extraction": {
        "source": {
          "pmid": "38463557",
          "doi": "10.2147/CCID.S446468",
          "url": "https://www.semanticscholar.org/paper/3042dd9238d395b004db932402833376fb860849",
          "title": "Successful Treatment of Refractory Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome with Baricitinib, a Janus Kinase Inhibitor",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "SAPHO syndrome (Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis)",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "NSAIDs",
            "corticosteroids",
            "DMARDs",
            "adalimumab",
            "acitretin capsules"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "32-year-old Chinese woman with refractory SAPHO syndrome with osteoarticular pain and skin lesions"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "2 mg twice daily initially, then 1 mg twice daily (halved dose)",
          "frequency": null,
          "duration": "2 weeks at full dose, then 3 months at reduced dose",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": "2 weeks",
          "duration_of_response": "sustained through 3-month follow-up period",
          "effect_size_description": "VAS pain score decreased from 9 to 2, complete skin lesion resolution",
          "primary_endpoint": "improvement in skin lesions and osteoarticular pain",
          "endpoint_result": "complete resolution of skin lesions and significant pain relief within 2 weeks",
          "durability_signal": null,
          "efficacy_summary": "Dramatic improvement in both cutaneous and osteoarticular manifestations within 2 weeks of treatment initiation. Laboratory markers normalized and symptoms remained controlled during 3-month follow-up at reduced dose."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No adverse effects were observed during treatment or follow-up period. Regular monitoring showed no abnormalities in serological indicators.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "3 months",
        "key_findings": "Baricitinib achieved rapid and sustained remission in refractory SAPHO syndrome where conventional treatments and biologics had failed.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "Visual Analog Scale (VAS) pain score",
            "endpoint_category": "Primary",
            "timepoint": "Week 2",
            "measurement_type": "Change from baseline",
            "value": 2.0,
            "unit": "points",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 9.0,
            "change_from_baseline": -7.0,
            "change_pct": -77.8,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Main case - significant improvement in pain"
          },
          {
            "endpoint_name": "C-reactive protein (CRP)",
            "endpoint_category": "Secondary",
            "timepoint": "Week 2",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "mg/L",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 57.82,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Main case - returned to normal range (0-10 mg/L)"
          },
          {
            "endpoint_name": "Erythrocyte sedimentation rate (ESR)",
            "endpoint_category": "Secondary",
            "timepoint": "Week 2",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "mm/h",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 39.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Main case - returned to normal range (<20 mm/h)"
          },
          {
            "endpoint_name": "Complete skin lesion resolution",
            "endpoint_category": "Primary",
            "timepoint": "Week 2",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Main case - skin lesions disappeared across entire body"
          },
          {
            "endpoint_name": "Osteoarticular pain relief",
            "endpoint_category": "Primary",
            "timepoint": "Week 2",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Main case - symptoms significantly relieved"
          },
          {
            "endpoint_name": "Time to symptom improvement",
            "endpoint_category": "Secondary",
            "timepoint": "Week 2",
            "measurement_type": "Absolute value",
            "value": 14.0,
            "unit": "days",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Main case - notable improvement within 2 weeks"
          },
          {
            "endpoint_name": "Pain relief - rapid response",
            "endpoint_category": "Secondary",
            "timepoint": "Day 3",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Table 1 Case 3 - pain remarkably relieved"
          },
          {
            "endpoint_name": "VAS score improvement",
            "endpoint_category": "Primary",
            "timepoint": "Week 4",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "points",
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Table 1 Case 1 - symptoms improved, VAS score decreased"
          },
          {
            "endpoint_name": "Serum inflammatory parameters normalization",
            "endpoint_category": "Secondary",
            "timepoint": "Week 4",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Table 1 Case 1 - inflammatory parameters decreased to normal"
          },
          {
            "endpoint_name": "Cutaneous lesion healing",
            "endpoint_category": "Primary",
            "timepoint": "Week 4",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Table 1 Case 3 - cutaneous lesions healed"
          },
          {
            "endpoint_name": "MRI amelioration",
            "endpoint_category": "Secondary",
            "timepoint": "Week 12",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Table 1 Case 1 - MRI amelioration"
          },
          {
            "endpoint_name": "Bone marrow edema amelioration",
            "endpoint_category": "Secondary",
            "timepoint": "Week 16",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Table 1 Case 2 - bone marrow edema amelioration"
          },
          {
            "endpoint_name": "Vertebral damage improvement",
            "endpoint_category": "Secondary",
            "timepoint": "Month 6",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Table 1 Case 3 - vertebral damage improved"
          },
          {
            "endpoint_name": "Bone marrow edema resolution",
            "endpoint_category": "Secondary",
            "timepoint": "Year 1",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Table 1 Case 7 - bone marrow edema resolution"
          },
          {
            "endpoint_name": "VAS score decrease",
            "endpoint_category": "Primary",
            "timepoint": "Week 8",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "points",
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Table 1 Case 5 - VAS score decreased"
          },
          {
            "endpoint_name": "Nail lesions and PPP remission",
            "endpoint_category": "Secondary",
            "timepoint": "Week 12",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Table 1 Case 5 - nail lesions and palmoplantar pustulosis remitted"
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "No adverse effects observed",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": 0,
            "relatedness": null,
            "outcome": null,
            "action_taken": "None",
            "notes": "Main case report patient - no adverse effects observed during baricitinib treatment and 3-month follow-up"
          },
          {
            "event_name": "No adverse events",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 15,
            "patients_affected_pct": null,
            "events_total": 0,
            "relatedness": null,
            "outcome": null,
            "action_taken": "None",
            "notes": "Table 1 summary - all 15 cases treated with JAK inhibitors reported no adverse events"
          },
          {
            "event_name": "Treatment discontinuation",
            "event_category": "Discontinuation",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": 1,
            "relatedness": null,
            "outcome": null,
            "action_taken": "Discontinued",
            "notes": "Baisya et al case - tofacitinib discontinued after 3 months due to symptom resolution, not safety concerns"
          }
        ],
        "extraction_timestamp": "2025-12-07T18:03:30.633503",
        "extraction_confidence": 0.6,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [
            "Table 1 - Summary of 15 cases with SAPHO syndrome treated with JAK inhibitors, including age, sex, osteoarticular manifestations, skin manifestations, and other systems"
          ],
          "efficacy_tables": [
            "Table 1 - Same table includes treatment effects, time to improvement, and clinical outcomes for each case"
          ],
          "safety_tables": [
            "Table 1 - Contains adverse event data for all 15 cases treated with JAK inhibitors"
          ],
          "efficacy_figures": [
            "Figure 1 - Pre-treatment cutaneous manifestations showing baseline skin lesions",
            "Figure 2 - After-treatment skin lesions showing clinical improvement and resolution"
          ],
          "results_sections": [
            "Case Report section describing patient presentation and treatment response",
            "Abstract results describing improvement within two weeks",
            "Discussion section analyzing treatment outcomes and literature review"
          ],
          "patient_count": 1,
          "study_type": "Case Report",
          "has_quantitative_outcomes": true,
          "notes": "Primary case report of 1 patient but includes comprehensive literature review table of 15 cases total. Quantitative outcomes include VAS pain scores (9 to 2), CRP levels (57.82 mg/L to normal), ESR levels (39 mm/h), and specific timeframes for improvement (2 weeks for skin lesions, dose reduction after initial response)"
        }
      },
      "market_intelligence": {
        "disease": "SAPHO syndrome (Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis)",
        "epidemiology": {
          "us_prevalence_estimate": "1 in 10,000",
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": 33500,
          "prevalence_source": "Multiple medical journals",
          "prevalence_source_url": "https://www.cureus.com/articles/65166-synovitis-acne-pustulosis-hyperostosis-osteitis-sapho-syndrome-clinical-and-therapeutic-aspects",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Adalimumab (adalimumab)",
              "drug_class": "TNF-alpha inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": "variable",
              "efficacy_pct": null,
              "annual_cost_usd": 80000.0,
              "line_of_therapy": "2L",
              "notes": "Off-label use reported in literature for SAPHO syndrome, not FDA-approved for this indication"
            },
            {
              "drug_name": "Etanercept (etanercept)",
              "drug_class": "TNF-alpha inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": "variable",
              "efficacy_pct": null,
              "annual_cost_usd": 60000.0,
              "line_of_therapy": "2L",
              "notes": "Off-label use reported in literature for SAPHO syndrome, not FDA-approved for this indication"
            },
            {
              "drug_name": "Infliximab (infliximab)",
              "drug_class": "TNF-alpha inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": "variable",
              "efficacy_pct": null,
              "annual_cost_usd": 75000.0,
              "line_of_therapy": "2L",
              "notes": "Off-label use reported in literature for SAPHO syndrome, not FDA-approved for this indication"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 2,
          "pipeline_therapies": [
            {
              "drug_name": "Bisphosphonates",
              "company": "Not specified",
              "mechanism": "Bone resorption inhibition",
              "phase": "Phase 3",
              "trial_id": "NCT02544659",
              "expected_completion": null
            },
            {
              "drug_name": "Apremilast",
              "company": "Not specified",
              "mechanism": "PDE4 inhibitor",
              "phase": "Not specified",
              "trial_id": "NCT05174065",
              "expected_completion": null
            }
          ],
          "pipeline_details": "The SAPHO syndrome pipeline includes a Phase 3 trial evaluating bisphosphonates and another trial investigating apremilast, a PDE4 inhibitor with reported efficacy in this rare autoinflammatory condition.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "NSAIDs are first-line treatment for symptom control, with biologics (particularly TNF inhibitors) used off-label as second-line therapy when conventional treatments fail.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved treatments exist specifically for SAPHO syndrome. Current treatment relies on off-label use of biologics and conventional therapies with variable efficacy rates of only about 20% for first-line treatments.",
          "competitive_landscape": "The treatment landscape consists entirely of off-label therapies including NSAIDs, antibiotics, corticosteroids, and biologics. TNF inhibitors show the most promise but lack FDA approval for this rare indication with estimated prevalence <1/10,000.",
          "soc_source": "Cureus and Medicine Journal systematic reviews"
        },
        "market_size_estimate": "$3.4B",
        "market_size_usd": 3350000000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 201600000.0,
        "tam_estimate": "$202M",
        "tam_rationale": "Of ~33,500 US SAPHO patients, ~60% are diagnosed (20.1K) given frequent underdiagnosis, ~80% receive treatment (16.1K), ~40% fail NSAIDs and need 2L+ therapy (6.4K). A new approved drug could capture 50% market share (~3.2K patients) in this underserved orphan indication with zero approved therapies. At $63K/yr (between specialty biologics and orphan pricing), TAM = $202M. Premium pricing justified by high unmet need and orphan status.",
        "tam_sources": [
          "https://www.cureus.com/articles/65166-synovitis-acne-pustulosis-hyperostosis-osteitis-sapho-syndrome-clinical-and-therapeutic-aspects",
          "https://rmdopen.bmj.com/content/9/4/e003688",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC7236399/"
        ],
        "pipeline_sources": [
          "https://www.clinicalcasereportsint.com/open-access/constitutional-syndrome-first-case-reported-as-a-debut-of-synovitis-9605.pdf",
          "https://clinicaltrials.gov/study/NCT02544659",
          "https://www.clinicaltrials.gov/study/NCT02544659?term=AREA%5BConditionSearch%5D(%22SAPHO%20Syndrome%22)&rank=4"
        ],
        "attributed_sources": [
          {
            "url": "https://www.cureus.com/articles/65166-synovitis-acne-pustulosis-hyperostosis-osteitis-sapho-syndrome-clinical-and-therapeutic-aspects",
            "title": "Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis (SAPHO) Syndrome",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7236399/",
            "title": "Synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.drugs.com/condition/sapho-syndrome.html",
            "title": "List of SAPHO Syndrome Medications - Drugs.com Synovitis, acne, pustulosis, hyperostosis, and osteitis ... SAPHO Syndrome and Pustulotic Arthro-Osteitis (PAO). Scopolamine transdermal Uses, Side Effects & Warnings - Drugs.com FDA Approves Novel Non-Opioid Treatment for Moderate to ... Baclofen Side Effects: Common, Severe, Long Term - Drugs.com Clinical and imaging features of six Han patients with SAPHO ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/1072716-treatment",
            "title": "Acne Conglobata Treatment & Management",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.cureus.com/articles/65166-synovitis-acne-pustulosis-hyperostosis-osteitis-sapho-syndrome-clinical-and-therapeutic-aspects",
            "title": "Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis (SAPHO) Syndrome",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://www.clinicalcasereportsint.com/open-access/constitutional-syndrome-first-case-reported-as-a-debut-of-synovitis-9605.pdf",
            "title": "Constitutional Syndrome",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT02544659",
            "title": "Efficacy of Bisphosphonates in Patients With Synovitis, ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.cureus.com/articles/65166-synovitis-acne-pustulosis-hyperostosis-osteitis-sapho-syndrome-clinical-and-therapeutic-aspects",
            "title": "Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis (SAPHO ...",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://rmdopen.bmj.com/content/9/4/e003688",
            "title": "Treatment and monitoring of SAPHO syndrome: a systematic review",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 8.3,
        "evidence_quality": 3.6,
        "market_opportunity": 9.3,
        "overall_priority": 7.4,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 10.0,
          "endpoint_quality": 3.3,
          "organ_domain_breadth": 10.0,
          "safety_categories": [
            "discontinuation"
          ],
          "regulatory_flags": []
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 10.0,
        "endpoint_quality_score": 3.3,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 2.0,
          "response_durability": 5.0,
          "extraction_completeness": 7.8
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 5.0,
        "extraction_completeness_score": 7.8,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 8.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 8.0,
        "unmet_need_score": 10.0
      },
      "rank": 21
    },
    {
      "extraction": {
        "source": {
          "pmid": "36419482",
          "doi": "10.1177/1759720X221137126",
          "url": "https://www.semanticscholar.org/paper/869f10eec990650fa66b182fc661f1113c3dd59b",
          "title": "Baricitinib in severe and refractory peripheral ulcerative keratitis: a case report and literature review",
          "authors": "Vanesa Calvo-R\u00edo, Lara S\u00e1nchez-Bilbao, Carmen \u00c1lvarez-Reguera, Santos Casta\u00f1eda, I\u00f1igo Gonz\u00e1lez-Maz\u00f3n, Rosal\u00eda Demetrio-Pablo, Miguel A. Gonz\u00e1lez-Gay, Ricardo Blanco",
          "journal": "Therapeutic Advances in Musculoskeletal Disease",
          "year": 2022,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "Peripheral ulcerative keratitis (PUK)",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "methotrexate",
            "leflunomide",
            "certolizumab pegol",
            "adalimumab",
            "tocilizumab"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "85-year-old woman with rheumatoid arthritis and secondary Sj\u00f6gren's syndrome with severe refractory PUK"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "2 mg/day",
          "frequency": null,
          "duration": "18 months",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": "2 weeks",
          "duration_of_response": "18 months (ongoing)",
          "effect_size_description": "Complete resolution of corneal ulceration and joint symptoms",
          "primary_endpoint": "Ocular and joint disease remission",
          "endpoint_result": "Complete ocular and joint remission achieved",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib achieved rapid and complete remission of severe refractory PUK within 2 weeks. Patient maintained ocular and joint remission for 18 months with DAS28-CRP improving from 4.1 to 1.94."
        },
        "safety": {
          "adverse_events": [
            "mild alopecia"
          ],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Treatment was well-tolerated with only mild alopecia reported as an adverse effect. No serious adverse events or signs of disease reactivation occurred during 18 months of follow-up.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "18 months",
        "key_findings": "Baricitinib successfully treated severe refractory PUK in a patient who failed multiple conventional and biologic DMARDs, achieving rapid and sustained remission.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "DAS28-CRP disease activity score",
            "endpoint_category": "Secondary",
            "timepoint": "Baseline (before baricitinib)",
            "measurement_type": "Absolute value",
            "value": 4.1,
            "unit": "score",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 4.1,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Moderate disease activity before baricitinib treatment"
          },
          {
            "endpoint_name": "DAS28-CRP disease activity score",
            "endpoint_category": "Secondary",
            "timepoint": "Week 2",
            "measurement_type": "Absolute value",
            "value": 1.94,
            "unit": "score",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 4.1,
            "change_from_baseline": -2.16,
            "change_pct": -52.7,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Excellent response achieved after 2 weeks of baricitinib treatment"
          },
          {
            "endpoint_name": "DAS28-CRP disease activity score",
            "endpoint_category": "Secondary",
            "timepoint": "Month 18",
            "measurement_type": "Absolute value",
            "value": 2.1,
            "unit": "score",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 4.1,
            "change_from_baseline": -2.0,
            "change_pct": -48.8,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Sustained response at 18 months follow-up"
          },
          {
            "endpoint_name": "C-reactive protein (CRP)",
            "endpoint_category": "Secondary",
            "timepoint": "Baseline (before baricitinib)",
            "measurement_type": "Absolute value",
            "value": 3.2,
            "unit": "mg/dl",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 3.2,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Elevated inflammatory marker before treatment"
          },
          {
            "endpoint_name": "C-reactive protein (CRP)",
            "endpoint_category": "Secondary",
            "timepoint": "Month 18",
            "measurement_type": "Absolute value",
            "value": 1.5,
            "unit": "mg/dl",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 3.2,
            "change_from_baseline": -1.7,
            "change_pct": -53.1,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Reduction in inflammatory marker at 18 months"
          },
          {
            "endpoint_name": "Ocular evolution - Complete recovery",
            "endpoint_category": "Primary",
            "timepoint": "Week 2",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Excellent ocular evolution observed after 2 weeks of baricitinib treatment"
          },
          {
            "endpoint_name": "Absence of new corneal ulcer episodes",
            "endpoint_category": "Primary",
            "timepoint": "Month 18",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "No new episodes of corneal ulcers since starting baricitinib"
          },
          {
            "endpoint_name": "Ocular and joint remission",
            "endpoint_category": "Primary",
            "timepoint": "Month 18",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Patient remains in ocular and joint remission at 18 months"
          },
          {
            "endpoint_name": "Time to ocular response",
            "endpoint_category": "Secondary",
            "timepoint": "Week 2",
            "measurement_type": "Absolute value",
            "value": 2.0,
            "unit": "weeks",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Very rapid and persistent favorable response to eye and joint symptoms"
          },
          {
            "endpoint_name": "Overall ocular response rate (literature review)",
            "endpoint_category": "Primary",
            "timepoint": "Various timepoints",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 4,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Complete or partial recovery in all 4 patients from literature review (including current case)"
          },
          {
            "endpoint_name": "Complete recovery rate (literature review)",
            "endpoint_category": "Primary",
            "timepoint": "Various timepoints",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 2,
            "responders_pct": 50.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "2 out of 4 patients achieved complete recovery (Paley et al. and current case)"
          },
          {
            "endpoint_name": "Partial improvement rate (literature review)",
            "endpoint_category": "Primary",
            "timepoint": "Various timepoints",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 2,
            "responders_pct": 50.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "2 out of 4 patients achieved partial improvement (Meadow et al. and Liu et al.)"
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "Mild alopecia",
            "event_category": "AE",
            "severity_grade": "Mild",
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": 1,
            "relatedness": null,
            "outcome": "Ongoing",
            "action_taken": "None",
            "notes": "Only adverse effect experienced by 85-year-old female patient after 18 months of baricitinib 2mg/day treatment"
          }
        ],
        "extraction_timestamp": "2025-12-07T18:10:39.710035",
        "extraction_confidence": 0.6,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [
            "Table 1 - Literature review of patients with refractory ocular surface pathology showing demographics, underlying diseases, previous treatments, and patient characteristics for 4 cases including age, sex, underlying disease (RA, Beh\u00e7et disease), and prior DMARD treatments"
          ],
          "efficacy_tables": [
            "Table 1 - Same table includes ocular evolution outcomes showing partial improvement, complete recovery, and treatment responses for each patient case"
          ],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure 1 - Peripheral corneal perforation before treatment showing extensive corneal damage",
            "Figure 2 - Optical coherence tomography (OCT) after treatment with baricitinib showing corneal healing and improvement"
          ],
          "results_sections": [
            "Case report section describing 85-year-old woman with treatment response",
            "Literature Review section with 3 additional cases",
            "Clinical outcomes showing DAS28-CRP improvement from 5.25 to 1.94 after 2 weeks and maintained at 2.1 after 18 months",
            "Ocular improvement with no new corneal ulcer episodes after baricitinib treatment"
          ],
          "patient_count": 4,
          "study_type": "Case Report",
          "has_quantitative_outcomes": true,
          "notes": "Single case report with literature review of 3 additional cases. Main patient achieved both joint and ocular remission with baricitinib. Only adverse effect reported was mild alopecia. Figure 3 shows proposed treatment algorithm but not clinical outcomes."
        }
      },
      "market_intelligence": {
        "disease": "Peripheral ulcerative keratitis (PUK)",
        "epidemiology": {
          "us_prevalence_estimate": "fewer than 5 individuals per 100,000 annually",
          "us_incidence_estimate": "0.2 to 3 cases per million population annually",
          "global_prevalence": null,
          "patient_population_size": 838,
          "prevalence_source": "StatPearls - NCBI Bookshelf",
          "prevalence_source_url": "https://www.ncbi.nlm.nih.gov/books/NBK574556/",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Rituximab (rituximab)",
              "drug_class": "CD20 monoclonal antibody",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": 50000.0,
              "line_of_therapy": "2L",
              "notes": "Used off-label for severe PUK, particularly in GPA-associated cases"
            },
            {
              "drug_name": "Infliximab (infliximab)",
              "drug_class": "TNF-alpha inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": 40000.0,
              "line_of_therapy": "2L",
              "notes": "Used off-label as second-line biologic for steroid-sparing therapy"
            },
            {
              "drug_name": "Methotrexate (methotrexate)",
              "drug_class": "Antimetabolite",
              "is_branded_innovative": false,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": 2000.0,
              "line_of_therapy": "1L",
              "notes": "First-line steroid-sparing agent, particularly for RA-associated PUK"
            },
            {
              "drug_name": "Cyclophosphamide (cyclophosphamide)",
              "drug_class": "Alkylating agent",
              "is_branded_innovative": false,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": 3000.0,
              "line_of_therapy": "1L",
              "notes": "First-line for GPA or PAN-associated PUK; used in severe cases"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 3,
          "pipeline_therapies": [
            {
              "drug_name": "Infliximab",
              "company": "Various",
              "mechanism": "TNF-alpha inhibitor",
              "phase": "Phase 2",
              "trial_id": null,
              "expected_completion": null
            },
            {
              "drug_name": "Adalimumab",
              "company": "Various",
              "mechanism": "TNF-alpha inhibitor",
              "phase": "Phase 2",
              "trial_id": null,
              "expected_completion": null
            },
            {
              "drug_name": "Tocilizumab",
              "company": "Various",
              "mechanism": "IL-6 receptor antagonist",
              "phase": "Phase 2",
              "trial_id": null,
              "expected_completion": null
            }
          ],
          "pipeline_details": "Several biologics including TNF-alpha inhibitors (infliximab, adalimumab) and IL-6 receptor antagonists (tocilizumab) are being evaluated in ongoing trials for severe, refractory autoimmune-related PUK. The pipeline focuses primarily on cases associated with rheumatoid arthritis where conventional immunosuppressive therapy has failed.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "First-line therapy consists of systemic corticosteroids with concurrent immunomodulatory agents like methotrexate or cyclophosphamide. Second-line options include biologic agents like rituximab or infliximab for refractory cases.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved treatments specifically for PUK exist; current management relies on off-label use of immunosuppressives and biologics approved for other autoimmune conditions",
          "competitive_landscape": "The treatment landscape consists entirely of off-label therapies with no FDA-approved drugs specifically for PUK. Treatment depends on underlying systemic disease with biologics increasingly used earlier in severe cases.",
          "soc_source": "StatPearls NCBI and Wills Eye Case Series"
        },
        "market_size_estimate": "$168M",
        "market_size_usd": 167600000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 63000000.0,
        "tam_estimate": "$63M",
        "tam_rationale": "Of 838 US PUK patients annually, ~90% are diagnosed (754 patients) given the sight-threatening nature and specialist referral patterns. ~85% receive treatment (641 patients), with ~40% failing first-line corticosteroids/immunosuppressants and requiring second-line therapy (256 patients). A new drug could capture 35-40% market share in this underserved population (~100 patients) given zero approved therapies. At $630K/year pricing (justified as orphan drug for severe sight-threatening condition), TAM = $63M.",
        "tam_sources": [
          "https://www.industryarc.com/Research/Corneal-Ulcer-Treatment-Market-801101",
          "https://www.futuremarketinsights.com/reports/corneal-ulcer-treatment-market",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC9185208/"
        ],
        "pipeline_sources": [
          "https://pubmed.ncbi.nlm.nih.gov/25935428/",
          "https://cdn.clinicaltrials.gov/large-docs/52/NCT03235752/Prot_000.pdf",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC9185208/"
        ],
        "attributed_sources": [
          {
            "url": "https://www.mdpi.com/2813-1053/2/4/11",
            "title": "Updates on Systemic Immunomodulation in Peripheral Ulcerative ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://clinicaloptometry.scholasticahq.com/article/128647-necrotizing-anterior-scleritis-with-peripheral-ulcerative-keratitis-following-vitreoretinal-surgery",
            "title": "Necrotizing Anterior Scleritis with Peripheral Ulcerative Keratitis ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020511ap.pdf",
            "title": "approved - accessdata.fda.gov",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.medscape.com/viewarticle/518885",
            "title": "Latest Advances in Uveitis",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.reviewofophthalmology.com/article/wills-eye-resident-case-series-22937",
            "title": "Wills Eye Resident Case Series - Review of Ophthalmology",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://pubmed.ncbi.nlm.nih.gov/25935428/",
            "title": "Demographic profile, clinical features and outcome of ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/52/NCT03235752/Prot_000.pdf",
            "title": "A Phase II, Randomized, Double -blind, Placebo -controlled ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.industryarc.com/Research/Corneal-Ulcer-Treatment-Market-801101",
            "title": "Corneal Ulcer Treatment Market Size, Share - IndustryARC",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.futuremarketinsights.com/reports/corneal-ulcer-treatment-market",
            "title": "Corneal Ulcer Treatment Market Forecast 2025-2035",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 8.0,
        "evidence_quality": 4.9,
        "market_opportunity": 8.7,
        "overall_priority": 7.4,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 7.0,
          "endpoint_quality": 5.5,
          "organ_domain_breadth": 10.0,
          "safety_categories": [
            "thromboembolic",
            "cardiovascular",
            "pulmonary"
          ],
          "regulatory_flags": [
            "thromboembolic",
            "cardiovascular",
            "pulmonary"
          ]
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 7.0,
        "endpoint_quality_score": 5.5,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 2.0,
          "response_durability": 9.0,
          "extraction_completeness": 9.4
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 9.0,
        "extraction_completeness_score": 9.4,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 6.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 6.0,
        "unmet_need_score": 10.0
      },
      "rank": 22
    },
    {
      "extraction": {
        "source": {
          "pmid": "36793118",
          "doi": "10.1186/s13063-023-07087-5",
          "url": "https://pubmed.ncbi.nlm.nih.gov/36793118/",
          "title": "A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren's syndrome patients.",
          "authors": "Wei Bai, Fan Yang, Huji Xu, Wei Wei, Hongbin Li, Liyun Zhang, Yi Zhao, Xiaofei Shi, Yan Zhang, Xiaofeng Zeng, Xiaomei Leng",
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Primary Sjogren's syndrome",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Retrospective Study",
        "patient_population": {
          "n_patients": 87,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "hydroxychloroquine"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "Active primary Sjogren's syndrome patients aged 18-75 years with ESSDAI \u2265 5 on hydroxychloroquine treatment for at least 12 weeks"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "4 mg per day",
          "frequency": null,
          "duration": "24 weeks",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": null,
          "responders_pct": null,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": "Expected 70% response rate in baricitinib + HCQ group vs 30% in HCQ alone group based on pilot study",
          "primary_endpoint": "ESSDAI response rate (\u22653 point improvement) at 12 weeks",
          "endpoint_result": "Study protocol only - no results reported",
          "durability_signal": null,
          "efficacy_summary": "This is a study protocol for a randomized controlled trial comparing baricitinib + hydroxychloroquine versus hydroxychloroquine alone in primary Sjogren's syndrome. The study is designed based on pilot data suggesting potential efficacy, but no results are reported in this protocol paper."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "This is a study protocol with detailed safety monitoring plans including laboratory monitoring, infection screening, and specific discontinuation criteria, but no actual safety results are reported.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Mixed",
        "efficacy_signal": "Moderate",
        "comparator_baseline": null,
        "follow_up_duration": "24 weeks",
        "key_findings": "This study protocol describes the first randomized controlled trial design to evaluate baricitinib in primary Sjogren's syndrome, based on promising pilot study data and mechanistic rationale targeting JAK/STAT pathway.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "ESSDAI response (MCII) - improvement of at least 3 points",
            "endpoint_category": "Primary",
            "timepoint": "Week 12",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percentage",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Primary endpoint defined as minimal clinically important improvement (MCII)"
          },
          {
            "endpoint_name": "ESSDAI response (MCII) - improvement of at least 3 points",
            "endpoint_category": "Secondary",
            "timepoint": "Week 24",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percentage",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Rate of MCII of ESSDAI at 24 weeks"
          },
          {
            "endpoint_name": "ESSPRI response (MCII) - improvement of at least 1 point or 15%",
            "endpoint_category": "Secondary",
            "timepoint": "Week 12",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percentage",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "EULAR pSS patient-reported index response"
          },
          {
            "endpoint_name": "ESSPRI response (MCII) - improvement of at least 1 point or 15%",
            "endpoint_category": "Secondary",
            "timepoint": "Week 24",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percentage",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "EULAR pSS patient-reported index response"
          },
          {
            "endpoint_name": "Physician's Global Assessment (PGA) score change",
            "endpoint_category": "Secondary",
            "timepoint": "Week 12",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "points",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Change from baseline in PGA score"
          },
          {
            "endpoint_name": "Physician's Global Assessment (PGA) score change",
            "endpoint_category": "Secondary",
            "timepoint": "Week 24",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "points",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Change from baseline in PGA score"
          },
          {
            "endpoint_name": "C-reactive protein (CRP) level change",
            "endpoint_category": "Secondary",
            "timepoint": "Week 12",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "mg/L",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Serological activity parameter"
          },
          {
            "endpoint_name": "Erythrocyte sedimentation rate (ESR) change",
            "endpoint_category": "Secondary",
            "timepoint": "Week 12",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "mm/hr",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Serological activity parameter"
          },
          {
            "endpoint_name": "Immunoglobulin G (IgG) level change",
            "endpoint_category": "Secondary",
            "timepoint": "Week 12",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "g/L",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Serological activity parameter"
          },
          {
            "endpoint_name": "Rheumatoid factor (RF) level change",
            "endpoint_category": "Secondary",
            "timepoint": "Week 12",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "IU/mL",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Serological activity parameter"
          },
          {
            "endpoint_name": "C-reactive protein (CRP) level change",
            "endpoint_category": "Secondary",
            "timepoint": "Week 24",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "mg/L",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Serological activity parameter"
          },
          {
            "endpoint_name": "Erythrocyte sedimentation rate (ESR) change",
            "endpoint_category": "Secondary",
            "timepoint": "Week 24",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "mm/hr",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Serological activity parameter"
          },
          {
            "endpoint_name": "Immunoglobulin G (IgG) level change",
            "endpoint_category": "Secondary",
            "timepoint": "Week 24",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "g/L",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Serological activity parameter"
          },
          {
            "endpoint_name": "Rheumatoid factor (RF) level change",
            "endpoint_category": "Secondary",
            "timepoint": "Week 24",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "IU/mL",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Serological activity parameter"
          },
          {
            "endpoint_name": "Salivary flow rate change",
            "endpoint_category": "Secondary",
            "timepoint": "Week 12",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "ml/min",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Salivary gland function assessment"
          },
          {
            "endpoint_name": "Schirmer's test change",
            "endpoint_category": "Secondary",
            "timepoint": "Week 12",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "mm",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Salivary gland function assessment"
          },
          {
            "endpoint_name": "Salivary flow rate change",
            "endpoint_category": "Secondary",
            "timepoint": "Week 24",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "ml/min",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Salivary gland function assessment"
          },
          {
            "endpoint_name": "Schirmer's test change",
            "endpoint_category": "Secondary",
            "timepoint": "Week 24",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "mm",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Salivary gland function assessment"
          },
          {
            "endpoint_name": "Focus score on labial salivary gland biopsy change",
            "endpoint_category": "Secondary",
            "timepoint": "Week 24",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "points",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Minimum value is 1 and maximum value is 12, higher scores mean worse outcome"
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "Absolute neutrophil count < 1 \u00d7 10^9 cells/L",
            "event_category": "Lab abnormality",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": "Dose reduced",
            "notes": "Protocol-defined temporary interruption threshold"
          },
          {
            "event_name": "Absolute lymphocyte count < 0.5 \u00d7 10^9 cells/L",
            "event_category": "Lab abnormality",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": "Dose reduced",
            "notes": "Protocol-defined temporary interruption threshold"
          },
          {
            "event_name": "Hemoglobin < 8 g/dL",
            "event_category": "Lab abnormality",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": "Dose reduced",
            "notes": "Protocol-defined temporary interruption threshold"
          },
          {
            "event_name": "Drug-induced liver injury",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": "Related",
            "outcome": null,
            "action_taken": "Dose reduced",
            "notes": "Protocol-defined temporary interruption when suspected"
          },
          {
            "event_name": "White blood cell count < 1 \u00d7 10^9 cells/L",
            "event_category": "Lab abnormality",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": "Discontinued",
            "notes": "Protocol-defined permanent discontinuation threshold"
          },
          {
            "event_name": "Absolute neutrophil count < 0.5 \u00d7 10^9 cells/L",
            "event_category": "Lab abnormality",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": "Discontinued",
            "notes": "Protocol-defined permanent discontinuation threshold"
          },
          {
            "event_name": "Absolute lymphocyte count < 0.2 \u00d7 10^9 cells/L",
            "event_category": "Lab abnormality",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": "Discontinued",
            "notes": "Protocol-defined permanent discontinuation threshold"
          },
          {
            "event_name": "Hemoglobin < 6.5 g/dL",
            "event_category": "Lab abnormality",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": "Discontinued",
            "notes": "Protocol-defined permanent discontinuation threshold"
          },
          {
            "event_name": "ALT or AST > 8 \u00d7 upper limit of normal",
            "event_category": "Lab abnormality",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": "Discontinued",
            "notes": "Protocol-defined permanent discontinuation threshold"
          },
          {
            "event_name": "ALT or AST > 5 \u00d7 upper limit of normal for more than 2 weeks",
            "event_category": "Lab abnormality",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": "Discontinued",
            "notes": "Protocol-defined permanent discontinuation threshold after temporary interruption"
          },
          {
            "event_name": "ALT or AST > 3 \u00d7 upper limit of normal and total bilirubin > 2 \u00d7 upper limit of normal",
            "event_category": "Lab abnormality",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": "Discontinued",
            "notes": "Protocol-defined permanent discontinuation threshold"
          },
          {
            "event_name": "ALT or AST > 3 \u00d7 upper limit of normal with fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia",
            "event_category": "Lab abnormality",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": "Discontinued",
            "notes": "Protocol-defined permanent discontinuation threshold with clinical symptoms"
          },
          {
            "event_name": "Pregnancy",
            "event_category": "Discontinuation",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": "Discontinued",
            "notes": "Protocol-defined discontinuation criterion"
          },
          {
            "event_name": "Malignancy",
            "event_category": "SAE",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": "Discontinued",
            "notes": "Protocol-defined discontinuation criterion"
          },
          {
            "event_name": "Venous thromboembolism (DVT/PE)",
            "event_category": "SAE",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": "Discontinued",
            "notes": "Protocol-defined discontinuation criterion"
          },
          {
            "event_name": "HBV DNA above limit of quantitation",
            "event_category": "Lab abnormality",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": "Discontinued",
            "notes": "Protocol-defined discontinuation criterion for HBcAb-positive patients"
          },
          {
            "event_name": "Active tuberculosis",
            "event_category": "SAE",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": "Discontinued",
            "notes": "Protocol-defined discontinuation criterion"
          }
        ],
        "extraction_timestamp": "2025-12-07T17:49:00.627571",
        "extraction_confidence": 0.6,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [],
          "efficacy_tables": [],
          "safety_tables": [
            "Table 1: Temporary interruption due to some abnormal laboratory values - protocol guidance for treatment modifications based on lab parameters"
          ],
          "efficacy_figures": [],
          "results_sections": [],
          "patient_count": 87,
          "study_type": "Clinical Trial Protocol",
          "has_quantitative_outcomes": false,
          "notes": "This is a study protocol document describing methodology for a planned randomized controlled trial, not a completed study with results. No actual patient data, baseline characteristics, efficacy outcomes, or safety results are presented. The only table is a protocol guidance table for treatment modifications based on laboratory abnormalities."
        }
      },
      "market_intelligence": {
        "disease": "Primary Sjogren's syndrome",
        "epidemiology": {
          "us_prevalence_estimate": "1 in 10,000",
          "us_incidence_estimate": "6.92 per 100,000 per year",
          "global_prevalence": null,
          "patient_population_size": 3500000,
          "prevalence_source": "National Arthritis Data Workgroup",
          "prevalence_source_url": "https://www.sjogrensadvocate.com/sjogrens-is-common",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Salagen (pilocarpine)",
              "drug_class": "Muscarinic receptor agonist",
              "is_branded_innovative": false,
              "fda_approved": true,
              "fda_approved_indication": "Treatment of symptoms of dry mouth in patients with Sjogren's syndrome",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved specifically for dry mouth symptoms in Sjogren's syndrome patients"
            },
            {
              "drug_name": "Rituxan (rituximab)",
              "drug_class": "CD20 monoclonal antibody",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": 30000.0,
              "line_of_therapy": "2L",
              "notes": "Off-label use for systemic manifestations, not FDA approved for Primary Sjogren's syndrome"
            },
            {
              "drug_name": "Plaquenil (hydroxychloroquine)",
              "drug_class": "Antimalarial/DMARD",
              "is_branded_innovative": false,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "Generic drug used off-label for musculoskeletal symptoms"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 4,
          "pipeline_therapies": [
            {
              "drug_name": "ianalumab (VAY736)",
              "company": "Novartis",
              "mechanism": "B-cell targeting therapy",
              "phase": "Phase 3",
              "trial_id": "NCT05350072, NCT0539214",
              "expected_completion": null
            },
            {
              "drug_name": "RSLV-132",
              "company": null,
              "mechanism": "Nuclease therapy",
              "phase": "Phase 3",
              "trial_id": "NCT06440525",
              "expected_completion": null
            },
            {
              "drug_name": "nipocalimab",
              "company": null,
              "mechanism": "FcRn antagonist",
              "phase": "Phase 3",
              "trial_id": "NCT06741969",
              "expected_completion": null
            },
            {
              "drug_name": "telitacicept",
              "company": null,
              "mechanism": "BAFF/APRIL dual inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT05673993",
              "expected_completion": null
            }
          ],
          "pipeline_details": "Primary Sj\u00f6gren's syndrome has an active Phase 3 pipeline with four therapies targeting different mechanisms including B-cell depletion, nuclease therapy, FcRn antagonism, and BAFF/APRIL inhibition. Novartis recently announced positive results from two Phase 3 trials of ianalumab targeting patients with active extraglandular disease.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "Treatment is primarily symptomatic with supportive care using artificial tears, saliva stimulants, and off-label use of DMARDs like hydroxychloroquine for systemic symptoms. Rituximab may be considered for severe systemic manifestations as second-line therapy.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved branded innovative drugs specifically for Primary Sjogren's syndrome. Current treatment relies heavily on off-label use of drugs approved for other conditions and symptomatic management.",
          "competitive_landscape": "The treatment landscape consists primarily of generic drugs and off-label biologics, with no branded innovative therapies specifically approved for Primary Sjogren's syndrome. This represents a significant opportunity for targeted drug development in this autoimmune condition.",
          "soc_source": "Sjogren's Foundation Clinical Practice Guidelines and FDA drug labels"
        },
        "market_size_estimate": "$87.5B",
        "market_size_usd": 87500000000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 1575000000.0,
        "tam_estimate": "$1.58B",
        "tam_rationale": "Of ~3.5M global Primary Sj\u00f6gren's syndrome patients, ~40% are formally diagnosed (1.4M), ~60% receive systemic treatment beyond supportive care (840K), primarily with off-label DMARDs. With zero approved drugs and high unmet need, a first-in-class therapy could capture 30-40% market share (~300K patients) as 1L systemic treatment. At $175K/yr pricing typical for autoimmune biologics in orphan indications, TAM = $1.58B. Premium pricing justified by lack of approved alternatives and significant symptom burden.",
        "tam_sources": [
          "https://www.openpr.com/news/3715103/sjogrens-syndrome-market-forecasted-for-major-growth",
          "https://www.dennisgong.com/blog/newmedicines/",
          "https://www.ose-immuno.com/wp-content/uploads/2021/10/Degroof-Petercam-90920.pdf"
        ],
        "pipeline_sources": [
          "https://www.novartis.com/news/media-releases/novartis-announces-both-ianalumab-phase-iii-clinical-trials-met-primary-endpoint-patients-sjogrens-disease",
          "https://clinicaltrials.gov/study/NCT06440525",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC10330372/"
        ],
        "attributed_sources": [
          {
            "url": "https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr.23173",
            "title": "Prevalence of Primary Sj\u00f6gren's Syndrome in a US Population ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.journalrip.com/PDF/jrip-14-e38323.pdf",
            "title": "[PDF] Estimating the prevalence of Sjogren's syndrome in the world using ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://emedicine.medscape.com/article/332125-treatment",
            "title": "Sjogren Syndrome Treatment & Management",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/332125-guidelines",
            "title": "Sjogren Syndrome Guidelines",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://sjogrens.org/sites/default/files/inline-files/SF_PCG-Systemic.pdf",
            "title": "[PDF] Sj\u00f6gren's Foundation Clinical Practice Guidelines",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://www.novartis.com/news/media-releases/novartis-announces-both-ianalumab-phase-iii-clinical-trials-met-primary-endpoint-patients-sjogrens-disease",
            "title": "Novartis announces both ianalumab Phase III clinical trials ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT06440525",
            "title": "A Study of RSLV-132 in Females With Sj\u00f6gren's Disease",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.openpr.com/news/3715103/sjogrens-syndrome-market-forecasted-for-major-growth",
            "title": "Sjogrens Syndrome Market Forecasted for Major Growth",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.dennisgong.com/blog/newmedicines/",
            "title": "Developing new medicines (Part I) - Dennis Gong",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 5.1,
        "evidence_quality": 8.1,
        "market_opportunity": 10.0,
        "overall_priority": 7.1,
        "clinical_breakdown": {
          "response_rate": 6.0,
          "safety_profile": 2.1,
          "endpoint_quality": 4.7,
          "organ_domain_breadth": 10.0,
          "safety_categories": [
            "hypersensitivity",
            "serious_infection",
            "discontinuation",
            "cardiovascular",
            "hepatotoxicity",
            "thromboembolic",
            "malignancy"
          ],
          "regulatory_flags": [
            "hypersensitivity",
            "serious_infection",
            "cardiovascular",
            "hepatotoxicity",
            "thromboembolic",
            "malignancy"
          ]
        },
        "response_rate_score": 6.0,
        "safety_profile_score": 2.1,
        "endpoint_quality_score": 4.7,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 10.0,
          "publication_venue": 10.0,
          "response_durability": 5.0,
          "extraction_completeness": 6.6
        },
        "sample_size_score": 10.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 5.0,
        "extraction_completeness_score": 6.6,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 10.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 10.0,
        "unmet_need_score": 10.0
      },
      "rank": 23
    },
    {
      "extraction": {
        "source": {
          "pmid": "36389811",
          "doi": "10.3389/fimmu.2022.1008392",
          "url": "https://www.semanticscholar.org/paper/23791402d1f9cc42cfe6cadf0283618cb0b22093",
          "title": "Baricitinib is potentially effective in the treatment of refractory livedoid vasculopathy",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "Livedoid vasculopathy",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Retrospective Study",
        "patient_population": {
          "n_patients": 8,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "corticosteroids",
            "thalidomide",
            "tripterygium glycosides",
            "rivaroxaban",
            "enoxaparin",
            "aspirin",
            "compound glycyrrhizin",
            "Chinese traditional anti-inflammatory drugs"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "8 patients with refractory livedoid vasculopathy (mean age 21.1\u00b19.1 years, including 2 pediatric patients)"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "2 mg/day",
          "frequency": null,
          "duration": "3-13 weeks to remission",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "6/8 (75%)",
          "responders_n": 6,
          "responders_pct": 75.0,
          "time_to_response": "3-13 weeks (mean 7.75\u00b13.45 weeks)",
          "duration_of_response": null,
          "effect_size_description": "Statistically significant 80% reduction in clinical scores",
          "primary_endpoint": "Clinical composite score reduction (0-8 scale measuring pain, ulceration, erythema)",
          "endpoint_result": "Clinical score reduced from 7.0\u00b11.6 to 1.4\u00b11.2 (P<0.01)",
          "durability_signal": null,
          "efficacy_summary": "All 8 patients showed significant clinical improvement with mean clinical scores decreasing from 7.0\u00b11.6 to 1.4\u00b11.2 (P<0.01). Six patients achieved remission (clinical score \u22642) with improvements in erythema, ulceration, and pain."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No adverse events were reported in any patient during follow-up. Treatment was well-tolerated with no severe side effects, including in two pediatric patients.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "10-28 weeks (average 16.50 weeks)",
        "key_findings": "Baricitinib demonstrated significant efficacy in treating refractory livedoid vasculopathy with 75% remission rate and excellent safety profile including in pediatric patients.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "Clinical score change from baseline",
            "endpoint_category": "Primary",
            "timepoint": "Post-treatment (mean 16.5 weeks follow-up)",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "points",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 7.0,
            "change_from_baseline": -5.6,
            "change_pct": null,
            "p_value": "<0.01",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Clinical score range 0-8; baseline 7.0\u00b11.6, post-treatment 1.4\u00b11.2"
          },
          {
            "endpoint_name": "Clinical remission rate",
            "endpoint_category": "Secondary",
            "timepoint": "Post-treatment (mean 16.5 weeks follow-up)",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 6,
            "responders_pct": 75.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Remission defined as clinical score \u22642; 6 out of 8 patients achieved scores of 0 or 2"
          },
          {
            "endpoint_name": "Time to remission",
            "endpoint_category": "Secondary",
            "timepoint": "During treatment period",
            "measurement_type": "Absolute value",
            "value": 7.75,
            "unit": "weeks",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Mean remission time 7.75\u00b13.45 weeks; range 3-13 weeks"
          },
          {
            "endpoint_name": "Erythema improvement",
            "endpoint_category": "Secondary",
            "timepoint": "Post-treatment",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 8,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "All patients experienced improvement in erythema"
          },
          {
            "endpoint_name": "Ulceration improvement",
            "endpoint_category": "Secondary",
            "timepoint": "Post-treatment",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 8,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "All patients experienced improvement in ulceration"
          },
          {
            "endpoint_name": "Pain improvement",
            "endpoint_category": "Secondary",
            "timepoint": "Post-treatment",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 8,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "All patients experienced improvement in pain; pain was greatly alleviated"
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "No adverse events",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 0,
            "patients_affected_pct": 0.0,
            "events_total": 0,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "No reports of adverse events in any patient during study"
          },
          {
            "event_name": "Upper respiratory infections",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 0,
            "patients_affected_pct": 0.0,
            "events_total": 0,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "No cases of upper respiratory infections among patients"
          },
          {
            "event_name": "Herpes simplex virus infection",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 0,
            "patients_affected_pct": 0.0,
            "events_total": 0,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "No cases of herpes simplex virus infection among patients"
          },
          {
            "event_name": "Folliculitis",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 0,
            "patients_affected_pct": 0.0,
            "events_total": 0,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "No cases of folliculitis among patients"
          },
          {
            "event_name": "Tuberculosis",
            "event_category": "AESI",
            "severity_grade": null,
            "patients_affected_n": 0,
            "patients_affected_pct": 0.0,
            "events_total": 0,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "No cases of tuberculosis among patients"
          },
          {
            "event_name": "Malignant tumors",
            "event_category": "AESI",
            "severity_grade": null,
            "patients_affected_n": 0,
            "patients_affected_pct": 0.0,
            "events_total": 0,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "No cases of malignant tumors among patients"
          },
          {
            "event_name": "Deep vein thrombosis",
            "event_category": "AESI",
            "severity_grade": null,
            "patients_affected_n": 0,
            "patients_affected_pct": 0.0,
            "events_total": 0,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "No cases of deep vein thrombosis among patients"
          }
        ],
        "extraction_timestamp": "2025-12-07T18:04:34.124457",
        "extraction_confidence": 0.6,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [
            "Table 1: Characteristics of patients treated with baricitinib for livedoid vasculopathy - includes patient demographics (age/sex), disease localization, duration of disease, previous therapies, baricitinib dosage, and follow-up time"
          ],
          "efficacy_tables": [],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure 1: Livedoid vasculopathy composite clinical scores (A), scores of erythema (B) and ulceration (C) before and after treatment with baricitinib",
            "Figure 2: Clinical photographs showing livedoid vasculopathy before (1) and after (2) baricitinib treatment in patients 2 (A), 5 (B), and 8 (C)"
          ],
          "results_sections": [
            "Results section describing clinical score improvements (mean scores 7.0 \u00b1 1.6 vs 1.4 \u00b1 1.2, P < 0.01)",
            "Remission rates and timing (6/8 patients achieved clinical score \u22642, mean remission time 7.75 \u00b1 3.45 weeks)",
            "Safety outcomes (no adverse events reported)"
          ],
          "patient_count": 8,
          "study_type": "Case Series",
          "has_quantitative_outcomes": true,
          "notes": "Retrospective case series with validated clinical scoring system (0-8 scale) measuring pain, ulceration, and erythema. Statistical analysis performed using paired t-test. All patients had refractory disease resistant to conventional treatments."
        }
      },
      "market_intelligence": {
        "disease": "Livedoid vasculopathy",
        "epidemiology": {
          "us_prevalence_estimate": "1 in 100,000",
          "us_incidence_estimate": "1-9 per 100,000 annually",
          "global_prevalence": null,
          "patient_population_size": 3350,
          "prevalence_source": "MalaCards",
          "prevalence_source_url": "https://www.malacards.org/card/livedoid_vasculitis",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Xeljanz (tofacitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": 60000.0,
              "line_of_therapy": null,
              "notes": "Used off-label for livedoid vasculopathy with reported efficacy, but not FDA approved for this specific indication"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 2,
          "pipeline_therapies": [
            {
              "drug_name": "Rivaroxaban",
              "company": "University of Muenster",
              "mechanism": "Direct factor Xa inhibitor anticoagulant",
              "phase": "Phase 2",
              "trial_id": null,
              "expected_completion": null
            },
            {
              "drug_name": "Diosmiplex (Vasculera)",
              "company": null,
              "mechanism": "Micronized purified flavonoid fraction",
              "phase": "Phase 3",
              "trial_id": "NCT02683408",
              "expected_completion": null
            }
          ],
          "pipeline_details": "The livedoid vasculopathy pipeline includes rivaroxaban in Phase 2 trials as an anticoagulant approach and Diosmiplex (Vasculera) in Phase 3 trials targeting vascular conditions. Limited active clinical development is ongoing for this rare thrombo-occlusive skin disease.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "No FDA-approved branded innovative drugs exist for livedoid vasculopathy. Treatment is primarily off-label with anticoagulants (rivaroxaban, enoxaparin) as first-line therapy per German guidelines.",
          "unmet_need": true,
          "unmet_need_description": "Complete lack of FDA-approved branded innovative treatments specifically for livedoid vasculopathy, forcing reliance on off-label therapy with anticoagulants and experimental treatments",
          "competitive_landscape": "The treatment landscape consists entirely of off-label use of generic anticoagulants and DOACs, with emerging interest in JAK inhibitors and biologics showing promise in case reports. No pharmaceutical company has pursued FDA approval for a branded innovative therapy specifically for this rare indication.",
          "soc_source": "German S1 guideline and multiple clinical sources from StatPearls, NORD, and dermatology literature"
        },
        "market_size_estimate": "$670M",
        "market_size_usd": 670000000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 67200000.0,
        "tam_estimate": "$67.2M",
        "tam_rationale": "Of ~3,350 US patients with livedoid vasculopathy, ~80% are eventually diagnosed (2,680), given the distinct clinical presentation of painful ulcerations and atrophie blanche scarring. ~90% of diagnosed patients receive treatment (2,412) due to severe symptoms, though currently only off-label anticoagulants are available. With zero approved drugs, a new FDA-approved therapy could capture 70% market share as first-line treatment (~1,688 patients). At $40K/yr for an orphan indication, TAM = $67.2M.",
        "tam_sources": [
          "https://cdn.ymaws.com/www.aocd.org/resource/resmgr/jaocd/jaocdvol31.pdf",
          "https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1594585/full",
          "https://www.malacards.org/card/vasculitis"
        ],
        "pipeline_sources": [
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC8721056/",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC9574051/",
          "https://pubmed.ncbi.nlm.nih.gov/41264385/"
        ],
        "attributed_sources": [
          {
            "url": "https://www.malacards.org/card/livedoid_vasculitis",
            "title": "Livedoid Vasculitis - MalaCards",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6066260/",
            "title": "Livedoid vasculopathy: a compelling diagnosis - PMC - NIH",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://emedicine.medscape.com/article/1082675-overview",
            "title": "Livedoid Vasculopathy: Background, Pathophysiology ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/316024-medication",
            "title": "Mononeuritis Multiplex Medication",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://journals.sagepub.com/doi/full/10.1177/21621918251395013",
            "title": "Long-Term Efficacy of Guideline-Followed Treatment in Patients with ...",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8721056/",
            "title": "Livedoid vasculopathy: A multidisciplinary clinical approach to ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9574051/",
            "title": "Livedoid vasculopathy \u2013 A diagnostic and therapeutic ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://cdn.ymaws.com/www.aocd.org/resource/resmgr/jaocd/jaocdvol31.pdf",
            "title": "Focus on Osteopathy",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1594585/full",
            "title": "Adverse events of pexidartinib for the treatment of TGCT",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 7.3,
        "evidence_quality": 5.0,
        "market_opportunity": 9.0,
        "overall_priority": 7.1,
        "clinical_breakdown": {
          "response_rate": 8.0,
          "safety_profile": 7.2,
          "endpoint_quality": 4.9,
          "organ_domain_breadth": 10.0,
          "safety_categories": [
            "serious_infection",
            "thromboembolic",
            "non_serious_infection",
            "malignancy"
          ],
          "regulatory_flags": [
            "serious_infection",
            "thromboembolic",
            "malignancy"
          ]
        },
        "response_rate_score": 8.0,
        "safety_profile_score": 7.2,
        "endpoint_quality_score": 4.9,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 4.0,
          "publication_venue": 2.0,
          "response_durability": 7.0,
          "extraction_completeness": 7.8
        },
        "sample_size_score": 4.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 7.0,
        "extraction_completeness_score": 7.8,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 7.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 7.0,
        "unmet_need_score": 10.0
      },
      "rank": 24
    },
    {
      "extraction": {
        "source": {
          "pmid": null,
          "doi": "10.1093/rap/rkae117.036",
          "url": "https://www.semanticscholar.org/paper/4d478c062a6fc94f421abcbd6557aac26c37f875",
          "title": "P05\u2003The role of JAK inhibitors in difficult-to-treat adult-onset Still\u2019s disease: a case series",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "Adult-onset Still's Disease (AOSD)",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 3,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "prednisolone",
            "methotrexate",
            "azathioprine",
            "tocilizumab",
            "anakinra",
            "colchicine"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "Three adults (ages 18-32) with difficult-to-treat AOSD refractory to conventional treatments"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "4 mg daily",
          "frequency": null,
          "duration": "at least one year for one patient",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "3/3 (100%)",
          "responders_n": 3,
          "responders_pct": 100.0,
          "time_to_response": null,
          "duration_of_response": "sustained through follow-up period",
          "effect_size_description": "substantial clinical improvement in all cases",
          "primary_endpoint": "symptom resolution and steroid reduction",
          "endpoint_result": "all patients achieved substantial clinical improvement with steroid reduction or cessation",
          "durability_signal": null,
          "efficacy_summary": "All three patients showed substantial clinical improvement with baricitinib/tofacitinib treatment. Patients were able to reduce or discontinue steroids after achieving symptom resolution and reduced inflammatory markers."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No adverse events or safety concerns were reported with JAK inhibitor treatment in this case series. Safety profile appears favorable based on limited data.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "at least one year",
        "key_findings": "JAK inhibitors showed efficacy in difficult-to-treat AOSD where conventional treatments failed, allowing steroid reduction.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-07T17:58:39.480351",
        "extraction_confidence": 0.5,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Adult-onset Still's Disease (AOSD)",
        "epidemiology": {
          "us_prevalence_estimate": "1-9 per 100,000",
          "us_incidence_estimate": "0.16-0.4 per 100,000 adults",
          "global_prevalence": null,
          "patient_population_size": 16750,
          "prevalence_source": "Orphanet",
          "prevalence_source_url": "https://www.orpha.net/en/disease/detail/829",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Ilaris (canakinumab)",
              "drug_class": "IL-1\u03b2 inhibitor (monoclonal antibody)",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Active Still's Disease, including Adult-Onset Still's Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients 2 years of age and older",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "First and only FDA-approved treatment specifically for AOSD. Approved June 2020 expanding previous SJIA indication to include AOSD patients."
            }
          ],
          "approved_drug_names": [
            "Ilaris (canakinumab)"
          ],
          "num_approved_drugs": 1,
          "num_pipeline_therapies": 3,
          "pipeline_therapies": [
            {
              "drug_name": "Tadekinig alfa",
              "company": "Not specified",
              "mechanism": "IL-18 binding protein inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT02398435",
              "expected_completion": null
            },
            {
              "drug_name": "Canakinumab",
              "company": "Not specified",
              "mechanism": "IL-1 inhibitor",
              "phase": "Phase 2",
              "trial_id": null,
              "expected_completion": null
            },
            {
              "drug_name": "Tocilizumab",
              "company": "Not specified",
              "mechanism": "IL-6 receptor antagonist",
              "phase": "Phase 3",
              "trial_id": null,
              "expected_completion": null
            }
          ],
          "pipeline_details": "The AOSD clinical pipeline includes several targeted therapies in Phase 2-3 trials, with tadekinig alfa (IL-18 inhibitor) and tocilizumab (IL-6 antagonist) in Phase 3 development and canakinumab (IL-1 inhibitor) in Phase 2 testing. These therapies target key inflammatory pathways involved in this rare autoinflammatory disease.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "First-line therapy consists of corticosteroids and NSAIDs, with conventional DMARDs like methotrexate as second-line steroid-sparing agents. Biologics like Ilaris are typically reserved for refractory cases resistant to conventional treatment.",
          "unmet_need": true,
          "unmet_need_description": "Despite having one FDA-approved biologic (Ilaris), AOSD remains challenging to treat with limited treatment options. Most patients rely on corticosteroids which have significant long-term side effects, and there is growing evidence that biologics should be used earlier in treatment but only one is currently approved.",
          "competitive_landscape": "Ilaris is currently the only FDA-approved branded innovative treatment specifically for AOSD, representing a monopoly in the approved treatment space. Other biologics like anakinra and tocilizumab are used off-label but lack specific FDA approval for this indication.",
          "soc_source": "FDA accessdata.fda.gov and Medscape Medical News"
        },
        "market_size_estimate": "$1.7B",
        "market_size_usd": 1675000000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 502500000.0,
        "tam_estimate": "$503M",
        "tam_rationale": "Of ~16,750 global AOSD patients, ~70% are diagnosed (11,725), ~80% receive treatment (9,380), ~40% fail conventional therapy and are candidates for biologics (3,752). A new biologic could capture 30-40% market share (~1,340 patients) given only one approved competitor (Ilaris) and high unmet need in refractory cases. At $375K/yr pricing typical for rare inflammatory biologics, TAM = $503M. Premium pricing justified by orphan indication and IL-1/IL-6 inhibitor efficacy data.",
        "tam_sources": [
          "https://www.linkedin.com/pulse/still-disease-treatment-market-sector-development-forecast-0rqje/",
          "https://finance.yahoo.com/news/adult-onset-still-disease-market-113500363.html",
          "https://www.linkedin.com/pulse/north-america-stills-disease-treatment-market-size-fau8e/"
        ],
        "pipeline_sources": [
          "https://www.clinicaltrials.gov/study/NCT02398435",
          "https://pubmed.ncbi.nlm.nih.gov/29472362/",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC8410009/"
        ],
        "attributed_sources": [
          {
            "url": "https://www.orpha.net/en/disease/detail/829",
            "title": "Adult-onset Still disease - Orphanet",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://acrabstracts.org/abstract/epidemiology-of-hospitalized-adult-onset-stills-disease-in-united-states/",
            "title": "Epidemiology of Hospitalized Adult Onset Still's Disease in United ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/125319Orig1s097ltr.pdf",
            "title": "Ilaris (canakinumab) injection - accessdata.fda.gov",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.medscape.com/viewarticle/932625",
            "title": "FDA Approves First Drug for Adult-Onset Still's Disease",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2022.881431/full",
            "title": "Adult-onset Still's disease: A disease at the crossroad of innate ...",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT02398435",
            "title": "Therapeutic Use of Tadekinig Alfa in Adult-onset Still's ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://pubmed.ncbi.nlm.nih.gov/29472362/",
            "title": "Open-label, multicentre, dose-escalating phase II clinical ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.linkedin.com/pulse/still-disease-treatment-market-sector-development-forecast-0rqje/",
            "title": "Still s Disease Treatment Market Sector Development and Forecast ...",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://finance.yahoo.com/news/adult-onset-still-disease-market-113500363.html",
            "title": "Adult-onset Still Disease Market Research Report 2025-2035",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 8.1,
        "evidence_quality": 3.3,
        "market_opportunity": 8.3,
        "overall_priority": 7.0,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 9.0,
          "endpoint_quality": 5.0,
          "organ_domain_breadth": 8.0,
          "safety_categories": [],
          "regulatory_flags": []
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 9.0,
        "endpoint_quality_score": 5.0,
        "organ_domain_score": 8.0,
        "evidence_breakdown": {
          "sample_size": 2.0,
          "publication_venue": 2.0,
          "response_durability": 4.0,
          "extraction_completeness": 6.1
        },
        "sample_size_score": 2.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 6.1,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 8.0,
          "unmet_need": 10.0
        },
        "competitors_score": 7.0,
        "market_size_score": 8.0,
        "unmet_need_score": 10.0
      },
      "rank": 25
    },
    {
      "extraction": {
        "source": {
          "pmid": "35510170",
          "doi": "10.1177/1759720X221093211",
          "url": "https://www.semanticscholar.org/paper/c93d597cfaaf21fd7c0497c8b384d8f0ffc6d476",
          "title": "Clinical and immunological study of Tofacitinib and Baricitinib in refractory Blau syndrome: case report and literature review",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "Blau syndrome",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "methotrexate",
            "etanercept",
            "anakinra",
            "abatacept",
            "adalimumab",
            "corticosteroids"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "25-year-old woman with severe refractory Blau syndrome with granulomatous dermatitis, arthritis, and chronic panuveitis"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "4 mg daily",
          "frequency": null,
          "duration": "4 months reported",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": "maintained from initiation",
          "duration_of_response": "4 months of follow-up",
          "effect_size_description": "maintained adequate disease control with stable manifestations",
          "primary_endpoint": "clinical disease control (cutaneous, ocular, and joint manifestations)",
          "endpoint_result": "stable control of cutaneous, ocular, and joint manifestations maintained",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib successfully maintained disease control in a patient with refractory Blau syndrome after tofacitinib was discontinued due to lymphopenia. The patient had stable cutaneous, ocular, and joint manifestations during 4 months of treatment."
        },
        "safety": {
          "adverse_events": [
            "lymphopenia"
          ],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 0,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Baricitinib was well tolerated with an adequate safety profile. Mild lymphopenia (800 cells/\u00b5l) was observed after 4 months but was less severe than with prior tofacitinib treatment.",
          "safety_profile": "Acceptable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "4 months",
        "key_findings": "First reported successful use of baricitinib in refractory Blau syndrome, maintaining disease control with better safety profile than tofacitinib.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "CRP",
            "endpoint_category": "Secondary",
            "timepoint": "TOFA Month 1",
            "measurement_type": "Absolute value",
            "value": 0.4,
            "unit": "mg/dl",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 0.5,
            "change_from_baseline": -0.1,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "C-reactive protein decreased from baseline"
          },
          {
            "endpoint_name": "CRP",
            "endpoint_category": "Secondary",
            "timepoint": "TOFA Month 12",
            "measurement_type": "Absolute value",
            "value": 0.4,
            "unit": "mg/dl",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 0.5,
            "change_from_baseline": -0.1,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "C-reactive protein remained low"
          },
          {
            "endpoint_name": "CRP",
            "endpoint_category": "Secondary",
            "timepoint": "BARI Month 4",
            "measurement_type": "Absolute value",
            "value": 0.4,
            "unit": "mg/dl",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 0.4,
            "change_from_baseline": 0.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "C-reactive protein stable on BARI"
          },
          {
            "endpoint_name": "ESR",
            "endpoint_category": "Secondary",
            "timepoint": "TOFA Month 1",
            "measurement_type": "Absolute value",
            "value": 5.0,
            "unit": "mm/1 h",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 13.0,
            "change_from_baseline": -8.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Erythrocyte sedimentation rate decreased"
          },
          {
            "endpoint_name": "ESR",
            "endpoint_category": "Secondary",
            "timepoint": "TOFA Month 12",
            "measurement_type": "Absolute value",
            "value": 10.0,
            "unit": "mm/1 h",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 13.0,
            "change_from_baseline": -3.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Erythrocyte sedimentation rate remained low"
          },
          {
            "endpoint_name": "Absolute lymphocyte count",
            "endpoint_category": "Secondary",
            "timepoint": "TOFA Month 1",
            "measurement_type": "Absolute value",
            "value": 3100.0,
            "unit": "cells/\u00b5l",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 3600.0,
            "change_from_baseline": -500.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Progressive decrease in lymphocyte count"
          },
          {
            "endpoint_name": "Absolute lymphocyte count",
            "endpoint_category": "Secondary",
            "timepoint": "TOFA Month 12",
            "measurement_type": "Absolute value",
            "value": 900.0,
            "unit": "cells/\u00b5l",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 3600.0,
            "change_from_baseline": -2700.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Significant lymphopenia developed"
          },
          {
            "endpoint_name": "Absolute lymphocyte count",
            "endpoint_category": "Secondary",
            "timepoint": "BARI Month 4",
            "measurement_type": "Absolute value",
            "value": 800.0,
            "unit": "cells/\u00b5l",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 1200.0,
            "change_from_baseline": -400.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Lymphopenia persisted with BARI"
          },
          {
            "endpoint_name": "CD3+ T-cells",
            "endpoint_category": "Secondary",
            "timepoint": "TOFA Month 1",
            "measurement_type": "Absolute value",
            "value": 2370.0,
            "unit": "cells/\u00b5l",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 2907.0,
            "change_from_baseline": -537.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "CD3+ T-cell count decreased"
          },
          {
            "endpoint_name": "CD3+ T-cells",
            "endpoint_category": "Secondary",
            "timepoint": "TOFA Month 12",
            "measurement_type": "Absolute value",
            "value": 855.0,
            "unit": "cells/\u00b5l",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 2907.0,
            "change_from_baseline": -2052.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Marked reduction in CD3+ T-cells"
          },
          {
            "endpoint_name": "CD3+ T-cells",
            "endpoint_category": "Secondary",
            "timepoint": "BARI Month 4",
            "measurement_type": "Absolute value",
            "value": 564.0,
            "unit": "cells/\u00b5l",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 1017.0,
            "change_from_baseline": -453.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Continued decrease with BARI"
          },
          {
            "endpoint_name": "CD4+ T-cells",
            "endpoint_category": "Secondary",
            "timepoint": "TOFA Month 1",
            "measurement_type": "Absolute value",
            "value": 1743.0,
            "unit": "cells/\u00b5l",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 2146.0,
            "change_from_baseline": -403.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "CD4+ T-cell count decreased"
          },
          {
            "endpoint_name": "CD4+ T-cells",
            "endpoint_category": "Secondary",
            "timepoint": "TOFA Month 12",
            "measurement_type": "Absolute value",
            "value": 624.0,
            "unit": "cells/\u00b5l",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 2146.0,
            "change_from_baseline": -1522.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Significant reduction in CD4+ T-cells"
          },
          {
            "endpoint_name": "CD4+ T-cells",
            "endpoint_category": "Secondary",
            "timepoint": "BARI Month 4",
            "measurement_type": "Absolute value",
            "value": 430.0,
            "unit": "cells/\u00b5l",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 703.0,
            "change_from_baseline": -273.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Continued decrease with BARI"
          },
          {
            "endpoint_name": "CD8+ T-cells",
            "endpoint_category": "Secondary",
            "timepoint": "TOFA Month 1",
            "measurement_type": "Absolute value",
            "value": 542.0,
            "unit": "cells/\u00b5l",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 799.0,
            "change_from_baseline": -257.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "CD8+ T-cell count decreased"
          },
          {
            "endpoint_name": "CD8+ T-cells",
            "endpoint_category": "Secondary",
            "timepoint": "TOFA Month 12",
            "measurement_type": "Absolute value",
            "value": 220.0,
            "unit": "cells/\u00b5l",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 799.0,
            "change_from_baseline": -579.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Significant reduction in CD8+ T-cells"
          },
          {
            "endpoint_name": "CD8+ T-cells",
            "endpoint_category": "Secondary",
            "timepoint": "BARI Month 4",
            "measurement_type": "Absolute value",
            "value": 116.0,
            "unit": "cells/\u00b5l",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 267.0,
            "change_from_baseline": -151.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Continued decrease with BARI"
          },
          {
            "endpoint_name": "CD19+ B-cells",
            "endpoint_category": "Secondary",
            "timepoint": "TOFA Month 1",
            "measurement_type": "Absolute value",
            "value": 614.0,
            "unit": "cells/\u00b5l",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 545.0,
            "change_from_baseline": 69.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "B-cells remained stable or increased"
          },
          {
            "endpoint_name": "CD19+ B-cells",
            "endpoint_category": "Secondary",
            "timepoint": "TOFA Month 12",
            "measurement_type": "Absolute value",
            "value": 136.0,
            "unit": "cells/\u00b5l",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 545.0,
            "change_from_baseline": -409.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "B-cell count decreased at 12 months"
          },
          {
            "endpoint_name": "CD19+ B-cells",
            "endpoint_category": "Secondary",
            "timepoint": "BARI Month 4",
            "measurement_type": "Absolute value",
            "value": 124.0,
            "unit": "cells/\u00b5l",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 182.0,
            "change_from_baseline": -58.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "B-cell count continued to decrease with BARI"
          },
          {
            "endpoint_name": "NK cells",
            "endpoint_category": "Secondary",
            "timepoint": "TOFA Month 1",
            "measurement_type": "Absolute value",
            "value": 103.0,
            "unit": "cells/\u00b5l",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 211.0,
            "change_from_baseline": -108.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Natural killer cell count decreased"
          },
          {
            "endpoint_name": "NK cells",
            "endpoint_category": "Secondary",
            "timepoint": "TOFA Month 12",
            "measurement_type": "Absolute value",
            "value": 120.0,
            "unit": "cells/\u00b5l",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 211.0,
            "change_from_baseline": -91.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "NK cells remained decreased"
          },
          {
            "endpoint_name": "NK cells",
            "endpoint_category": "Secondary",
            "timepoint": "BARI Month 4",
            "measurement_type": "Absolute value",
            "value": 110.0,
            "unit": "cells/\u00b5l",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 185.0,
            "change_from_baseline": -75.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "NK cells decreased with BARI"
          },
          {
            "endpoint_name": "Central foveal thickness",
            "endpoint_category": "Primary",
            "timepoint": "After TOFA treatment",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "\u00b5m",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 372.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Cystoid macular edema resolved, exact final value not provided"
          },
          {
            "endpoint_name": "Best-corrected visual acuity",
            "endpoint_category": "Primary",
            "timepoint": "After TOFA treatment",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "fraction",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 0.5,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Visual acuity improved from 0.5/1, exact final value not provided"
          },
          {
            "endpoint_name": "Arthritis resolution",
            "endpoint_category": "Primary",
            "timepoint": "TOFA Month 1",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Arthritis signs in knees and wrists disappeared"
          },
          {
            "endpoint_name": "Skin rash resolution",
            "endpoint_category": "Primary",
            "timepoint": "TOFA Month 1",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Erythematous plaques on chest and lower extremities disappeared"
          },
          {
            "endpoint_name": "Macular edema resolution",
            "endpoint_category": "Primary",
            "timepoint": "TOFA Month 2",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Macular edema not present at ophthalmological evaluation after 2 months"
          },
          {
            "endpoint_name": "Anterior uveitis resolution",
            "endpoint_category": "Primary",
            "timepoint": "TOFA Month 2",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Anterior uveitis signs not present after 2 months"
          },
          {
            "endpoint_name": "Steroid withdrawal",
            "endpoint_category": "Secondary",
            "timepoint": "During TOFA treatment",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": 6.0,
            "change_from_baseline": -6.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Progressive reduction in corticosteroids dose up to withdrawal from 6 mg/day methylprednisolone"
          },
          {
            "endpoint_name": "Duration of response TOFA",
            "endpoint_category": "Secondary",
            "timepoint": "TOFA discontinuation",
            "measurement_type": "Absolute value",
            "value": 19.0,
            "unit": "months",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Maintained disease control for 19 months until discontinuation due to lymphopenia"
          },
          {
            "endpoint_name": "Time to response TOFA",
            "endpoint_category": "Secondary",
            "timepoint": "TOFA treatment",
            "measurement_type": "Absolute value",
            "value": 1.0,
            "unit": "month",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Rapid response observed within first weeks to 1 month"
          },
          {
            "endpoint_name": "Disease control maintenance BARI",
            "endpoint_category": "Primary",
            "timepoint": "BARI Month 4",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Cutaneous, ocular, and joint manifestations remained stable"
          },
          {
            "endpoint_name": "Serum IL-4",
            "endpoint_category": "Exploratory",
            "timepoint": "TOFA Month 12",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "pg/ml",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Serum IL-4 levels increased after 12 months of TOFA"
          },
          {
            "endpoint_name": "Serum TNF-\u03b1",
            "endpoint_category": "Exploratory",
            "timepoint": "TOFA Month 12",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "pg/ml",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Serum TNF-\u03b1 levels increased after 12 months of TOFA"
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "Lymphopenia",
            "event_category": "Lab abnormality",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": 1,
            "relatedness": "Related",
            "outcome": "Ongoing",
            "action_taken": "None",
            "notes": "Lymphocyte count decreased to 800 cells/\u00b5l after 4 months of baricitinib treatment (normal range 1200-5000)"
          },
          {
            "event_name": "CD3+ T-cell count decrease",
            "event_category": "Lab abnormality",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": 1,
            "relatedness": "Related",
            "outcome": "Ongoing",
            "action_taken": "None",
            "notes": "CD3+ count decreased from 1017 to 564 cells/\u00b5l over 4 months of baricitinib treatment"
          },
          {
            "event_name": "CD4+ T-cell count decrease",
            "event_category": "Lab abnormality",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": 1,
            "relatedness": "Related",
            "outcome": "Ongoing",
            "action_taken": "None",
            "notes": "CD4+ count decreased from 703 to 430 cells/\u00b5l over 4 months of baricitinib treatment"
          },
          {
            "event_name": "CD8+ T-cell count decrease",
            "event_category": "Lab abnormality",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": 1,
            "relatedness": "Related",
            "outcome": "Ongoing",
            "action_taken": "None",
            "notes": "CD8+ count decreased from 267 to 116 cells/\u00b5l over 4 months of baricitinib treatment"
          },
          {
            "event_name": "Natural killer cell count decrease",
            "event_category": "Lab abnormality",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": 1,
            "relatedness": "Related",
            "outcome": "Ongoing",
            "action_taken": "None",
            "notes": "NK cell count decreased from 185 to 110 cells/\u00b5l over 4 months of baricitinib treatment"
          },
          {
            "event_name": "B-cell count decrease",
            "event_category": "Lab abnormality",
            "severity_grade": "Mild",
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": 1,
            "relatedness": "Related",
            "outcome": "Ongoing",
            "action_taken": "None",
            "notes": "CD19+ B-cell count decreased from 182 to 124 cells/\u00b5l over 4 months, remained within reference range"
          },
          {
            "event_name": "Red blood cell count decrease",
            "event_category": "Lab abnormality",
            "severity_grade": "Mild",
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": 1,
            "relatedness": "Related",
            "outcome": "Ongoing",
            "action_taken": "None",
            "notes": "RBC count decreased from 3.89 to 3.85 x10^6/\u00b5l (below normal range of 4.00-5.40)"
          }
        ],
        "extraction_timestamp": "2025-12-07T18:09:26.228513",
        "extraction_confidence": 0.6,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [
            "Table 1 - Complete laboratory and immunological test results showing TOFA baseline values for acute phase reactants, lymphocyte subsets, T-cell subsets, B-cell subsets, and myeloid lineage cells"
          ],
          "efficacy_tables": [
            "Table 1 - Shows clinical response data at months 1 and 12 for TOFA and month 4 for BARI including lymphocyte counts, inflammatory markers, and immunological parameters"
          ],
          "safety_tables": [
            "Table 1 - Contains safety parameters including lymphocyte counts, hemoglobin, platelets, and other hematological parameters showing lymphopenia development"
          ],
          "efficacy_figures": [
            "Figure 1 - Clinical outcomes showing skin rash resolution (before/after TOFA) and macular edema improvement on OCT imaging",
            "Figure 2a - Leukocytes, lymphocytes, and hemoglobin evolution through follow-up with both treatments",
            "Figure 2b - Cytokines evolution showing IL-4, TNF-\u03b1, IL-2, IL-6, IL-10, and IL-17A levels"
          ],
          "results_sections": [
            "Laboratory Immunological study - detailed analysis of immune parameters during treatment",
            "Clinical response description - rapid control of arthritis, skin rash, and macular edema within 1-2 months",
            "Safety outcomes - lymphopenia development leading to TOFA discontinuation at 19 months"
          ],
          "patient_count": 1,
          "study_type": "Case Report",
          "has_quantitative_outcomes": true,
          "notes": "Single patient with Blau syndrome treated sequentially with tofacitinib then baricitinib. Includes comprehensive immunological monitoring and literature review. Primary efficacy shown through clinical improvement and imaging. Main safety concern was progressive lymphopenia requiring treatment discontinuation."
        }
      },
      "market_intelligence": {
        "disease": "Blau syndrome",
        "epidemiology": {
          "us_prevalence_estimate": "fewer than 1000 patients",
          "us_incidence_estimate": "1 case per 2 million people annually",
          "global_prevalence": null,
          "patient_population_size": 1000,
          "prevalence_source": "Dermatology Times",
          "prevalence_source_url": "https://www.dermatologytimes.com/view/blau-syndrome-a-look-into-a-rare-disease-requiring-collaborative-treatment",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Adalimumab (adalimumab)",
              "drug_class": "TNF-alpha inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": "80%",
              "efficacy_pct": null,
              "annual_cost_usd": 80000.0,
              "line_of_therapy": "2L",
              "notes": "Not FDA approved for Blau syndrome specifically, but commonly used off-label as second-line therapy for uveitis"
            },
            {
              "drug_name": "Infliximab (infliximab)",
              "drug_class": "TNF-alpha inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": "70%",
              "efficacy_pct": null,
              "annual_cost_usd": 75000.0,
              "line_of_therapy": "2L",
              "notes": "Not FDA approved for Blau syndrome specifically, used off-label for arthritis and uveitis"
            },
            {
              "drug_name": "Anakinra (anakinra)",
              "drug_class": "IL-1 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": "60%",
              "efficacy_pct": null,
              "annual_cost_usd": 70000.0,
              "line_of_therapy": "3L",
              "notes": "Not FDA approved for Blau syndrome specifically, used off-label as third-line therapy"
            },
            {
              "drug_name": "Canakinumab (canakinumab)",
              "drug_class": "IL-1 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": "65%",
              "efficacy_pct": null,
              "annual_cost_usd": 200000.0,
              "line_of_therapy": "3L",
              "notes": "Not FDA approved for Blau syndrome specifically, used off-label as third-line therapy"
            },
            {
              "drug_name": "Tocilizumab (tocilizumab)",
              "drug_class": "IL-6 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": "60%",
              "efficacy_pct": null,
              "annual_cost_usd": 65000.0,
              "line_of_therapy": "3L",
              "notes": "Not FDA approved for Blau syndrome specifically, used off-label as third-line therapy"
            },
            {
              "drug_name": "Tofacitinib (tofacitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": "55%",
              "efficacy_pct": null,
              "annual_cost_usd": 55000.0,
              "line_of_therapy": "3L",
              "notes": "Not FDA approved for Blau syndrome specifically, used off-label as third or fourth-line therapy"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 2,
          "pipeline_therapies": [
            {
              "drug_name": "Tofacitinib",
              "company": "Not specified",
              "mechanism": "JAK1/3 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT06660329",
              "expected_completion": null
            },
            {
              "drug_name": "JAK1/3 inhibitor (unspecified)",
              "company": "Not specified",
              "mechanism": "JAK1/3 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT06688838",
              "expected_completion": null
            }
          ],
          "pipeline_details": "The Blau syndrome pipeline consists of JAK inhibitors including tofacitinib and other JAK1/3 inhibitors in Phase 2 studies. Current activity focuses on targeting the JAK pathway to treat this rare autoinflammatory disorder.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "Systemic corticosteroids and methotrexate are first-line therapy, followed by TNF-alpha inhibitors for refractory arthritis and uveitis. Third-line options include IL-1 inhibitors, IL-6 inhibitors, and JAK inhibitors.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved treatments specifically for Blau syndrome exist. Current management relies entirely on off-label use of biologics and conventional immunosuppressants, with many patients experiencing refractory disease requiring multiple treatment switches.",
          "competitive_landscape": "The Blau syndrome treatment landscape consists entirely of off-label biologics with no FDA-approved therapies for this rare autoinflammatory condition. Treatment decisions are based on limited case series and expert opinion rather than controlled clinical trials.",
          "soc_source": "Blau Syndrome (Juvenile Systemic Granulomatosis): State - https://onlinelibrary.wiley.com/doi/10.1111/pde.16001?af=R"
        },
        "market_size_estimate": "$200M",
        "market_size_usd": 200000000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 45000000.0,
        "tam_estimate": "$45M",
        "tam_rationale": "Of ~1,000 global Blau syndrome patients, ~80% are diagnosed (800), ~90% receive treatment (720) given severity of symptoms. With no approved drugs, a new drug would likely be positioned as 1L therapy and could capture 60-70% market share (~450 patients) as first-to-market. At $100K/yr orphan drug pricing, TAM = $45M. Ultra-rare indication with high unmet need supports premium pricing despite small patient population.",
        "tam_sources": [
          "https://reumaped.es/images/site/pdf/PRES_Valencia2010_Abstracts.pdf",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC3933243/",
          "https://www.mdpi.com/2076-2607/10/8/1526"
        ],
        "pipeline_sources": [
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC9058350/",
          "https://clinicaltrials.gov/study/NCT06688838?term=AREA%5BConditionSearch%5D(%22Uveitis%22)%20AND%20AREA%5BInterventionSearch%5D(%22janus%20kinase%20inhibitors%22)&rank=2",
          "https://clinicaltrials.gov/study/NCT06660329"
        ],
        "attributed_sources": [
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9762981/",
            "title": "Distinguishing Blau Syndrome from Systemic Sarcoidosis - PMC",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://onlinelibrary.wiley.com/doi/10.1111/pde.16001?af=R",
            "title": "Blau Syndrome (Juvenile Systemic Granulomatosis): State\u2010Of\u2010The ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.fda.gov/drugs/nda-and-bla-approvals/breakthrough-therapy-approvals",
            "title": "Breakthrough Therapy Approvals | FDA",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://purplebooksearch.fda.gov/",
            "title": "FDA Purplebook",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://pubmed.ncbi.nlm.nih.gov/37735224/",
            "title": "Management of Blau syndrome: review and proposal of a treatment ...",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9058350/",
            "title": "Clinical and immunological study of Tofacitinib and Baricitinib ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT06688838?term=AREA%5BConditionSearch%5D(%22Uveitis%22)%20AND%20AREA%5BInterventionSearch%5D(%22janus%20kinase%20inhibitors%22)&rank=2",
            "title": "Effective Treatment of Jak1/3 Inhibitor in Blau Syndrome",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://reumaped.es/images/site/pdf/PRES_Valencia2010_Abstracts.pdf",
            "title": "PRES Abstracts 1-99 - SERPE",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3933243/",
            "title": "Update on the use of systemic biologic agents in the treatment ... - NIH",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 7.8,
        "evidence_quality": 3.7,
        "market_opportunity": 8.7,
        "overall_priority": 7.0,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 8.1,
          "endpoint_quality": 3.6,
          "organ_domain_breadth": 10.0,
          "safety_categories": [
            "thromboembolic",
            "cytopenia"
          ],
          "regulatory_flags": [
            "thromboembolic",
            "cytopenia"
          ]
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 8.1,
        "endpoint_quality_score": 3.6,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 2.0,
          "response_durability": 5.0,
          "extraction_completeness": 8.3
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 5.0,
        "extraction_completeness_score": 8.3,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 6.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 6.0,
        "unmet_need_score": 10.0
      },
      "rank": 26
    },
    {
      "extraction": {
        "source": {
          "pmid": "34747511",
          "doi": "10.1111/ced.15005",
          "url": "https://pubmed.ncbi.nlm.nih.gov/34747511/",
          "title": "Treatment of refractory subacute cuataneous lupus erythematosus with baricitinib.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "refractory subacute cutaneous lupus erythematosus",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [],
          "disease_severity": null,
          "comorbidities": null,
          "description": "patient with refractory subacute cutaneous lupus erythematosus presenting with scaly annular and polycyclic patches/plaques, and hyperkeratotic lesions on multiple fingers"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": null,
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": "rapid",
          "duration_of_response": null,
          "effect_size_description": "rapid improvement of cutaneous manifestations",
          "primary_endpoint": "improvement of cutaneous lesions",
          "endpoint_result": "rapid improvement of scaly annular and polycyclic patches/plaques, and hyperkeratotic lesions on multiple fingers",
          "durability_signal": null,
          "efficacy_summary": "The patient with refractory subacute cutaneous lupus erythematosus showed rapid improvement of cutaneous lesions after baricitinib treatment. All manifestations including scaly annular and polycyclic patches/plaques and hyperkeratotic lesions improved."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No safety information was reported in this case report.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "Baricitinib demonstrated rapid efficacy in treating refractory subacute cutaneous lupus erythematosus with improvement of multiple cutaneous manifestations.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-07T17:44:27.411362",
        "extraction_confidence": 0.5,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "refractory subacute cutaneous lupus erythematosus",
        "epidemiology": {
          "us_prevalence_estimate": null,
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": 3350,
          "prevalence_source": "NIH",
          "prevalence_source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7880122/",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Benlysta (belimumab)",
              "drug_class": "B-lymphocyte stimulator inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": "Systemic Lupus Erythematosus (SLE)",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "FDA approved for SLE, not specifically for refractory subacute cutaneous lupus erythematosus"
            },
            {
              "drug_name": "Saphnelo (anifrolumab)",
              "drug_class": "Type I interferon receptor antagonist",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": "Systemic Lupus Erythematosus (SLE)",
              "efficacy_range": "49%",
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "FDA approved for moderate to severe SLE, showed benefit in lupus-associated skin disease but not specifically approved for refractory subacute cutaneous lupus erythematosus"
            },
            {
              "drug_name": "Thalidomide",
              "drug_class": "Immunomodulatory agent",
              "is_branded_innovative": false,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Used off-label for refractory cutaneous lupus, not FDA approved for this indication"
            },
            {
              "drug_name": "Rituximab",
              "drug_class": "Anti-CD20 monoclonal antibody",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Used off-label, not FDA approved for refractory subacute cutaneous lupus erythematosus"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 4,
          "pipeline_therapies": [
            {
              "drug_name": "Upadacitinib",
              "company": "Not specified",
              "mechanism": "JAK1 inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT05843643",
              "expected_completion": null
            },
            {
              "drug_name": "VIB7734",
              "company": "Not specified",
              "mechanism": "Not specified",
              "phase": "Phase 2",
              "trial_id": null,
              "expected_completion": null
            },
            {
              "drug_name": "SAR443122",
              "company": "Sanofi",
              "mechanism": "RIPK1 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT04781816",
              "expected_completion": null
            },
            {
              "drug_name": "Anifrolumab",
              "company": "Not specified",
              "mechanism": "IFNAR1 antagonist",
              "phase": "Phase 2",
              "trial_id": "NCT02847598",
              "expected_completion": null
            }
          ],
          "pipeline_details": "The pipeline for refractory subacute cutaneous lupus erythematosus includes multiple active clinical trials testing JAK inhibitors, interferon pathway modulators, and novel kinase inhibitors. Key Phase 2/3 trials are evaluating Upadacitinib, VIB7734, SAR443122, and subcutaneous anifrolumab formulations specifically for cutaneous lupus manifestations.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "First-line treatment includes topical corticosteroids and antimalarials (hydroxychloroquine). Second-line treatments for refractory disease include immunosuppressants like methotrexate, thalidomide, and off-label biologics.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved branded innovative treatments exist specifically for refractory subacute cutaneous lupus erythematosus. Current therapies rely on off-label use of drugs approved for other indications or generic immunosuppressants.",
          "competitive_landscape": "The treatment landscape relies primarily on off-label use of SLE-approved biologics like belimumab and anifrolumab, along with generic immunosuppressants. This represents a significant unmet medical need for targeted therapies specifically approved for this indication.",
          "soc_source": "Medscape and PubMed Central articles on cutaneous lupus treatment"
        },
        "market_size_estimate": "$670M",
        "market_size_usd": 670000000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 167000000.0,
        "tam_estimate": "$167M",
        "tam_rationale": "Of 3,350 refractory subacute cutaneous lupus patients, ~90% are diagnosed (3,015), ~85% receive treatment (2,563). Since these are already refractory patients who failed antimalarials, they're candidates for 2L+ therapy. With zero approved drugs in this space, a first-to-market drug could capture 60-70% market share (~1,670 patients). At $100K/yr pricing (justified by orphan indication and high unmet need), TAM = $167M.",
        "tam_sources": [
          "https://www.actasdermo.org/en-refractory-subacute-cutaneous-lupus-erythematosus-articulo-S1578219012001941",
          "https://go.gale.com/ps/i.do?id=GALE%7CA217606145&sid=googleScholar&v=2.1&it=r&linkaccess=abs&issn=11750561&p=AONE&sw=w",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC10821374/"
        ],
        "pipeline_sources": [
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC12519497/",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC9537468/",
          "https://cdn.clinicaltrials.gov/large-docs/16/NCT04781816/Prot_000.pdf"
        ],
        "attributed_sources": [
          {
            "url": "https://emedicine.medscape.com/article/1065657-overview",
            "title": "Subacute Cutaneous Lupus Erythematosus (SCLE)",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10013735/",
            "title": "Epidemiology of Cutaneous Lupus Erythematosus Among Adults ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761123Orig1s000MultidisciplineR.pdf",
            "title": "761123Orig1s000 - accessdata.fda.gov",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/1065292-treatment",
            "title": "Acute Cutaneous Lupus Erythematosus (ACLE) Treatment ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/1065657-treatment",
            "title": "Subacute Cutaneous Lupus Erythematosus (SCLE) Treatment ...",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12519497/",
            "title": "Focus on Interferon Signature in Cutaneous Lupus ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9537468/",
            "title": "An update on the management of refractory cutaneous lupus ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.actasdermo.org/en-refractory-subacute-cutaneous-lupus-erythematosus-articulo-S1578219012001941",
            "title": "Refractory Subacute Cutaneous Lupus Erythematosus Treated ...",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://go.gale.com/ps/i.do?id=GALE%7CA217606145&sid=googleScholar&v=2.1&it=r&linkaccess=abs&issn=11750561&p=AONE&sw=w",
            "title": "Cutaneous lupus erythematosus: issues in diagnosis and ...",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 7.0,
        "evidence_quality": 4.8,
        "market_opportunity": 9.0,
        "overall_priority": 6.9,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 5.0,
          "endpoint_quality": 5.0,
          "organ_domain_breadth": 8.0,
          "safety_categories": [],
          "regulatory_flags": []
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": 5.0,
        "organ_domain_score": 8.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 10.0,
          "response_durability": 4.0,
          "extraction_completeness": 4.9
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 4.9,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 7.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 7.0,
        "unmet_need_score": 10.0
      },
      "rank": 27
    },
    {
      "extraction": {
        "source": {
          "pmid": "36754594",
          "doi": "10.1136/ard-2022-223815",
          "url": "https://www.semanticscholar.org/paper/1c1e553132b6a66b1c2bb0f74c056b13cd942c8d",
          "title": "Baricitinib for juvenile idiopathic arthritis: a monocentric case series",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "Juvenile Idiopathic Arthritis",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 4,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "methotrexate",
            "adalimumab",
            "etanercept",
            "tocilizumab",
            "corticosteroids"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "4 children with polyarticular JIA (ages 12-16), including psoriatic arthritis and RF+ variants, with multi-drug resistant disease"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "4 mg",
          "frequency": null,
          "duration": "12-19 months",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "3/4 (75%)",
          "responders_n": 3,
          "responders_pct": 75.0,
          "time_to_response": "6 months",
          "duration_of_response": "maintained at 12-19 months follow-up",
          "effect_size_description": "complete clinical remission in responders, including articular and cutaneous symptoms",
          "primary_endpoint": "clinical remission",
          "endpoint_result": "clinical remission achieved in 3/4 patients",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib achieved clinical remission in 3 out of 4 children with multi-drug resistant polyarticular JIA. Response was sustained over 12-19 months of follow-up in responders."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": 0,
          "sae_percentage": 0.0,
          "discontinuations_n": 1,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [
            "inefficacy"
          ],
          "safety_summary": "No adverse events occurred during the observation period in any of the 4 patients. Safety monitoring included checking for JC and BK viruses.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Moderate",
        "comparator_baseline": null,
        "follow_up_duration": "12-19 months",
        "key_findings": "Baricitinib showed beneficial effects in 75% of children with multi-drug resistant JIA with excellent safety profile.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-07T17:57:22.375368",
        "extraction_confidence": 0.5,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Juvenile Idiopathic Arthritis",
        "epidemiology": {
          "us_prevalence_estimate": "294,000 children affected in the United States",
          "us_incidence_estimate": "2-20 cases per 100,000 individuals annually",
          "global_prevalence": null,
          "patient_population_size": 294000,
          "prevalence_source": "POSNA",
          "prevalence_source_url": "https://posna.org/physician-education/study-guide/juvenile-idiopathic-arthritis",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Rinvoq (upadacitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more TNF blockers",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "FDA approved for polyarticular JIA in patients 2 years and older after inadequate response to TNF blockers"
            },
            {
              "drug_name": "Actemra (tocilizumab)",
              "drug_class": "IL-6 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "treatment of polyarticular JIA in children aged 2 years and older with active disease",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved IL-6 inhibitor for polyarticular JIA, can be used alone or with methotrexate"
            },
            {
              "drug_name": "Humira (adalimumab)",
              "drug_class": "TNF inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Juvenile Idiopathic Arthritis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "TNF inhibitor approved for JIA, conditionally recommended as first biologic DMARD"
            },
            {
              "drug_name": "Gamifant (emapalumab-lzsg)",
              "drug_class": "IFN-gamma inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "treatment of adult and pediatric patients with hemophagocytic lymphohistiocytosis/macrophage activation syndrome in known or suspected Still's disease, including systemic Juvenile Idiopathic Arthritis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "First FDA-approved treatment for MAS in systemic JIA with inadequate response to glucocorticoids"
            }
          ],
          "approved_drug_names": [
            "Rinvoq (upadacitinib)",
            "Actemra (tocilizumab)",
            "Humira (adalimumab)",
            "Gamifant (emapalumab-lzsg)"
          ],
          "num_approved_drugs": 4,
          "num_pipeline_therapies": 4,
          "pipeline_therapies": [
            {
              "drug_name": "Tofacitinib",
              "company": "Not specified",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT02592434",
              "expected_completion": null
            },
            {
              "drug_name": "Upadacitinib",
              "company": "Not specified",
              "mechanism": "JAK1 inhibitor",
              "phase": "Not specified",
              "trial_id": "NCT05609630",
              "expected_completion": null
            },
            {
              "drug_name": "Tofacitinib",
              "company": "Not specified",
              "mechanism": "JAK inhibitor",
              "phase": "Long-term safety study",
              "trial_id": "NCT01500551",
              "expected_completion": null
            },
            {
              "drug_name": "Secukinumab",
              "company": "Not specified",
              "mechanism": "IL-17A inhibitor",
              "phase": "Not specified",
              "trial_id": "NCT03031782",
              "expected_completion": null
            }
          ],
          "pipeline_details": "The JIA clinical trial pipeline features JAK inhibitors like tofacitinib and upadacitinib in Phase 3 studies, along with IL-17A inhibitor secukinumab. Multiple trials are evaluating targeted therapies for different JIA subtypes including systemic JIA and enthesitis-related arthritis.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "Treatment approach varies by JIA subtype with IL-1 and IL-6 inhibitors strongly recommended as first-line for systemic JIA, while TNF inhibitors like adalimumab are preferred first biologics for polyarticular disease. NSAIDs are no longer recommended as initial monotherapy.",
          "unmet_need": false,
          "unmet_need_description": null,
          "competitive_landscape": "Multiple FDA-approved biologics are available targeting different pathways including TNF, IL-6, and IFN-gamma with JAK inhibitors available as second-line options. Treatment guidelines emphasize early use of biologics over traditional approaches with NSAIDs and corticosteroids.",
          "soc_source": "Medscape and FDA drug labels"
        },
        "market_size_estimate": "$7.3B",
        "market_size_usd": 7350000000.0,
        "growth_rate": "4-7% CAGR (active pipeline)",
        "tam_usd": 367500000.0,
        "tam_estimate": "$367.5M",
        "tam_rationale": "Of ~294,000 US JIA patients, ~85% are diagnosed (250K), ~70% receive treatment beyond NSAIDs (175K), ~40% eventually require biologic therapy (70K patients). With 4 approved competitors and differentiated IL-1/IL-6 positioning for systemic JIA, a new drug could capture 15-20% market share (~12.25K patients). At $30K/yr average pricing (mix of oral/biologic formulations), TAM = $367.5M. Strong growth driven by shift away from NSAID monotherapy.",
        "tam_sources": [
          "https://www.linkedin.com/pulse/united-states-juvenile-idiopathic-arthritis-treatment-market-wlblc/",
          "https://www.reanin.com/reports/polyarticular-juvenile-idiopathic-arthritis-market",
          "https://www.precedenceresearch.com/rheumatoid-arthritis-drugs-market"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov/study/NCT03841357",
          "https://www.clinicaltrials.gov/study/NCT02592434",
          "https://clinicaltrials.gov/study/NCT05609630"
        ],
        "attributed_sources": [
          {
            "url": "https://posna.org/physician-education/study-guide/juvenile-idiopathic-arthritis",
            "title": "Juvenile Idiopathic Arthritis",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://emedicine.medscape.com/article/1007276-overview",
            "title": "Juvenile Idiopathic Arthritis - Medscape Reference",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://emedicine.medscape.com/article/1007276-treatment",
            "title": "Juvenile Idiopathic Arthritis Treatment & Management",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/1007276-medication",
            "title": "Juvenile Idiopathic Arthritis Medication: Nonsteroidal Anti- ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.the-rheumatologist.org/article/experts-discuss-draft-of-new-jia-guideline/",
            "title": "Experts Discuss Draft of New JIA Guideline - The Rheumatologist",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT03841357",
            "title": "Preventing Extension of Oligoarticular Juvenile Idiopathic ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT02592434",
            "title": "Efficacy Study Of Tofacitinib In Pediatric JIA Population",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.linkedin.com/pulse/united-states-juvenile-idiopathic-arthritis-treatment-market-wlblc/",
            "title": "United States Juvenile Idiopathic Arthritis Treatment Market Size ...",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.reanin.com/reports/polyarticular-juvenile-idiopathic-arthritis-market",
            "title": "Polyarticular Juvenile Idiopathic Arthritis (PJIA) Market - ReAnIn",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 8.2,
        "evidence_quality": 4.8,
        "market_opportunity": 6.3,
        "overall_priority": 6.9,
        "clinical_breakdown": {
          "response_rate": 8.0,
          "safety_profile": 10.0,
          "endpoint_quality": 5.0,
          "organ_domain_breadth": 10.0,
          "safety_categories": [],
          "regulatory_flags": []
        },
        "response_rate_score": 8.0,
        "safety_profile_score": 10.0,
        "endpoint_quality_score": 5.0,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 2.0,
          "publication_venue": 2.0,
          "response_durability": 9.0,
          "extraction_completeness": 7.2
        },
        "sample_size_score": 2.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 9.0,
        "extraction_completeness_score": 7.2,
        "market_breakdown": {
          "competitors": 5.0,
          "market_size": 9.0,
          "unmet_need": 5.0
        },
        "competitors_score": 5.0,
        "market_size_score": 9.0,
        "unmet_need_score": 5.0
      },
      "rank": 28
    },
    {
      "extraction": {
        "source": {
          "pmid": null,
          "doi": null,
          "url": "https://www.sciencedirect.com/science/article/pii/S0960896624001408",
          "title": "Baricitinib as a treatment for myasthenia gravis: a case report",
          "authors": null,
          "journal": "Neuromuscular Disorders",
          "year": 2024,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "myasthenia gravis",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "steroids",
            "pyridostigmine"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "58-year-old woman with ocular myasthenia gravis and alopecia areata"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": null,
          "frequency": null,
          "duration": "six months",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": null,
          "duration_of_response": "maintained through 6 months of treatment",
          "effect_size_description": "complete symptom resolution with decreased anti-acetylcholine receptor antibody titer",
          "primary_endpoint": "resolution of myasthenia gravis symptoms",
          "endpoint_result": "complete resolution of MG symptoms",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib resulted in complete resolution of myasthenia gravis symptoms in a patient with inadequate response to steroids and pyridostigmine. The treatment also led to decreased anti-acetylcholine receptor antibody titers and allowed for tapering of steroids and discontinuation of pyridostigmine."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No adverse events or safety concerns were reported in this case report during the six-month treatment period.",
          "safety_profile": "Favorable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "six months",
        "key_findings": "First reported case of JAK inhibitor treatment for anti-acetylcholine receptor positive myasthenia gravis showing complete symptom resolution and antibody titer reduction.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-07T17:19:55.196023",
        "extraction_confidence": 0.5,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "myasthenia gravis",
        "epidemiology": {
          "us_prevalence_estimate": "37 per 100,000",
          "us_incidence_estimate": "5.16 per 100,000 patient-years",
          "global_prevalence": null,
          "patient_population_size": 123900,
          "prevalence_source": "Journal of Managed Care & Specialty Pharmacy",
          "prevalence_source_url": "https://www.jmcp.org/doi/10.18553/jmcp.2025.31.5.472",
          "trend": "increasing"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Vyvgart (efgartigimod)",
              "drug_class": "FcRn receptor blocker",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "treatment of generalized myasthenia gravis (gMG) in adults who test positive for the anti-acetylcholine receptor (AChR) antibody",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "First-in-class FcRn receptor blocker approved in 2021, received Fast Track and Orphan Drug designations"
            },
            {
              "drug_name": "Rystiggo (rozanolixizumab)",
              "drug_class": "FcRn receptor blocker",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "FDA approved June 26, 2023, approved for both AChR and MuSK antibody positive patients"
            },
            {
              "drug_name": "Soliris (eculizumab)",
              "drug_class": "C5 complement inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients six years of age and older who are anti-acetylcholine receptor (AChR) antibody positive",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Initially approved October 23, 2017 for adults, expanded to pediatric patients 6+ in February 2025"
            },
            {
              "drug_name": "Ultomiris (ravulizumab)",
              "drug_class": "C5 complement inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "treatment of adult patients with gMG who are anti-acetylcholine receptor (AChR) antibody positive",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Second FDA-approved C5 complement inhibitor for myasthenia gravis"
            },
            {
              "drug_name": "Zilbrysq (zilucoplan)",
              "drug_class": "C5 complement inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "treatment of generalized myasthenia gravis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Referenced as FDA-approved complement inhibitor in 2023 FDA documents"
            },
            {
              "drug_name": "Imaavy (nipocalimab)",
              "drug_class": "FcRn receptor blocker",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "treatment of generalized myasthenia gravis (gMG) in adults and pediatric patients, 12 years and older, who are antibody positive",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Recently approved for both AChR and MuSK antibody positive patients, includes pediatric indication down to age 12"
            }
          ],
          "approved_drug_names": [
            "Vyvgart (efgartigimod)",
            "Rystiggo (rozanolixizumab)",
            "Soliris (eculizumab)",
            "Ultomiris (ravulizumab)",
            "Zilbrysq (zilucoplan)",
            "Imaavy (nipocalimab)"
          ],
          "num_approved_drugs": 6,
          "num_pipeline_therapies": 5,
          "pipeline_therapies": [
            {
              "drug_name": "ZILBRYSQ (zilucoplan)",
              "company": "UCB",
              "mechanism": "Complement C5 inhibitor",
              "phase": "Phase 3",
              "trial_id": null,
              "expected_completion": null
            },
            {
              "drug_name": "Inebilizumab",
              "company": null,
              "mechanism": "Anti-CD19 monoclonal antibody",
              "phase": "Phase 3",
              "trial_id": "NCT04524273",
              "expected_completion": null
            },
            {
              "drug_name": "Satralizumab",
              "company": "Roche/Genentech",
              "mechanism": "Anti-IL-6 receptor monoclonal antibody",
              "phase": "Phase 3",
              "trial_id": "NCT04963270",
              "expected_completion": null
            },
            {
              "drug_name": "NMD670",
              "company": null,
              "mechanism": null,
              "phase": "Phase 3",
              "trial_id": "NCT06414954",
              "expected_completion": null
            },
            {
              "drug_name": "IMVT-1402",
              "company": null,
              "mechanism": null,
              "phase": "Phase 2",
              "trial_id": "NCT07039916",
              "expected_completion": null
            }
          ],
          "pipeline_details": "The myasthenia gravis pipeline shows active Phase 2 and 3 trials testing multiple novel mechanisms including complement inhibition, B-cell depletion, and IL-6 receptor blockade. Several late-stage trials are evaluating treatments as add-on therapy to standard of care for generalized myasthenia gravis.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "Treatment typically starts with pyridostigmine for symptomatic relief, followed by immunosuppressive therapy with corticosteroids and steroid-sparing agents. FDA-approved targeted therapies including FcRn receptor blockers and complement inhibitors are used as second-line treatments for patients who do not achieve treatment goals with conventional therapy.",
          "unmet_need": true,
          "unmet_need_description": "Not all patients with gMG are able to receive, tolerate, or adequately benefit from currently available clinical treatments, indicating ongoing unmet medical need despite multiple FDA-approved targeted therapies",
          "competitive_landscape": "The myasthenia gravis treatment landscape has rapidly evolved with six FDA-approved innovative therapies targeting two main mechanisms: FcRn receptor blockade (Vyvgart, Rystiggo, Imaavy) and complement inhibition (Soliris, Ultomiris, Zilbrysq). These targeted therapies represent significant advances over traditional immunosuppressive approaches for patients with refractory or inadequately controlled disease.",
          "soc_source": "FDA Orphan Drug Database and FDA Drug Approval Documents"
        },
        "market_size_estimate": "$6.2B",
        "market_size_usd": 6195000000.0,
        "growth_rate": "5-10% CAGR (increasing prevalence)",
        "tam_usd": 930000000.0,
        "tam_estimate": "$930M",
        "tam_rationale": "Of ~123,900 global MG patients, ~80% are diagnosed (99K), ~75% receive treatment (74K), ~40% progress to 2L+ biologics after inadequate response to conventional therapy (30K). A new targeted therapy could capture 20-25% market share (~7K patients) given 6 existing competitors but significant unmet need. At $130K/yr pricing (typical for rare disease biologics), TAM = $930M. Strong growth driven by expanding biologic adoption and broadening treatment criteria to include seronegative/ocular patients.",
        "tam_sources": [
          "https://www.strategicmarketresearch.com/market-report/myasthenia-gravis-treatment-market",
          "https://www.mordorintelligence.com/industry-reports/myasthenia-gravis-therapeutics-market",
          "https://finance.yahoo.com/quote/HALO/earnings/HALO-Q2-2025-earnings_call-343075.html/"
        ],
        "pipeline_sources": [
          "https://www.zilbrysqhcp.com/clinical-trial",
          "https://clinicaltrials.gov/study/NCT04524273",
          "https://cdn.clinicaltrials.gov/large-docs/70/NCT04963270/Prot_000.pdf"
        ],
        "attributed_sources": [
          {
            "url": "https://www.neurology.org/doi/10.1212/WNL.0000000000204748",
            "title": "Incidence and Prevalence of Myasthenia Gravis: Analysis of a US ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.jmcp.org/doi/10.18553/jmcp.2025.31.5.472",
            "title": "Health care costs and resource utilization among patients with ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=669918",
            "title": "Search Orphan Drug Designations and Approvals - FDA",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-myasthenia-gravis",
            "title": "FDA Approves New Treatment for Myasthenia Gravis",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7358547/",
            "title": "A Practical Approach to Managing Patients With Myasthenia Gravis ...",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://www.zilbrysqhcp.com/clinical-trial",
            "title": "ZILBRYSQ\u00ae Clinical Trial Data For gMG",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT04524273",
            "title": "NCT04524273 | Myasthenia Gravis Inebilizumab Trial",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.strategicmarketresearch.com/market-report/myasthenia-gravis-treatment-market",
            "title": "Myasthenia Gravis Treatment Market Size ($2.35 Billion) 2030",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.mordorintelligence.com/industry-reports/myasthenia-gravis-therapeutics-market",
            "title": "Myasthenia Gravis Therapeutics Market Size & Share Analysis",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 8.4,
        "evidence_quality": 3.1,
        "market_opportunity": 7.3,
        "overall_priority": 6.8,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 9.0,
          "endpoint_quality": 5.0,
          "organ_domain_breadth": 10.0,
          "safety_categories": [],
          "regulatory_flags": []
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 9.0,
        "endpoint_quality_score": 5.0,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 2.0,
          "response_durability": 4.0,
          "extraction_completeness": 6.6
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 6.6,
        "market_breakdown": {
          "competitors": 3.0,
          "market_size": 9.0,
          "unmet_need": 10.0
        },
        "competitors_score": 3.0,
        "market_size_score": 9.0,
        "unmet_need_score": 10.0
      },
      "rank": 29
    },
    {
      "extraction": {
        "source": {
          "pmid": "40852724",
          "doi": "10.3389/fimmu.2025.1568338",
          "url": "https://pubmed.ncbi.nlm.nih.gov/40852724/",
          "title": "A pilot transcriptomic study of a novel multitargeted BRT regimen for anti-MDA5 antibody-positive dermatomyositis: improving survival over conventional therapy.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "anti-MDA5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 7,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "tacrolimus-cyclophosphamide combination therapy"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "Japanese patients with MDA5-DM and multiple poor prognostic factors including ILD, high anti-MDA5 antibody titers, elevated ferritin, LDH, CRP, KL-6"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "4 mg daily (2 mg if eGFR <60)",
          "frequency": null,
          "duration": "until ferritin normalization in controlled disease",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "7/7 (100%)",
          "responders_n": 7,
          "responders_pct": 100.0,
          "time_to_response": null,
          "duration_of_response": "12 months",
          "effect_size_description": "100% survival vs 43% with conventional therapy",
          "primary_endpoint": "12-month survival rate",
          "endpoint_result": "100% survival at 12 months",
          "durability_signal": null,
          "efficacy_summary": "All 7 patients treated with BRT regimen survived 12 months compared to 4/7 deaths in historical controls treated with tacrolimus-cyclophosphamide. Only 1 patient required rescue therapy with plasma exchange."
        },
        "safety": {
          "adverse_events": [
            "cytomegalovirus reactivation"
          ],
          "serious_adverse_events": [
            "limbic encephalitis"
          ],
          "sae_count": 1,
          "sae_percentage": 14.3,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "CMV reactivation occurred in 5/7 patients but was successfully treated. One case of limbic encephalitis occurred. No treatment-related deaths were observed.",
          "safety_profile": "Acceptable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": "12 months",
        "key_findings": "BRT combination therapy achieved 100% survival in high-risk MDA5-DM patients with transcriptomic evidence of B-cell suppression and reduced interferon signatures in survivors.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "12-month survival rate",
            "endpoint_category": "Primary",
            "timepoint": "12 months",
            "measurement_type": "Responder",
            "value": 100.0,
            "unit": "%",
            "responders_n": 7,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": "0.045",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "BRT-Tx group survival rate"
          },
          {
            "endpoint_name": "12-month survival rate",
            "endpoint_category": "Primary",
            "timepoint": "12 months",
            "measurement_type": "Responder",
            "value": 42.9,
            "unit": "%",
            "responders_n": 3,
            "responders_pct": 42.9,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": "0.045",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "TC-Tx group survival rate (historical control)"
          },
          {
            "endpoint_name": "Combined rescue therapy requirement",
            "endpoint_category": "Secondary",
            "timepoint": "12 months",
            "measurement_type": "Responder",
            "value": 14.3,
            "unit": "%",
            "responders_n": 1,
            "responders_pct": 14.3,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "BRT-Tx group requiring rescue therapy (mPSL pulse, PE, IVIG)"
          },
          {
            "endpoint_name": "Cytomegalovirus reactivation rate",
            "endpoint_category": "Secondary",
            "timepoint": "12 months",
            "measurement_type": "Responder",
            "value": 71.4,
            "unit": "%",
            "responders_n": 5,
            "responders_pct": 71.4,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "BRT-Tx group CMV reactivation"
          },
          {
            "endpoint_name": "Cytomegalovirus reactivation rate",
            "endpoint_category": "Secondary",
            "timepoint": "12 months",
            "measurement_type": "Responder",
            "value": 85.7,
            "unit": "%",
            "responders_n": 6,
            "responders_pct": 85.7,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "TC-Tx group CMV reactivation"
          },
          {
            "endpoint_name": "Leukocyte transendothelial migration suppression",
            "endpoint_category": "Exploratory",
            "timepoint": "3 months",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "GSVA score",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": "0.0198",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "BRT-Tx vs TC-Tx comparison by GSVA"
          },
          {
            "endpoint_name": "B-cell receptor signaling pathway gene expression",
            "endpoint_category": "Exploratory",
            "timepoint": "3 months",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "Gene expression",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": "6.10E-06",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Downregulated in BRT group"
          },
          {
            "endpoint_name": "Lymphocyte proliferation gene expression",
            "endpoint_category": "Exploratory",
            "timepoint": "3 months",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "Gene expression",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": "2.11E-06",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Downregulated in BRT group"
          },
          {
            "endpoint_name": "B-cell proliferation gene expression",
            "endpoint_category": "Exploratory",
            "timepoint": "3 months",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "Gene expression",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": "1.14E-05",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Downregulated in BRT group"
          },
          {
            "endpoint_name": "Immunoglobulin complex gene expression",
            "endpoint_category": "Exploratory",
            "timepoint": "3 months",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "Gene expression",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": "2.83E-07",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Downregulated in survivors"
          },
          {
            "endpoint_name": "Type I interferon signature score",
            "endpoint_category": "Exploratory",
            "timepoint": "2-3 months",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "IFN score",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Significantly lower in survivors vs deceased patients"
          },
          {
            "endpoint_name": "Type II interferon signature score",
            "endpoint_category": "Exploratory",
            "timepoint": "2-3 months",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "IFN score",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Significantly lower in survivors vs deceased patients"
          },
          {
            "endpoint_name": "Type III interferon signature score",
            "endpoint_category": "Exploratory",
            "timepoint": "2-3 months",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "IFN score",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Significantly lower in survivors vs deceased patients"
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "Limbic encephalitis",
            "event_category": "SAE",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": 14.3,
            "events_total": 1,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "Occurred in BRT-1 patient on day 91; described as unexplained limbic encephalitis with fever and seizures; diagnosed based on CSF analysis and head MRI; viral involvement suspected but not confirmed; described as sole serious adverse event in BRT patients"
          },
          {
            "event_name": "Fever",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": 14.3,
            "events_total": 1,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "Occurred in BRT-1 patient on day 91 in association with limbic encephalitis"
          },
          {
            "event_name": "Seizures",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": 14.3,
            "events_total": 1,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "Occurred in BRT-1 patient on day 91 in association with limbic encephalitis"
          },
          {
            "event_name": "Cytomegalovirus reactivation",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 5,
            "patients_affected_pct": 71.4,
            "events_total": 5,
            "relatedness": null,
            "outcome": "Resolved",
            "action_taken": null,
            "notes": "Occurred in 5 out of 7 BRT patients; all affected patients received appropriate antiviral treatment and achieved recovery; one BRT patient did not experience CMV reactivation due to prophylactic acyclovir"
          },
          {
            "event_name": "Need for combined rescue therapy",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": 14.3,
            "events_total": 1,
            "relatedness": null,
            "outcome": "Resolved",
            "action_taken": null,
            "notes": "BRT-4 patient required combined rescue therapy including mPSL pulse therapy, plasma exchange, and IVIG due to mild worsening of ILD and increase in anti-MDA5 antibody titer at 3 months; led to recovery without recurrence"
          }
        ],
        "extraction_timestamp": "2025-12-07T17:47:27.895228",
        "extraction_confidence": 0.6,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [
            "Table 2: Baseline characteristics of the patients comparing TC group (n=7) vs BRT group (n=7), including demographics, laboratory values, clinical symptoms, and poor prognostic factors"
          ],
          "efficacy_tables": [
            "Table 3: GO analysis of DEGs (suppressed genes) comparing BRT and TC treatment groups showing differential gene expression patterns",
            "Table 4: Characteristics of surviving patients (n=4) vs fatal patients (n=2) according to GO analysis of differentially expressed genes"
          ],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure 1: Clustering of DEGs (pre- vs posttreatment) showing hierarchical clustering that distinguished deceased patients from survivors irrespective of treatment type"
          ],
          "results_sections": [
            "Characteristics of patients at baseline",
            "Treatment course of each patient",
            "Gene expression differences observed before and after treatment are more closely linked to prognosis than to the specific treatment modality",
            "Characteristics of gene expression changes following BRT and TC",
            "Characteristics of the surviving and fatal patients",
            "Comparison of IFN signatures before and after treatment"
          ],
          "patient_count": 14,
          "study_type": "Retrospective Study",
          "has_quantitative_outcomes": true,
          "notes": "Primary efficacy outcome is 12-month survival (BRT: 7/7 survived vs TC: 3/7 survived, p=0.045). Safety data described in text includes CMV reactivation (BRT: 5/7, TC: 6/7) and one case of limbic encephalitis in BRT group. Study includes extensive transcriptomic analysis with gene expression profiling."
        }
      },
      "market_intelligence": {
        "disease": "anti-MDA5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease",
        "epidemiology": {
          "us_prevalence_estimate": null,
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": 2300,
          "prevalence_source": "Cleveland Clinic Journal of Medicine",
          "prevalence_source_url": "https://www.ccjm.org/content/92/10/627",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Corticosteroids (prednisone)",
              "drug_class": "Corticosteroid",
              "is_branded_innovative": false,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "Standard of care but not specifically approved for anti-MDA5 DM with RP-ILD"
            },
            {
              "drug_name": "Cyclophosphamide (generic)",
              "drug_class": "Alkylating agent",
              "is_branded_innovative": false,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "Used off-label for rapidly progressive disease but not specifically approved for anti-MDA5 DM with RP-ILD"
            },
            {
              "drug_name": "Mycophenolate (generic)",
              "drug_class": "Antimetabolite immunosuppressant",
              "is_branded_innovative": false,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "Used off-label but not specifically approved for anti-MDA5 DM with RP-ILD"
            },
            {
              "drug_name": "Rituximab (Rituxan)",
              "drug_class": "CD20 monoclonal antibody",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": 50000.0,
              "line_of_therapy": "2L",
              "notes": "Used off-label but not specifically approved for anti-MDA5 DM with RP-ILD"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 4,
          "pipeline_therapies": [
            {
              "drug_name": "ravulizumab (ALXN1210)",
              "company": "Alexion",
              "mechanism": "Complement C5 inhibitor",
              "phase": "Phase 2/Phase 3",
              "trial_id": "NCT04999020",
              "expected_completion": null
            },
            {
              "drug_name": "KZR-616",
              "company": "Kezar Life Sciences",
              "mechanism": "Selective immunoproteasome inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT04033926",
              "expected_completion": null
            },
            {
              "drug_name": "PF-06823859",
              "company": "Pfizer",
              "mechanism": "Unknown",
              "phase": "Phase 2",
              "trial_id": "NCT03181893",
              "expected_completion": null
            },
            {
              "drug_name": "baricitinib",
              "company": "Eli Lilly",
              "mechanism": "JAK1/JAK2 inhibitor",
              "phase": "Phase 2/Phase 3",
              "trial_id": "NCT04517253",
              "expected_completion": null
            }
          ],
          "pipeline_details": "Several therapies are in development for dermatomyositis with interstitial lung disease complications, including complement inhibitors, immunoproteasome inhibitors, and JAK inhibitors. The pipeline focuses on targeting inflammatory pathways and immune dysregulation associated with severe dermatomyositis presentations.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "Combined immunosuppressive treatment with corticosteroids plus cyclophosphamide or mycophenolate is considered first-line therapy. Rituximab may be used as second-line therapy.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved treatments specifically for anti-MDA5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease. Current treatment relies on off-label use of immunosuppressants with high mortality rates.",
          "competitive_landscape": "The field lacks targeted therapies with all current treatments being off-label immunosuppressants. Anti-MDA5 positive dermatomyositis with rapidly progressive ILD has poor prognosis and high mortality despite aggressive treatment.",
          "soc_source": "PMC Article PMC8476986 - https://pmc.ncbi.nlm.nih.gov/articles/PMC8476986/"
        },
        "market_size_estimate": "$460M",
        "market_size_usd": 460000000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 230000000.0,
        "tam_estimate": "$230M",
        "tam_rationale": "Of ~2,300 global patients with anti-MDA5+ dermatomyositis with RP-ILD, ~90% are diagnosed due to rapidly progressive nature (2,070), ~95% receive aggressive treatment given severity (1,967). With no approved drugs and current therapies often failing, a first-in-class targeted therapy could capture 60% market share (~1,180 patients). At ultra-orphan pricing of $195K/yr given high mortality and unmet need, TAM = $230M.",
        "tam_sources": [
          "https://pubmed.ncbi.nlm.nih.gov/33910791/",
          "https://argenx.com/content/dam/argenx-corp/media-documents/argenx_report_march_21_2021.pdf",
          "https://www.avast.com/pt-br/index"
        ],
        "pipeline_sources": [
          "https://cdn.clinicaltrials.gov/large-docs/20/NCT04999020/Prot_000.pdf",
          "https://cdn.clinicaltrials.gov/large-docs/26/NCT04033926/Prot_SAP_000.pdf",
          "https://cdn.clinicaltrials.gov/large-docs/93/NCT03181893/Prot_000.pdf"
        ],
        "attributed_sources": [
          {
            "url": "https://www.ccjm.org/content/92/10/627",
            "title": "MDA5 dermatomyositis: Unveiling a potentially life-threatening ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1286973/full",
            "title": "Rapidly progressive interstitial lung disease risk prediction in anti ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://emedicine.medscape.com/article/332783-medication",
            "title": "Dermatomyositis Medication: Disease-Modifying ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/332783-treatment",
            "title": "Dermatomyositis Treatment & Management: Approach ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8094376/",
            "title": "Anti-MDA5 antibody-positive dermatomyositis with rapidly ... - NIH",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/20/NCT04999020/Prot_000.pdf",
            "title": "TITLE PAGE",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/26/NCT04033926/Prot_SAP_000.pdf",
            "title": "kzr-616-003 a phase 2 randomized, double-blind, placebo- ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://pubmed.ncbi.nlm.nih.gov/33910791/",
            "title": "Anti-MDA5 antibody-positive dermatomyositis with rapidly ... - PubMed",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://argenx.com/content/dam/argenx-corp/media-documents/argenx_report_march_21_2021.pdf",
            "title": "[PDF] Annual Report 2021 | Argenx",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 5.5,
        "evidence_quality": 7.6,
        "market_opportunity": 8.7,
        "overall_priority": 6.8,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 2.2,
          "endpoint_quality": 1.5,
          "organ_domain_breadth": 10.0,
          "safety_categories": [
            "neurological",
            "serious_infection"
          ],
          "regulatory_flags": [
            "serious_infection"
          ]
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 2.2,
        "endpoint_quality_score": 1.5,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 4.0,
          "publication_venue": 10.0,
          "response_durability": 9.0,
          "extraction_completeness": 8.3
        },
        "sample_size_score": 4.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 9.0,
        "extraction_completeness_score": 8.3,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 6.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 6.0,
        "unmet_need_score": 10.0
      },
      "rank": 30
    },
    {
      "extraction": {
        "source": {
          "pmid": "39737175",
          "doi": "10.3389/fimmu.2024.1501146",
          "url": "https://pubmed.ncbi.nlm.nih.gov/39737175/",
          "title": "Impact of Janus kinase inhibitors and methotrexate on interstitial lung disease in rheumatoid arthritis patients.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "rheumatoid arthritis-associated interstitial lung disease (RA-ILD)",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Retrospective Study",
        "patient_population": {
          "n_patients": 7,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "conventional DMARDs"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "RA patients with interstitial lung disease, 7 patients treated specifically with baricitinib as part of 36 JAKi patients"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "not specified",
          "frequency": null,
          "duration": "mean 14 months (range 6-51 months)",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": null,
          "responders_pct": null,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": "Similar ILD progression rates compared to other treatments (JAKi 19.4% vs abatacept 16.7% vs TNFi 22.2%)",
          "primary_endpoint": "worsening interstitial lung disease based on chest CT score changes",
          "endpoint_result": "19.4% (7/36) of JAKi patients had worsening ILD",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib (as part of JAKi group) showed comparable efficacy to abatacept and TNFi in preventing ILD progression in RA patients. In vitro studies demonstrated that baricitinib combined with methotrexate significantly impeded epithelial-mesenchymal transition, a key mechanism in pulmonary fibrosis."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No specific safety data reported for baricitinib in this study. The study focused on efficacy outcomes regarding ILD progression rather than safety endpoints.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Moderate",
        "comparator_baseline": null,
        "follow_up_duration": "mean 14 months (range 6-51 months)",
        "key_findings": "Baricitinib showed comparable efficacy to established treatments for RA-ILD, with combination baricitinib plus methotrexate demonstrating superior anti-fibrotic effects in vitro.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "Worsening ILD - Overall",
            "endpoint_category": "Primary",
            "timepoint": "Mean 14 months (range 6-51 months)",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percentage",
            "responders_n": 18,
            "responders_pct": 19.4,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "CT score worsening in 18 of 93 patients"
          },
          {
            "endpoint_name": "Worsening ILD - JAKi Group",
            "endpoint_category": "Primary",
            "timepoint": "Mean 14 months (range 6-51 months)",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percentage",
            "responders_n": 7,
            "responders_pct": 19.4,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "7 of 36 patients treated with JAKi (29 tofacitinib, 7 baricitinib)"
          },
          {
            "endpoint_name": "Worsening ILD - CTLA4-Ig Group",
            "endpoint_category": "Primary",
            "timepoint": "Mean 14 months (range 6-51 months)",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percentage",
            "responders_n": 5,
            "responders_pct": 16.7,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "5 of 30 patients treated with abatacept"
          },
          {
            "endpoint_name": "Worsening ILD - TNFi Group",
            "endpoint_category": "Primary",
            "timepoint": "Mean 14 months (range 6-51 months)",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percentage",
            "responders_n": 6,
            "responders_pct": 22.2,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "6 of 27 patients treated with TNF inhibitors"
          },
          {
            "endpoint_name": "DAS28-ESR Baseline - Overall",
            "endpoint_category": "Secondary",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": 4.85,
            "unit": "DAS28-ESR score",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 4.85,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Median (IQR 3.88-5.55)"
          },
          {
            "endpoint_name": "DAS28-ESR Baseline - JAKi Group",
            "endpoint_category": "Secondary",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": 5.19,
            "unit": "DAS28-ESR score",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 5.19,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Median (IQR 4.39-5.93)"
          },
          {
            "endpoint_name": "DAS28-ESR Baseline - CTLA4-Ig Group",
            "endpoint_category": "Secondary",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": 4.9,
            "unit": "DAS28-ESR score",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 4.9,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Median (IQR 3.52-5.46)"
          },
          {
            "endpoint_name": "DAS28-ESR Baseline - TNFi Group",
            "endpoint_category": "Secondary",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": 4.54,
            "unit": "DAS28-ESR score",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 4.54,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Median (IQR 3.40-5.18)"
          },
          {
            "endpoint_name": "High Disease Activity - Baseline",
            "endpoint_category": "Secondary",
            "timepoint": "Baseline",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percentage",
            "responders_n": null,
            "responders_pct": 40.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "DAS28-ESR >5.1, n=79 patients with continuous assessment"
          },
          {
            "endpoint_name": "Moderate Disease Activity - Baseline",
            "endpoint_category": "Secondary",
            "timepoint": "Baseline",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percentage",
            "responders_n": null,
            "responders_pct": 48.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "DAS28-ESR \u22653.2 to \u22645.1"
          },
          {
            "endpoint_name": "Low Disease Activity - Baseline",
            "endpoint_category": "Secondary",
            "timepoint": "Baseline",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percentage",
            "responders_n": null,
            "responders_pct": 6.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "DAS28-ESR \u22652.6 to <3.2"
          },
          {
            "endpoint_name": "Remission - Baseline",
            "endpoint_category": "Secondary",
            "timepoint": "Baseline",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percentage",
            "responders_n": null,
            "responders_pct": 6.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "DAS28-ESR <2.6"
          },
          {
            "endpoint_name": "High Disease Activity - Follow-up",
            "endpoint_category": "Secondary",
            "timepoint": "Mean 14 months follow-up",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percentage",
            "responders_n": null,
            "responders_pct": 8.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "DAS28-ESR >5.1"
          },
          {
            "endpoint_name": "Moderate Disease Activity - Follow-up",
            "endpoint_category": "Secondary",
            "timepoint": "Mean 14 months follow-up",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percentage",
            "responders_n": null,
            "responders_pct": 49.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "DAS28-ESR \u22653.2 to \u22645.1"
          },
          {
            "endpoint_name": "Low Disease Activity - Follow-up",
            "endpoint_category": "Secondary",
            "timepoint": "Mean 14 months follow-up",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percentage",
            "responders_n": null,
            "responders_pct": 25.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "DAS28-ESR \u22652.6 to <3.2"
          },
          {
            "endpoint_name": "Remission - Follow-up",
            "endpoint_category": "Secondary",
            "timepoint": "Mean 14 months follow-up",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percentage",
            "responders_n": null,
            "responders_pct": 18.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "DAS28-ESR <2.6"
          },
          {
            "endpoint_name": "Worsening CT Score - LDA/Remission vs HDA/MDA",
            "endpoint_category": "Secondary",
            "timepoint": "Mean 14 months follow-up",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percentage",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": "0.78",
            "confidence_interval": null,
            "statistical_significance": false,
            "notes": "LDA/remission: 17.7% (6/34) vs HDA/MDA: 22.2% (10/45)"
          },
          {
            "endpoint_name": "EULAR Non-responders - CT Score Worsening",
            "endpoint_category": "Secondary",
            "timepoint": "Mean 14 months follow-up",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percentage",
            "responders_n": 9,
            "responders_pct": 42.9,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": "0.0085",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "9 of 21 non-responders vs 7 of 58 good/moderate responders (12.1%)"
          },
          {
            "endpoint_name": "EULAR Good/Moderate Responders - CT Score Worsening",
            "endpoint_category": "Secondary",
            "timepoint": "Mean 14 months follow-up",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percentage",
            "responders_n": 7,
            "responders_pct": 12.1,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": "0.0085",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "7 of 58 good/moderate responders vs 9 of 21 non-responders (42.9%)"
          },
          {
            "endpoint_name": "Female Gender - Risk Factor for Worsening",
            "endpoint_category": "Secondary",
            "timepoint": "Mean 14 months follow-up",
            "measurement_type": "Change from baseline",
            "value": 3.76,
            "unit": "hazard ratio",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": "0.043",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Multivariate HR 3.76 (95% CI 1.05-13.52)"
          },
          {
            "endpoint_name": "Fibrotic Lesions >10% - Risk Factor for Worsening",
            "endpoint_category": "Secondary",
            "timepoint": "Mean 14 months follow-up",
            "measurement_type": "Change from baseline",
            "value": 3.51,
            "unit": "hazard ratio",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": "0.015",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Multivariate HR 3.51 (95% CI 1.28-9.63)"
          },
          {
            "endpoint_name": "MTX Co-treatment - Protective Factor",
            "endpoint_category": "Secondary",
            "timepoint": "Mean 14 months follow-up",
            "measurement_type": "Change from baseline",
            "value": 0.19,
            "unit": "hazard ratio",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": "0.061",
            "confidence_interval": null,
            "statistical_significance": false,
            "notes": "Multivariate HR 0.19 (95% CI 0.03-1.08), trend towards significance"
          },
          {
            "endpoint_name": "Worsening ILD - MTX Group",
            "endpoint_category": "Secondary",
            "timepoint": "Mean 14 months follow-up",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percentage",
            "responders_n": 1,
            "responders_pct": 3.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": "0.033",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "1 of 33 patients with fibrotic lesions \u226410%"
          },
          {
            "endpoint_name": "Worsening ILD - Non-MTX Group",
            "endpoint_category": "Secondary",
            "timepoint": "Mean 14 months follow-up",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percentage",
            "responders_n": 8,
            "responders_pct": 21.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": "0.033",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "8 of 39 patients with fibrotic lesions \u226410%"
          },
          {
            "endpoint_name": "EULAR Non-responders - MTX Group",
            "endpoint_category": "Secondary",
            "timepoint": "Mean 14 months follow-up",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percentage",
            "responders_n": 3,
            "responders_pct": 12.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": "0.038",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "3 of 25 patients in MTX group"
          },
          {
            "endpoint_name": "EULAR Non-responders - Non-MTX Group",
            "endpoint_category": "Secondary",
            "timepoint": "Mean 14 months follow-up",
            "measurement_type": "Responder",
            "value": null,
            "unit": "percentage",
            "responders_n": 13,
            "responders_pct": 38.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": "0.038",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "13 of 34 patients in non-MTX group"
          },
          {
            "endpoint_name": "CT Score Baseline - Overall",
            "endpoint_category": "Secondary",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": 122.0,
            "unit": "CT score",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 122.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Median (IQR 109-147)"
          },
          {
            "endpoint_name": "CT Score Baseline - JAKi Group",
            "endpoint_category": "Secondary",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": 110.0,
            "unit": "CT score",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 110.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Median (IQR 106-132)"
          },
          {
            "endpoint_name": "CT Score Baseline - CTLA4-Ig Group",
            "endpoint_category": "Secondary",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": 126.0,
            "unit": "CT score",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 126.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Median (IQR 112-153)"
          },
          {
            "endpoint_name": "CT Score Baseline - TNFi Group",
            "endpoint_category": "Secondary",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": 129.0,
            "unit": "CT score",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 129.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Median (IQR 114-145)"
          },
          {
            "endpoint_name": "Inflammatory Lesion Changes - Non-responders vs Responders",
            "endpoint_category": "Exploratory",
            "timepoint": "Mean 14 months follow-up",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "lesion change",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": "0.0050",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Inflammatory lesions significantly worse in non-responders"
          },
          {
            "endpoint_name": "Fibrotic Lesion Changes - Non-responders vs Responders",
            "endpoint_category": "Exploratory",
            "timepoint": "Mean 14 months follow-up",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "lesion change",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": "0.0024",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Fibrotic lesions significantly worse in non-responders"
          },
          {
            "endpoint_name": "N-cadherin Expression - Baricitinib + MTX vs IL-6",
            "endpoint_category": "Exploratory",
            "timepoint": "In vitro study",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "relative expression",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": "<0.01",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Significant reduction in IL-6-induced N-cadherin vs IL-6 group"
          },
          {
            "endpoint_name": "N-cadherin Expression - Baricitinib + MTX vs Baricitinib Alone",
            "endpoint_category": "Exploratory",
            "timepoint": "In vitro study",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "relative expression",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": "<0.05",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Superior reduction vs baricitinib alone, suggesting additive effect"
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "Worsening interstitial lung disease",
            "event_category": "AESI",
            "severity_grade": null,
            "patients_affected_n": 7,
            "patients_affected_pct": 19.4,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "JAKi group - worsening ILD detected on CT imaging"
          },
          {
            "event_name": "Worsening interstitial lung disease",
            "event_category": "AESI",
            "severity_grade": null,
            "patients_affected_n": 5,
            "patients_affected_pct": 16.7,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "Abatacept group - worsening ILD detected on CT imaging"
          },
          {
            "event_name": "Worsening interstitial lung disease",
            "event_category": "AESI",
            "severity_grade": null,
            "patients_affected_n": 6,
            "patients_affected_pct": 22.2,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": null,
            "notes": "TNFi group - worsening ILD detected on CT imaging"
          },
          {
            "event_name": "Treatment discontinuation within 6 months",
            "event_category": "Discontinuation",
            "severity_grade": null,
            "patients_affected_n": 138,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": null,
            "outcome": null,
            "action_taken": "Discontinued",
            "notes": "Patients excluded from analysis due to discontinuation within 6 months of treatment initiation - specific reasons not provided"
          }
        ],
        "extraction_timestamp": "2025-12-07T17:52:56.532615",
        "extraction_confidence": 0.6,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [
            "Table 1: Demographic and clinical characteristics of RA patients by treatment group - shows patient demographics, disease characteristics, and baseline measurements across JAKi, CTLA4-Ig, and TNFi treatment groups"
          ],
          "efficacy_tables": [
            "Table 2: Multivariate analysis of factors associated with worsening CT score in RA-ILD patients - compares characteristics between patients with worsening vs not worsening ILD, includes hazard ratios and confidence intervals"
          ],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure 2: Comparison of inflammatory and fibrotic lesion changes between good/moderate responders and non-responders - shows changes in lung lesions based on treatment response",
            "Figure 3: Cumulative probability plots of change from baseline in CT scores - displays CT score changes for all patients and subgroups based on MTX treatment"
          ],
          "results_sections": [
            "Characteristics of participants",
            "CT score evaluation of chest CT images",
            "Association between disease activity and worsening CT score",
            "Analysis of predictive factors for CT score worsening",
            "In vitro effects of MTX and baricitinib on EMT of A549 cells"
          ],
          "patient_count": 93,
          "study_type": "Retrospective Study",
          "has_quantitative_outcomes": true,
          "notes": "This is a retrospective cohort study, not a case report/series. The paper includes both clinical outcomes data and in vitro experimental results. Primary outcome is worsening of interstitial lung disease based on CT imaging scores. No safety/adverse event tables are present in this study."
        }
      },
      "market_intelligence": {
        "disease": "rheumatoid arthritis-associated interstitial lung disease (RA-ILD)",
        "epidemiology": {
          "us_prevalence_estimate": "3.2 to 6.0 cases per 100,000 people",
          "us_incidence_estimate": "2.7 to 3.8 cases per 100,000 people annually",
          "global_prevalence": null,
          "patient_population_size": 15575,
          "prevalence_source": "The Journal of Rheumatology",
          "prevalence_source_url": "https://www.jrheum.org/content/early/2018/12/07/jrheum.171315",
          "trend": "increasing"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Actemra (tocilizumab)",
              "drug_class": "IL-6 receptor antagonist",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": "Systemic Sclerosis-Associated Interstitial Lung Disease",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": 60000.0,
              "line_of_therapy": null,
              "notes": "FDA approved for SSc-ILD but not specifically for RA-ILD"
            },
            {
              "drug_name": "Ofev (nintedanib)",
              "drug_class": "Tyrosine kinase inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": "Chronic fibrosing ILD with progressive phenotype",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": 95000.0,
              "line_of_therapy": null,
              "notes": "FDA approved for progressive fibrosing ILD but not specifically for RA-ILD"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 3,
          "pipeline_therapies": [
            {
              "drug_name": "pirfenidone",
              "company": "Not specified",
              "mechanism": "Anti-fibrotic agent",
              "phase": "Phase 2",
              "trial_id": "NCT02808871",
              "expected_completion": null
            },
            {
              "drug_name": "rituximab",
              "company": "Not specified",
              "mechanism": "CD20 monoclonal antibody",
              "phase": "Not specified",
              "trial_id": "NCT00578565",
              "expected_completion": null
            },
            {
              "drug_name": "tofacitinib",
              "company": "Not specified",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT05246293",
              "expected_completion": null
            }
          ],
          "pipeline_details": "The RA-ILD pipeline includes three active clinical trials testing pirfenidone (anti-fibrotic), rituximab (anti-CD20), and tofacitinib (JAK inhibitor) as potential treatments. Most trials are in Phase 2 development stage focusing on safety, tolerability and efficacy in this high unmet need indication.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "First-line treatment typically involves mycophenolate mofetil or short-term corticosteroids, with multidisciplinary management approach recommended. No FDA-approved drugs specifically for RA-ILD indication.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved branded innovative treatments specifically for rheumatoid arthritis-associated interstitial lung disease, with current treatment relying on off-label use of immunosuppressants",
          "competitive_landscape": "Treatment relies on generic immunosuppressants like mycophenolate mofetil and corticosteroids. Some branded drugs are approved for related ILD conditions but not specifically for RA-ILD.",
          "soc_source": "PMC11735032 and FDA drug approval documents"
        },
        "market_size_estimate": "$1.6B",
        "market_size_usd": 1557500000.0,
        "growth_rate": "5-10% CAGR (increasing prevalence)",
        "tam_usd": 218000000.0,
        "tam_estimate": "$218M",
        "tam_rationale": "Of ~15,575 US patients with RA-ILD, ~60% are diagnosed (~9,300), and ~80% of diagnosed patients receive systemic treatment (~7,400). As first-in-class therapy for an orphan indication with high unmet need, a new drug could capture 40-50% market share (~3,100 patients) over time. At $70K/yr pricing (justified by specialty orphan status and serious prognosis), TAM = $218M. Zero approved competitors and significant mortality risk support premium positioning.",
        "tam_sources": [
          "https://www.futuremarketinsights.com/reports/pulmonary-fibrosis-biomarkers-market",
          "https://www.jrheum.org/content/early/2025/11/27/jrheum.2025-0797",
          "https://radiopaedia.org/articles/interstitial-lung-disease"
        ],
        "pipeline_sources": [
          "https://pubmed.ncbi.nlm.nih.gov/36075242/",
          "https://clinicaltrials.gov/study/NCT02808871",
          "https://www.clinicaltrials.gov/study/NCT00578565"
        ],
        "attributed_sources": [
          {
            "url": "https://www.nature.com/articles/s41598-023-37452-y",
            "title": "Epidemiology and clinical characteristics of interstitial lung disease ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://pubmed.ncbi.nlm.nih.gov/30442831/",
            "title": "Rheumatoid Arthritis-Interstitial Lung Disease in the United States",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/125276Orig1s131.pdf",
            "title": "CENTER FOR DRUG EVALUATION AND RESEARCH",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/205832Orig1s013.pdf",
            "title": "Approval Package - accessdata.fda.gov",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11735032/",
            "title": "Treatment of rheumatoid arthritis-associated interstitial lung disease",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://pubmed.ncbi.nlm.nih.gov/36075242/",
            "title": "Safety, tolerability, and efficacy of pirfenidone in patients ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT02808871",
            "title": "Phase ll Study of Pirfenidone in Patients With RAILD ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.futuremarketinsights.com/reports/pulmonary-fibrosis-biomarkers-market",
            "title": "Pulmonary Fibrosis Biomarker Market | Global Market Analysis Report",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.jrheum.org/content/early/2025/11/27/jrheum.2025-0797",
            "title": "Screening for rheumatoid arthritis-associated interstitial ...",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 5.3,
        "evidence_quality": 7.3,
        "market_opportunity": 9.3,
        "overall_priority": 6.8,
        "clinical_breakdown": {
          "response_rate": 6.0,
          "safety_profile": 3.7,
          "endpoint_quality": 3.5,
          "organ_domain_breadth": 10.0,
          "safety_categories": [
            "discontinuation",
            "pulmonary"
          ],
          "regulatory_flags": [
            "pulmonary"
          ]
        },
        "response_rate_score": 6.0,
        "safety_profile_score": 3.7,
        "endpoint_quality_score": 3.5,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 4.0,
          "publication_venue": 10.0,
          "response_durability": 9.0,
          "extraction_completeness": 6.6
        },
        "sample_size_score": 4.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 9.0,
        "extraction_completeness_score": 6.6,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 8.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 8.0,
        "unmet_need_score": 10.0
      },
      "rank": 31
    },
    {
      "extraction": {
        "source": {
          "pmid": null,
          "doi": null,
          "url": "https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2021.764067/full",
          "title": "Effectiveness of Baricitinib in Refractory Seronegative Rheumatoid ...",
          "authors": "Kaneko Y, Murakami T, Nishitsuka K, Takakubo Y, Takagi M, Yamashita H",
          "journal": "Frontiers in Medicine",
          "year": 2022,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "uveitis",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": null,
          "disease_severity": null,
          "comorbidities": null,
          "description": "patient with refractory seronegative rheumatoid arthritis and uveitis"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": "effective treatment of refractory uveitis",
          "primary_endpoint": "effectiveness in treating uveitis",
          "endpoint_result": "effectiveness demonstrated",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib demonstrated effectiveness in treating refractory uveitis in a patient with seronegative rheumatoid arthritis. The treatment showed beneficial effects on the ocular manifestations."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No safety information provided in the available abstract.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Moderate",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "Baricitinib showed effectiveness in treating refractory uveitis associated with seronegative rheumatoid arthritis.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-07T17:20:01.971427",
        "extraction_confidence": 0.5,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "uveitis",
        "epidemiology": {
          "us_prevalence_estimate": "234 cases per 100,000 persons",
          "us_incidence_estimate": "52 cases per 100,000 persons annually",
          "global_prevalence": null,
          "patient_population_size": 784000,
          "prevalence_source": "IOVS - ARVO Journals",
          "prevalence_source_url": "https://iovs.arvojournals.org/article.aspx?articleid=2807096",
          "trend": "increasing"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Humira (adalimumab)",
              "drug_class": "TNF-alpha inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "First and only FDA-approved noncorticosteroid therapy for adults with noninfectious intermediate uveitis, posterior uveitis, and panuveitis. Approved June 2016 for adults, September 2018 for pediatrics 2+ years. Has orphan drug designation."
            }
          ],
          "approved_drug_names": [
            "Humira (adalimumab)"
          ],
          "num_approved_drugs": 1,
          "num_pipeline_therapies": 3,
          "pipeline_therapies": [
            {
              "drug_name": "REGN7041",
              "company": "Regeneron",
              "mechanism": "Unknown from available data",
              "phase": "Phase 2/3",
              "trial_id": "NCT07218770",
              "expected_completion": null
            },
            {
              "drug_name": "Adalimumab",
              "company": "Unknown from available data",
              "mechanism": "TNF-alpha inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT03816397",
              "expected_completion": null
            },
            {
              "drug_name": "Filgotinib",
              "company": "Unknown from available data",
              "mechanism": "JAK1 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT03207815",
              "expected_completion": null
            }
          ],
          "pipeline_details": "The uveitis clinical trial pipeline shows active development of biologic therapies including TNF-alpha inhibitors and JAK inhibitors, with several Phase 2 and 3 trials ongoing for noninfectious uveitis treatment.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "First-line treatment consists of topical corticosteroids and mydriatics for acute outbreaks, with systemic corticosteroids for cases requiring systemic treatment. Second-line therapy includes conventional immunosuppressives like methotrexate, with biologics like adalimumab reserved for refractory cases.",
          "unmet_need": true,
          "unmet_need_description": "Limited FDA-approved treatment options beyond corticosteroids, with only one approved biologic therapy. Lack of guidance on treatment initiation timing, limited options for anterior uveitis, and need for additional steroid-sparing agents.",
          "competitive_landscape": "Adalimumab (Humira) is currently the only FDA-approved branded innovative therapy specifically for uveitis, representing a significant unmet medical need. The market relies heavily on off-label use of other immunosuppressives and corticosteroids as standard care.",
          "soc_source": "Medscape Medical Reference and FDA Orphan Drug Database"
        },
        "market_size_estimate": "$19.6B",
        "market_size_usd": 19600000000.0,
        "growth_rate": "5-10% CAGR (increasing prevalence)",
        "tam_usd": 624000000.0,
        "tam_estimate": "$624M",
        "tam_rationale": "Of ~784K US uveitis patients, ~70% are diagnosed (549K), ~40% require systemic treatment beyond topical therapies (220K), ~25% progress to second-line therapy after corticosteroid failure (55K). A new biologic positioned as 2L/3L therapy could capture 20-25% market share (~12K patients) given only 1 approved drug exists and high unmet need. At $52K/yr average biologic cost, TAM = $624M.",
        "tam_sources": [
          "https://www.mordorintelligence.com/industry-reports/uveitis-treatment-market",
          "https://straitsresearch.com/report/uveitis-treatment-market",
          "https://www.gminsights.com/industry-analysis/uveitis-treatment-market"
        ],
        "pipeline_sources": [
          "https://pubmed.ncbi.nlm.nih.gov/38129984/",
          "https://www.clinicaltrials.gov/study/NCT03816397",
          "https://www.clinicaltrials.gov/study/NCT07218770"
        ],
        "attributed_sources": [
          {
            "url": "https://iovs.arvojournals.org/article.aspx?articleid=2807096",
            "title": "Epidemiology of Uveitis in the United States - IOVS - ARVO Journals",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2551695",
            "title": "Prevalence of Noninfectious Uveitis in the United States",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://emedicine.medscape.com/article/798323-medication",
            "title": "Iritis and Uveitis Medication",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.medscape.com/viewarticle/865654",
            "title": "FDA Clears Adalimumab (Humira) for Uveitis",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.jrheum.org/content/41/1/3",
            "title": "Treat to Target in the Management of Chronic Uveitis",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://pubmed.ncbi.nlm.nih.gov/38129984/",
            "title": "Recent advances in uveitis therapy: focus on selected ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT03816397",
            "title": "Adalimumab in JIA-associated Uveitis Stopping Trial",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.mordorintelligence.com/industry-reports/uveitis-treatment-market",
            "title": "Uveitis Treatment Market Size & Share Analysis - Mordor Intelligence",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://straitsresearch.com/report/uveitis-treatment-market",
            "title": "Uveitis Treatment Market Size, Share & Trends | Industry Report, 2033",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 7.0,
        "evidence_quality": 2.9,
        "market_opportunity": 9.0,
        "overall_priority": 6.5,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 5.0,
          "endpoint_quality": 5.0,
          "organ_domain_breadth": 8.0,
          "safety_categories": [],
          "regulatory_flags": []
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": 5.0,
        "organ_domain_score": 8.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 2.0,
          "response_durability": 4.0,
          "extraction_completeness": 5.5
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 5.5,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 10.0,
          "unmet_need": 10.0
        },
        "competitors_score": 7.0,
        "market_size_score": 10.0,
        "unmet_need_score": 10.0
      },
      "rank": 32
    },
    {
      "extraction": {
        "source": {
          "pmid": null,
          "doi": null,
          "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10668263/",
          "title": "a case report and review of baricitinib use in the treatment of chronic ...",
          "authors": "SH, KK, SD-F",
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "immune checkpoint inhibitor-related myocarditis",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "steroids"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "patient with steroid-refractory immune checkpoint inhibitor-related myocarditis"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": null,
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": "complete recovery",
          "primary_endpoint": "recovery from myocarditis",
          "endpoint_result": "recovery achieved",
          "durability_signal": null,
          "efficacy_summary": "Single patient with steroid-refractory immune checkpoint inhibitor-related myocarditis achieved recovery with baricitinib treatment. This represents the first reported case of baricitinib use for this indication."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No safety data provided in the abstract. Safety outcomes not reported.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Moderate",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "First reported case of baricitinib successfully treating steroid-refractory immune checkpoint inhibitor-related myocarditis.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-07T17:20:18.048614",
        "extraction_confidence": 0.5,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "immune checkpoint inhibitor-related myocarditis",
        "epidemiology": {
          "us_prevalence_estimate": "1.14%",
          "us_incidence_estimate": "0.35% at 36 months",
          "global_prevalence": null,
          "patient_population_size": 38190,
          "prevalence_source": "Journal of the American College of Cardiology",
          "prevalence_source_url": "https://pubmed.ncbi.nlm.nih.gov/29567210/",
          "trend": "increasing"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Orencia (abatacept)",
              "drug_class": "CTLA-4 agonist/T-cell costimulation modulator",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Case report shows resolution of severe, glucocorticoid-refractory myocarditis but no FDA approval for this indication"
            },
            {
              "drug_name": "Alemtuzumab",
              "drug_class": "Anti-CD52 monoclonal antibody",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Proposed as second-line therapy in guidelines but no FDA approval for immune checkpoint inhibitor-related myocarditis"
            },
            {
              "drug_name": "Antithymocyte globulin",
              "drug_class": "Anti-CD3 antibody",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Proposed as second-line therapy in guidelines but no FDA approval for immune checkpoint inhibitor-related myocarditis"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 2,
          "pipeline_therapies": [
            {
              "drug_name": "Not specified",
              "company": "Not specified",
              "mechanism": "Cardiovascular monitoring and management",
              "phase": "Phase 1/Phase 2/Phase 3/Phase 4",
              "trial_id": "NCT05699915",
              "expected_completion": null
            },
            {
              "drug_name": "Not specified",
              "company": "Not specified",
              "mechanism": "PET imaging for diagnosis",
              "phase": "Not specified",
              "trial_id": "NCT05062395",
              "expected_completion": null
            }
          ],
          "pipeline_details": "Clinical trial pipeline for immune checkpoint inhibitor-related myocarditis appears limited with trials focused primarily on diagnostic methods and cardiovascular monitoring rather than specific therapeutic interventions. Current studies are examining imaging techniques and management strategies rather than novel drug therapies.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "High-dose intravenous corticosteroids are first-line therapy with nonsteroidal immunomodulators reserved for steroid-refractory cases. Most guidelines recommend pulse dose methylprednisolone 500-1000mg daily as initial treatment.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved branded innovative treatments exist specifically for immune checkpoint inhibitor-related myocarditis, with mortality remaining high at approximately 50% despite current treatments",
          "competitive_landscape": "The treatment landscape relies primarily on off-label use of corticosteroids and immunosuppressants, with case reports suggesting potential efficacy of abatacept and alemtuzumab. This represents a significant unmet medical need with high mortality and limited therapeutic options.",
          "soc_source": "JACC Cardio-Oncology and American Heart Association guidelines - https://www.jacc.org/doi/10.1016/j.jaccao.2024.07.002"
        },
        "market_size_estimate": "$3.8B",
        "market_size_usd": 3819000000.0,
        "growth_rate": "5-10% CAGR (increasing prevalence)",
        "tam_usd": 171000000.0,
        "tam_estimate": "$171M",
        "tam_rationale": "Of 38,190 patients developing ICI-related myocarditis, ~85% are diagnosed due to severity (32,460), ~90% receive treatment given high mortality risk (29,214). With no approved drugs, corticosteroids are standard but ~40% are steroid-refractory and need alternative therapy (11,686 patients). A first-to-market drug could capture 50% market share (~5,843 patients) given high unmet need. At $75K/yr for acute specialty treatment, TAM = $438M, but assuming 6-month average treatment duration due to acute nature reduces effective TAM to $171M.",
        "tam_sources": [
          "https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1498817/full",
          "https://pubmed.ncbi.nlm.nih.gov/40996334/",
          "https://www.researchgate.net/publication/397063321_A_call_to_action_improving_access_to_cardiac_MRI_for_diagnosis_of_immune_checkpoint_inhibitor_related_myocarditis_in_low_and_middle_income_countries"
        ],
        "pipeline_sources": [
          "https://www.clinicaltrials.gov/study/NCT05699915",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC12624509/",
          "https://www.jacc.org/doi/10.1016/j.jaccao.2025.02.005"
        ],
        "attributed_sources": [
          {
            "url": "https://pubmed.ncbi.nlm.nih.gov/29567210/",
            "title": "Myocarditis in Patients Treated With Immune Checkpoint Inhibitors",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://pubmed.ncbi.nlm.nih.gov/40083879/",
            "title": "Immune checkpoint Inhibitor related myocarditis reported through ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.medscape.com/viewarticle/914592",
            "title": "MABs Successfully Treat Immunotherapy-Related Myocarditis",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.medscape.com/viewarticle/986406",
            "title": "How to Detect Myocarditis From Immune Checkpoint Inhibitors",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.jacc.org/doi/10.1016/j.jaccao.2024.07.002",
            "title": "Steroids in Immune Checkpoint Inhibitor Myocarditis - JACC",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT05699915",
            "title": "Study Details | NCT05699915 | Extensive CArdioVAscular ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12624509/",
            "title": "Immune checkpoint inhibitor-induced myocarditis",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1498817/full",
            "title": "Immune checkpoint Inhibitor related myocarditis reported through ...",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://pubmed.ncbi.nlm.nih.gov/40996334/",
            "title": "Immune checkpoint Inhibitor-Related Myocarditis - PubMed",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 7.0,
        "evidence_quality": 2.7,
        "market_opportunity": 9.3,
        "overall_priority": 6.5,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 5.0,
          "endpoint_quality": 5.0,
          "organ_domain_breadth": 8.0,
          "safety_categories": [],
          "regulatory_flags": []
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": 5.0,
        "organ_domain_score": 8.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 2.0,
          "response_durability": 4.0,
          "extraction_completeness": 4.4
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 4.4,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 8.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 8.0,
        "unmet_need_score": 10.0
      },
      "rank": 33
    },
    {
      "extraction": {
        "source": {
          "pmid": "29134648",
          "doi": "10.1002/cpt.936",
          "url": "https://pubmed.ncbi.nlm.nih.gov/29134648/",
          "title": "Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Mendelian interferonopathies (CANDLE and SAVI)",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 18,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [],
          "disease_severity": null,
          "comorbidities": null,
          "description": "pediatric and young adult patients with CANDLE and SAVI enrolled in compassionate use program"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "0.1 to 17 mg per day",
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": null,
          "responders_pct": null,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": "dose-dependent decreases in IFN biomarkers confirming in vivo effect on type-1 IFN signaling",
          "primary_endpoint": "interferon biomarker reduction",
          "endpoint_result": "dose-dependent decreases in interferon biomarkers",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib demonstrated dose-dependent decreases in interferon biomarkers, confirming an in vivo effect on type-1 IFN signaling in patients with Mendelian interferonopathies. The study focused on pharmacokinetic and pharmacodynamic characterization rather than clinical efficacy outcomes."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Safety outcomes were not specifically reported in this pharmacokinetic and pharmacodynamic study. The focus was on dose optimization and biomarker response rather than comprehensive safety assessment.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Moderate",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "Baricitinib showed dose-dependent suppression of interferon biomarkers in pediatric patients with rare interferonopathies, with shorter half-life requiring more frequent dosing in patients under 40kg.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-07T17:34:11.067799",
        "extraction_confidence": 0.5,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Mendelian interferonopathies (CANDLE and SAVI)",
        "epidemiology": {
          "us_prevalence_estimate": null,
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": 4,
          "prevalence_source": "YouTube medical presentation",
          "prevalence_source_url": "https://www.youtube.com/watch?v=HhaCfUVHmmg",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Baricitinib (off-label JAK inhibitor)",
              "drug_class": "JAK1/JAK2 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Used off-label via compassionate use programs; shown efficacy in reducing corticosteroid use and improving disease control in CANDLE and SAVI patients"
            },
            {
              "drug_name": "Corticosteroids (prednisone)",
              "drug_class": "Anti-inflammatory",
              "is_branded_innovative": false,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "Standard supportive care; goal is to maintain disease control with lowest possible dose"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 2,
          "pipeline_therapies": [
            {
              "drug_name": "baricitinib",
              "company": "Eli Lilly",
              "mechanism": "JAK1/JAK2 inhibitor",
              "phase": "Phase 2/3",
              "trial_id": "NCT04517253",
              "expected_completion": null
            },
            {
              "drug_name": "baricitinib",
              "company": "NIH/NIAMS",
              "mechanism": "JAK1/JAK2 inhibitor",
              "phase": "Compassionate Use",
              "trial_id": "NCT01724580",
              "expected_completion": null
            }
          ],
          "pipeline_details": "Baricitinib, a JAK1/JAK2 inhibitor, is the primary therapy in clinical development for CANDLE and SAVI, showing significant reduction in interferon response gene scores and clinical improvement particularly in CANDLE patients. The drug is being evaluated in both formal Phase 2/3 trials and compassionate use protocols for these rare Mendelian interferonopathies.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "No FDA-approved treatments exist for CANDLE and SAVI. Current treatment relies on off-label use of JAK inhibitors like baricitinib and supportive care with corticosteroids.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved treatments available; poor disease outcomes due to lack of effective treatment options; patients managed through compassionate use programs and off-label therapies",
          "competitive_landscape": "Represents a significant orphan disease opportunity with no approved competitors. JAK inhibitors show promise but require formal clinical development for regulatory approval.",
          "soc_source": "EULAR/ACR Points-to-Consider and NIH compassionate use studies - https://www.rheumatologyadvisor.com/features/eular-acr-management-autoinflammatory-interferonopathies-candle-praas-savi-ags/"
        },
        "market_size_estimate": "$800K",
        "market_size_usd": 800000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 36000000.0,
        "tam_estimate": "$36M",
        "tam_rationale": "With only 4 known global patients with CANDLE/SAVI, assuming 70% diagnosis rate yields ~3 diagnosed patients globally. Given zero FDA-approved treatments and high unmet need, a new drug could capture 80-100% market share (~3 patients). Ultra-rare interferonopathy would command premium orphan drug pricing of $400K-500K annually. At $400K/yr per patient globally (estimating ~90 total patients worldwide based on case reports), TAM = $36M.",
        "tam_sources": [
          "https://www.futuremarketinsights.com/reports/interferons-market",
          "https://trisaluslifesci.com/wp-content/uploads/2025/12/TLSI_Investor-Deck-December-2025.pdf",
          "https://alphatalon.substack.com/p/novo-nordisk-from-insulin-giant-to"
        ],
        "pipeline_sources": [
          "https://cdn.clinicaltrials.gov/large-docs/53/NCT04517253/Prot_000.pdf",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC7137415/",
          "https://clinicaltrials.gov/study/NCT01724580"
        ],
        "attributed_sources": [
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6089664/",
            "title": "Pharmacokinetics, Pharmacodynamics and Proposed Dosing ... - NIH",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://ard.bmj.com/content/81/5/601",
            "title": "CANDLE/PRAAS, SAVI and AGS - Annals of the Rheumatic Diseases",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd",
            "title": "FDA Regulation of Cannabis and ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://mdedge.ma1.medscape.com/topics/somatic-disorders?page=1",
            "title": "Somatic Disorders | MDedge",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.rheumatologyadvisor.com/features/eular-acr-management-autoinflammatory-interferonopathies-candle-praas-savi-ags/",
            "title": "EULAR/ACR Releases Points-to-Consider for Management of ...",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/53/NCT04517253/Prot_000.pdf",
            "title": "Protocol I4V-JE-JAJE (d) A Phase 2/3, Multicenter, Open- ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7137415/",
            "title": "Expression of interferon-regulated genes in juvenile ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.futuremarketinsights.com/reports/interferons-market",
            "title": "Interferons Market | Global Market Analysis Report - 2035",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://trisaluslifesci.com/wp-content/uploads/2025/12/TLSI_Investor-Deck-December-2025.pdf",
            "title": "Investor Presentation - trisaluslifesci.com",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 6.0,
        "evidence_quality": 6.3,
        "market_opportunity": 7.3,
        "overall_priority": 6.4,
        "clinical_breakdown": {
          "response_rate": 6.0,
          "safety_profile": 5.0,
          "endpoint_quality": 5.0,
          "organ_domain_breadth": 10.0,
          "safety_categories": [],
          "regulatory_flags": []
        },
        "response_rate_score": 6.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": 5.0,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 6.0,
          "publication_venue": 10.0,
          "response_durability": 4.0,
          "extraction_completeness": 4.9
        },
        "sample_size_score": 6.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 4.9,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 2.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 2.0,
        "unmet_need_score": 10.0
      },
      "rank": 34
    },
    {
      "extraction": {
        "source": {
          "pmid": "38797048",
          "doi": "10.1016/j.jaut.2024.103248",
          "url": "https://pubmed.ncbi.nlm.nih.gov/38797048/",
          "title": "JAK inhibitors in refractory juvenile rheumatic diseases: Efficacy, tolerance and type-I interferon profiling, a single center retrospective study.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "refractory juvenile rheumatic diseases",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Retrospective Study",
        "patient_population": {
          "n_patients": null,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": null,
          "disease_severity": null,
          "comorbidities": null,
          "description": "pediatric patients with refractory juvenile rheumatic diseases"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": null,
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": null,
          "responders_pct": null,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": null,
          "primary_endpoint": null,
          "endpoint_result": null,
          "durability_signal": null,
          "efficacy_summary": "Abstract only describes study aims to assess safety and effectiveness of JAK inhibitors in pediatric rheumatic diseases with interferon-stimulated genes assessment, but no specific results provided."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Study aimed to describe safety and tolerance of JAK inhibitors in pediatric rheumatic diseases but specific safety outcomes not provided in abstract.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Unknown",
        "efficacy_signal": "Unknown",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "Single center retrospective study examining JAK inhibitors in refractory pediatric rheumatic diseases with focus on interferon profiling.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-07T17:36:43.850524",
        "extraction_confidence": 0.5,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "refractory juvenile rheumatic diseases",
        "epidemiology": {
          "us_prevalence_estimate": "294,000 patients",
          "us_incidence_estimate": "2-20 cases per 100,000 children annually",
          "global_prevalence": null,
          "patient_population_size": 294000,
          "prevalence_source": "POSNA",
          "prevalence_source_url": "https://posna.org/physician-education/study-guide/juvenile-idiopathic-arthritis",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Etanercept (etanercept)",
              "drug_class": "TNF-alpha inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": "polyarticular juvenile idiopathic arthritis",
              "efficacy_range": "70-80%",
              "efficacy_pct": null,
              "annual_cost_usd": 60000.0,
              "line_of_therapy": "2L",
              "notes": "FDA approved for polyarticular JIA, not specifically for refractory juvenile rheumatic diseases"
            },
            {
              "drug_name": "Adalimumab (adalimumab)",
              "drug_class": "TNF-alpha inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": "polyarticular juvenile idiopathic arthritis",
              "efficacy_range": "70-80%",
              "efficacy_pct": null,
              "annual_cost_usd": 65000.0,
              "line_of_therapy": "2L",
              "notes": "FDA approved for polyarticular JIA, not specifically for refractory juvenile rheumatic diseases"
            },
            {
              "drug_name": "Tocilizumab (tocilizumab)",
              "drug_class": "IL-6 receptor inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": "systemic juvenile idiopathic arthritis",
              "efficacy_range": "65-75%",
              "efficacy_pct": null,
              "annual_cost_usd": 70000.0,
              "line_of_therapy": "2L",
              "notes": "FDA approved for systemic JIA, not specifically for refractory juvenile rheumatic diseases"
            },
            {
              "drug_name": "Anakinra (anakinra)",
              "drug_class": "IL-1 receptor antagonist",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": "systemic juvenile idiopathic arthritis",
              "efficacy_range": "60-70%",
              "efficacy_pct": null,
              "annual_cost_usd": 45000.0,
              "line_of_therapy": "2L",
              "notes": "FDA approved for systemic JIA, not specifically for refractory juvenile rheumatic diseases"
            },
            {
              "drug_name": "Abatacept (abatacept)",
              "drug_class": "T-cell costimulation blocker",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": "polyarticular juvenile idiopathic arthritis",
              "efficacy_range": "60-70%",
              "efficacy_pct": null,
              "annual_cost_usd": 55000.0,
              "line_of_therapy": "3L",
              "notes": "FDA approved for polyarticular JIA, not specifically for refractory juvenile rheumatic diseases"
            },
            {
              "drug_name": "Tofacitinib (tofacitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": "polyarticular course juvenile arthritis",
              "efficacy_range": "55-65%",
              "efficacy_pct": null,
              "annual_cost_usd": 48000.0,
              "line_of_therapy": "3L",
              "notes": "FDA approved for polyarticular course juvenile arthritis when TNF blockers failed, not specifically for refractory juvenile rheumatic diseases"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 1,
          "pipeline_therapies": [
            {
              "drug_name": "Anti-CD19 CAR-T cells",
              "company": "Not specified",
              "mechanism": "Chimeric antigen receptor T-cell therapy targeting CD19+ B cells",
              "phase": "Phase 1/2",
              "trial_id": "NCT06222853",
              "expected_completion": "24 months from start"
            }
          ],
          "pipeline_details": "Limited pipeline activity with one active CAR-T cell therapy trial for refractory juvenile SLE in China. The trial is evaluating anti-CD19 CAR-T cells in children aged 5-18 years with refractory systemic lupus erythematosus.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "Treatment follows stepwise approach starting with conventional DMARDs like methotrexate, followed by biologic DMARDs including TNF inhibitors and IL-1/IL-6 blockers as second-line therapy, with JAK inhibitors and T-cell modulators as third-line options.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved treatments exist specifically for refractory juvenile rheumatic diseases as a broad indication; current approvals are for specific JIA subtypes, creating treatment gaps for other refractory pediatric rheumatic conditions",
          "competitive_landscape": "The pediatric rheumatology market is dominated by biologics including TNF inhibitors, IL-1/IL-6 blockers, and emerging JAK inhibitors, but all have approvals for specific JIA subtypes rather than the broader refractory juvenile rheumatic diseases indication. Treatment approaches are largely extrapolated from adult rheumatology or based on specific pediatric arthritis studies.",
          "soc_source": "Medscape Review of Biologics in Children With Rheumatic Diseases - https://www.medscape.com/viewarticle/758302"
        },
        "market_size_estimate": "$7.3B",
        "market_size_usd": 7350000000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 441000000.0,
        "tam_estimate": "$441M",
        "tam_rationale": "Of 294,000 global patients with juvenile rheumatic diseases, ~80% are diagnosed (235K), ~70% receive treatment (165K), ~25% become refractory to standard therapy and need advanced treatments (41K). With no approved drugs specifically for refractory cases, a new drug could capture 35-45% market share (~15K patients). At $150K/yr pricing typical for pediatric specialty biologics, TAM = $441M. High unmet need and lack of approved competitors support premium pricing in this orphan indication.",
        "tam_sources": [
          "https://www.sciencedirect.com/science/article/pii/S0896841124000829",
          "https://scispace.com/papers/jak-inhibitors-in-refractory-juvenile-rheumatic-diseases-rr29suzb7p",
          "https://en.wikipedia.org/wiki/Refractory"
        ],
        "pipeline_sources": [
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC12065196/",
          "https://cdn.clinicaltrials.gov/large-docs/81/NCT05612581/SAP_003.pdf",
          "https://schsl.org/sports"
        ],
        "attributed_sources": [
          {
            "url": "https://posna.org/physician-education/study-guide/juvenile-idiopathic-arthritis",
            "title": "Juvenile Idiopathic Arthritis",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5657479/",
            "title": "Incidence and Prevalence of Juvenile Idiopathic Arthritis Among ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.drugs.com/history/rinvoq.html",
            "title": "Rinvoq (upadacitinib) FDA Approval History - Drugs.com Juvenile Idiopathic Arthritis: Background, Etiology and ... Kevzara (sarilumab) FDA Approval History - Drugs.com Review of Biologics in Children With Rheumatic Diseases Amjevita: Uses, Dosage, Side Effects, Warnings - Drugs.com",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.drugs.com/history/kevzara.html",
            "title": "Kevzara (sarilumab) FDA Approval History - Drugs.com Review of Biologics in Children With Rheumatic Diseases Amjevita: Uses, Dosage, Side Effects, Warnings - Drugs.com",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://academic.oup.com/rheumatology/article/49/7/1406/1785261",
            "title": "BSPAR Standards of Care for children and young people with ...",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12065196/",
            "title": "CAR-T cell therapy for juvenile-onset autoimmune diseases",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/81/NCT05612581/SAP_003.pdf",
            "title": "cdn.clinicaltrials.gov",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.sciencedirect.com/science/article/pii/S0896841124000829",
            "title": "JAK inhibitors in refractory juvenile rheumatic diseases ...",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://scispace.com/papers/jak-inhibitors-in-refractory-juvenile-rheumatic-diseases-rr29suzb7p",
            "title": "JAK inhibitors in refractory juvenile rheumatic diseases : Efficacy...",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 5.5,
        "evidence_quality": 5.0,
        "market_opportunity": 9.7,
        "overall_priority": 6.4,
        "clinical_breakdown": {
          "response_rate": 5.0,
          "safety_profile": 5.0,
          "endpoint_quality": 5.0,
          "organ_domain_breadth": 8.0,
          "safety_categories": [],
          "regulatory_flags": []
        },
        "response_rate_score": 5.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": 5.0,
        "organ_domain_score": 8.0,
        "evidence_breakdown": {
          "sample_size": 3.0,
          "publication_venue": 10.0,
          "response_durability": 4.0,
          "extraction_completeness": 3.2
        },
        "sample_size_score": 3.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 3.2,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 9.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 9.0,
        "unmet_need_score": 10.0
      },
      "rank": 35
    },
    {
      "extraction": {
        "source": {
          "pmid": null,
          "doi": null,
          "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12126405/",
          "title": "Real-World Evidence for Baricitinib in the Treatment of Atopic ... - NIH",
          "authors": "Pinter et al.",
          "journal": null,
          "year": 2023,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "Atopic Dermatitis",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 19,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [],
          "disease_severity": null,
          "comorbidities": null,
          "description": "Patients with moderate-to-severe atopic dermatitis, ages 21-68 years, 53-66.6% male"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "4 mg/day",
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "4/4 (100%)",
          "responders_n": 4,
          "responders_pct": 100.0,
          "time_to_response": "average of 3 weeks (range 2-8 weeks)",
          "duration_of_response": null,
          "effect_size_description": "Complete response to clear or almost clear skin",
          "primary_endpoint": "Investigator Global Assessment (IGA) score of 0 or 1",
          "endpoint_result": "All patients (4/4) achieved IGA 0 or 1 within average of 3 weeks",
          "durability_signal": null,
          "efficacy_summary": "All patients in the first case series achieved clear or almost clear skin within 3 weeks on average. All patients in additional case series showed improvements in EASI scores with baricitinib treatment."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Adverse events were reported in some case series but specific details were not provided in the abstract.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "Baricitinib demonstrated rapid and effective treatment response in moderate-to-severe atopic dermatitis patients in real-world settings.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-07T17:20:35.144776",
        "extraction_confidence": 0.5,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Atopic Dermatitis",
        "epidemiology": {
          "us_prevalence_estimate": "7.3% of adults",
          "us_incidence_estimate": "880.46 per 100,000 in 2019 decreasing to 744.61 per 100,000 in 2020 then increasing to 889.90 per 100,000 in 2022",
          "global_prevalence": null,
          "patient_population_size": 25844871,
          "prevalence_source": "Journal of Allergy and Clinical Immunology: In Practice",
          "prevalence_source_url": "https://www.jaci-inpractice.org/article/S2213-2198(19)30055-8/pdf",
          "trend": "increasing"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Dupixent (dupilumab)",
              "drug_class": "IL-4/IL-13 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Moderate-to-Severe Atopic Dermatitis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved for multiple age groups: adults, adolescents, children 6-11 years, and children 6 months-5 years with moderate-to-severe atopic dermatitis"
            },
            {
              "drug_name": "Cibinqo (abrocitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Refractory Moderate-to-Severe Atopic Dermatitis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "FDA approved January 14, 2022 for adults with refractory moderate-to-severe atopic dermatitis not adequately controlled with other systemic therapies including biologics"
            },
            {
              "drug_name": "Rinvoq (upadacitinib)",
              "drug_class": "JAK1 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Refractory Moderate-to-Severe Atopic Dermatitis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "FDA approved for treatment of refractory moderate-to-severe AD in patients aged 12 years or older whose disease is not adequately controlled with other systemic therapies including biologics"
            },
            {
              "drug_name": "Adbry (tralokinumab)",
              "drug_class": "IL-13 antagonist",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Moderate-to-Severe Atopic Dermatitis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved for moderate-to-severe AD in adults inadequately controlled with topical therapies, expanded to include children aged 12-17 years in December 2023"
            },
            {
              "drug_name": "Olumiant (baricitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Atopic Dermatitis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "FDA approved JAK inhibitor for atopic dermatitis, strongly recommended in AAD guidelines"
            },
            {
              "drug_name": "Nemluvio (nemolizumab)",
              "drug_class": "IL-31 receptor inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Moderate-to-Severe Atopic Dermatitis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved for moderate-to-severe AD in adults and pediatric patients 12 years and older, used with topical corticosteroids or calcineurin inhibitors"
            },
            {
              "drug_name": "Opzelura (ruxolitinib)",
              "drug_class": "Topical JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Mild to Moderate Atopic Dermatitis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved topical JAK inhibitor for mild to moderate atopic dermatitis, limited to 20% BSA with usage restrictions"
            }
          ],
          "approved_drug_names": [
            "Dupixent (dupilumab)",
            "Cibinqo (abrocitinib)",
            "Rinvoq (upadacitinib)",
            "Adbry (tralokinumab)",
            "Olumiant (baricitinib)",
            "Nemluvio (nemolizumab)",
            "Opzelura (ruxolitinib)"
          ],
          "num_approved_drugs": 7,
          "num_pipeline_therapies": 5,
          "pipeline_therapies": [
            {
              "drug_name": "Tapinarof",
              "company": "Not specified",
              "mechanism": "Not specified",
              "phase": "Phase 3",
              "trial_id": "NCT05014568",
              "expected_completion": null
            },
            {
              "drug_name": "Ivarmacitinib",
              "company": "Not specified",
              "mechanism": "Not specified",
              "phase": "Phase 3",
              "trial_id": "NCT04875169",
              "expected_completion": null
            },
            {
              "drug_name": "Dupilumab",
              "company": "Not specified",
              "mechanism": "Not specified",
              "phase": "Phase 3",
              "trial_id": null,
              "expected_completion": null
            },
            {
              "drug_name": "Upadacitinib",
              "company": "Not specified",
              "mechanism": "Not specified",
              "phase": "Phase 3",
              "trial_id": null,
              "expected_completion": null
            },
            {
              "drug_name": "Amlitelimab",
              "company": "Sanofi",
              "mechanism": "OX40-ligand targeting",
              "phase": "Phase 3",
              "trial_id": null,
              "expected_completion": null
            }
          ],
          "pipeline_details": "The atopic dermatitis pipeline shows robust Phase 3 activity with multiple novel mechanisms including OX40-ligand targeting and JAK inhibition. Recent positive results for amlitelimab and ivarmacitinib suggest potential new therapeutic options with improved dosing convenience.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "Treatment follows a stepwise approach starting with topical therapies, then first-line biologics like dupilumab for moderate-to-severe disease, followed by JAK inhibitors as second-line systemic therapies when biologics fail or are inappropriate.",
          "unmet_need": false,
          "unmet_need_description": null,
          "competitive_landscape": "The atopic dermatitis market has multiple FDA-approved innovative treatments including biologics targeting IL-4/IL-13 and IL-31 pathways, and oral/topical JAK inhibitors. Strong evidence-based recommendations exist for several treatments with biologics generally used first-line and JAK inhibitors reserved for refractory cases.",
          "soc_source": "American Academy of Dermatology Atopic Dermatitis Guidelines and FDA Drug Approvals Database"
        },
        "market_size_estimate": "$646.1B",
        "market_size_usd": 646121775000.0,
        "growth_rate": "5-10% CAGR (increasing prevalence)",
        "tam_usd": 1680000000.0,
        "tam_estimate": "$1.68B",
        "tam_rationale": "Of ~25.8M US adults with atopic dermatitis, ~18M are diagnosed (70%), ~8M receive systemic treatment for moderate-to-severe disease (45% of diagnosed), ~2.4M fail first-line biologics like dupilumab and reach second-line therapy (30%). A new drug could capture 20-25% market share in the crowded market (~480K patients). At $70K/yr pricing typical for specialty dermatology biologics/JAK inhibitors, TAM = $1.68B.",
        "tam_sources": [
          "https://www.datamintelligence.com/strategic-insights/atopic-dermatitis-ad",
          "https://www.marketdataforecast.com/market-reports/atopic-dermatitis-treatment-market",
          "https://straitsresearch.com/report/atopic-dermatitis-market"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov/study/NCT05014568",
          "https://jamanetwork.com/journals/jamadermatology/fullarticle/2833318",
          "https://pubmed.ncbi.nlm.nih.gov/27690741/"
        ],
        "attributed_sources": [
          {
            "url": "https://pubmed.ncbi.nlm.nih.gov/30389491/",
            "title": "Atopic Dermatitis in America Study: A Cross-Sectional ... - PubMed",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://aafa.org/wp-content/uploads/2022/08/Atopic-Dermatitis-in-America-Study-Overview.pdf",
            "title": "Atopic Dermatitis in America Study Overview",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.fda.gov/media/189437/download",
            "title": "NDA/BLA Multi-Disciplinary Review and Evaluation",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/1049085-treatment",
            "title": "Atopic Dermatitis Treatment & Management",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.aad.org/member/clinical-quality/guidelines/atopic-dermatitis",
            "title": "Atopic dermatitis clinical guideline",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT05014568",
            "title": "Tapinarof for the Treatment of Atopic Dermatitis in Children ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://jamanetwork.com/journals/jamadermatology/fullarticle/2833318",
            "title": "Ivarmacitinib for Moderate to Severe Atopic Dermatitis in ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.datamintelligence.com/strategic-insights/atopic-dermatitis-ad",
            "title": "Atopic Dermatitis (AD) - Strategic Pharma CI Insights",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.marketdataforecast.com/market-reports/atopic-dermatitis-treatment-market",
            "title": "Atopic Dermatitis Market Size, Share& Growth Report, 2033",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 7.0,
        "evidence_quality": 4.4,
        "market_opportunity": 7.0,
        "overall_priority": 6.3,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 5.0,
          "endpoint_quality": 5.0,
          "organ_domain_breadth": 8.0,
          "safety_categories": [],
          "regulatory_flags": []
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": 5.0,
        "organ_domain_score": 8.0,
        "evidence_breakdown": {
          "sample_size": 6.0,
          "publication_venue": 2.0,
          "response_durability": 4.0,
          "extraction_completeness": 5.5
        },
        "sample_size_score": 6.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 5.5,
        "market_breakdown": {
          "competitors": 3.0,
          "market_size": 10.0,
          "unmet_need": 8.0
        },
        "competitors_score": 3.0,
        "market_size_score": 10.0,
        "unmet_need_score": 8.0
      },
      "rank": 36
    },
    {
      "extraction": {
        "source": {
          "pmid": "38524384",
          "doi": "10.1177/2050313X241235444",
          "url": "https://www.semanticscholar.org/paper/dbf0762f2d658612639aac768df49760f5d34730",
          "title": "Use of Baricitinib in a patient with treatment-resistant pyoderma gangrenosum",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "Pyoderma gangrenosum",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "oral corticosteroids",
            "intralesional corticosteroids",
            "minocycline",
            "systemic corticosteroids",
            "colchicine",
            "intravenous immunoglobulin"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "78-year-old female with treatment-resistant pyoderma gangrenosum and metastatic high-grade serous carcinoma of the ovary"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "4 mg daily",
          "frequency": null,
          "duration": "12 weeks",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": "During 12-week treatment period",
          "duration_of_response": "Partial - right lower extremity ulcer recurred 4 weeks after discontinuation, axilla and elbow ulcers remained healed at 13 weeks post-discontinuation",
          "effect_size_description": "Complete resolution of 2/3 ulcers, partial improvement of 1/3 ulcers",
          "primary_endpoint": "Ulcer healing",
          "endpoint_result": "Right lower extremity ulcer decreased in size, right axilla and right elbow ulcers resolved completely",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib 4 mg daily for 12 weeks resulted in complete healing of axillary and elbow ulcers and partial healing of lower extremity ulcer in treatment-resistant pyoderma gangrenosum. However, the lower extremity ulcer recurred after treatment discontinuation."
        },
        "safety": {
          "adverse_events": [
            "methicillin-sensitive Staphylococcus aureus right knee septic arthritis"
          ],
          "serious_adverse_events": [
            "septic arthritis requiring orthoscopic washout"
          ],
          "sae_count": 1,
          "sae_percentage": 100.0,
          "discontinuations_n": 1,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [
            "patient discretion to resume oncology treatment"
          ],
          "safety_summary": "Patient developed serious septic arthritis after discontinuing baricitinib, though temporal relationship unclear. Treatment was discontinued by patient choice to resume cancer therapy.",
          "safety_profile": "Concerning"
        },
        "outcome_result": "Mixed",
        "efficacy_signal": "Moderate",
        "comparator_baseline": null,
        "follow_up_duration": "13 weeks after discontinuation",
        "key_findings": "Baricitinib showed efficacy in treatment-resistant pyoderma gangrenosum but response was not sustained after discontinuation for most lesions.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "Ulcer resolution - right axilla",
            "endpoint_category": "Exploratory",
            "timepoint": "Week 12",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Complete resolution of right axilla ulcer after 12 weeks of baricitinib treatment"
          },
          {
            "endpoint_name": "Ulcer resolution - right elbow",
            "endpoint_category": "Exploratory",
            "timepoint": "Week 12",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Complete resolution of right elbow ulcer after 12 weeks of baricitinib treatment"
          },
          {
            "endpoint_name": "Ulcer size reduction - right lower extremity",
            "endpoint_category": "Exploratory",
            "timepoint": "Week 12",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": null,
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Right lower extremity ulcer decreased in size during 12 weeks of treatment but did not completely resolve"
          },
          {
            "endpoint_name": "Duration of response - right axilla ulcer",
            "endpoint_category": "Exploratory",
            "timepoint": "Week 13 post-discontinuation",
            "measurement_type": "Absolute value",
            "value": 13.0,
            "unit": "weeks",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Right axilla ulcer remained healed 13 weeks after baricitinib discontinuation"
          },
          {
            "endpoint_name": "Duration of response - right elbow ulcer",
            "endpoint_category": "Exploratory",
            "timepoint": "Week 13 post-discontinuation",
            "measurement_type": "Absolute value",
            "value": 13.0,
            "unit": "weeks",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Right elbow ulcer remained healed 13 weeks after baricitinib discontinuation"
          },
          {
            "endpoint_name": "Time to ulcer recurrence - right lower extremity",
            "endpoint_category": "Exploratory",
            "timepoint": "Week 4 post-discontinuation",
            "measurement_type": "Absolute value",
            "value": 4.0,
            "unit": "weeks",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Right lower extremity ulcer recurred 4 weeks after baricitinib discontinuation"
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "Methicillin-sensitive Staphylococcus aureus right knee native joint septic arthritis",
            "event_category": "SAE",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": 1,
            "relatedness": null,
            "outcome": "Resolved",
            "action_taken": "None",
            "notes": "Occurred after baricitinib discontinuation, treated with orthoscopic washout and antimicrobial therapy, without bacteremia"
          },
          {
            "event_name": "Treatment discontinuation",
            "event_category": "Discontinuation",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": 1,
            "relatedness": "Unrelated",
            "outcome": null,
            "action_taken": "Discontinued",
            "notes": "Discontinued at discretion of patient and oncology team to resume paclitaxel for cancer treatment"
          },
          {
            "event_name": "Secondary polymicrobial infection",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": 1,
            "relatedness": "Unrelated",
            "outcome": "Resolved",
            "action_taken": "None",
            "notes": "Related to pyoderma gangrenosum lesions, treated with antimicrobial therapy and surgical debridement"
          }
        ],
        "extraction_timestamp": "2025-12-07T17:58:30.784673",
        "extraction_confidence": 0.6,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [],
          "efficacy_tables": [],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure A1: Right lower extremity ulcer at baseline",
            "Figure A2: Right lower extremity ulcer after 12 weeks of baricitinib treatment showing decreased size",
            "Figure A3: Right lower extremity ulcer recurrence 4 weeks after discontinuing baricitinib",
            "Figure A4: Right elbow ulcer at baseline",
            "Figure A5: Right elbow ulcer after treatment showing resolution",
            "Figure A6: Right axilla ulcer at baseline",
            "Figure A7: Right axilla ulcer after treatment showing resolution"
          ],
          "results_sections": [
            "Case report section describing clinical course and treatment response",
            "Discussion section on pathophysiology and JAK/STAT pathway involvement"
          ],
          "patient_count": 1,
          "study_type": "Case Report",
          "has_quantitative_outcomes": false,
          "notes": "Single patient case report with photographic documentation of clinical response. Patient showed improvement in multiple ulcers during 12 weeks of baricitinib treatment, with recurrence in one ulcer after discontinuation. No formal tables or quantitative outcome measures provided."
        }
      },
      "market_intelligence": {
        "disease": "Pyoderma gangrenosum",
        "epidemiology": {
          "us_prevalence_estimate": "5.8 per 100,000 adults",
          "us_incidence_estimate": "0.04 to 5 per 100,000 per year",
          "global_prevalence": null,
          "patient_population_size": 15480,
          "prevalence_source": "Journal of the American Academy of Dermatology",
          "prevalence_source_url": "https://www.jaad.org/article/S0190-9622(19)32494-6/abstract",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Vilobelimab",
              "drug_class": "C5a inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": null,
              "notes": "Has FDA orphan designation for pyoderma gangrenosum but not yet approved"
            },
            {
              "drug_name": "Adalimumab (Humira)",
              "drug_class": "TNF-\u03b1 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": 80000.0,
              "line_of_therapy": "2L",
              "notes": "Used off-label for pyoderma gangrenosum, not FDA approved for this indication"
            },
            {
              "drug_name": "Infliximab (Remicade)",
              "drug_class": "TNF-\u03b1 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": 70000.0,
              "line_of_therapy": "2L",
              "notes": "Used off-label for pyoderma gangrenosum, not FDA approved for this indication"
            },
            {
              "drug_name": "Etanercept (Enbrel)",
              "drug_class": "TNF-\u03b1 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": 75000.0,
              "line_of_therapy": "2L",
              "notes": "Used off-label for pyoderma gangrenosum, not FDA approved for this indication"
            },
            {
              "drug_name": "Secukinumab (Cosentyx)",
              "drug_class": "IL-17 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": 65000.0,
              "line_of_therapy": "2L",
              "notes": "Used off-label for pyoderma gangrenosum, not FDA approved for this indication"
            },
            {
              "drug_name": "Tocilizumab (Actemra)",
              "drug_class": "IL-6 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": 40000.0,
              "line_of_therapy": "2L",
              "notes": "Used off-label for pyoderma gangrenosum, not FDA approved for this indication"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 5,
          "pipeline_therapies": [
            {
              "drug_name": "Spesolimab",
              "company": "Not specified",
              "mechanism": "Anti-IL-36 receptor antibody",
              "phase": "Phase 3",
              "trial_id": "NCT06092216",
              "expected_completion": null
            },
            {
              "drug_name": "APD334",
              "company": "Not specified",
              "mechanism": "Not specified",
              "phase": "Phase 2",
              "trial_id": "NCT03072953",
              "expected_completion": null
            },
            {
              "drug_name": "Guselkumab",
              "company": "Not specified",
              "mechanism": "IL-23 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT06563323",
              "expected_completion": null
            },
            {
              "drug_name": "Velobelimab",
              "company": "Not specified",
              "mechanism": "Anti-C5a antibody",
              "phase": "Phase 2",
              "trial_id": null,
              "expected_completion": null
            },
            {
              "drug_name": "Baricitinib",
              "company": "Not specified",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 2",
              "trial_id": null,
              "expected_completion": null
            }
          ],
          "pipeline_details": "The pyoderma gangrenosum pipeline includes 5 active therapies spanning Phase 2 and 3 trials, with spesolimab advancing to Phase 3 as an anti-IL-36 receptor antibody. Multiple mechanisms are being explored including IL-23 inhibition, JAK inhibition, and complement pathway targeting.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "First-line treatment typically involves systemic corticosteroids or cyclosporine with topical corticosteroids. Second-line therapy includes TNF-\u03b1 inhibitors and other biologics used off-label.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved treatments exist specifically for pyoderma gangrenosum. Current treatment relies entirely on off-label use of immunosuppressive agents and biologics approved for other inflammatory conditions.",
          "competitive_landscape": "The treatment landscape consists entirely of off-label therapies including TNF-\u03b1 inhibitors, IL-17 inhibitors, and traditional immunosuppressants. Vilobelimab has orphan designation but remains unapproved, representing a significant unmet medical need.",
          "soc_source": "Medscape Pyoderma Gangrenosum Treatment & Management - https://emedicine.medscape.com/article/1123821-treatment"
        },
        "market_size_estimate": "$1.5B",
        "market_size_usd": 1548000000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 232200000.0,
        "tam_estimate": "$232M",
        "tam_rationale": "Of ~15,480 US patients with pyoderma gangrenosum, ~80% are diagnosed (12,384), ~85% receive systemic treatment (10,526), ~40% fail first-line corticosteroids/cyclosporine and need second-line biologics (4,210). With no approved drugs and high unmet need, a new drug could capture 40-50% market share in 2L (~2,000 patients). At $116K/yr (orphan drug pricing for rare inflammatory condition), TAM = $232M. Premium pricing justified by orphan status and lack of approved alternatives.",
        "tam_sources": [
          "https://www.delveinsight.com/report-store/pyoderma-gangrenosum-market",
          "https://www.linkedin.com/pulse/pyoderma-gangrenosum-pipeline-insight-2025-unlocking-new-gaurav-bora-zonvc",
          "https://investors.abbvie.com/static-files/62df4b7e-2544-4d8b-88cd-c863e8f23003"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov/study/NCT06092216",
          "https://www.jidonline.org/article/S0022-202X(25)00023-5/fulltext",
          "https://www.clinicaltrials.gov/study/NCT03072953"
        ],
        "attributed_sources": [
          {
            "url": "https://www.droracle.ai/articles/112672/what-is-the-incidence-of-pyoderma-gangrenosum-pg-in",
            "title": "What is the incidence of Pyoderma Gangrenosum (PG ... - Dr.Oracle",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.sciencedirect.com/science/article/abs/pii/S0190962219324946",
            "title": "Prevalence estimates for pyoderma gangrenosum in the ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://emedicine.medscape.com/article/1123821-treatment",
            "title": "Pyoderma Gangrenosum Treatment & Management",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=884822",
            "title": "Search Orphan Drug Designations and Approvals - FDA",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.binasss.sa.cr/abr24/30.pdf",
            "title": "[PDF] Treatment of Pyoderma Gangrenosum - BINASSS",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT06092216",
            "title": "NCT06092216 | Spesolimab in Pyoderma Gangrenosum",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.jidonline.org/article/S0022-202X(25)00023-5/fulltext",
            "title": "The Changing Landscape of Clinical Research in ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.delveinsight.com/report-store/pyoderma-gangrenosum-market",
            "title": "Pyoderma Gangrenosum Treatment Market Size, Drugs, Companies",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.linkedin.com/pulse/pyoderma-gangrenosum-pipeline-insight-2025-unlocking-new-gaurav-bora-zonvc",
            "title": "Pyoderma Gangrenosum Pipeline Insight 2025: Unlocking New ...",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 6.0,
        "evidence_quality": 3.7,
        "market_opportunity": 9.3,
        "overall_priority": 6.3,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 1.0,
          "endpoint_quality": 5.0,
          "organ_domain_breadth": 10.0,
          "safety_categories": [
            "serious_infection",
            "discontinuation",
            "cardiovascular"
          ],
          "regulatory_flags": [
            "serious_infection",
            "cardiovascular"
          ]
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 1.0,
        "endpoint_quality_score": 5.0,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 2.0,
          "response_durability": 5.0,
          "extraction_completeness": 8.3
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 5.0,
        "extraction_completeness_score": 8.3,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 8.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 8.0,
        "unmet_need_score": 10.0
      },
      "rank": 37
    },
    {
      "extraction": {
        "source": {
          "pmid": null,
          "doi": null,
          "url": "https://academic.oup.com/skinhd/article/5/1/66/7972527",
          "title": "Dual improvement of alopecia areata and immune ...",
          "authors": "Chelsea Moon, Sarah E Park, Jennifer L Hsiao, Katrina H Lee",
          "journal": "Skin Health and Disease",
          "year": 2025,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "immune thrombocytopenia",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [],
          "disease_severity": null,
          "comorbidities": null,
          "description": "patient with concurrent alopecia areata and immune thrombocytopenia"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": "dual improvement in both autoimmune conditions",
          "primary_endpoint": "improvement in immune thrombocytopenia and alopecia areata",
          "endpoint_result": "dual improvement of both conditions",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib monotherapy resulted in dual improvement of both alopecia areata and immune thrombocytopenia in a single patient. This suggests potential linked autoimmune pathophysiology between the two conditions that may be addressed by JAK inhibition."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No specific adverse events reported in this case. The authors note that phase III trials reported rare hematological adverse events including neutropenia and anemia.",
          "safety_profile": "Acceptable"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Moderate",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "Baricitinib demonstrated efficacy for immune thrombocytopenia as an off-label use, suggesting shared autoimmune pathways with alopecia areata that are responsive to JAK inhibition.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-07T17:20:09.962213",
        "extraction_confidence": 0.5,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "immune thrombocytopenia",
        "epidemiology": {
          "us_prevalence_estimate": "9.5 per 100,000 people",
          "us_incidence_estimate": "3.3 per 100,000 people annually",
          "global_prevalence": null,
          "patient_population_size": 31825,
          "prevalence_source": "Rare Disease Advisor",
          "prevalence_source_url": "https://www.rarediseaseadvisor.com/disease-info-pages/immune-thrombocytopenia-epidemiology/",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Wayrilz (rilzabrutinib)",
              "drug_class": "BTK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "treatment of adult patients with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "FDA approved August 29, 2025 for persistent or chronic ITP; oral BTK inhibitor with fast track designation"
            },
            {
              "drug_name": "Nplate (romiplostim)",
              "drug_class": "Thrombopoietin receptor agonist",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "treatment of thrombocytopenia in adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy",
              "efficacy_range": "52-88%",
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "FDA approved for adults and pediatric patients 1 year and older with ITP; also approved for pediatric patients with ITP for at least 6 months"
            },
            {
              "drug_name": "Promacta (eltrombopag)",
              "drug_class": "Thrombopoietin receptor agonist",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "treatment of thrombocytopenia in patients with chronic immune thrombocytopenia",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "TPO receptor agonist recommended as second-line therapy for both adults and children"
            }
          ],
          "approved_drug_names": [
            "Wayrilz (rilzabrutinib)",
            "Nplate (romiplostim)",
            "Promacta (eltrombopag)"
          ],
          "num_approved_drugs": 3,
          "num_pipeline_therapies": 1,
          "pipeline_therapies": [
            {
              "drug_name": "Iptacopan (LNP023)",
              "company": "Novartis",
              "mechanism": "Factor B inhibitor targeting complement pathway",
              "phase": "Phase 2",
              "trial_id": "NCT05086744",
              "expected_completion": null
            }
          ],
          "pipeline_details": "The immune thrombocytopenia pipeline shows limited activity with one notable Phase 2 trial testing iptacopan, a complement inhibitor from Novartis targeting primary ITP patients.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "First-line therapy typically involves short-course corticosteroids, followed by second-line options including thrombopoietin receptor agonists, rituximab, or splenectomy for patients with persistent/chronic ITP lasting \u22653 months.",
          "unmet_need": false,
          "unmet_need_description": "Multiple FDA-approved second-line options are available, with recent approval of rilzabrutinib providing an additional oral treatment option for refractory patients",
          "competitive_landscape": "The ITP market includes established TPO receptor agonists (romiplostim, eltrombopag) and the newly approved BTK inhibitor rilzabrutinib for second-line treatment. Treatment selection is based on patient preferences, route of administration, and response to prior therapies.",
          "soc_source": "American Society of Hematology ITP Guidelines and FDA Orphan Drug Database"
        },
        "market_size_estimate": "$3.2B",
        "market_size_usd": 3182500000.0,
        "growth_rate": "3-5% CAGR (estimated)",
        "tam_usd": 238000000.0,
        "tam_estimate": "$238M",
        "tam_rationale": "Of ~32K US ITP patients, ~85% are diagnosed (27K), ~70% receive systemic treatment (19K), ~40% fail first-line corticosteroids and progress to second-line therapy (7.6K patients). A new second-line drug could realistically capture 20-25% market share in this established but growing market (~1.9K patients). At specialty drug pricing of $125K/year for chronic ITP treatment, TAM = $238M. Market supports premium pricing given chronic nature and limited second-line options.",
        "tam_sources": [
          "https://www.researchnester.com/reports/immune-thrombocytopenia-market/7455",
          "https://www.researchandmarkets.com/reports/6174357/eltrombopag-drugs-market-report?srsltid=AfmBOoq7gD0frwNTa--Mlrb2q4cwemGSmtdEleedwkLAngsyReqIMaK2",
          "https://www.sec.gov/Archives/edgar/data/1768446/000095017025044350/clym-20241231.htm"
        ],
        "pipeline_sources": [
          "https://cdn.clinicaltrials.gov/large-docs/44/NCT05086744/Prot_000.pdf",
          "https://cdn.clinicaltrials.gov/large-docs/12/NCT02420912/Prot_SAP_000.pdf",
          "https://cdn.clinicaltrials.gov/large-docs/97/NCT04860297/Prot_000.pdf"
        ],
        "attributed_sources": [
          {
            "url": "https://www.rarediseaseadvisor.com/disease-info-pages/immune-thrombocytopenia-epidemiology/",
            "title": "Immune Thrombocytopenia Epidemiology - Rare Disease Advisor",
            "attribution": "Epidemiology"
          },
          {
            "url": "http://waocp.com/journal/index.php/apjcb/article/view/1290",
            "title": "Epidemiology and Management of Immune Thrombocytopenia in ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.fda.gov/drugs/news-events-human-drugs/notable-approvals-drugs",
            "title": "Notable Approvals | Drugs",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=165402",
            "title": "Search Orphan Drug Designations and Approvals - FDA",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.hematology.org/-/media/hematology/files/education/clinicians/guidelines-quality/documents/ash-itp-pocket-guide-for-web-1204.pdf",
            "title": "[PDF] Management of Immune Thrombocytopenia (ITP)",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/44/NCT05086744/Prot_000.pdf",
            "title": "Clinical Trial Protocol CLNP023L12201 / NCT05086744",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/12/NCT02420912/Prot_SAP_000.pdf",
            "title": "Frontline FCR for CLL",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.researchnester.com/reports/immune-thrombocytopenia-market/7455",
            "title": "Immune Thrombocytopenia Market Size & Trends | Global Forecast ...",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.researchandmarkets.com/reports/6174357/eltrombopag-drugs-market-report?srsltid=AfmBOoq7gD0frwNTa--Mlrb2q4cwemGSmtdEleedwkLAngsyReqIMaK2",
            "title": "Eltrombopag Drugs Market Report 2025",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 7.8,
        "evidence_quality": 2.9,
        "market_opportunity": 6.0,
        "overall_priority": 6.2,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 7.0,
          "endpoint_quality": 5.0,
          "organ_domain_breadth": 10.0,
          "safety_categories": [],
          "regulatory_flags": []
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 7.0,
        "endpoint_quality_score": 5.0,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 2.0,
          "response_durability": 4.0,
          "extraction_completeness": 5.5
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 5.5,
        "market_breakdown": {
          "competitors": 5.0,
          "market_size": 8.0,
          "unmet_need": 5.0
        },
        "competitors_score": 5.0,
        "market_size_score": 8.0,
        "unmet_need_score": 5.0
      },
      "rank": 38
    },
    {
      "extraction": {
        "source": {
          "pmid": "40947519",
          "doi": "10.1002/acr.25644",
          "url": "https://pubmed.ncbi.nlm.nih.gov/40947519/",
          "title": "Effectiveness and safety of baricitinib for juvenile idiopathic arthritis associated uveitis or chronic anterior antinuclear antibody positive uveitis.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "juvenile idiopathic arthritis associated uveitis and chronic anterior antinuclear antibody positive uveitis",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": null,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "MTX",
            "bDMARDs"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "paediatric patients with active JIA-U or chronic anterior ANA-positive uveitis"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": null,
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": null,
          "responders_pct": null,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": null,
          "primary_endpoint": null,
          "endpoint_result": null,
          "durability_signal": null,
          "efficacy_summary": "Study evaluates baricitinib efficacy in pediatric patients with JIA-associated uveitis or chronic anterior ANA-positive uveitis who had inadequate response to prior treatments. Specific outcomes not detailed in abstract."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Safety evaluation was conducted but specific adverse events not detailed in abstract.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Unknown",
        "efficacy_signal": "Unknown",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "Baricitinib was evaluated for efficacy and safety in pediatric uveitis patients with inadequate response to standard treatments.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-07T17:39:39.565455",
        "extraction_confidence": 0.5,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "juvenile idiopathic arthritis associated uveitis and chronic anterior antinuclear antibody positive uveitis",
        "epidemiology": {
          "us_prevalence_estimate": "30,000 to 50,000 cases",
          "us_incidence_estimate": "1.2 per 100,000 annually for JIA-associated uveitis",
          "global_prevalence": null,
          "patient_population_size": 40000,
          "prevalence_source": "MERSI and TriNetX database study",
          "prevalence_source_url": "https://mersi.com/juvenile-idiopathic-arthritis-uveitis-effect-eye/",
          "trend": "decreasing"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Humira (adalimumab)",
              "drug_class": "TNF inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "uveitis",
              "efficacy_range": "60-70%",
              "efficacy_pct": null,
              "annual_cost_usd": 80000.0,
              "line_of_therapy": "2L",
              "notes": "FDA approved for uveitis indication, shown superior efficacy compared to infliximab and etanercept for JIA-associated uveitis"
            },
            {
              "drug_name": "Actemra (tocilizumab)",
              "drug_class": "IL-6 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": "50-60%",
              "efficacy_pct": null,
              "annual_cost_usd": 75000.0,
              "line_of_therapy": "2L",
              "notes": "Used off-label as second-line biologic, FDA approved for JIA but not specifically for uveitis indication"
            },
            {
              "drug_name": "Orencia (abatacept)",
              "drug_class": "T-cell co-stimulation inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": "40-50%",
              "efficacy_pct": null,
              "annual_cost_usd": 70000.0,
              "line_of_therapy": "2L",
              "notes": "Used as second-line therapy, FDA approved for JIA but not specifically for uveitis indication"
            },
            {
              "drug_name": "Enbrel (etanercept)",
              "drug_class": "TNF inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": "30-40%",
              "efficacy_pct": null,
              "annual_cost_usd": 65000.0,
              "line_of_therapy": "2L",
              "notes": "Less effective than adalimumab for uveitis, FDA approved for JIA but not specifically for uveitis indication"
            }
          ],
          "approved_drug_names": [
            "Humira (adalimumab)"
          ],
          "num_approved_drugs": 1,
          "num_pipeline_therapies": 2,
          "pipeline_therapies": [
            {
              "drug_name": "Baricitinib (LY3009104)",
              "company": "Eli Lilly",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT04088409",
              "expected_completion": null
            },
            {
              "drug_name": "Secukinumab (AIN457)",
              "company": "Novartis",
              "mechanism": "IL-17A inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT03769168",
              "expected_completion": null
            }
          ],
          "pipeline_details": "The clinical pipeline for JIA-associated uveitis includes JAK inhibitor baricitinib in Phase 3 testing against adalimumab as active comparator, and IL-17A inhibitor secukinumab in Phase 3 extension studies for juvenile arthritis with uveitis assessment.",
          "avg_annual_cost_usd": 72500.0,
          "treatment_paradigm": "Topical corticosteroids are first-line treatment, followed by methotrexate as first-line systemic therapy, then adalimumab as preferred biologic for refractory cases.",
          "unmet_need": true,
          "unmet_need_description": "Only one FDA-approved biologic specifically for uveitis indication, with many patients requiring off-label use of other biologics for adequate disease control",
          "competitive_landscape": "Adalimumab is the only FDA-approved biologic for uveitis, creating limited competition in this specific indication. Multiple other biologics are used off-label with varying efficacy profiles.",
          "soc_source": "EyeWiki and Canadian Rheumatology Association Guidelines"
        },
        "market_size_estimate": "$2.9B",
        "market_size_usd": 2900000000.0,
        "growth_rate": "0-2% CAGR (decreasing prevalence)",
        "tam_usd": 217500000.0,
        "tam_estimate": "$218M",
        "tam_rationale": "Of ~40,000 US patients with JIA-associated uveitis, ~85% are diagnosed (34K), ~75% receive treatment beyond topical corticosteroids (25.5K), ~40% fail methotrexate and are candidates for biologic therapy (10.2K). With only adalimumab approved, a new biologic could capture 30-35% market share (~3K patients) given high unmet need. At $72.5K/yr average cost, TAM = $218M.",
        "tam_sources": [
          "https://eyewiki.org/Juvenile_Idiopathic_Arthritis_Associated_Uveitis",
          "https://en.wiktionary.org/wiki/juvenile",
          "https://dictionary.cambridge.org/dictionary/english/juvenile"
        ],
        "pipeline_sources": [
          "https://cdn.clinicaltrials.gov/large-docs/09/NCT04088409/Prot_000.pdf",
          "https://cdn.clinicaltrials.gov/large-docs/97/NCT03816397/Prot_000.pdf",
          "https://cdn.clinicaltrials.gov/large-docs/44/NCT02277444/Prot_000.pdf"
        ],
        "attributed_sources": [
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11964343/",
            "title": "Juvenile idiopathic arthritis and associated uveitis - PubMed Central",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://mersi.com/juvenile-idiopathic-arthritis-uveitis-effect-eye/",
            "title": "Juvenile Idiopathic Arthritis and Uveitis: What is it and what ... - MERSI",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761054Orig1s000MedR.pdf",
            "title": "761054Orig1s000 - accessdata.fda.gov",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/1007276-medication",
            "title": "Juvenile Idiopathic Arthritis Medication: Nonsteroidal Anti- ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://eyewiki.org/Juvenile_Idiopathic_Arthritis_Associated_Uveitis",
            "title": "Juvenile Idiopathic Arthritis Associated Uveitis - EyeWiki",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/09/NCT04088409/Prot_000.pdf",
            "title": "I4V-MC-JAHW(e) Open-label, Active-Controlled, Safety, and ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/97/NCT03816397/Prot_000.pdf",
            "title": "ADJUST Protocol v1.8_clean plus NCT on cover page",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://eyewiki.org/Juvenile_Idiopathic_Arthritis_Associated_Uveitis",
            "title": "Juvenile Idiopathic Arthritis Associated Uveitis",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://en.wiktionary.org/wiki/juvenile",
            "title": "juvenile - Wiktionary, the free dictionary",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 5.8,
        "evidence_quality": 5.0,
        "market_opportunity": 8.3,
        "overall_priority": 6.2,
        "clinical_breakdown": {
          "response_rate": 5.0,
          "safety_profile": 5.0,
          "endpoint_quality": 5.0,
          "organ_domain_breadth": 10.0,
          "safety_categories": [],
          "regulatory_flags": []
        },
        "response_rate_score": 5.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": 5.0,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 3.0,
          "publication_venue": 10.0,
          "response_durability": 4.0,
          "extraction_completeness": 3.2
        },
        "sample_size_score": 3.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 3.2,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 8.0,
          "unmet_need": 10.0
        },
        "competitors_score": 7.0,
        "market_size_score": 8.0,
        "unmet_need_score": 10.0
      },
      "rank": 39
    },
    {
      "extraction": {
        "source": {
          "pmid": "36702180",
          "doi": "10.1016/j.clim.2023.109241",
          "url": "https://pubmed.ncbi.nlm.nih.gov/36702180/",
          "title": "Baricitinib for the treatment of intestinal Beh\u00e7et's disease: A pilot study.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "intestinal Beh\u00e7et's disease",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": null,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": null,
          "disease_severity": null,
          "comorbidities": null,
          "description": "patients with refractory intestinal Beh\u00e7et's disease"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": null,
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": null,
          "responders_pct": null,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": null,
          "primary_endpoint": null,
          "endpoint_result": null,
          "durability_signal": null,
          "efficacy_summary": "This pilot study explored the efficacy of baricitinib in treating refractory intestinal Beh\u00e7et's disease. Specific efficacy outcomes were not detailed in the abstract provided."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "The study aimed to explore safety of baricitinib in intestinal Beh\u00e7et's disease patients. Specific safety outcomes were not detailed in the abstract provided.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Unknown",
        "efficacy_signal": "Unknown",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "Pilot study investigating baricitinib for refractory intestinal Beh\u00e7et's disease, representing a novel off-label application of this JAK inhibitor.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-07T17:42:56.486036",
        "extraction_confidence": 0.5,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "intestinal Beh\u00e7et's disease",
        "epidemiology": {
          "us_prevalence_estimate": "0.12-5.2 per 100,000 population",
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": 9045,
          "prevalence_source": "Arthritis & Rheumatism / Olmsted County study",
          "prevalence_source_url": "https://emedicine.medscape.com/article/329099-overview",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Infliximab (infliximab)",
              "drug_class": "TNF-alpha inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": 50000.0,
              "line_of_therapy": "1L-2L",
              "notes": "TNF-alpha inhibitor used off-label for intestinal Beh\u00e7et's disease, not FDA approved for this specific indication"
            },
            {
              "drug_name": "Adalimumab (adalimumab)",
              "drug_class": "TNF-alpha inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": 60000.0,
              "line_of_therapy": "1L-2L",
              "notes": "TNF-alpha inhibitor used off-label for intestinal Beh\u00e7et's disease, not FDA approved for this specific indication"
            },
            {
              "drug_name": "Otezla (apremilast)",
              "drug_class": "Phosphodiesterase-4 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": "oral ulcers associated with Beh\u00e7et's disease",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": 40000.0,
              "line_of_therapy": "2L",
              "notes": "FDA approved for oral ulcers in Beh\u00e7et's disease in 2019, not specifically for intestinal Beh\u00e7et's disease"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 1,
          "pipeline_therapies": [
            {
              "drug_name": "Hemay005",
              "company": "Not specified",
              "mechanism": "Not specified",
              "phase": "Phase 3",
              "trial_id": "NCT06145893",
              "expected_completion": null
            }
          ],
          "pipeline_details": "Limited pipeline activity for intestinal Beh\u00e7et's disease with one Phase 3 trial of Hemay005 tablets for Beh\u00e7et's disease, though specific focus on intestinal manifestations is unclear from available data.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "No FDA-approved branded innovative treatments exist specifically for intestinal Beh\u00e7et's disease. Treatment relies on off-label use of TNF-alpha inhibitors and immunosuppressants.",
          "unmet_need": true,
          "unmet_need_description": "Complete absence of FDA-approved branded innovative treatments specifically for intestinal Beh\u00e7et's disease represents a significant unmet medical need",
          "competitive_landscape": "The treatment landscape consists entirely of off-label use of biologics like infliximab and adalimumab. Apremilast is FDA-approved only for oral ulcers, not intestinal manifestations of Beh\u00e7et's disease.",
          "soc_source": "Medscape Behcet Disease Treatment & Management - https://emedicine.medscape.com/article/329099-treatment"
        },
        "market_size_estimate": "$1.8B",
        "market_size_usd": 1809000000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 271350000.0,
        "tam_estimate": "$271M",
        "tam_rationale": "Of ~9,045 US patients with intestinal Beh\u00e7et's disease, ~60% are diagnosed (5,427), ~80% receive treatment (4,342) given severity of GI complications. With no approved therapies, a first-to-market drug could capture 50-60% market share (~2,500 patients) as current off-label treatments have limited efficacy. At $108K/yr (orphan disease premium pricing similar to other rare inflammatory conditions), TAM = $271M. Zero competition and high unmet need support premium positioning.",
        "tam_sources": [
          "https://investors.abbvie.com/static-files/62df4b7e-2544-4d8b-88cd-c863e8f23003",
          "https://stocklight.com/stocks/us/nyse-abbv/abbvie/annual-reports/nyse-abbv-2023-10K-23641440.pdf",
          "https://www.annualreports.co.uk/HostedData/AnnualReportArchive/a/NYSE_ABBV_2020.pdf"
        ],
        "pipeline_sources": [
          "https://www.clinicaltrials.gov/study/NCT06145893?term=hemay005&viewType=Table&checkSpell=&rank=7",
          "https://cdn.clinicaltrials.gov/large-docs/75/NCT02814175/Prot_000.pdf",
          "https://cdn.clinicaltrials.gov/large-docs/81/NCT05612581/Prot_001.pdf"
        ],
        "attributed_sources": [
          {
            "url": "https://emedicine.medscape.com/article/329099-overview",
            "title": "Behcet Disease: Background, Pathophysiology, Etiology",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4385527/",
            "title": "Gastrointestinal Beh\u00e7et's disease: A review - PMC - PubMed Central",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://emedicine.medscape.com/article/329099-medication",
            "title": "Behcet Disease Medication",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/329099-treatment",
            "title": "Behcet Disease Treatment & Management",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.chi.gov.sa/Style%20Library/IDF_Branding/Indication/185%20-%20Behcet%20Disease-New%20Indication.pdf",
            "title": "BEHCET DISEASE",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT06145893?term=hemay005&viewType=Table&checkSpell=&rank=7",
            "title": "A Study of Efficacy and Safety of Hemay005 Tablets in ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/75/NCT02814175/Prot_000.pdf",
            "title": "Clinical Study Protocol M14-496 A Phase 4 open-label ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://investors.abbvie.com/static-files/62df4b7e-2544-4d8b-88cd-c863e8f23003",
            "title": "[PDF] People. Passion. Possibilities. - AbbVie Investor Relations",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://stocklight.com/stocks/us/nyse-abbv/abbvie/annual-reports/nyse-abbv-2023-10K-23641440.pdf",
            "title": "[PDF] AbbVie Annual Report 2023 Form 10-K (NYSE:ABBV) Published",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 5.2,
        "evidence_quality": 5.0,
        "market_opportunity": 9.3,
        "overall_priority": 6.2,
        "clinical_breakdown": {
          "response_rate": 5.0,
          "safety_profile": 5.0,
          "endpoint_quality": 5.0,
          "organ_domain_breadth": 6.0,
          "safety_categories": [],
          "regulatory_flags": []
        },
        "response_rate_score": 5.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": 5.0,
        "organ_domain_score": 6.0,
        "evidence_breakdown": {
          "sample_size": 3.0,
          "publication_venue": 10.0,
          "response_durability": 4.0,
          "extraction_completeness": 3.2
        },
        "sample_size_score": 3.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 3.2,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 8.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 8.0,
        "unmet_need_score": 10.0
      },
      "rank": 40
    },
    {
      "extraction": {
        "source": {
          "pmid": "38980207",
          "doi": "10.1002/ajh.27433",
          "url": "https://pubmed.ncbi.nlm.nih.gov/38980207/",
          "title": "Safety and efficacy of baricitinib in steroid-resistant or relapsed immune thrombocytopenia: An open-label pilot study.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "immune thrombocytopenia (ITP)",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": null,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "corticosteroids",
            "at least one subsequent treatment"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "adults with primary ITP who were refractory to corticosteroids and at least one subsequent treatment, with platelet counts below 30 \u00d7 10^9/L"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": null,
          "responders_pct": null,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": null,
          "primary_endpoint": null,
          "endpoint_result": null,
          "durability_signal": null,
          "efficacy_summary": "Study designed to explore efficacy of baricitinib in steroid-resistant or relapsed ITP patients. Complete results not provided in abstract."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Safety outcomes not detailed in abstract. Study designed as open-label pilot to assess safety and efficacy.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Unknown",
        "efficacy_signal": "Unknown",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "Open-label pilot study evaluating baricitinib for steroid-resistant ITP, rationale based on JAK inhibition addressing immune disorders without inducing thrombocytopenia.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-07T17:23:15.148770",
        "extraction_confidence": 0.5,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "immune thrombocytopenia (ITP)",
        "epidemiology": {
          "us_prevalence_estimate": "9.5 per 100,000",
          "us_incidence_estimate": "6.0-6.1 per 100,000 per year",
          "global_prevalence": null,
          "patient_population_size": 31825,
          "prevalence_source": "Maryland Health Care Commission study",
          "prevalence_source_url": "https://www.sciencedirect.com/science/article/pii/S153878362211648X",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Nplate (romiplostim)",
              "drug_class": "Thrombopoietin receptor agonist",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "immune thrombocytopenia (ITP)",
              "efficacy_range": "65-85%",
              "efficacy_pct": null,
              "annual_cost_usd": 150000.0,
              "line_of_therapy": "2L",
              "notes": "FDA approved for adult patients with ITP who have had insufficient response to corticosteroids, immunoglobulins, or splenectomy. Also approved for pediatric patients 1 year and older."
            },
            {
              "drug_name": "Wayrilz (rilzabrutinib)",
              "drug_class": "BTK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "immune thrombocytopenia (ITP)",
              "efficacy_range": "55-70%",
              "efficacy_pct": null,
              "annual_cost_usd": 180000.0,
              "line_of_therapy": "2L",
              "notes": "FDA approved August 2025 for treatment of adult patients with persistent or chronic ITP who have had insufficient response to previous treatment. Oral BTK inhibitor with orphan designation."
            },
            {
              "drug_name": "Tavalisse (fostamatinib)",
              "drug_class": "SYK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "immune thrombocytopenia (ITP)",
              "efficacy_range": "40-60%",
              "efficacy_pct": null,
              "annual_cost_usd": 120000.0,
              "line_of_therapy": "2L",
              "notes": "FDA approved April 2018 for treatment of thrombocytopenia in adult patients with chronic ITP who have had insufficient response to previous treatment. Oral SYK inhibitor."
            }
          ],
          "approved_drug_names": [
            "Nplate (romiplostim)",
            "Wayrilz (rilzabrutinib)",
            "Tavalisse (fostamatinib)"
          ],
          "num_approved_drugs": 3,
          "num_pipeline_therapies": 4,
          "pipeline_therapies": [
            {
              "drug_name": "rilzabrutinib",
              "company": "Not specified",
              "mechanism": "Covalent, reversible Bruton tyrosine kinase inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT04562766",
              "expected_completion": null
            },
            {
              "drug_name": "ianalumab",
              "company": "Not specified",
              "mechanism": "Targets autoantibody-producing plasma cells",
              "phase": "Phase 3",
              "trial_id": null,
              "expected_completion": null
            },
            {
              "drug_name": "efgartigimod",
              "company": "Not specified",
              "mechanism": "FcRn antagonist",
              "phase": "Phase 3",
              "trial_id": null,
              "expected_completion": null
            },
            {
              "drug_name": "iptacopan",
              "company": "Novartis",
              "mechanism": "Not specified",
              "phase": "Phase 2",
              "trial_id": "NCT05086744",
              "expected_completion": null
            }
          ],
          "pipeline_details": "The ITP clinical trial pipeline shows active Phase 2-3 development with rilzabrutinib completing Phase 3 trials and multiple FcRn antagonists advancing through late-stage development. Pipeline activity focuses on novel mechanisms including BTK inhibition and targeting autoantibody-producing plasma cells for sustained responses.",
          "avg_annual_cost_usd": 150000.0,
          "treatment_paradigm": "First-line therapy typically uses corticosteroids, with second-line options including thrombopoietin receptor agonists, BTK/SYK inhibitors, or rituximab for patients with insufficient response.",
          "unmet_need": true,
          "unmet_need_description": "Current treatments have limited long-term complete response rates (20-50%) and many patients require chronic therapy with ongoing bleeding risks and treatment-related toxicities.",
          "competitive_landscape": "The ITP market features multiple FDA-approved targeted therapies competing in the second-line setting, with newer oral options like BTK inhibitors challenging established thrombopoietin receptor agonists. Treatment selection is individualized based on patient preferences, comorbidities, and response to prior therapies.",
          "soc_source": "FDA Drug Approvals and ASH Guidelines - https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fostamatinib-tablets-itp"
        },
        "market_size_estimate": "$4.8B",
        "market_size_usd": 4773750000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 381600000.0,
        "tam_estimate": "$382M",
        "tam_rationale": "Of ~31,825 ITP patients globally, approximately 80% are diagnosed (25,460), with 75% receiving treatment (19,095). Given treatment paradigm, ~40% of patients fail first-line corticosteroids and need second-line therapy (7,638). A new drug positioned as second-line could realistically capture 20-25% market share (~1,908 patients) in a market with 3 existing competitors but high unmet need. At $200K/yr average price for specialty ITP therapies, TAM = $382M.",
        "tam_sources": [
          "https://www.giikorea.co.kr/report/tbrc1730904-immune-thrombocytopenia-global-market-report.html",
          "https://www.fortunebusinessinsights.com/industry-reports/immune-thrombocytopenia-itp-market-101682",
          "https://www.researchnester.com/reports/immune-thrombocytopenia-market/7455"
        ],
        "pipeline_sources": [
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC11469945/",
          "https://www.clinicaltrials.gov/study/NCT05338190",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC6282556/"
        ],
        "attributed_sources": [
          {
            "url": "https://rarediseases.org/rare-diseases/immune-thrombocytopenia/",
            "title": "Immune Thrombocytopenia - Symptoms, Causes, Treatment | NORD",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://pubmed.ncbi.nlm.nih.gov/31547724/",
            "title": "incidence and healthcare burden in first 12 months following diagnosis",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=165402",
            "title": "Search Orphan Drug Designations and Approvals - FDA",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=605717",
            "title": "Search Orphan Drug Designations and Approvals - FDA",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.hematology.org/-/media/hematology/files/education/clinicians/guidelines-quality/documents/ash-itp-pocket-guide-for-web-1204.pdf",
            "title": "[PDF] Management of Immune Thrombocytopenia (ITP)",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11469945/",
            "title": "2025 Update on Clinical Trials in Immune Thrombocytopenia",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT05338190",
            "title": "Study Details | NCT05338190 | Efficacy and Safety of ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.giikorea.co.kr/report/tbrc1730904-immune-thrombocytopenia-global-market-report.html",
            "title": "\uc138\uacc4\uc758 \uba74\uc5ed\uc131 \ud608\uc18c\ud310 \uac10\uc18c\uc99d \uc2dc\uc7a5 \ubcf4\uace0\uc11c(2025\ub144) - \uae00\ub85c\ubc8c\uc778\ud3ec\uba54\uc774\uc158",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.fortunebusinessinsights.com/industry-reports/immune-thrombocytopenia-itp-market-101682",
            "title": "Immune Thrombocytopenia Market Size, Share | Global Report, 2032",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 5.8,
        "evidence_quality": 5.0,
        "market_opportunity": 7.7,
        "overall_priority": 6.1,
        "clinical_breakdown": {
          "response_rate": 5.0,
          "safety_profile": 5.0,
          "endpoint_quality": 5.0,
          "organ_domain_breadth": 10.0,
          "safety_categories": [],
          "regulatory_flags": []
        },
        "response_rate_score": 5.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": 5.0,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 3.0,
          "publication_venue": 10.0,
          "response_durability": 4.0,
          "extraction_completeness": 3.2
        },
        "sample_size_score": 3.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 3.2,
        "market_breakdown": {
          "competitors": 5.0,
          "market_size": 8.0,
          "unmet_need": 10.0
        },
        "competitors_score": 5.0,
        "market_size_score": 8.0,
        "unmet_need_score": 10.0
      },
      "rank": 41
    },
    {
      "extraction": {
        "source": {
          "pmid": "38653530",
          "doi": "10.1136/ard-2023-225463",
          "url": "https://pubmed.ncbi.nlm.nih.gov/38653530/",
          "title": "Disease flares with baricitinib dose reductions and development of flare criteria in patients with CANDLE/PRAAS.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "CANDLE/PRAAS (Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated Temperature/Proteasome-Associated Autoinflammatory Syndrome)",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Retrospective Study",
        "patient_population": {
          "n_patients": 10,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [],
          "disease_severity": null,
          "comorbidities": null,
          "description": "Patients with genetically confirmed CANDLE/PRAAS, mean age 11.5 years (range 2.3-19.6)"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "Higher exposure than rheumatoid arthritis doses (median 9.00 mg/day for high-dose period, 6.00 mg/day for low-dose period)",
          "frequency": null,
          "duration": "Mean duration of 6.3 years (\u00b12.3 years)",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "5/10 (50%)",
          "responders_n": 5,
          "responders_pct": 50.0,
          "time_to_response": "Mean time to establish clinically effective dose was 1.06 years",
          "duration_of_response": "Lasting clinical remission with normalisation of IFN response gene signature",
          "effect_size_description": "50% of patients achieved lasting clinical remission with normalized interferon signature",
          "primary_endpoint": "Disease flare rates with dose reductions",
          "endpoint_result": "50% (7/14) of dose reductions resulted in disease flares; 100% of >25% dose reductions triggered flares vs 20% of <25% reductions",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib demonstrated efficacy in CANDLE/PRAAS with 50% of patients achieving lasting clinical remission and normalized interferon signatures. However, dose reductions frequently triggered disease flares, with all dose reductions >25% resulting in flares."
        },
        "safety": {
          "adverse_events": [
            "BK viral reactivation in urine",
            "cytopenias",
            "BK viraemia",
            "BK nephropathy"
          ],
          "serious_adverse_events": [
            "BK nephropathy",
            "macrophage activation syndrome",
            "azotaemia"
          ],
          "sae_count": 2,
          "sae_percentage": 20.0,
          "discontinuations_n": 1,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [
            "BK nephropathy with elevated creatinine"
          ],
          "safety_summary": "Safety concerns included BK viral reactivation, cytopenias, and nephropathy at higher exposures required for CANDLE/PRAAS treatment. One patient developed macrophage activation syndrome after abrupt discontinuation.",
          "safety_profile": "Concerning"
        },
        "outcome_result": "Mixed",
        "efficacy_signal": "Moderate",
        "comparator_baseline": null,
        "follow_up_duration": "Median 6.9 years",
        "key_findings": "Baricitinib shows efficacy in CANDLE/PRAAS but requires higher doses than RA, leading to increased safety concerns. Dose reductions must be gradual to avoid disease flares.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "Disease flare rate after baricitinib dose reduction",
            "endpoint_category": "Primary",
            "timepoint": "Post-dose reduction (up to 60 days)",
            "measurement_type": "Responder",
            "value": 50.0,
            "unit": "percentage",
            "responders_n": 7,
            "responders_pct": 50.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "7 of 14 dose reductions resulted in disease flares"
          },
          {
            "endpoint_name": "Disease flare rate with >25% dose reduction",
            "endpoint_category": "Primary",
            "timepoint": "Post-dose reduction (up to 60 days)",
            "measurement_type": "Responder",
            "value": 100.0,
            "unit": "percentage",
            "responders_n": 4,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": "<0.05",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "All four dose reductions >25% triggered disease flare"
          },
          {
            "endpoint_name": "Disease flare rate with <25% dose reduction",
            "endpoint_category": "Primary",
            "timepoint": "Post-dose reduction (up to 60 days)",
            "measurement_type": "Responder",
            "value": 20.0,
            "unit": "percentage",
            "responders_n": 2,
            "responders_pct": 20.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "2 of 10 dose reductions <25% resulted in clinical flares"
          },
          {
            "endpoint_name": "Disease flare criteria fulfillment during low-dose visits",
            "endpoint_category": "Primary",
            "timepoint": "During study visits",
            "measurement_type": "Responder",
            "value": 43.14,
            "unit": "percentage",
            "responders_n": null,
            "responders_pct": 43.14,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": "<0.0001",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Compared to 12.75% during high-dose visits"
          },
          {
            "endpoint_name": "Disease flare criteria fulfillment during high-dose visits",
            "endpoint_category": "Primary",
            "timepoint": "During study visits",
            "measurement_type": "Responder",
            "value": 12.75,
            "unit": "percentage",
            "responders_n": null,
            "responders_pct": 12.75,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": "<0.0001",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Compared to 43.14% during low-dose visits"
          },
          {
            "endpoint_name": "Daily diary score change with flare (minimum)",
            "endpoint_category": "Secondary",
            "timepoint": "Reference visit vs flare visit",
            "measurement_type": "Change from baseline",
            "value": 15.0,
            "unit": "percentage increase",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": 15.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Available DDS (n=6) worsened between 15% to >500%"
          },
          {
            "endpoint_name": "Daily diary score change with flare (maximum)",
            "endpoint_category": "Secondary",
            "timepoint": "Reference visit vs flare visit",
            "measurement_type": "Change from baseline",
            "value": 500.0,
            "unit": "percentage increase",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": 500.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Available DDS (n=6) worsened between 15% to >500%"
          },
          {
            "endpoint_name": "Daily diary score absolute change (minimum)",
            "endpoint_category": "Secondary",
            "timepoint": "Reference visit vs flare visit",
            "measurement_type": "Change from baseline",
            "value": 0.055,
            "unit": "absolute change",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": 0.055,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Absolute change ranged between 0.055 and 0.314"
          },
          {
            "endpoint_name": "Daily diary score absolute change (maximum)",
            "endpoint_category": "Secondary",
            "timepoint": "Reference visit vs flare visit",
            "measurement_type": "Change from baseline",
            "value": 0.314,
            "unit": "absolute change",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": 0.314,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Absolute change ranged between 0.055 and 0.314"
          },
          {
            "endpoint_name": "C-reactive protein increase during flare (minimum)",
            "endpoint_category": "Secondary",
            "timepoint": "Reference visit vs flare visit",
            "measurement_type": "Change from baseline",
            "value": 91.0,
            "unit": "percentage increase",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": 91.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "CRP increased between 91% to >500%"
          },
          {
            "endpoint_name": "C-reactive protein increase during flare (maximum)",
            "endpoint_category": "Secondary",
            "timepoint": "Reference visit vs flare visit",
            "measurement_type": "Change from baseline",
            "value": 500.0,
            "unit": "percentage increase",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": 500.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "CRP increased between 91% to >500%"
          },
          {
            "endpoint_name": "Erythrocyte sedimentation rate increase during flare (minimum)",
            "endpoint_category": "Secondary",
            "timepoint": "Reference visit vs flare visit",
            "measurement_type": "Change from baseline",
            "value": 39.0,
            "unit": "percentage increase",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": 39.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "ESR increased between 39% to >500%"
          },
          {
            "endpoint_name": "Erythrocyte sedimentation rate increase during flare (maximum)",
            "endpoint_category": "Secondary",
            "timepoint": "Reference visit vs flare visit",
            "measurement_type": "Change from baseline",
            "value": 500.0,
            "unit": "percentage increase",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": 500.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "ESR increased between 39% to >500%"
          },
          {
            "endpoint_name": "White blood cell count decrease during flare (minimum)",
            "endpoint_category": "Secondary",
            "timepoint": "Reference visit vs flare visit",
            "measurement_type": "Change from baseline",
            "value": 34.0,
            "unit": "percentage decrease",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": -34.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "WBC decreased between 34% and 41%"
          },
          {
            "endpoint_name": "White blood cell count decrease during flare (maximum)",
            "endpoint_category": "Secondary",
            "timepoint": "Reference visit vs flare visit",
            "measurement_type": "Change from baseline",
            "value": 41.0,
            "unit": "percentage decrease",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": -41.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "WBC decreased between 34% and 41%"
          },
          {
            "endpoint_name": "Absolute lymphocyte count decrease during flare (minimum)",
            "endpoint_category": "Secondary",
            "timepoint": "Reference visit vs flare visit",
            "measurement_type": "Change from baseline",
            "value": 15.0,
            "unit": "percentage decrease",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": -15.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "ALC decreased between 15% and 89%"
          },
          {
            "endpoint_name": "Absolute lymphocyte count decrease during flare (maximum)",
            "endpoint_category": "Secondary",
            "timepoint": "Reference visit vs flare visit",
            "measurement_type": "Change from baseline",
            "value": 89.0,
            "unit": "percentage decrease",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": -89.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "ALC decreased between 15% and 89%"
          },
          {
            "endpoint_name": "Platelet count decrease during flare (minimum)",
            "endpoint_category": "Secondary",
            "timepoint": "Reference visit vs flare visit",
            "measurement_type": "Change from baseline",
            "value": 24.0,
            "unit": "percentage decrease",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": -24.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "PLT count decreased between 24% and 47%"
          },
          {
            "endpoint_name": "Platelet count decrease during flare (maximum)",
            "endpoint_category": "Secondary",
            "timepoint": "Reference visit vs flare visit",
            "measurement_type": "Change from baseline",
            "value": 47.0,
            "unit": "percentage decrease",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": -47.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "PLT count decreased between 24% and 47%"
          },
          {
            "endpoint_name": "Hemoglobin decrease during flare (minimum)",
            "endpoint_category": "Secondary",
            "timepoint": "Reference visit vs flare visit",
            "measurement_type": "Change from baseline",
            "value": 1.0,
            "unit": "percentage decrease",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": -1.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "HGB decreased between 1% and 14%"
          },
          {
            "endpoint_name": "Hemoglobin decrease during flare (maximum)",
            "endpoint_category": "Secondary",
            "timepoint": "Reference visit vs flare visit",
            "measurement_type": "Change from baseline",
            "value": 14.0,
            "unit": "percentage decrease",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": -14.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "HGB decreased between 1% and 14%"
          },
          {
            "endpoint_name": "Interferon score change during flare (Patient P1)",
            "endpoint_category": "Secondary",
            "timepoint": "Before vs after dose reduction",
            "measurement_type": "Change from baseline",
            "value": 236.29,
            "unit": "absolute value",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 31.21,
            "change_from_baseline": 205.08,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "IFN score increased from 31.21 to 236.29 (cut-off 44.2)"
          },
          {
            "endpoint_name": "Time to disease flare",
            "endpoint_category": "Secondary",
            "timepoint": "Post-dose reduction",
            "measurement_type": "Absolute value",
            "value": 15.3,
            "unit": "days (mean)",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Ranged from 1 to 55 days (mean 15.3 \u00b120.7 days)"
          },
          {
            "endpoint_name": "Median baricitinib dose during high-dose visits",
            "endpoint_category": "Secondary",
            "timepoint": "During study visits",
            "measurement_type": "Absolute value",
            "value": 9.0,
            "unit": "mg/day",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": "<0.0001",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "IQR 2.00, compared to low-dose period"
          },
          {
            "endpoint_name": "Median baricitinib dose during low-dose visits",
            "endpoint_category": "Secondary",
            "timepoint": "During study visits",
            "measurement_type": "Absolute value",
            "value": 6.0,
            "unit": "mg/day",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": "<0.0001",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "IQR 3.00, compared to high-dose period"
          },
          {
            "endpoint_name": "Median prednisone dose during high-dose baricitinib period",
            "endpoint_category": "Secondary",
            "timepoint": "During study visits",
            "measurement_type": "Absolute value",
            "value": 0.0,
            "unit": "mg/kg/day",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": "<0.0001",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "IQR 0.136, compared to low-dose period"
          },
          {
            "endpoint_name": "Median prednisone dose during low-dose baricitinib period",
            "endpoint_category": "Secondary",
            "timepoint": "During study visits",
            "measurement_type": "Absolute value",
            "value": 0.149,
            "unit": "mg/kg/day",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": "<0.0001",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "IQR 0.13, compared to high-dose period"
          },
          {
            "endpoint_name": "Median interferon score during low-dose baricitinib visits",
            "endpoint_category": "Secondary",
            "timepoint": "During study visits",
            "measurement_type": "Absolute value",
            "value": 254.46,
            "unit": "IFN score",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": "<0.0001",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "IQR 267.56, compared to high-dose period"
          },
          {
            "endpoint_name": "Median interferon score during high-dose baricitinib visits",
            "endpoint_category": "Secondary",
            "timepoint": "During study visits",
            "measurement_type": "Absolute value",
            "value": 45.93,
            "unit": "IFN score",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": "<0.0001",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "IQR 117.78, compared to low-dose period"
          },
          {
            "endpoint_name": "Disease flare criteria fulfillment with IFN score (low-dose visits)",
            "endpoint_category": "Exploratory",
            "timepoint": "During study visits",
            "measurement_type": "Responder",
            "value": 58.62,
            "unit": "percentage",
            "responders_n": null,
            "responders_pct": 58.62,
            "baseline_value": 37.93,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": "<0.001",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Increased from 37.93% when IFN score criterion added"
          },
          {
            "endpoint_name": "Disease flare criteria fulfillment with IFN score (high-dose visits)",
            "endpoint_category": "Exploratory",
            "timepoint": "During study visits",
            "measurement_type": "Responder",
            "value": 20.25,
            "unit": "percentage",
            "responders_n": null,
            "responders_pct": 20.25,
            "baseline_value": 10.13,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": "<0.001",
            "confidence_interval": null,
            "statistical_significance": true,
            "notes": "Increased from 10.13% when IFN score criterion added"
          },
          {
            "endpoint_name": "Clinical remission rate (historical reference)",
            "endpoint_category": "Secondary",
            "timepoint": "During expanded access programme",
            "measurement_type": "Responder",
            "value": 50.0,
            "unit": "percentage",
            "responders_n": null,
            "responders_pct": 50.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "50% of patients achieved lasting clinical remission on baricitinib with normalisation of IFN response gene signature"
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "BK viral reactivation in urine",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": "Related",
            "outcome": null,
            "action_taken": "Dose reduced",
            "notes": "Occurred at higher baricitinib exposures required for CANDLE/PRAAS treatment"
          },
          {
            "event_name": "BK viraemia",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": "Related",
            "outcome": null,
            "action_taken": "Dose reduced",
            "notes": "Occurred at higher baricitinib exposures required for CANDLE/PRAAS treatment"
          },
          {
            "event_name": "BK nephropathy",
            "event_category": "SAE",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": "Related",
            "outcome": null,
            "action_taken": "Dose reduced",
            "notes": "Occurred at higher baricitinib exposures required for CANDLE/PRAAS treatment"
          },
          {
            "event_name": "Cytopenias",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": "Related",
            "outcome": null,
            "action_taken": "Dose reduced",
            "notes": "Observed at higher baricitinib exposure required for treatment of CANDLE/PRAAS"
          },
          {
            "event_name": "Disease flares",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 7,
            "patients_affected_pct": 50.0,
            "events_total": 7,
            "relatedness": "Related",
            "outcome": null,
            "action_taken": null,
            "notes": "7 out of 14 dose reductions resulted in disease flares; presenting with fevers, rashes, musculoskeletal symptoms, headaches and elevation of inflammatory markers"
          },
          {
            "event_name": "Presumed BK nephropathy",
            "event_category": "SAE",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": 1,
            "relatedness": "Related",
            "outcome": null,
            "action_taken": "Discontinued",
            "notes": "Patient P7 with presumed BK nephropathy and elevated creatinine"
          },
          {
            "event_name": "Elevated creatinine",
            "event_category": "Lab abnormality",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": 1,
            "relatedness": "Related",
            "outcome": null,
            "action_taken": "Discontinued",
            "notes": "Patient P7 stopped baricitinib due to elevated creatinine"
          },
          {
            "event_name": "Macrophage activation syndrome",
            "event_category": "SAE",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": 1,
            "relatedness": "Related",
            "outcome": null,
            "action_taken": "Discontinued",
            "notes": "Patient P7 developed MAS after stopping baricitinib, required treatment with pulse methylprednisolone and prednisolone 30 mg daily"
          },
          {
            "event_name": "Azotaemia",
            "event_category": "SAE",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": 1,
            "relatedness": "Related",
            "outcome": null,
            "action_taken": "Discontinued",
            "notes": "Patient P7 discontinued baricitinib secondary to azotaemia"
          },
          {
            "event_name": "Increased C-reactive protein",
            "event_category": "Lab abnormality",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": "Related",
            "outcome": null,
            "action_taken": null,
            "notes": "Laboratory changes during disease flares, increases of 91% to >500%"
          },
          {
            "event_name": "Increased erythrocyte sedimentation rate",
            "event_category": "Lab abnormality",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": "Related",
            "outcome": null,
            "action_taken": null,
            "notes": "Laboratory changes during disease flares, increases of 39% to >500%"
          },
          {
            "event_name": "Decreased white blood cell count",
            "event_category": "Lab abnormality",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": "Related",
            "outcome": null,
            "action_taken": null,
            "notes": "Laboratory changes during disease flares, decreases between 34% and 41%"
          },
          {
            "event_name": "Decreased absolute lymphocyte count",
            "event_category": "Lab abnormality",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": "Related",
            "outcome": null,
            "action_taken": null,
            "notes": "Laboratory changes during disease flares, decreases between 15% and 89%"
          },
          {
            "event_name": "Decreased platelet count",
            "event_category": "Lab abnormality",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": "Related",
            "outcome": null,
            "action_taken": null,
            "notes": "Laboratory changes during disease flares, decreases between 24% and 47%"
          },
          {
            "event_name": "Decreased haemoglobin",
            "event_category": "Lab abnormality",
            "severity_grade": null,
            "patients_affected_n": null,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": "Related",
            "outcome": null,
            "action_taken": null,
            "notes": "Laboratory changes during disease flares, decreases between 1% and 14%"
          }
        ],
        "extraction_timestamp": "2025-12-07T17:32:41.047750",
        "extraction_confidence": 0.6,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [],
          "efficacy_tables": [
            "Table 1: Definition of clinical and subclinical CANDLE/PRAAS disease flare criteria with specific laboratory biomarker thresholds"
          ],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure 1: Timeline of baricitinib dose changes and development of CANDLE/PRAAS disease flares over study period",
            "Figure 2: Acute clinical and laboratory biomarker changes with baricitinib dose reduction in seven patients with disease flares",
            "Figure 3: Kaplan-Meier curve showing time from baricitinib reduction to fulfillment of disease flare criteria, stratified by dose reduction magnitude",
            "Figure 4: Proportion of disease flares comparing low-dose vs high-dose baricitinib visits"
          ],
          "results_sections": [
            "Patients with CANDLE/PRAAS who had baricitinib dose reductions developed dose-dependent disease flares",
            "Establishing CANDLE/PRAAS disease flare criteria",
            "Confirmation of the CANDLE/PRAAS flare criteria",
            "Addition of IFN score criterion to the CANDLE/PRAAS disease flare criteria"
          ],
          "patient_count": 10,
          "study_type": "Retrospective Study",
          "has_quantitative_outcomes": true,
          "notes": "Study developed novel flare criteria for ultra-rare disease CANDLE/PRAAS. Key finding: dose reductions >25% resulted in 100% flare rate vs 20% for <25% reductions. Flare criteria included clinical symptoms plus laboratory changes or laboratory changes alone for subclinical flares."
        }
      },
      "market_intelligence": {
        "disease": "CANDLE/PRAAS (Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated Temperature/Proteasome-Associated Autoinflammatory Syndrome)",
        "epidemiology": {
          "us_prevalence_estimate": null,
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": 2,
          "prevalence_source": "PRINTO Pediatric Rheumatology",
          "prevalence_source_url": "https://www.printo.it/pediatric-rheumatology/GB/info/29/Chronic-Atypical-Neutrophilic-Dermatosis-with-Lipodystrophy-and-Elevated-Temperature-(CANDLE)",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Olumiant (baricitinib)",
              "drug_class": "JAK1/2 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": "50-70%",
              "efficacy_pct": null,
              "annual_cost_usd": 60000.0,
              "line_of_therapy": "1L",
              "notes": "Used off-label through expanded access program for CANDLE/PRAAS at higher doses than RA indication, but no specific FDA approval for this indication"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 2,
          "pipeline_therapies": [
            {
              "drug_name": "Baricitinib",
              "company": "Eli Lilly",
              "mechanism": "JAK1/JAK2 inhibitor targeting type I interferon signaling pathway",
              "phase": "Phase 2",
              "trial_id": "NCT04517253",
              "expected_completion": null
            },
            {
              "drug_name": "Baricitinib",
              "company": "Eli Lilly",
              "mechanism": "JAK1/JAK2 inhibitor targeting type I interferon signaling pathway",
              "phase": "Compassionate Use",
              "trial_id": "NCT01724580",
              "expected_completion": null
            }
          ],
          "pipeline_details": "The clinical pipeline for CANDLE/PRAAS is limited, with baricitinib being the primary therapy under investigation through both a Phase 2 study and compassionate use protocol targeting the type I interferon pathway. Development activity appears focused on JAK inhibition as the main therapeutic approach for this rare autoinflammatory condition.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "JAK inhibitors like baricitinib are used off-label as first-line therapy for CANDLE/PRAAS through expanded access programs, typically requiring higher doses than standard rheumatoid arthritis treatment.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved treatments exist specifically for CANDLE/PRAAS, with patients relying on off-label use of JAK inhibitors through expanded access programs",
          "competitive_landscape": "The treatment landscape consists entirely of off-label therapies, primarily JAK inhibitors used through compassionate use programs. This rare autoinflammatory interferonopathy represents a significant unmet medical need with no approved targeted therapies.",
          "soc_source": "BMJ Annals of Rheumatic Diseases and EULAR/ACR guidelines - https://ard.bmj.com/content/83/9/1181"
        },
        "market_size_estimate": "$400K",
        "market_size_usd": 400000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 150000.0,
        "tam_estimate": "$150K",
        "tam_rationale": "CANDLE/PRAAS is an ultra-rare disease with only ~2 known patients globally based on available data. Given the extreme rarity and case report nature of publications, we estimate ~5-10 patients worldwide might be diagnosed. With 100% treatment rate due to severity (off-label JAK inhibitors), and orphan drug pricing at $150K-300K/yr for ultra-rare conditions, assuming 1 treatable patient at $150K/yr yields TAM of $150K. This represents the practical market size for an ultra-orphan indication.",
        "tam_sources": [
          "https://pubmed.ncbi.nlm.nih.gov/26567544/",
          "https://www.marketdataforecast.com/market-reports/candle-market",
          "https://pubmed.ncbi.nlm.nih.gov/20553399/"
        ],
        "pipeline_sources": [
          "https://www.sciencedirect.com/science/article/pii/S0003496724080166",
          "https://clinicaltrials.gov/study/NCT04517253",
          "https://cdn.clinicaltrials.gov/large-docs/12/NCT03616912/Prot_000.pdf"
        ],
        "attributed_sources": [
          {
            "url": "https://ard.bmj.com/content/annrheumdis/early/2022/03/21/annrheumdis-2021-221814.full.pdf",
            "title": "The 2021 Eurpean Alliance of Associations for Rheumatology ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.sciencedirect.com/science/article/pii/S0003496724080166",
            "title": "CANDLE/PRAAS, SAVI and AGS - ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.target.com/c/candles-home-fragrances-decor/-/N-5xtu8",
            "title": "Affordable Candles at Target - Illuminate Your Home with Style",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://passwords.google.com/",
            "title": "Google Password Manager",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://ard.bmj.com/content/83/9/1181",
            "title": "Disease flares with baricitinib dose reductions and development of ...",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://www.sciencedirect.com/science/article/pii/S0003496724080166",
            "title": "CANDLE/PRAAS, SAVI and AGS - ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT04517253",
            "title": "NCT04517253 | A Study of Baricitinib (LY3009104) in Adult ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://pubmed.ncbi.nlm.nih.gov/26567544/",
            "title": "CANDLE syndrome: chronic atypical neutrophilic dermatosis with ...",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.marketdataforecast.com/market-reports/candle-market",
            "title": "Candle Market Size, Share, Trends & Analysis, 2033",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 4.3,
        "evidence_quality": 8.5,
        "market_opportunity": 7.3,
        "overall_priority": 6.1,
        "clinical_breakdown": {
          "response_rate": 6.0,
          "safety_profile": 1.0,
          "endpoint_quality": 2.8,
          "organ_domain_breadth": 10.0,
          "safety_categories": [
            "cytopenia",
            "non_serious_infection",
            "neurological",
            "cardiovascular",
            "thromboembolic"
          ],
          "regulatory_flags": [
            "cytopenia",
            "thromboembolic",
            "cardiovascular"
          ]
        },
        "response_rate_score": 6.0,
        "safety_profile_score": 1.0,
        "endpoint_quality_score": 2.8,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 6.0,
          "publication_venue": 10.0,
          "response_durability": 10.0,
          "extraction_completeness": 8.3
        },
        "sample_size_score": 6.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 10.0,
        "extraction_completeness_score": 8.3,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 2.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 2.0,
        "unmet_need_score": 10.0
      },
      "rank": 42
    },
    {
      "extraction": {
        "source": {
          "pmid": "32669454",
          "doi": "10.1136/rmdopen-2020-001246",
          "url": "https://www.semanticscholar.org/paper/b8c4ffbf3c1761bff7ad4f5fdec37b9d1347d713",
          "title": "Mixed results with baricitinib in biological-resistant adult-onset Still\u2019s disease and undifferentiated systemic autoinflammatory disease",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "Adult-onset Still's disease (AOSD) and undifferentiated systemic autoinflammatory disease",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 3,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "methotrexate",
            "ciclosporin",
            "anakinra",
            "tocilizumab",
            "sarilumab",
            "rituximab",
            "infliximab"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "Two patients with biological-resistant AOSD meeting Yamaguchi criteria and one patient with AOSD-like autoinflammatory disease in context of myelodysplastic syndrome"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "4 mg once daily",
          "frequency": null,
          "duration": "15 months for P1, 9 months for P2, 9 months for P3",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "2/3 (67%)",
          "responders_n": 2,
          "responders_pct": 67.0,
          "time_to_response": "8\u00b12 weeks for initial follow-up assessment",
          "duration_of_response": "15 months for P1, 9 months for P3",
          "effect_size_description": "Complete clinical and biochemical remission in responders with CRP normalization and ability to discontinue other therapies",
          "primary_endpoint": "clinical and biochemical remission",
          "endpoint_result": "complete remission in 2/3 patients (P1 and P3), no response in 1/3 patients (P2)",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib showed mixed results with complete remission in 2 of 3 patients with refractory AOSD. One patient achieved sustained remission on monotherapy for 15 months, while another patient showed no response and required alternative treatments."
        },
        "safety": {
          "adverse_events": [
            "Pneumocystis jirovecii pneumonia"
          ],
          "serious_adverse_events": [
            "Pneumocystis jirovecii pneumonia"
          ],
          "sae_count": 1,
          "sae_percentage": 33.0,
          "discontinuations_n": 1,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [
            "lack of efficacy"
          ],
          "safety_summary": "One serious opportunistic infection (Pneumocystis jirovecii pneumonia) occurred in a patient with underlying myelodysplastic syndrome. This represents the first reported case of PCP infection following baricitinib use.",
          "safety_profile": "Concerning"
        },
        "outcome_result": "Mixed",
        "efficacy_signal": "Moderate",
        "comparator_baseline": null,
        "follow_up_duration": "9-15 months",
        "key_findings": "Baricitinib may be effective in biological-resistant AOSD but carries risk of opportunistic infections. Variable response suggests need for patient selection criteria.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "Clinical response at first follow-up",
            "endpoint_category": "Primary",
            "timepoint": "8\u00b12 weeks",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 2,
            "responders_pct": 66.7,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "2 out of 3 patients achieved asymptomatic state"
          },
          {
            "endpoint_name": "C-reactive protein (CRP)",
            "endpoint_category": "Secondary",
            "timepoint": "8\u00b12 weeks",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "mg/L",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 231.0,
            "change_from_baseline": -226.0,
            "change_pct": -97.8,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Patient 1: 231 to <5 mg/L"
          },
          {
            "endpoint_name": "C-reactive protein (CRP)",
            "endpoint_category": "Secondary",
            "timepoint": "8\u00b12 weeks",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "mg/L",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 94.0,
            "change_from_baseline": -38.0,
            "change_pct": -40.4,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Patient 2: 94 to 56 mg/L"
          },
          {
            "endpoint_name": "C-reactive protein (CRP)",
            "endpoint_category": "Secondary",
            "timepoint": "8\u00b12 weeks",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "mg/L",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 48.0,
            "change_from_baseline": -46.0,
            "change_pct": -95.8,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Patient 3: 48 to 2 mg/L"
          },
          {
            "endpoint_name": "Erythrocyte sedimentation rate (ESR)",
            "endpoint_category": "Secondary",
            "timepoint": "8\u00b12 weeks",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "mm/hour",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 125.0,
            "change_from_baseline": -108.0,
            "change_pct": -86.4,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Patient 1: 125 to 17 mm/hour"
          },
          {
            "endpoint_name": "Erythrocyte sedimentation rate (ESR)",
            "endpoint_category": "Secondary",
            "timepoint": "8\u00b12 weeks",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "mm/hour",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 16.0,
            "change_from_baseline": -7.0,
            "change_pct": -43.8,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Patient 2: 16 to 9 mm/hour"
          },
          {
            "endpoint_name": "Ferritin",
            "endpoint_category": "Secondary",
            "timepoint": "8\u00b12 weeks",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "ng/mL",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 38940.0,
            "change_from_baseline": -38922.0,
            "change_pct": -99.95,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Patient 1: 38,940 to 18 ng/mL"
          },
          {
            "endpoint_name": "Ferritin",
            "endpoint_category": "Secondary",
            "timepoint": "8\u00b12 weeks",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "ng/mL",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 679.0,
            "change_from_baseline": -375.0,
            "change_pct": -55.2,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Patient 2: 679 to 304 ng/mL"
          },
          {
            "endpoint_name": "Ferritin",
            "endpoint_category": "Secondary",
            "timepoint": "8\u00b12 weeks",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "ng/mL",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 1812.0,
            "change_from_baseline": -104.0,
            "change_pct": -5.7,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Patient 3: 1812 to 1708 ng/mL - elevation reflects transfusion dependence, not disease activity"
          },
          {
            "endpoint_name": "Duration of clinical remission",
            "endpoint_category": "Primary",
            "timepoint": "Long-term follow-up",
            "measurement_type": "Absolute value",
            "value": 15.0,
            "unit": "months",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Patient 1 maintained clinical and biochemical remission for 15 months"
          },
          {
            "endpoint_name": "Duration of clinical remission",
            "endpoint_category": "Primary",
            "timepoint": "Long-term follow-up",
            "measurement_type": "Absolute value",
            "value": 9.0,
            "unit": "months",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Patient 3 maintained clinical and biochemical remission for 9 months"
          },
          {
            "endpoint_name": "Time to baricitinib discontinuation",
            "endpoint_category": "Exploratory",
            "timepoint": "Long-term follow-up",
            "measurement_type": "Absolute value",
            "value": 9.0,
            "unit": "months",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Patient 2 discontinued baricitinib after 9 months due to lack of efficacy"
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "Pneumocystis jirovecii pneumonia",
            "event_category": "SAE",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": 1,
            "relatedness": "Possibly related",
            "outcome": "Resolved",
            "action_taken": "None",
            "notes": "Occurred at 7 months in Patient 3, responded to trimethoprim-sulfamethoxazole, patient remains on prophylactic treatment. Described as first case of Pneumocystis jirovecii infection following baricitinib use."
          },
          {
            "event_name": "Treatment discontinuation due to lack of efficacy",
            "event_category": "Discontinuation",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": 1,
            "relatedness": null,
            "outcome": null,
            "action_taken": "Discontinued",
            "notes": "Patient 2 discontinued baricitinib after 9 months due to lack of improvement in severe synovitis"
          },
          {
            "event_name": "Severe generalised toxic drug eruption",
            "event_category": "SAE",
            "severity_grade": "Severe",
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": 1,
            "relatedness": "Unrelated",
            "outcome": null,
            "action_taken": null,
            "notes": "Patient 1 experienced this with methotrexate, not baricitinib. Mentioned as reason for lack of response to MTX."
          }
        ],
        "extraction_timestamp": "2025-12-07T18:07:34.416672",
        "extraction_confidence": 0.6,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [
            "Table 1: Demographics, clinical characteristics and results - contains patient demographics, clinical features at presentation, and laboratory results"
          ],
          "efficacy_tables": [
            "Table 2: Treatments used before baricitinib implementation and their efficacy - shows prior treatment responses",
            "Table 3: Clinical characteristics, lab results and concomitant medication prebaricitinib and postbaricitinib implementation - contains pre/post baricitinib clinical and laboratory data"
          ],
          "safety_tables": [],
          "efficacy_figures": [],
          "results_sections": [
            "CASE REPORT section describing individual patient outcomes",
            "Table 3 showing pre/post baricitinib laboratory values (CRP, ESR, ferritin)",
            "Clinical response descriptions for each patient (P1: remission, P2: no improvement, P3: remission)"
          ],
          "patient_count": 3,
          "study_type": "Case Series",
          "has_quantitative_outcomes": true,
          "notes": "Mixed efficacy results - 2/3 patients achieved remission. One patient (P3) developed Pneumocystis jirovecii pneumonia as an adverse event. Study includes patients with biological-resistant AOSD and one with AOSD-like syndrome in context of myelodysplastic syndrome."
        }
      },
      "market_intelligence": {
        "disease": "Adult-onset Still's disease (AOSD) and undifferentiated systemic autoinflammatory disease",
        "epidemiology": {
          "us_prevalence_estimate": "1-9/100,000 population for AOSD",
          "us_incidence_estimate": "0.16-0.4 per 100,000 adults annually for AOSD",
          "global_prevalence": null,
          "patient_population_size": 16750,
          "prevalence_source": "Orphanet",
          "prevalence_source_url": "https://www.delveinsight.com/blog/adult-onset-stills-disease-treatment-market",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Ilaris (canakinumab)",
              "drug_class": "IL-1 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Active Still's Disease, including Adult-Onset Still's Disease (AOSD)",
              "efficacy_range": "70-80%",
              "efficacy_pct": null,
              "annual_cost_usd": 200000.0,
              "line_of_therapy": "2L",
              "notes": "FDA approved June 2020 for AOSD, first FDA-approved biologic for this indication"
            },
            {
              "drug_name": "Kineret (anakinra)",
              "drug_class": "IL-1 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": "70-75%",
              "efficacy_pct": null,
              "annual_cost_usd": 80000.0,
              "line_of_therapy": "2L",
              "notes": "Off-label use, most commonly used biologic (84% of patients) but not FDA approved for AOSD"
            },
            {
              "drug_name": "Actemra (tocilizumab)",
              "drug_class": "IL-6 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": "65-75%",
              "efficacy_pct": null,
              "annual_cost_usd": 120000.0,
              "line_of_therapy": "2L",
              "notes": "Off-label use, used in some patients but not FDA approved for AOSD"
            },
            {
              "drug_name": "Gamifant (emapalumab-lzsg)",
              "drug_class": "IFN-gamma inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "HLH/MAS in Still's disease with inadequate response or intolerance to glucocorticoids",
              "efficacy_range": "54-82%",
              "efficacy_pct": null,
              "annual_cost_usd": 300000.0,
              "line_of_therapy": "3L",
              "notes": "FDA approved 2024 for MAS in Still's disease, first treatment for MAS indication"
            }
          ],
          "approved_drug_names": [
            "Ilaris (canakinumab)",
            "Gamifant (emapalumab-lzsg)"
          ],
          "num_approved_drugs": 2,
          "num_pipeline_therapies": 0,
          "pipeline_therapies": [],
          "pipeline_details": "No active clinical trials specifically targeting Adult-onset Still's disease or undifferentiated systemic autoinflammatory disease were identified in the search results, with only one observational study evaluating diagnostic criteria for AOSD.",
          "avg_annual_cost_usd": 250000.0,
          "treatment_paradigm": "First-line therapy includes NSAIDs and corticosteroids, followed by IL-1 or IL-6 inhibitors as second-line biologic therapy with priority on early initiation to avoid long-term steroid complications.",
          "unmet_need": true,
          "unmet_need_description": "Limited FDA-approved options with only two branded innovative drugs approved for AOSD/Still's disease, requiring off-label use of other biologics and reliance on corticosteroids with significant side effects",
          "competitive_landscape": "Ilaris dominates as the primary FDA-approved biologic for AOSD with Gamifant addressing the specific MAS complication. Most treatment relies on off-label use of IL-1 inhibitors like anakinra despite lack of FDA approval for this indication.",
          "soc_source": "Drugs.com FDA Approval History and Medscape Medical News"
        },
        "market_size_estimate": "$4.2B",
        "market_size_usd": 4187500000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 627750000.0,
        "tam_estimate": "$628M",
        "tam_rationale": "Of ~16,750 global AOSD patients, ~80% are diagnosed (13,400), ~90% receive treatment (12,060), with ~60% requiring 2L biologics after NSAIDs/steroids fail (7,236). A new IL-1/IL-6 inhibitor could capture 30-40% market share (~2,511 patients) given only 2 approved competitors and high unmet need. At $250K/yr average cost for biologics, TAM = $628M. Premium pricing justified by rare disease status and chronic treatment requirements.",
        "tam_sources": [
          "https://www.databridgemarketresearch.com/reports/global-stills-disease-treatment-market?srsltid=AfmBOoqj1Oih-Vv_0e00yW2YE3mG20B6Uw1TsVvCbgqmXvXT_VviIV5E",
          "https://www.databridgemarketresearch.com/reports/global-stills-disease-treatment-market?srsltid=AfmBOopht6LiRZQt26wXD4kMJT9yk0IBdeSWcg0LdBPOs9P8YEr4-Pny",
          "https://finance.yahoo.com/news/adult-onset-still-disease-market-113500363.html"
        ],
        "pipeline_sources": [
          "https://cdn.clinicaltrials.gov/large-docs/30/NCT00134030/Prot_SAP_ICF_000.pdf",
          "https://www.clinicaltrials.gov/study/NCT06915025",
          "https://clinicaltrials.gov/study/NCT00059748"
        ],
        "attributed_sources": [
          {
            "url": "https://esmed.org/impact-of-covid-19-on-systemic-autoinflammatory-diseases/",
            "title": "Impact of COVID-19 on Systemic Autoinflammatory Diseases",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://acrabstracts.org/abstract/epidemiology-of-hospitalized-adult-onset-stills-disease-in-united-states/",
            "title": "Epidemiology of Hospitalized Adult Onset Still's Disease in United ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.medscape.com/viewarticle/993364",
            "title": "Systemic JIA and AOSD Are the Same Disease, EULAR Says FDA Approves Gamifant (emapalumab-lzsg) as First-Ever ... Biologics Outperform Conventional Therapy in Still\u2019s Disease List of 7 Still's Disease Medications Compared - Drugs.com",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.medscape.com/viewarticle/biologics-outperform-conventional-therapy-stills-disease-2025a10008dw",
            "title": "Biologics Outperform Conventional Therapy in Still\u2019s Disease",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.mdpi.com/1422-0067/23/21/12810",
            "title": "Adult-Onset Still's Disease\u2014A Complex Disease, a Challenging ...",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/30/NCT00134030/Prot_SAP_ICF_000.pdf",
            "title": "Microsoft Word - AOST0331_Amd#4__4_15_10 - ClinicalTrials.gov",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.clinicaltrials.gov/study/NCT06915025",
            "title": "Study Details | NCT06915025 | Phase 3 Trial Evaluating ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.databridgemarketresearch.com/reports/global-stills-disease-treatment-market?srsltid=AfmBOoqj1Oih-Vv_0e00yW2YE3mG20B6Uw1TsVvCbgqmXvXT_VviIV5E",
            "title": "Global Still's Disease Treatment Market Size, Share, and Trends ...",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.databridgemarketresearch.com/reports/global-stills-disease-treatment-market?srsltid=AfmBOopht6LiRZQt26wXD4kMJT9yk0IBdeSWcg0LdBPOs9P8YEr4-Pny",
            "title": "Global Still's Disease Treatment Market Size, Share, and Trends ...",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 5.5,
        "evidence_quality": 5.0,
        "market_opportunity": 8.3,
        "overall_priority": 6.1,
        "clinical_breakdown": {
          "response_rate": 8.0,
          "safety_profile": 1.0,
          "endpoint_quality": 5.2,
          "organ_domain_breadth": 10.0,
          "safety_categories": [
            "serious_infection",
            "discontinuation"
          ],
          "regulatory_flags": [
            "serious_infection"
          ]
        },
        "response_rate_score": 8.0,
        "safety_profile_score": 1.0,
        "endpoint_quality_score": 5.2,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 2.0,
          "publication_venue": 2.0,
          "response_durability": 9.0,
          "extraction_completeness": 8.3
        },
        "sample_size_score": 2.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 9.0,
        "extraction_completeness_score": 8.3,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 8.0,
          "unmet_need": 10.0
        },
        "competitors_score": 7.0,
        "market_size_score": 8.0,
        "unmet_need_score": 10.0
      },
      "rank": 43
    },
    {
      "extraction": {
        "source": {
          "pmid": null,
          "doi": null,
          "url": "https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.914265/full",
          "title": "Case Report: Baricitinib as an Alternative in the Maintenance ...",
          "authors": "Yi G, Huang Z, Huang Z, Wang Y, Deng W, Zheng S, Li T",
          "journal": "Frontiers in Immunology",
          "year": 2022,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "Macrophage Activation Syndrome Secondary to Nodular Panniculitis",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": null,
          "disease_severity": null,
          "comorbidities": null,
          "description": "Patient with macrophage activation syndrome secondary to nodular panniculitis"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": "Complete prevention of recurrence during maintenance phase",
          "primary_endpoint": "Prevention of recurrence in maintenance therapy",
          "endpoint_result": "Successful maintenance therapy without recurrence",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib demonstrated effectiveness as maintenance therapy for macrophage activation syndrome secondary to nodular panniculitis. The case report suggests potential benefit in preventing recurrence of the condition."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Safety data not explicitly reported in the available abstract and limited case information.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Moderate",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "Baricitinib appears to be a viable option for maintenance therapy in macrophage activation syndrome and may help prevent disease recurrence.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-07T17:19:38.490254",
        "extraction_confidence": 0.5,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Macrophage Activation Syndrome Secondary to Nodular Panniculitis",
        "epidemiology": {
          "us_prevalence_estimate": null,
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": 1,
          "prevalence_source": "Frontiers in Immunology",
          "prevalence_source_url": "https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1200289/full",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Olumiant (baricitinib)",
              "drug_class": "JAK1/2 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Used off-label as maintenance therapy in case report for MAS secondary to nodular panniculitis, FDA approved for rheumatoid arthritis and atopic dermatitis but not this specific indication"
            },
            {
              "drug_name": "Kineret (anakinra)",
              "drug_class": "IL-1 receptor antagonist",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "First-line biologic for secondary HLH/MAS per treatment recommendations, FDA approved for rheumatoid arthritis but not MAS secondary to nodular panniculitis"
            },
            {
              "drug_name": "Actemra (tocilizumab)",
              "drug_class": "IL-6 receptor antagonist",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Used for sHLH/MAS due to IL-6 role but results inconsistent, not FDA approved for this specific indication"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 1,
          "pipeline_therapies": [
            {
              "drug_name": "anakinra",
              "company": "Not specified",
              "mechanism": "IL-1 receptor antagonist",
              "phase": "Not specified",
              "trial_id": null,
              "expected_completion": null
            }
          ],
          "pipeline_details": "Limited pipeline activity identified with anakinra showing therapeutic potential for MAS treatment based on case reports and retrospective experiences. No specific active clinical trials were identified for Macrophage Activation Syndrome Secondary to Nodular Panniculitis.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "First-line therapy consists of high-dose corticosteroids with cyclosporine and/or IVIG. For refractory cases, biologic agents like anakinra are preferred as second-line treatment.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved branded innovative treatments exist specifically for Macrophage Activation Syndrome Secondary to Nodular Panniculitis, with treatment relying on off-label use of drugs approved for other conditions",
          "competitive_landscape": "Current treatment is largely supportive with corticosteroids and immunosuppressants, with emerging off-label use of JAK inhibitors and IL-1 antagonists. No specific FDA-approved therapies exist for this rare indication, representing a significant unmet medical need.",
          "soc_source": "Case Report: Baricitinib as an Alternative in the Maintenance - https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.914265/full"
        },
        "market_size_estimate": "$200K",
        "market_size_usd": 200000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 750000.0,
        "tam_estimate": "$750K",
        "tam_rationale": "With only 1 known US patient with MAS secondary to nodular panniculitis, this represents an ultra-rare condition. Assuming 100% diagnosis rate given severity, 100% treatment rate (life-threatening condition), and positioning as 2L therapy after corticosteroid failure. A new drug could capture 50-75% market share in this underserved ultra-orphan indication. At $750K/yr orphan drug pricing (typical for life-threatening ultra-rare conditions), TAM = $750K based on single known patient population.",
        "tam_sources": [
          "https://www.researchgate.net/publication/361819343_Case_Report_Baricitinib_as_an_Alternative_in_the_Maintenance_Therapy_for_Macrophage_Activation_Syndrome_Secondary_to_Nodular_Panniculitis"
        ],
        "pipeline_sources": [
          "https://cdn.clinicaltrials.gov/large-docs/99/NCT01578499/Prot_001.pdf",
          "https://cdn.clinicaltrials.gov/large-docs/53/NCT04517253/Prot_000.pdf",
          "https://cdn.clinicaltrials.gov/large-docs/89/NCT02291289/Prot_000.pdf"
        ],
        "attributed_sources": [
          {
            "url": "https://emedicine.medscape.com/article/1380671-overview",
            "title": "Macrophage Activation Syndrome - Medscape Reference",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1200289/full",
            "title": "Advances in attractive therapeutic approach for ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761029Orig1s000MedR.pdf",
            "title": "761029Orig1s000 - accessdata.fda.gov",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761079Orig1s000MultidisciplineR.pdf",
            "title": "761079Orig1s000 - accessdata.fda.gov",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.nature.com/articles/s12276-024-01182-6",
            "title": "Immunopathology of and potential therapeutics for secondary ...",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/99/NCT01578499/Prot_001.pdf",
            "title": "A Randomized, Open-Label, Phase 3 Trial of brentuximab ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/53/NCT04517253/Prot_000.pdf",
            "title": "Protocol I4V-JE-JAJE (d) A Phase 2/3, Multicenter, Open- ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.researchgate.net/publication/361819343_Case_Report_Baricitinib_as_an_Alternative_in_the_Maintenance_Therapy_for_Macrophage_Activation_Syndrome_Secondary_to_Nodular_Panniculitis",
            "title": "(PDF) Case Report: Baricitinib as an Alternative in the Maintenance ...",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 7.0,
        "evidence_quality": 2.9,
        "market_opportunity": 7.3,
        "overall_priority": 6.0,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 5.0,
          "endpoint_quality": 5.0,
          "organ_domain_breadth": 8.0,
          "safety_categories": [],
          "regulatory_flags": []
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": 5.0,
        "organ_domain_score": 8.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 2.0,
          "response_durability": 4.0,
          "extraction_completeness": 5.5
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 5.5,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 2.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 2.0,
        "unmet_need_score": 10.0
      },
      "rank": 44
    },
    {
      "extraction": {
        "source": {
          "pmid": null,
          "doi": null,
          "url": "https://www.rheumatologyadvisor.com/news/case-report-baricitinib-successfully-treatment-of-refractory-eosinophilic-fasciitis/",
          "title": "Baricitinib Successfully Treats Refractory Eosinophilic Fasciitis",
          "authors": "Segal R, Ernste FC, Eckloff S",
          "journal": "The Journal of Rheumatology",
          "year": 2021,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "eosinophilic fasciitis",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [],
          "disease_severity": null,
          "comorbidities": null,
          "description": "patient with refractory eosinophilic fasciitis"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": null,
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "1/1 (100%)",
          "responders_n": 1,
          "responders_pct": 100.0,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": "successful treatment of refractory condition",
          "primary_endpoint": "treatment response in eosinophilic fasciitis",
          "endpoint_result": "successful treatment",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib was found to be a successful treatment option for a patient with refractory eosinophilic fasciitis. The JAK inhibitor demonstrated efficacy in this difficult-to-treat connective tissue disorder."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No safety information was provided in the available abstract.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Moderate",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "Baricitinib successfully treated refractory eosinophilic fasciitis in a single patient case report.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-07T17:19:47.532846",
        "extraction_confidence": 0.5,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "eosinophilic fasciitis",
        "epidemiology": {
          "us_prevalence_estimate": "approximately 300 cases reported worldwide",
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": 12,
          "prevalence_source": "NORD (National Organization for Rare Disorders)",
          "prevalence_source_url": "https://rarediseases.org/rare-diseases/eosinophilic-fasciitis/",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Actemra (tocilizumab)",
              "drug_class": "IL-6 receptor inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": 65000.0,
              "line_of_therapy": "2L",
              "notes": "Used off-label for refractory cases based on case reports, not FDA approved for eosinophilic fasciitis"
            },
            {
              "drug_name": "Olumiant (baricitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": 60000.0,
              "line_of_therapy": "2L",
              "notes": "Case report showing successful treatment in refractory patient, not FDA approved for eosinophilic fasciitis"
            },
            {
              "drug_name": "Rituxan (rituximab)",
              "drug_class": "CD20 monoclonal antibody",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": 55000.0,
              "line_of_therapy": "2L",
              "notes": "Used off-label for refractory cases, not FDA approved for eosinophilic fasciitis"
            },
            {
              "drug_name": "Remicade (infliximab)",
              "drug_class": "TNF inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": 50000.0,
              "line_of_therapy": "2L",
              "notes": "Used off-label for refractory cases, not FDA approved for eosinophilic fasciitis"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 2,
          "pipeline_therapies": [
            {
              "drug_name": "Mepolizumab",
              "company": "Not specified",
              "mechanism": "Anti-IL-5 monoclonal antibody",
              "phase": "Proof of concept pilot study",
              "trial_id": "NCT04305678",
              "expected_completion": null
            },
            {
              "drug_name": "High dose methotrexate",
              "company": "Not specified",
              "mechanism": "Immunosuppressant/anti-metabolite",
              "phase": "Pilot study",
              "trial_id": "NCT00441961",
              "expected_completion": null
            }
          ],
          "pipeline_details": "The clinical pipeline for eosinophilic fasciitis is limited, with only two small pilot studies identified testing mepolizumab (anti-IL-5 antibody) and high-dose methotrexate. No large-scale Phase 2 or 3 trials are currently active for this rare fibrosing disorder.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "First-line treatment is high-dose systemic corticosteroids (prednisone 20-100mg/day). Second-line includes immunosuppressive agents like methotrexate, with biologics reserved for refractory cases.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved branded innovative treatments exist specifically for eosinophilic fasciitis. Current treatment relies on off-label use of biologics and generic immunosuppressants after corticosteroid failure.",
          "competitive_landscape": "The treatment landscape consists entirely of off-label use of biologics approved for other autoimmune conditions. A clinical trial with mepolizumab is planned but no FDA approvals exist for this specific indication.",
          "soc_source": "Medscape Eosinophilic Fasciitis Treatment & Management - https://emedicine.medscape.com/article/329515-treatment"
        },
        "market_size_estimate": "$2M",
        "market_size_usd": 2400000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 22500000.0,
        "tam_estimate": "$22.5M",
        "tam_rationale": "Of ~300 global EF cases, ~80% are diagnosed (240), ~90% receive systemic treatment (216), given no approved drugs and high unmet need, a first-in-class therapy could capture 50-60% market share (~125 patients). At $180K/yr reflecting orphan drug pricing for rare autoimmune conditions requiring chronic immunosuppression, TAM = $22.5M. Limited patient pool constrains market size despite premium pricing opportunity.",
        "tam_sources": [
          "https://hawaiijournalhealth.org/past_issues/HMJ_Mar07.pdf",
          "https://www.aetna.com/cpb/medical/data/300_399/0341.html",
          "https://www.medlink.com/articles/viral-and-retroviral-myositis"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov/study/NCT05878717",
          "https://apfed.org/research/clinical-trials/",
          "https://cdn.clinicaltrials.gov/large-docs/56/NCT02453256/Prot_002.pdf"
        ],
        "attributed_sources": [
          {
            "url": "https://link.springer.com/article/10.1007/s40674-024-00222-6",
            "title": "Treatment and Monitoring of Eosinophilic Fasciitis",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.mdpi.com/1422-0067/24/3/1982",
            "title": "Eosinophilic Fasciitis: Current and Remaining Challenges",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://emedicine.medscape.com/article/329515-overview",
            "title": "Eosinophilic Fasciitis: Practice Essentials, Pathophysiology ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761334Orig1s000correctedlbl.pdf",
            "title": "Zynyz (retifanlimab-dlwr) injection - accessdata.fda.gov",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/329515-treatment",
            "title": "Eosinophilic Fasciitis Treatment & Management",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT05878717",
            "title": "NCT05878717 | A Study of the Efficacy and Safety ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://apfed.org/research/clinical-trials/",
            "title": "Clinical Trials",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://hawaiijournalhealth.org/past_issues/HMJ_Mar07.pdf",
            "title": "Hawai'i Medical Journal",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.aetna.com/cpb/medical/data/300_399/0341.html",
            "title": "Infliximab - Medical Clinical Policy Bulletins",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 7.0,
        "evidence_quality": 2.9,
        "market_opportunity": 7.3,
        "overall_priority": 6.0,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 5.0,
          "endpoint_quality": 5.0,
          "organ_domain_breadth": 8.0,
          "safety_categories": [],
          "regulatory_flags": []
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": 5.0,
        "organ_domain_score": 8.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 2.0,
          "response_durability": 4.0,
          "extraction_completeness": 5.5
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 5.5,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 2.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 2.0,
        "unmet_need_score": 10.0
      },
      "rank": 45
    },
    {
      "extraction": {
        "source": {
          "pmid": null,
          "doi": null,
          "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9306776/",
          "title": "Baricitinib treatment of severe chronic hand eczema: Two case reports",
          "authors": "Rosenberg FM, Loman L, Schuttelaar MLA",
          "journal": "Contact Dermatitis",
          "year": 2022,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "Chronic Hand Eczema",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 2,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [],
          "disease_severity": null,
          "comorbidities": null,
          "description": "Two patients with severe chronic hand eczema - Case 1 had severe refractory CHE and Case 2 had atopic dermatitis with concomitant severe CHE"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "4 mg once daily",
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "2/2 (100%)",
          "responders_n": 2,
          "responders_pct": 100.0,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": "Improvement with great impact on quality of life",
          "primary_endpoint": "Clinical improvement in chronic hand eczema",
          "endpoint_result": "Both patients showed improvement with great impact on quality of life",
          "durability_signal": null,
          "efficacy_summary": "Both patients with severe chronic hand eczema treated with baricitinib 4 mg daily showed clinical improvement. The treatment had a great positive impact on their quality of life."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No specific safety information was provided in the available abstract.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Moderate",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "Baricitinib 4 mg daily appears effective for severe chronic hand eczema in both refractory cases and those with concomitant atopic dermatitis.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-07T17:20:25.522968",
        "extraction_confidence": 0.5,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Chronic Hand Eczema",
        "epidemiology": {
          "us_prevalence_estimate": "9.6% of adults self-reported physician-diagnosed chronic hand eczema",
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": 32160000,
          "prevalence_source": "CHECK study",
          "prevalence_source_url": "https://www.biospace.com/press-releases/leo-pharma-unveils-data-on-the-u-s-prevalence-of-chronic-hand-eczema-at-fall-clinical-dermatology-conference",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Anzupgo (delgocitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Chronic Hand Eczema",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "FDA approved July 23, 2025 as first and only treatment specifically for moderate-to-severe chronic hand eczema in adults who have had inadequate response to or for whom topical corticosteroids are not advisable"
            }
          ],
          "approved_drug_names": [
            "Anzupgo (delgocitinib)"
          ],
          "num_approved_drugs": 1,
          "num_pipeline_therapies": 3,
          "pipeline_therapies": [
            {
              "drug_name": "Roflumilast",
              "company": "Not specified",
              "mechanism": "Phosphodiesterase-4 inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT05682859",
              "expected_completion": null
            },
            {
              "drug_name": "Delgocitinib cream",
              "company": "Not specified",
              "mechanism": "Topical pan-Janus kinase inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT04949841",
              "expected_completion": null
            },
            {
              "drug_name": "Ruxolitinib",
              "company": "Not specified",
              "mechanism": "JAK1/JAK2 inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT05293717",
              "expected_completion": null
            }
          ],
          "pipeline_details": "The chronic hand eczema pipeline includes three Phase 3 trials testing oral roflumilast, topical delgocitinib cream, and topical ruxolitinib, representing promising JAK inhibitor and PDE4 inhibitor approaches for this condition.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "First-line treatment consists of topical corticosteroids with protective measures and emollients. Second-line options include Anzupgo (delgocitinib) for patients with inadequate response to corticosteroids, along with phototherapy and systemic treatments like alitretinoin.",
          "unmet_need": false,
          "unmet_need_description": "Until July 2025, there were no FDA-approved treatments specifically for chronic hand eczema, creating a significant unmet need that has now been addressed with Anzupgo approval",
          "competitive_landscape": "Anzupgo represents the first FDA-approved branded innovative treatment specifically for chronic hand eczema, establishing LEO Pharma as the pioneer in this indication. The approval addresses a previously unmet medical need where patients relied on off-label use of topical corticosteroids and systemic treatments.",
          "soc_source": "Drugs.com FDA approval announcement https://www.drugs.com/newdrugs/fda-approves-anzupgo-delgocitinib-cream-chronic-hand-eczema-6576.html"
        },
        "market_size_estimate": "$804.0B",
        "market_size_usd": 804000000000.0,
        "growth_rate": "3-5% CAGR (estimated)",
        "tam_usd": 1870000000.0,
        "tam_estimate": "$1.87B",
        "tam_rationale": "Of ~32.16M adults with chronic hand eczema globally, ~70% are diagnosed (22.5M), ~40% receive prescription treatment beyond basic topicals (9M), ~25% fail first-line corticosteroids and are candidates for second-line therapy (2.25M). A new second-line drug could realistically capture 20-25% market share (~500K patients) given limited competition (only 1 approved drug). At $3,740/year average treatment cost (based on specialty dermatology pricing for chronic conditions), TAM = $1.87B. Significant unmet need exists as most patients rely on inadequate topical corticosteroids.",
        "tam_sources": [
          "https://bisresearch.com/industry-report/chronic-hand-eczema-market.html",
          "https://www.globenewswire.com/news-release/2025/08/12/3131963/28124/en/Chronic-Hand-Eczema-Market-Forecasts-Report-2025-2035-Emerging-Markets-Safer-Therapies-and-Digital-Health-Solutions-for-Chronic-Skin-Conditions-Spur-Opportunities.html",
          "https://thelansis.com/reports/chronic-hand-eczema-che-market-outlook-forecast/"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov/study/NCT05682859",
          "https://pubmed.ncbi.nlm.nih.gov/39033766/",
          "https://www.jaad.org/article/S0190-9622(25)00424-4/fulltext"
        ],
        "attributed_sources": [
          {
            "url": "https://www.biospace.com/press-releases/leo-pharma-unveils-data-on-the-u-s-prevalence-of-chronic-hand-eczema-at-fall-clinical-dermatology-conference",
            "title": "LEO Pharma Unveils Data on the U.S. Prevalence of ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://nationaleczema.org/eczema-facts/",
            "title": "Eczema Statistics - National Eczema Association",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.drugs.com/newdrugs/fda-approves-anzupgo-delgocitinib-cream-chronic-hand-eczema-6576.html",
            "title": "FDA Approves Anzupgo (delgocitinib) Cream for ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.drugs.com/news/fda-approves-first-cream-treating-chronic-hand-eczema-anzupgo-125941.html",
            "title": "FDA Approves First Cream for Treating Chronic Hand ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.actasdermo.org/en-management-chronic-hand-eczema-articulo-S1578219015001675",
            "title": "Management of Chronic Hand Eczema",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT05682859",
            "title": "Treatment of Chronic Hand Eczema With Oral Roflumilast ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://pubmed.ncbi.nlm.nih.gov/39033766/",
            "title": "Efficacy and safety of delgocitinib cream in adults with ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://bisresearch.com/industry-report/chronic-hand-eczema-market.html",
            "title": "Chronic Hand Eczema Market Report | BIS Research",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.globenewswire.com/news-release/2025/08/12/3131963/28124/en/Chronic-Hand-Eczema-Market-Forecasts-Report-2025-2035-Emerging-Markets-Safer-Therapies-and-Digital-Health-Solutions-for-Chronic-Skin-Conditions-Spur-Opportunities.html",
            "title": "Chronic Hand Eczema Market Forecasts Report 2025-2035 |",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 6.7,
        "evidence_quality": 3.3,
        "market_opportunity": 7.3,
        "overall_priority": 6.0,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 5.0,
          "endpoint_quality": 5.0,
          "organ_domain_breadth": 6.0,
          "safety_categories": [],
          "regulatory_flags": []
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": 5.0,
        "organ_domain_score": 6.0,
        "evidence_breakdown": {
          "sample_size": 2.0,
          "publication_venue": 2.0,
          "response_durability": 4.0,
          "extraction_completeness": 6.1
        },
        "sample_size_score": 2.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 6.1,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 10.0,
          "unmet_need": 5.0
        },
        "competitors_score": 7.0,
        "market_size_score": 10.0,
        "unmet_need_score": 5.0
      },
      "rank": 46
    },
    {
      "extraction": {
        "source": {
          "pmid": null,
          "doi": null,
          "url": "https://link.springer.com/article/10.1007/s13555-025-01425-y",
          "title": "Real-World Evidence for Baricitinib in the Treatment of Atopic ...",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "Atopic Dermatitis",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": 4,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [],
          "disease_severity": null,
          "comorbidities": null,
          "description": "Adults aged 21-36 years with moderate-to-severe atopic dermatitis"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": null,
          "frequency": null,
          "duration": "average of 3 weeks",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "4/4 (100%)",
          "responders_n": 4,
          "responders_pct": 100.0,
          "time_to_response": "average of 3 weeks",
          "duration_of_response": null,
          "effect_size_description": "Complete response in all patients achieving clear or almost clear skin",
          "primary_endpoint": "Investigator Global Assessment score of 0 or 1 (clear or almost clear)",
          "endpoint_result": "All patients achieved IGA 0 or 1 within average of 3 weeks",
          "durability_signal": null,
          "efficacy_summary": "All 4 patients with moderate-to-severe atopic dermatitis achieved clear or almost clear skin (IGA 0-1) within an average of 3 weeks of baricitinib treatment. This represents a 100% response rate in this small case series."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No safety data was reported in this case series. Safety profile remains unknown for this specific patient population and treatment duration.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Strong",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "Baricitinib demonstrated 100% efficacy in achieving clear or almost clear skin in patients with moderate-to-severe atopic dermatitis within 3 weeks of treatment.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-07T17:20:42.881107",
        "extraction_confidence": 0.5,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Atopic Dermatitis",
        "epidemiology": {
          "us_prevalence_estimate": "7.3% of adults",
          "us_incidence_estimate": "880.46 per 100,000 in 2019 decreasing to 744.61 per 100,000 in 2020 then increasing to 889.90 per 100,000 in 2022",
          "global_prevalence": null,
          "patient_population_size": 25844871,
          "prevalence_source": "Journal of Allergy and Clinical Immunology: In Practice",
          "prevalence_source_url": "https://www.jaci-inpractice.org/article/S2213-2198(19)30055-8/pdf",
          "trend": "increasing"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Dupixent (dupilumab)",
              "drug_class": "IL-4/IL-13 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Moderate-to-Severe Atopic Dermatitis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved for multiple age groups: adults, adolescents, children 6-11 years, and children 6 months-5 years with moderate-to-severe atopic dermatitis"
            },
            {
              "drug_name": "Cibinqo (abrocitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Refractory Moderate-to-Severe Atopic Dermatitis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "FDA approved January 14, 2022 for adults with refractory moderate-to-severe atopic dermatitis not adequately controlled with other systemic therapies including biologics"
            },
            {
              "drug_name": "Rinvoq (upadacitinib)",
              "drug_class": "JAK1 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Refractory Moderate-to-Severe Atopic Dermatitis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "FDA approved for treatment of refractory moderate-to-severe AD in patients aged 12 years or older whose disease is not adequately controlled with other systemic therapies including biologics"
            },
            {
              "drug_name": "Adbry (tralokinumab)",
              "drug_class": "IL-13 antagonist",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Moderate-to-Severe Atopic Dermatitis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved for moderate-to-severe AD in adults inadequately controlled with topical therapies, expanded to include children aged 12-17 years in December 2023"
            },
            {
              "drug_name": "Olumiant (baricitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Atopic Dermatitis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "FDA approved JAK inhibitor for atopic dermatitis, strongly recommended in AAD guidelines"
            },
            {
              "drug_name": "Nemluvio (nemolizumab)",
              "drug_class": "IL-31 receptor inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Moderate-to-Severe Atopic Dermatitis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved for moderate-to-severe AD in adults and pediatric patients 12 years and older, used with topical corticosteroids or calcineurin inhibitors"
            },
            {
              "drug_name": "Opzelura (ruxolitinib)",
              "drug_class": "Topical JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Mild to Moderate Atopic Dermatitis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved topical JAK inhibitor for mild to moderate atopic dermatitis, limited to 20% BSA with usage restrictions"
            }
          ],
          "approved_drug_names": [
            "Dupixent (dupilumab)",
            "Cibinqo (abrocitinib)",
            "Rinvoq (upadacitinib)",
            "Adbry (tralokinumab)",
            "Olumiant (baricitinib)",
            "Nemluvio (nemolizumab)",
            "Opzelura (ruxolitinib)"
          ],
          "num_approved_drugs": 7,
          "num_pipeline_therapies": 5,
          "pipeline_therapies": [
            {
              "drug_name": "Tapinarof",
              "company": "Not specified",
              "mechanism": "Not specified",
              "phase": "Phase 3",
              "trial_id": "NCT05014568",
              "expected_completion": null
            },
            {
              "drug_name": "Ivarmacitinib",
              "company": "Not specified",
              "mechanism": "Not specified",
              "phase": "Phase 3",
              "trial_id": "NCT04875169",
              "expected_completion": null
            },
            {
              "drug_name": "Dupilumab",
              "company": "Not specified",
              "mechanism": "Not specified",
              "phase": "Phase 3",
              "trial_id": null,
              "expected_completion": null
            },
            {
              "drug_name": "Upadacitinib",
              "company": "Not specified",
              "mechanism": "Not specified",
              "phase": "Phase 3",
              "trial_id": null,
              "expected_completion": null
            },
            {
              "drug_name": "Amlitelimab",
              "company": "Sanofi",
              "mechanism": "OX40-ligand targeting",
              "phase": "Phase 3",
              "trial_id": null,
              "expected_completion": null
            }
          ],
          "pipeline_details": "The atopic dermatitis pipeline shows robust Phase 3 activity with multiple novel mechanisms including OX40-ligand targeting and JAK inhibition. Recent positive results for amlitelimab and ivarmacitinib suggest potential new therapeutic options with improved dosing convenience.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "Treatment follows a stepwise approach starting with topical therapies, then first-line biologics like dupilumab for moderate-to-severe disease, followed by JAK inhibitors as second-line systemic therapies when biologics fail or are inappropriate.",
          "unmet_need": false,
          "unmet_need_description": null,
          "competitive_landscape": "The atopic dermatitis market has multiple FDA-approved innovative treatments including biologics targeting IL-4/IL-13 and IL-31 pathways, and oral/topical JAK inhibitors. Strong evidence-based recommendations exist for several treatments with biologics generally used first-line and JAK inhibitors reserved for refractory cases.",
          "soc_source": "American Academy of Dermatology Atopic Dermatitis Guidelines and FDA Drug Approvals Database"
        },
        "market_size_estimate": "$646.1B",
        "market_size_usd": 646121775000.0,
        "growth_rate": "5-10% CAGR (increasing prevalence)",
        "tam_usd": 1680000000.0,
        "tam_estimate": "$1.68B",
        "tam_rationale": "Of ~25.8M US adults with atopic dermatitis, ~18M are diagnosed (70%), ~8M receive systemic treatment for moderate-to-severe disease (45% of diagnosed), ~2.4M fail first-line biologics like dupilumab and reach second-line therapy (30%). A new drug could capture 20-25% market share in the crowded market (~480K patients). At $70K/yr pricing typical for specialty dermatology biologics/JAK inhibitors, TAM = $1.68B.",
        "tam_sources": [
          "https://www.datamintelligence.com/strategic-insights/atopic-dermatitis-ad",
          "https://www.marketdataforecast.com/market-reports/atopic-dermatitis-treatment-market",
          "https://straitsresearch.com/report/atopic-dermatitis-market"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov/study/NCT05014568",
          "https://jamanetwork.com/journals/jamadermatology/fullarticle/2833318",
          "https://pubmed.ncbi.nlm.nih.gov/27690741/"
        ],
        "attributed_sources": [
          {
            "url": "https://pubmed.ncbi.nlm.nih.gov/30389491/",
            "title": "Atopic Dermatitis in America Study: A Cross-Sectional ... - PubMed",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://aafa.org/wp-content/uploads/2022/08/Atopic-Dermatitis-in-America-Study-Overview.pdf",
            "title": "Atopic Dermatitis in America Study Overview",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.fda.gov/media/189437/download",
            "title": "NDA/BLA Multi-Disciplinary Review and Evaluation",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/1049085-treatment",
            "title": "Atopic Dermatitis Treatment & Management",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.aad.org/member/clinical-quality/guidelines/atopic-dermatitis",
            "title": "Atopic dermatitis clinical guideline",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT05014568",
            "title": "Tapinarof for the Treatment of Atopic Dermatitis in Children ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://jamanetwork.com/journals/jamadermatology/fullarticle/2833318",
            "title": "Ivarmacitinib for Moderate to Severe Atopic Dermatitis in ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.datamintelligence.com/strategic-insights/atopic-dermatitis-ad",
            "title": "Atopic Dermatitis (AD) - Strategic Pharma CI Insights",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.marketdataforecast.com/market-reports/atopic-dermatitis-treatment-market",
            "title": "Atopic Dermatitis Market Size, Share& Growth Report, 2033",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 7.0,
        "evidence_quality": 3.1,
        "market_opportunity": 7.0,
        "overall_priority": 6.0,
        "clinical_breakdown": {
          "response_rate": 10.0,
          "safety_profile": 5.0,
          "endpoint_quality": 5.0,
          "organ_domain_breadth": 8.0,
          "safety_categories": [],
          "regulatory_flags": []
        },
        "response_rate_score": 10.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": 5.0,
        "organ_domain_score": 8.0,
        "evidence_breakdown": {
          "sample_size": 2.0,
          "publication_venue": 2.0,
          "response_durability": 4.0,
          "extraction_completeness": 4.9
        },
        "sample_size_score": 2.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 4.9,
        "market_breakdown": {
          "competitors": 3.0,
          "market_size": 10.0,
          "unmet_need": 8.0
        },
        "competitors_score": 3.0,
        "market_size_score": 10.0,
        "unmet_need_score": 8.0
      },
      "rank": 47
    },
    {
      "extraction": {
        "source": {
          "pmid": "36967024",
          "doi": "10.1016/j.clim.2023.109298",
          "url": "https://pubmed.ncbi.nlm.nih.gov/36967024/",
          "title": "Baricitinib for the treatment of refractory vascular Beh\u00e7et's disease.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Beh\u00e7et's disease with vascular involvement",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": null,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": null,
          "disease_severity": null,
          "comorbidities": null,
          "description": "Beh\u00e7et's Disease patients with refractory vascular involvement"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": null,
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": null,
          "responders_pct": null,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": null,
          "primary_endpoint": null,
          "endpoint_result": null,
          "durability_signal": null,
          "efficacy_summary": "Pilot study evaluating baricitinib effectiveness in refractory vascular Beh\u00e7et's disease. Specific efficacy outcomes not provided in abstract."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Safety evaluation planned as part of pilot study. Specific safety outcomes not reported in abstract.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Unknown",
        "efficacy_signal": "Unknown",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "Pilot study investigating baricitinib for refractory vascular Beh\u00e7et's disease.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-07T17:42:49.927982",
        "extraction_confidence": 0.5,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Beh\u00e7et's disease with vascular involvement",
        "epidemiology": {
          "us_prevalence_estimate": "5.2 cases per 100,000 population",
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": 17420,
          "prevalence_source": "StatPearls - NCBI Bookshelf",
          "prevalence_source_url": "https://www.ncbi.nlm.nih.gov/books/NBK470257/",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Otezla (apremilast)",
              "drug_class": "PDE4 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": "Oral ulcers associated with Beh\u00e7et's Disease",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": null,
              "notes": "FDA approved for oral ulcers associated with Beh\u00e7et's Disease, not specifically for vascular involvement"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 1,
          "pipeline_therapies": [
            {
              "drug_name": "canakinumab",
              "company": "Not specified",
              "mechanism": "IL-1\u03b2 inhibitor",
              "phase": "Phase 2",
              "trial_id": "NCT02756650",
              "expected_completion": null
            }
          ],
          "pipeline_details": "Limited pipeline activity for Beh\u00e7et's disease with vascular involvement, with one Phase 2 trial evaluating canakinumab, an IL-1\u03b2 inhibitor, for safety and efficacy in patients with neurologic and vascular involvement.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "No FDA-approved branded innovative treatments exist specifically for Beh\u00e7et's disease with vascular involvement. Treatment relies on off-label use of immunosuppressants and biologics such as corticosteroids, cyclophosphamide, and anti-TNF agents as first and second-line therapies.",
          "unmet_need": true,
          "unmet_need_description": "Complete lack of FDA-approved branded innovative treatments specifically for Beh\u00e7et's disease with vascular involvement, despite this being a severe and potentially life-threatening manifestation requiring specialized therapeutic intervention",
          "competitive_landscape": "The treatment landscape relies entirely on off-label use of existing immunosuppressive and biologic therapies, with no dedicated FDA approvals for this specific indication. This represents a significant gap in approved therapeutic options for this serious vascular complication of Beh\u00e7et's disease.",
          "soc_source": "FDA Drug Labels and Clinical Guidelines from accessdata.fda.gov"
        },
        "market_size_estimate": "$1.7B",
        "market_size_usd": 1742000000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 392700000.0,
        "tam_estimate": "$393M",
        "tam_rationale": "Of 17,420 US patients with Beh\u00e7et's disease with vascular involvement, ~80% are diagnosed (13,936), ~85% receive systemic treatment (11,846) given the severity of vascular complications. With no FDA-approved drugs specifically for this indication, a first-to-market drug could capture 60-70% market share (~7,900 patients). At $50K/yr pricing for this rare autoimmune condition requiring chronic treatment, TAM = $393M. Strong positioning as first branded therapy addresses significant unmet need in this underserved population.",
        "tam_sources": [
          "https://www.annualreports.com/HostedData/AnnualReportArchive/c/NASDAQ_CHRS_2018.pdf",
          "https://www.researchgate.net/publication/43051417_A_Novel_Transdermal_Delivery_System_for_the_Anti-Inflammatory_Lumiracoxib_Influence_of_Oleic_Acid_on_In_Vitro_Percutaneous_Absorption_and_In_Vivo_Potential_Cutaneous_Irritation",
          "https://ard.bmj.com/content/82/7/887"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov/study/NCT02756650",
          "https://cdn.clinicaltrials.gov/large-docs/46/NCT04818346/Prot_000.pdf",
          "https://clinicaltrials.gov/"
        ],
        "attributed_sources": [
          {
            "url": "https://journals.lww.com/md-journal/fulltext/2025/12050/beh_et_s_disease_unraveled__insights_into_clinical.139.aspx",
            "title": "Beh\u00e7et's disease unraveled: Insights into clinical... - Medicine",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10600606/",
            "title": "Vascular Involvement in Behcet's Disease: An Evaluation of 147 ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/205437s014lbl.pdf",
            "title": "OTEZLA\u00ae (apremilast) tablets, for oral use - accessdata.fda.gov",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/205437Orig1s013correctedlbl.pdf",
            "title": "OTEZLA\u00ae (apremilast) tablets, for oral use - accessdata.fda.gov",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7886245/",
            "title": "Experimental Therapeutic Solutions for Behcet's Disease - PMC",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT02756650",
            "title": "Study Details | NCT02756650 | 1 Year of Treatment With ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/46/NCT04818346/Prot_000.pdf",
            "title": "Official Title: A Phase 2, Randomized, Double-Blind, Placebo ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.annualreports.com/HostedData/AnnualReportArchive/c/NASDAQ_CHRS_2018.pdf",
            "title": "[PDF] Coherus BioSciences, Inc. - Annual Reports",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.researchgate.net/publication/43051417_A_Novel_Transdermal_Delivery_System_for_the_Anti-Inflammatory_Lumiracoxib_Influence_of_Oleic_Acid_on_In_Vitro_Percutaneous_Absorption_and_In_Vivo_Potential_Cutaneous_Irritation",
            "title": "Influence of Oleic Acid on In Vitro Percutaneous Absorption and In ...",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 4.8,
        "evidence_quality": 5.0,
        "market_opportunity": 9.3,
        "overall_priority": 6.0,
        "clinical_breakdown": {
          "response_rate": 5.0,
          "safety_profile": 5.0,
          "endpoint_quality": 5.0,
          "organ_domain_breadth": 4.0,
          "safety_categories": [],
          "regulatory_flags": []
        },
        "response_rate_score": 5.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": 5.0,
        "organ_domain_score": 4.0,
        "evidence_breakdown": {
          "sample_size": 3.0,
          "publication_venue": 10.0,
          "response_durability": 4.0,
          "extraction_completeness": 3.2
        },
        "sample_size_score": 3.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 3.2,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 8.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 8.0,
        "unmet_need_score": 10.0
      },
      "rank": 48
    },
    {
      "extraction": {
        "source": {
          "pmid": "40316508",
          "doi": "10.1093/rheumatology/keaf225",
          "url": "https://pubmed.ncbi.nlm.nih.gov/40316508/",
          "title": "Long-term effectiveness and safety of baricitinib treatment on refractory or severe juvenile dermatomyositis.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "refractory or severe juvenile dermatomyositis",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": null,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [],
          "disease_severity": null,
          "comorbidities": null,
          "description": "patients with refractory or severe juvenile dermatomyositis"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": null,
          "responders_pct": null,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": null,
          "primary_endpoint": null,
          "endpoint_result": null,
          "durability_signal": null,
          "efficacy_summary": "Study evaluated long-term effectiveness of baricitinib add-on therapy for refractory or severe juvenile dermatomyositis in real-world setting. Specific efficacy outcomes not provided in abstract."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Long-term safety of baricitinib was evaluated but specific safety outcomes not detailed in abstract.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Unknown",
        "efficacy_signal": "Unknown",
        "comparator_baseline": null,
        "follow_up_duration": "long-term",
        "key_findings": "Baricitinib was used as add-on therapy for refractory or severe juvenile dermatomyositis in a real-world setting.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-07T17:27:29.949610",
        "extraction_confidence": 0.5,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "refractory or severe juvenile dermatomyositis",
        "epidemiology": {
          "us_prevalence_estimate": null,
          "us_incidence_estimate": "2-4 per million children per year",
          "global_prevalence": null,
          "patient_population_size": 219,
          "prevalence_source": "PMC article on inpatient burden of juvenile dermatomyositis",
          "prevalence_source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6234588/",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Rituximab (rituximab)",
              "drug_class": "Anti-CD20 monoclonal antibody",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": 25000.0,
              "line_of_therapy": "2L",
              "notes": "Used off-label for refractory juvenile dermatomyositis in clinical trials, but no specific FDA approval for this indication"
            },
            {
              "drug_name": "Octagam 10% (immune globulin intravenous)",
              "drug_class": "Intravenous immunoglobulin",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": "dermatomyositis in adults",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": 50000.0,
              "line_of_therapy": "2L",
              "notes": "FDA approved for dermatomyositis in adults only, not specifically for juvenile or refractory/severe forms"
            },
            {
              "drug_name": "Infliximab (infliximab)",
              "drug_class": "Anti-TNF-alpha monoclonal antibody",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": 30000.0,
              "line_of_therapy": "2L",
              "notes": "Used off-label for refractory juvenile dermatomyositis with calcinosis, no FDA approval for this indication"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 2,
          "pipeline_therapies": [
            {
              "drug_name": "Baricitinib",
              "company": "Not specified",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 2/3",
              "trial_id": "NCT05524311",
              "expected_completion": null
            },
            {
              "drug_name": "Experimental drug",
              "company": "Not specified",
              "mechanism": "Not specified",
              "phase": "Phase 2/3",
              "trial_id": "NCT05523167",
              "expected_completion": null
            }
          ],
          "pipeline_details": "Limited active pipeline for refractory juvenile dermatomyositis with baricitinib (JAK inhibitor) being tested in new-onset cases and one additional experimental therapy in phase 2/3 trials. JAK inhibitors have shown promise in retrospective studies for refractory JDM cases.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "First-line therapy consists of high-dose corticosteroids combined with methotrexate. Second-line biologics like rituximab and IVIG are used off-label for refractory cases.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved branded innovative treatments exist specifically for refractory or severe juvenile dermatomyositis. Current biologics are used off-label based on limited clinical trial data.",
          "competitive_landscape": "The treatment landscape relies heavily on off-label use of biologics and traditional immunosuppressants. There is a significant opportunity for targeted therapies specifically approved for this pediatric indication.",
          "soc_source": "Medscape and PMC articles on juvenile dermatomyositis treatment guidelines"
        },
        "market_size_estimate": "$44M",
        "market_size_usd": 43800000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 16425000.0,
        "tam_estimate": "$16.4M",
        "tam_rationale": "Of 219 global severe/refractory JDM patients, ~90% are diagnosed due to severity (197 patients), ~85% receive treatment (167 patients), ~100% are candidates for new therapies given refractory nature and zero approved drugs. A first-to-market drug could capture 50-60% market share (~98 patients) given high unmet need. At $167K/yr orphan drug pricing, TAM = $16.4M. Premium pricing justified by orphan status and lack of approved alternatives.",
        "tam_sources": [
          "https://www.openpr.com/news/4200870/unlocking-juvenile-dermatomyositis-treatment-united-states",
          "https://www.openpr.com/news/4263830/united-states-juvenile-dermatomyositis-treatment-jdm-market",
          "https://www.delveinsight.com/report-store/dermatomyositis-market"
        ],
        "pipeline_sources": [
          "https://www.malacards.org/card/childhood_type_dermatomyositis",
          "https://clinicaltrials.gov/study/NCT05523167",
          "https://www.clinicaltrials.gov/study/NCT05524311"
        ],
        "attributed_sources": [
          {
            "url": "https://www.healio.com/clinical-guidance/dermatomyositis/epidemiology-of-dm",
            "title": "Dermatomyositis Epidemiology | Clinical Guidance - Healio",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6234588/",
            "title": "Inpatient burden of juvenile dermatomyositis among children in the ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.medscape.com/viewarticle/758302",
            "title": "Review of Biologics in Children with Rheumatic Diseases",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/332783-treatment",
            "title": "Dermatomyositis Treatment & Management: Approach ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.myositis.org/wp-content/uploads/2018/02/Advances_JDM_Feldman2006.pdf",
            "title": "[PDF] Advances in the treatment of juvenile dermatomyositis",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://www.malacards.org/card/childhood_type_dermatomyositis",
            "title": "Childhood Type Dermatomyositis",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT05523167",
            "title": "NCT05523167 | A Study to Investigate the Efficacy and ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.openpr.com/news/4200870/unlocking-juvenile-dermatomyositis-treatment-united-states",
            "title": "Unlocking Juvenile Dermatomyositis Treatment",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.openpr.com/news/4263830/united-states-juvenile-dermatomyositis-treatment-jdm-market",
            "title": "United States Juvenile Dermatomyositis Treatment (JDM) ...",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 5.2,
        "evidence_quality": 5.2,
        "market_opportunity": 8.0,
        "overall_priority": 5.9,
        "clinical_breakdown": {
          "response_rate": 5.0,
          "safety_profile": 5.0,
          "endpoint_quality": 5.0,
          "organ_domain_breadth": 6.0,
          "safety_categories": [],
          "regulatory_flags": []
        },
        "response_rate_score": 5.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": 5.0,
        "organ_domain_score": 6.0,
        "evidence_breakdown": {
          "sample_size": 3.0,
          "publication_venue": 10.0,
          "response_durability": 4.0,
          "extraction_completeness": 3.8
        },
        "sample_size_score": 3.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 3.8,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 4.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 4.0,
        "unmet_need_score": 10.0
      },
      "rank": 49
    },
    {
      "extraction": {
        "source": {
          "pmid": "37935260",
          "doi": "10.1016/j.jaci.2023.10.018",
          "url": "https://pubmed.ncbi.nlm.nih.gov/37935260/",
          "title": "JAK inhibitor treatment for inborn errors of JAK/STAT signaling: An ESID/EBMT-IEWP retrospective study.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Inborn errors of JAK/STAT signaling",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Retrospective Study",
        "patient_population": {
          "n_patients": null,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "hematopoietic stem cell transplantation"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "Patients with inborn errors of immunity with dysregulated JAK/STAT signaling presenting with immune dysregulation and infections"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": null,
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": null,
          "responders_pct": null,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": null,
          "primary_endpoint": null,
          "endpoint_result": null,
          "durability_signal": null,
          "efficacy_summary": "JAK inhibitors offered as targeted treatment option that may be alternative or bridge to HSCT for patients with dysregulated JAK/STAT signaling. Specific efficacy outcomes not provided in abstract."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Abstract mentions that data on adverse events are limited but does not provide specific safety outcomes.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Mixed",
        "efficacy_signal": "Weak",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "JAK inhibitors may serve as targeted treatment for inborn errors of JAK/STAT signaling, potentially as alternative or bridge to HSCT.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-07T17:29:15.541974",
        "extraction_confidence": 0.5,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Inborn errors of JAK/STAT signaling",
        "epidemiology": {
          "us_prevalence_estimate": null,
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": null,
          "prevalence_source": null,
          "prevalence_source_url": null,
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 1,
          "pipeline_therapies": [
            {
              "drug_name": "Baricitinib",
              "company": "Not specified",
              "mechanism": "JAK1/2 inhibitor",
              "phase": "Expanded access",
              "trial_id": "NCT03921554",
              "expected_completion": null
            }
          ],
          "pipeline_details": "Limited pipeline activity identified with baricitinib being evaluated in expanded access programs for JAK/STAT pathway disorders including Aicardi Gouti\u00e8res syndrome. The therapeutic approach focuses on JAK inhibition to block downstream interferon signaling.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "JAK inhibitors are used off-label as targeted therapy for inborn errors of JAK/STAT signaling, often serving as bridging therapy to hematopoietic stem cell transplantation (HSCT), which remains the potentially curative treatment.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved treatments exist specifically for inborn errors of JAK/STAT signaling. Current management relies on off-label use of JAK inhibitors and HSCT, with limited treatment options for this rare group of inborn errors of immunity.",
          "competitive_landscape": "This represents a significant unmet medical need with no FDA-approved branded innovative treatments specifically indicated for inborn errors of JAK/STAT signaling. JAK inhibitors show promise in research settings but lack formal FDA approval for this specific indication.",
          "soc_source": "PubMed - JAK inhibitor treatment for inborn errors of JAK/STAT signaling (https://pubmed.ncbi.nlm.nih.gov/37935260/)"
        },
        "market_size_estimate": null,
        "market_size_usd": null,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 150000000.0,
        "tam_estimate": "$150M",
        "tam_rationale": "Inborn errors of JAK/STAT signaling are ultra-rare with estimated ~2,000 patients globally across all conditions. ~80% are diagnosed due to severe manifestations (~1,600 patients), ~70% receive treatment with off-label JAK inhibitors (~1,120 patients). With no approved drugs and high unmet need, a purpose-built therapy could capture 40-50% market share (~500 patients globally). At $300K/yr orphan drug pricing typical for rare genetic disorders, TAM = $150M.",
        "tam_sources": [
          "https://pubmed.ncbi.nlm.nih.gov/37935260/",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC9632491/",
          "https://cemm.at/fileadmin/img/Research/Research_Reports/CeMM_ResearchReport_2024.pdf"
        ],
        "pipeline_sources": [
          "https://www.sciencedirect.com/science/article/pii/S0091674924010224",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC11840193/",
          "https://clinicaltrials.gov/study/NCT07021495"
        ],
        "attributed_sources": [
          {
            "url": "https://www.sciencedirect.com/science/article/pii/S0091674924010224",
            "title": "JAK-STAT signaling pathway, immunodeficiency, inflammation ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://rupress.org/jem/article/221/6/e20232387/276675/Individuals-with-JAK1-variants-are-affected-by",
            "title": "Individuals with JAK1 variants are affected by syndromic features ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.drugs.com/medical-answers/what-jak-inhibitors-how-work-3575417/",
            "title": "What are JAK inhibitors and how do they work? - Drugs.com FDA Advances Rare Disease Drug Development with New Evidence ... Rare Diseases: Considerations for the Development of Drugs ... Table of Pharmacogenetic Associations | FDA FDA Adverse Event Reporting System (FAERS) Database CDER/CBER Rare Disease Evidence Principles (RDEP) | FDA",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.fda.gov/drugs/guidances-drugs/guidance-documents-rare-disease-drug-development",
            "title": "Guidance Documents for Rare Disease Drug Development | FDA",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://pubmed.ncbi.nlm.nih.gov/37935260/",
            "title": "JAK inhibitor treatment for inborn errors of JAK/STAT signaling",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://www.sciencedirect.com/science/article/pii/S0091674924010224",
            "title": "JAK-STAT signaling pathway, immunodeficiency ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11840193/",
            "title": "Janus kinase inhibitor treatment for inflammatory diseases",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://pubmed.ncbi.nlm.nih.gov/37935260/",
            "title": "JAK inhibitor treatment for inborn errors of JAK/STAT signaling",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9632491/",
            "title": "Role of protein phosphorylation in cell signaling, disease, and the ...",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 4.8,
        "evidence_quality": 5.0,
        "market_opportunity": 8.3,
        "overall_priority": 5.8,
        "clinical_breakdown": {
          "response_rate": 3.0,
          "safety_profile": 5.0,
          "endpoint_quality": 5.0,
          "organ_domain_breadth": 8.0,
          "safety_categories": [],
          "regulatory_flags": []
        },
        "response_rate_score": 3.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": 5.0,
        "organ_domain_score": 8.0,
        "evidence_breakdown": {
          "sample_size": 3.0,
          "publication_venue": 10.0,
          "response_durability": 4.0,
          "extraction_completeness": 3.2
        },
        "sample_size_score": 3.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 3.2,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 5.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 5.0,
        "unmet_need_score": 10.0
      },
      "rank": 50
    },
    {
      "extraction": {
        "source": {
          "pmid": "39447041",
          "doi": "10.1093/rheumatology/keae589",
          "url": "https://pubmed.ncbi.nlm.nih.gov/39447041/",
          "title": "The place of JAK inhibitors in systemic juvenile idiopathic arthritis with lung disease (SJIA-LD): French experience.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Systemic juvenile idiopathic arthritis with lung disease (SJIA-LD)",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": null,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "multiple lines of treatment"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "Patients with systemic juvenile idiopathic arthritis with associated lung disease"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": null,
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": null,
          "responders_pct": null,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": null,
          "primary_endpoint": null,
          "endpoint_result": null,
          "durability_signal": null,
          "efficacy_summary": "The abstract describes real-life experience with JAK inhibitors in SJIA-LD but does not provide specific efficacy outcomes. Clinical evidence of efficacy was noted as still being weak."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No safety outcomes reported in the abstract.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Unknown",
        "efficacy_signal": "Weak",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "JAK inhibitors have been used in French real-life experience for SJIA-LD, though clinical evidence of efficacy remains weak.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-07T17:39:46.849456",
        "extraction_confidence": 0.5,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Systemic juvenile idiopathic arthritis with lung disease (SJIA-LD)",
        "epidemiology": {
          "us_prevalence_estimate": "6.8% of sJIA patients",
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": 204,
          "prevalence_source": "Lung Involvement in Systemic Juvenile Idiopathic Arthritis",
          "prevalence_source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9777523/",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Actemra (tocilizumab)",
              "drug_class": "IL-6 receptor antagonist",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": "Systemic Juvenile Idiopathic Arthritis (SJIA) - not specifically with lung disease",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved for SJIA in patients 2+ years but not specifically for SJIA with lung disease"
            },
            {
              "drug_name": "Ilaris (canakinumab)",
              "drug_class": "IL-1 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "IL-1 inhibitor mentioned for SJIA treatment but no specific FDA approval for SJIA-LD found in search results"
            },
            {
              "drug_name": "Kineret (anakinra)",
              "drug_class": "IL-1 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "IL-1 inhibitor mentioned for SJIA treatment but no specific FDA approval for SJIA-LD found in search results"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 2,
          "pipeline_therapies": [
            {
              "drug_name": "TJ003234",
              "company": "Not specified",
              "mechanism": "Not specified",
              "phase": "Phase 2/3",
              "trial_id": "NCT04341116",
              "expected_completion": null
            },
            {
              "drug_name": "tofacitinib",
              "company": "Not specified",
              "mechanism": "JAK inhibitor",
              "phase": "Phase 3",
              "trial_id": "NCT03000439",
              "expected_completion": null
            }
          ],
          "pipeline_details": "Limited pipeline activity for SJIA-LD specifically, with trials primarily focusing on systemic JIA that may include lung manifestations. The search results show broader JIA trials but minimal specific SJIA-LD targeted development.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "IL-1 and IL-6 inhibitors are strongly recommended as first-line therapy for systemic JIA, but no drugs are specifically FDA-approved for SJIA with lung disease.",
          "unmet_need": true,
          "unmet_need_description": "No drugs are specifically FDA-approved for systemic juvenile idiopathic arthritis with lung disease (SJIA-LD). Treatment is not uniform and there is no unified guideline for JIA-associated lung damage.",
          "competitive_landscape": "While biologics like tocilizumab are approved for SJIA generally, the specific indication of SJIA with lung disease lacks FDA-approved treatments. Various biological agents and targeted therapies are used off-label based on individual case reports and clinical experience.",
          "soc_source": "PMC articles and FDA prescribing information from accessdata.fda.gov"
        },
        "market_size_estimate": "$41M",
        "market_size_usd": 40800000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 12240000.0,
        "tam_estimate": "$12.2M",
        "tam_rationale": "Of 204 SJIA-LD patients globally, ~85% are diagnosed (173), ~90% receive treatment (156) given severity of condition. With no approved drugs specifically for SJIA-LD, a first-to-market therapy could capture 60-70% market share (~110 patients). At $110K/yr pricing (orphan drug premium for ultra-rare indication), TAM = $12.2M. Ultra-rare population with high unmet need justifies premium pricing despite small patient pool.",
        "tam_sources": [
          "https://www.techsciresearch.com/report/systemic-juvenile-idiopathic-arthritis-market/16786.html",
          "https://www.imarcgroup.com/systemic-juvenile-idiopathic-arthritis-market",
          "https://www.biospace.com/press-releases/systemic-juvenile-idiopathic-arthritis-market-size-to-reach-usd-1-250-million-by-2035-impelled-by-advancements-in-biologic-therapies"
        ],
        "pipeline_sources": [
          "https://cdn.clinicaltrials.gov/large-docs/16/NCT04341116/Prot_000.pdf",
          "https://cdn.clinicaltrials.gov/large-docs/39/NCT03000439/SAP_001.pdf",
          "https://cdn.clinicaltrials.gov/large-docs/59/NCT04377659/Prot_SAP_000.pdf"
        ],
        "attributed_sources": [
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9777523/",
            "title": "Lung Involvement in Systemic Juvenile Idiopathic Arthritis",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.medrxiv.org/content/10.1101/19002923v1.full.pdf",
            "title": "An emergent, high-fatality lung disease in systemic juvenile ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-biosimilar-actemra-treat-adult-and-pediatric-arthritis",
            "title": "FDA approves first biosimilar to Actemra to treat adult and ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125276s149lbl.pdf",
            "title": "Reference ID: 5639738 - accessdata.fda.gov",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.the-rheumatologist.org/article/experts-discuss-draft-of-new-jia-guideline/",
            "title": "Experts Discuss Draft of New JIA Guideline - The Rheumatologist",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/16/NCT04341116/Prot_000.pdf",
            "title": "Clinical Trial Protocol: A Phase 2/3, Randomized, Double- ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/39/NCT03000439/SAP_001.pdf",
            "title": "Protocol A3921165",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.techsciresearch.com/report/systemic-juvenile-idiopathic-arthritis-market/16786.html",
            "title": "Systemic Juvenile Idiopathic Arthritis Market - TechSci Research",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.imarcgroup.com/systemic-juvenile-idiopathic-arthritis-market",
            "title": "Systemic Juvenile Idiopathic Arthritis Market Size 2025-2035",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 4.5,
        "evidence_quality": 5.0,
        "market_opportunity": 8.0,
        "overall_priority": 5.5,
        "clinical_breakdown": {
          "response_rate": 3.0,
          "safety_profile": 5.0,
          "endpoint_quality": 5.0,
          "organ_domain_breadth": 6.0,
          "safety_categories": [],
          "regulatory_flags": []
        },
        "response_rate_score": 3.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": 5.0,
        "organ_domain_score": 6.0,
        "evidence_breakdown": {
          "sample_size": 3.0,
          "publication_venue": 10.0,
          "response_durability": 4.0,
          "extraction_completeness": 3.2
        },
        "sample_size_score": 3.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 3.2,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 4.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 4.0,
        "unmet_need_score": 10.0
      },
      "rank": 51
    },
    {
      "extraction": {
        "source": {
          "pmid": "40664380",
          "doi": "10.1093/ced/llaf302",
          "url": "https://pubmed.ncbi.nlm.nih.gov/40664380/",
          "title": "Therapeutic outcomes across Janus kinase inhibitors in\u00a0prurigo nodularis.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "Prurigo nodularis",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Series",
        "patient_population": {
          "n_patients": null,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [],
          "disease_severity": null,
          "comorbidities": null,
          "description": "Patients with prurigo nodularis with inadequate disease control or contraindications to other systemic therapies"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": null,
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": null,
          "responders_pct": null,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": null,
          "primary_endpoint": null,
          "endpoint_result": null,
          "durability_signal": null,
          "efficacy_summary": "Abstract only provides limited information about therapeutic outcomes across JAK inhibitors in prurigo nodularis. Specific efficacy data not available in provided abstract."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "Safety outcomes not reported in the provided abstract.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Unknown",
        "efficacy_signal": "Unknown",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "JAK inhibitors may be considered for prurigo nodularis when other systemic therapies fail or are contraindicated, though real-world evidence remains limited.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-07T17:53:03.402316",
        "extraction_confidence": 0.5,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "Prurigo nodularis",
        "epidemiology": {
          "us_prevalence_estimate": "0.19% (95% CI, 0.18%-0.2%)",
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": 636500,
          "prevalence_source": "All of Us Research Program",
          "prevalence_source_url": "https://www.healio.com/news/dermatology/20230719/prurigo-nodularis-prevalence-proves-higher-than-previously-estimated",
          "trend": "increasing"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Dupixent (dupilumab)",
              "drug_class": "IL-4/IL-13 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Prurigo nodularis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "First FDA-approved treatment for prurigo nodularis in adults, approved September 2022"
            },
            {
              "drug_name": "Nemluvio (nemolizumab)",
              "drug_class": "IL-31 receptor antagonist",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "Prurigo nodularis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "Second FDA-approved treatment for prurigo nodularis in adults, approved 2024"
            }
          ],
          "approved_drug_names": [
            "Dupixent (dupilumab)",
            "Nemluvio (nemolizumab)"
          ],
          "num_approved_drugs": 2,
          "num_pipeline_therapies": 3,
          "pipeline_therapies": [
            {
              "drug_name": "nemolizumab",
              "company": "Not specified",
              "mechanism": "IL-31 receptor antagonist",
              "phase": "Phase 3",
              "trial_id": "OLYMPIA 1",
              "expected_completion": null
            },
            {
              "drug_name": "dupilumab",
              "company": "Not specified",
              "mechanism": "IL-4/IL-13 receptor antagonist",
              "phase": "Phase 3",
              "trial_id": "LIBERTY-PN PRIME/PRIME2",
              "expected_completion": null
            },
            {
              "drug_name": "Investigational drug",
              "company": "Incyte Corporation",
              "mechanism": "Not specified",
              "phase": "Phase 2/3",
              "trial_id": "NCT05755438",
              "expected_completion": null
            }
          ],
          "pipeline_details": "The prurigo nodularis pipeline includes several active Phase 3 trials, with nemolizumab and dupilumab showing positive results in completed studies, and Incyte Corporation conducting an ongoing Phase 2/3 trial. Multiple therapeutic approaches targeting different inflammatory pathways are being evaluated for this chronic inflammatory skin condition.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "Previously reliant on off-label therapies including topical corticosteroids and systemic immunosuppressants, now has two FDA-approved biologics targeting different inflammatory pathways as first-line options",
          "unmet_need": false,
          "unmet_need_description": "Recently addressed with FDA approval of two targeted biologics, though treatment personalization and long-term outcomes remain areas for optimization",
          "competitive_landscape": "Dupixent established as first FDA-approved treatment in 2022, followed by Nemluvio in 2024 targeting IL-31 pathway. Both represent significant advancement from previous off-label treatment approach.",
          "soc_source": "FDA approval documents and Drugs.com monographs"
        },
        "market_size_estimate": "$15.9B",
        "market_size_usd": 15912500000.0,
        "growth_rate": "5-10% CAGR (increasing prevalence)",
        "tam_usd": 285000000.0,
        "tam_estimate": "$285M",
        "tam_rationale": "Of ~636,500 global PN patients, approximately 300,000 are in the US market. With ~70% diagnosed (210K), ~50% receiving systemic treatment (105K), and ~40% being candidates for biologic therapy (42K patients). A new biologic could realistically capture 15-20% market share (~7,600 patients) given two existing FDA-approved competitors in this previously underserved market. At specialist biologic pricing of $37,500/year (lower than typical due to moderate market size), TAM = $285M.",
        "tam_sources": [
          "https://www.futuremarketinsights.com/reports/prurigo-nodularis-treatment-and-management-market",
          "https://www.openpr.com/news/3715289/prurigo-nodularis-treatment-market-poised-for-massive-growth",
          "https://www.researchandmarkets.com/reports/6076038/prescription-dermatological-drugs-market-report?srsltid=AfmBOop-6WWj2s6ZcfLZPqu0g9uGtqI7TWHLBQpdFmQ88NNQXtebnmYP"
        ],
        "pipeline_sources": [
          "https://pubmed.ncbi.nlm.nih.gov/38629497/",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC12126366/",
          "https://www.jaadinternational.org/article/S2666-3287(24)00068-3/fulltext"
        ],
        "attributed_sources": [
          {
            "url": "https://www.healio.com/news/dermatology/20230719/prurigo-nodularis-prevalence-proves-higher-than-previously-estimated",
            "title": "Prurigo nodularis prevalence proves higher than previously estimated",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8362303/",
            "title": "Prevalence of prurigo nodularis in the United States of America - NIH",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.drugs.com/monograph/nemolizumab.html",
            "title": "Nemolizumab Monograph for Professionals",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.drugs.com/history/dupixent.html",
            "title": "Dupixent (dupilumab) FDA Approval History",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://onlinelibrary.wiley.com/doi/10.1111/1346-8138.16067",
            "title": "2020 guidelines for the diagnosis and treatment of prurigo",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://pubmed.ncbi.nlm.nih.gov/38629497/",
            "title": "results from a randomized double-blind placebo-controlled ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12126366/",
            "title": "Emerging Therapies in the Treatment of Prurigo Nodularis",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.futuremarketinsights.com/reports/prurigo-nodularis-treatment-and-management-market",
            "title": "Prurigo Nodularis Treatment Market Size & Growth 2025-2035",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.openpr.com/news/3715289/prurigo-nodularis-treatment-market-poised-for-massive-growth",
            "title": "Prurigo Nodularis Treatment Market Poised for Massive Growth",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 4.8,
        "evidence_quality": 5.0,
        "market_opportunity": 7.3,
        "overall_priority": 5.5,
        "clinical_breakdown": {
          "response_rate": 5.0,
          "safety_profile": 5.0,
          "endpoint_quality": 5.0,
          "organ_domain_breadth": 4.0,
          "safety_categories": [],
          "regulatory_flags": []
        },
        "response_rate_score": 5.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": 5.0,
        "organ_domain_score": 4.0,
        "evidence_breakdown": {
          "sample_size": 3.0,
          "publication_venue": 10.0,
          "response_durability": 4.0,
          "extraction_completeness": 3.2
        },
        "sample_size_score": 3.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 3.2,
        "market_breakdown": {
          "competitors": 7.0,
          "market_size": 10.0,
          "unmet_need": 5.0
        },
        "competitors_score": 7.0,
        "market_size_score": 10.0,
        "unmet_need_score": 5.0
      },
      "rank": 52
    },
    {
      "extraction": {
        "source": {
          "pmid": "40007227",
          "doi": "10.1002/art.43145",
          "url": "https://pubmed.ncbi.nlm.nih.gov/40007227/",
          "title": "Sustained Interferon Signature Suppression With Anifrolumab in a Patient With STING-Associated Vasculopathy with Onset in Infancy Refractory to JAK Inhibitor and Dazukibart Therapy.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "STING-associated vasculopathy with onset in infancy (SAVI)",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "dazukibart",
            "optimized JAK inhibitor regimens"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "22-year-old patient with SAVI and de novo STING1 p.(Asn154Ser) mutation, with vasculitic ulcers, progressive osteolysis, minimal lung disease, and persistent systemic inflammation"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "7 mg daily",
          "frequency": null,
          "duration": "over 10 years, then tapered and discontinued after anifrolumab initiation",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": 0,
          "responders_pct": 0.0,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": "Partial response only, requiring combination therapy and eventual discontinuation",
          "primary_endpoint": "IFN I score suppression",
          "endpoint_result": "Failed to achieve sustained IFN I score suppression with baricitinib monotherapy or combination with tocilizumab",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib provided only partial response despite over 10 years of treatment, with persistently elevated IFN I scores and continued vasculitic lesions. Even combination therapy with tocilizumab failed to achieve adequate disease control, necessitating switch to anifrolumab."
        },
        "safety": {
          "adverse_events": [
            "BK viruria",
            "BK viremia",
            "Epstein-Barr virus viremia",
            "facial molluscum contagiosum"
          ],
          "serious_adverse_events": [
            "BK viremia",
            "EBV viremia"
          ],
          "sae_count": 1,
          "sae_percentage": 100.0,
          "discontinuations_n": 1,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [
            "inadequate efficacy",
            "adverse events",
            "successful transition to anifrolumab"
          ],
          "safety_summary": "Baricitinib caused significant JAK inhibitor-related side effects including BK viruria/viremia, EBV viremia, and facial molluscum contagiosum. These adverse effects resolved after baricitinib discontinuation following anifrolumab initiation.",
          "safety_profile": "Concerning"
        },
        "outcome_result": "Fail",
        "efficacy_signal": "Weak",
        "comparator_baseline": null,
        "follow_up_duration": "over 10 years",
        "key_findings": "Baricitinib monotherapy and combination therapy failed to achieve sustained disease control in SAVI, causing significant immunosuppression-related adverse events that resolved upon discontinuation.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "C-reactive protein (CRP) level",
            "endpoint_category": "Primary",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": 51.0,
            "unit": "mg/L",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 51.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Normal <5 mg/L; transient decrease after first dazukibart infusion but rebounded by day 5"
          },
          {
            "endpoint_name": "IFN I score",
            "endpoint_category": "Primary",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": 789.0,
            "unit": "score",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 789.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Normal <25; persistently elevated despite over 10 years of baricitinib treatment"
          },
          {
            "endpoint_name": "IFN I score",
            "endpoint_category": "Primary",
            "timepoint": "During anifrolumab treatment",
            "measurement_type": "Change from baseline",
            "value": null,
            "unit": "score",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 789.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Sustained and remarkable normalization of IFN I scores within first two months of anifrolumab treatment"
          },
          {
            "endpoint_name": "Serum-free IFN\u03b2 level",
            "endpoint_category": "Secondary",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": 1083.0,
            "unit": "fg/mL",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 1083.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Normal: 0\u2013573 fg/mL"
          },
          {
            "endpoint_name": "IFN\u03b1 level",
            "endpoint_category": "Secondary",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": 4565.0,
            "unit": "fg/mL",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 4565.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Normal 0\u201342 fg/mL"
          },
          {
            "endpoint_name": "IFN\u03b1 level",
            "endpoint_category": "Secondary",
            "timepoint": "During anifrolumab treatment",
            "measurement_type": "Absolute value",
            "value": null,
            "unit": "fg/mL to pg/mL",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 4565.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Ranging from 119 fg/mL to 20.6 pg/mL"
          },
          {
            "endpoint_name": "IFN\u03b2 level",
            "endpoint_category": "Secondary",
            "timepoint": "During anifrolumab treatment",
            "measurement_type": "Absolute value",
            "value": null,
            "unit": "fg/mL to pg/mL",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 1083.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Ranging from 6,775 fg/mL to 26 pg/mL"
          },
          {
            "endpoint_name": "Vasculitic ulcer healing",
            "endpoint_category": "Primary",
            "timepoint": "During anifrolumab treatment",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Complete closure of all vasculitic wounds that had been refractory to previous treatments"
          },
          {
            "endpoint_name": "Baricitinib discontinuation",
            "endpoint_category": "Secondary",
            "timepoint": "During anifrolumab treatment",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Allowed for the tapering and discontinuation of baricitinib"
          },
          {
            "endpoint_name": "Viral reactivation clearance (BK viremia)",
            "endpoint_category": "Secondary",
            "timepoint": "During baricitinib tapering with anifrolumab",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Gradual improvement and ultimate clearance during baricitinib tapering"
          },
          {
            "endpoint_name": "Viral reactivation clearance (EBV viremia)",
            "endpoint_category": "Secondary",
            "timepoint": "During baricitinib tapering with anifrolumab",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Gradual improvement and ultimate clearance during baricitinib tapering"
          },
          {
            "endpoint_name": "Facial molluscum contagiosum clearance",
            "endpoint_category": "Secondary",
            "timepoint": "During baricitinib tapering with anifrolumab",
            "measurement_type": "Responder",
            "value": null,
            "unit": null,
            "responders_n": 1,
            "responders_pct": 100.0,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Gradual improvement and ultimate clearance during baricitinib tapering"
          },
          {
            "endpoint_name": "Duration of anifrolumab response",
            "endpoint_category": "Secondary",
            "timepoint": "Over 15 months",
            "measurement_type": "Absolute value",
            "value": 15.0,
            "unit": "months",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Vasculitic lesions significantly improved with rare and limited flares throughout the course"
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "BK viruria and viremia",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": "Related",
            "outcome": "Resolved",
            "action_taken": "Discontinued",
            "notes": "JAKi-related side effect from baricitinib, resolved after baricitinib discontinuation"
          },
          {
            "event_name": "Epstein-Barr virus (EBV) viremia",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": "Related",
            "outcome": "Resolved",
            "action_taken": "Discontinued",
            "notes": "JAKi-related side effect from baricitinib, resolved after baricitinib discontinuation"
          },
          {
            "event_name": "Facial molluscum contagiosum",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": "Related",
            "outcome": "Resolved",
            "action_taken": "Discontinued",
            "notes": "JAKi-related side effect from baricitinib, remained limited to focal areas on face during treatment, cleared after baricitinib discontinuation"
          },
          {
            "event_name": "Subclavian port thrombosis",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": "Possibly related",
            "outcome": "Resolved",
            "action_taken": "None",
            "notes": "Occurred during dazukibart treatment, necessitated port removal and led to escalation of systemic inflammatory response"
          },
          {
            "event_name": "Acneiform pustular eruptions",
            "event_category": "AE",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": null,
            "relatedness": "Related",
            "outcome": "Ongoing",
            "action_taken": "None",
            "notes": "Adverse skin reactions observed during dazukibart treatment, required topical management"
          }
        ],
        "extraction_timestamp": "2025-12-07T17:34:02.365966",
        "extraction_confidence": 0.6,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [],
          "efficacy_tables": [],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure 1: Schematic of SAVI pathogenesis and targeted treatments, clinical images of vasculitic lesions at baseline and during treatment, plots showing associations between CRP levels and IFN I scores, serum levels of bound and free IFN\u03b2 during dazukibart treatment, and serum IFN\u03b1 levels",
            "Figure 2: Impact of anifrolumab on IFN I scores, vasculitic lesions, and clinical outcomes showing sustained normalization of IFN I scores, serum cytokine levels, marked improvement in vasculitic skin lesions with complete wound closure, and clearance of molluscum lesions"
          ],
          "results_sections": [
            "RESULTS section describing dazukibart treatment outcomes including initial response, rebound inflammation, dose escalations, complications, and pharmacokinetic/pharmacodynamic analysis",
            "RESULTS section describing transition to anifrolumab treatment with sustained IFN I score suppression, wound healing, and discontinuation of baricitinib with resolution of viral complications"
          ],
          "patient_count": 1,
          "study_type": "Case Report",
          "has_quantitative_outcomes": true,
          "notes": "Single patient case report with detailed longitudinal monitoring of IFN I scores, cytokine levels, and clinical outcomes across multiple treatment regimens. No formal tables present - all data presented in text and figures. Includes pharmacokinetic/pharmacodynamic modeling for dazukibart treatment."
        }
      },
      "market_intelligence": {
        "disease": "STING-associated vasculopathy with onset in infancy (SAVI)",
        "epidemiology": {
          "us_prevalence_estimate": "less than 1 in 1,000,000",
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": 335,
          "prevalence_source": "Orphanet",
          "prevalence_source_url": "https://www.orpha.net/en/disease/detail/425120",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Jakafi (ruxolitinib)",
              "drug_class": "JAK1/JAK2 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "Used off-label for SAVI treatment, no FDA approval for this specific indication"
            },
            {
              "drug_name": "Olumiant (baricitinib)",
              "drug_class": "JAK1/JAK2 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "Used off-label for SAVI treatment, no FDA approval for this specific indication"
            },
            {
              "drug_name": "Xeljanz (tofacitinib)",
              "drug_class": "JAK3 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Less suitable than JAK1/JAK2 inhibitors for SAVI, no FDA approval for this indication"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 1,
          "pipeline_therapies": [
            {
              "drug_name": "baricitinib",
              "company": "Eli Lilly",
              "mechanism": "JAK1/2 inhibitor",
              "phase": "Phase 2/3",
              "trial_id": "NCT04517253",
              "expected_completion": null
            }
          ],
          "pipeline_details": "The SAVI clinical pipeline is limited with one active Phase 2/3 trial evaluating baricitinib, a JAK1/2 inhibitor, specifically for Japanese patients with SAVI and other interferonopathies.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "JAK inhibitors are the primary treatment approach for SAVI, with ruxolitinib and baricitinib preferred over tofacitinib as first-line therapy.",
          "unmet_need": true,
          "unmet_need_description": "No FDA-approved treatments exist specifically for SAVI. Current treatments including corticosteroids, anti-TNF agents, IVIG, and anti-CD20 therapy are largely ineffective, with lung damage being irreversible and often fatal.",
          "competitive_landscape": "SAVI represents a significant unmet medical need with no FDA-approved therapies for this rare autoinflammatory disorder. JAK inhibitors show promise but are used off-label, highlighting the need for dedicated drug development in this ultra-rare disease.",
          "soc_source": "MDPI Journal and PMC articles on SAVI treatment approaches"
        },
        "market_size_estimate": "$67M",
        "market_size_usd": 67000000.0,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 46200000.0,
        "tam_estimate": "$46.2M",
        "tam_rationale": "Of ~335 global SAVI patients, ~80% are diagnosed (268 patients) given the severe phenotype and specialized care networks. ~90% of diagnosed patients receive JAK inhibitor treatment (241 patients) due to life-threatening manifestations. With no approved drugs specifically for SAVI, a targeted therapy could capture 60-70% market share (~154 patients). At $300K/yr orphan drug pricing for this ultra-rare, severe condition, TAM = $46.2M.",
        "tam_sources": [
          "https://academic.oup.com/rheumatology/article-abstract/57/suppl_8/key273.006/5123443",
          "https://rarediseases.org/mondo-disease/sting-associated-vasculopathy-with-onset-in-infancy/",
          "https://www.mdpi.com/2673-5261/4/4/24"
        ],
        "pipeline_sources": [
          "https://cdn.clinicaltrials.gov/large-docs/53/NCT04517253/Prot_000.pdf",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC7867893/",
          "https://pubmed.ncbi.nlm.nih.gov/33217613/"
        ],
        "attributed_sources": [
          {
            "url": "https://rarediseases.info.nih.gov/diseases/12357/sting-associated-vasculopathy-with-onset-in-infancy",
            "title": "STING-associated vasculopathy with onset in infancy",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.orpha.net/en/disease/detail/425120",
            "title": "STING-associated vasculopathy with onset in infancy - Orphanet",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.fda.gov/files/drugs/published/Biosimilars_Overview.pdf",
            "title": "Overview of Biosimilar Products - U.S. Food and Drug ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-gene-therapy-treatment-spinal-muscular-atrophy",
            "title": "FDA Approves Gene Therapy for Treatment of Spinal Muscular ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.orpha.net/en/disease/detail/425120",
            "title": "STING-associated vasculopathy with onset in infancy - Orphanet",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/53/NCT04517253/Prot_000.pdf",
            "title": "Protocol I4V-JE-JAJE (d) A Phase 2/3, Multicenter, Open- ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7867893/",
            "title": "STING-associated vasculopathy with onset in infancy",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://academic.oup.com/rheumatology/article-abstract/57/suppl_8/key273.006/5123443",
            "title": "P04 STING: associated vasculopathy with onset in infancy (SAVI)",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://rarediseases.org/mondo-disease/sting-associated-vasculopathy-with-onset-in-infancy/",
            "title": "STING-associated vasculopathy with onset in infancy",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 3.2,
        "evidence_quality": 7.0,
        "market_opportunity": 8.3,
        "overall_priority": 5.4,
        "clinical_breakdown": {
          "response_rate": 2.0,
          "safety_profile": 1.0,
          "endpoint_quality": 3.3,
          "organ_domain_breadth": 10.0,
          "safety_categories": [
            "serious_infection",
            "cardiovascular",
            "non_serious_infection"
          ],
          "regulatory_flags": [
            "serious_infection",
            "cardiovascular"
          ]
        },
        "response_rate_score": 2.0,
        "safety_profile_score": 1.0,
        "endpoint_quality_score": 3.3,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 10.0,
          "response_durability": 10.0,
          "extraction_completeness": 8.3
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 10.0,
        "extraction_completeness_score": 8.3,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 5.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 5.0,
        "unmet_need_score": 10.0
      },
      "rank": 53
    },
    {
      "extraction": {
        "source": {
          "pmid": "37877023",
          "doi": "10.3389/fmed.2023.1253795",
          "url": "https://www.semanticscholar.org/paper/03bf722fb89644135cad9b4bd84f3c9c461b5758",
          "title": "Case report: Dupilumab therapy for alopecia areata in a 4-year-old patient resistant to baricitinib",
          "authors": "LC, YW, MZ, JZ, XT, ML",
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "pediatric alopecia universalis",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "topical corticosteroids",
            "dupilumab"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "4-year-old patient with alopecia universalis for 3 years, with allergic rhinitis"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": "oral",
          "dose": "2 mg once daily",
          "frequency": null,
          "duration": "6 months",
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": "0/1 (0%)",
          "responders_n": 0,
          "responders_pct": 0.0,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": "no clinical improvement",
          "primary_endpoint": "SALT score improvement",
          "endpoint_result": "no improvement in SALT score (remained 0)",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib showed no efficacy in this 4-year-old patient with alopecia universalis after 6 months of treatment. The patient remained completely bald with SALT score of 0 throughout the treatment period."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": 1,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [
            "lack of efficacy"
          ],
          "safety_summary": "No specific adverse events were reported during the 6-month treatment period with baricitinib.",
          "safety_profile": "Acceptable"
        },
        "outcome_result": "Fail",
        "efficacy_signal": "None",
        "comparator_baseline": null,
        "follow_up_duration": "6 months",
        "key_findings": "Baricitinib was ineffective in pediatric alopecia universalis, leading to successful treatment with dupilumab after discontinuation.",
        "detailed_efficacy_endpoints": [
          {
            "endpoint_name": "SALT score",
            "endpoint_category": "Primary",
            "timepoint": "Baseline",
            "measurement_type": "Absolute value",
            "value": 0.0,
            "unit": "SALT score",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 0.0,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Baseline before baricitinib treatment"
          },
          {
            "endpoint_name": "SALT score",
            "endpoint_category": "Primary",
            "timepoint": "Month 6",
            "measurement_type": "Absolute value",
            "value": 0.0,
            "unit": "SALT score",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 0.0,
            "change_from_baseline": 0.0,
            "change_pct": 0.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "After 6 months of baricitinib treatment - no improvement"
          },
          {
            "endpoint_name": "SALT score",
            "endpoint_category": "Primary",
            "timepoint": "Month 3",
            "measurement_type": "Absolute value",
            "value": 58.0,
            "unit": "SALT score",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 0.0,
            "change_from_baseline": 58.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "After 3 months of dupilumab therapy"
          },
          {
            "endpoint_name": "SALT percentage improvement",
            "endpoint_category": "Primary",
            "timepoint": "Month 3",
            "measurement_type": "Change from baseline",
            "value": 58.0,
            "unit": "percent",
            "responders_n": null,
            "responders_pct": 58.0,
            "baseline_value": 0.0,
            "change_from_baseline": null,
            "change_pct": 58.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "After 3 months of dupilumab therapy"
          },
          {
            "endpoint_name": "SALT score",
            "endpoint_category": "Primary",
            "timepoint": "Month 10",
            "measurement_type": "Absolute value",
            "value": 85.0,
            "unit": "SALT score",
            "responders_n": null,
            "responders_pct": null,
            "baseline_value": 0.0,
            "change_from_baseline": 85.0,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "After 10 months of dupilumab therapy"
          },
          {
            "endpoint_name": "SALT percentage improvement",
            "endpoint_category": "Primary",
            "timepoint": "Month 10",
            "measurement_type": "Change from baseline",
            "value": 85.0,
            "unit": "percent",
            "responders_n": null,
            "responders_pct": 85.0,
            "baseline_value": 0.0,
            "change_from_baseline": null,
            "change_pct": 85.0,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "After 10 months of dupilumab therapy"
          },
          {
            "endpoint_name": "Pull test result",
            "endpoint_category": "Secondary",
            "timepoint": "Month 3",
            "measurement_type": "Responder",
            "value": null,
            "unit": "negative/positive",
            "responders_n": 1,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Negative pull test after 3 months of dupilumab therapy"
          },
          {
            "endpoint_name": "Pull test result",
            "endpoint_category": "Secondary",
            "timepoint": "Month 10",
            "measurement_type": "Responder",
            "value": null,
            "unit": "negative/positive",
            "responders_n": 1,
            "responders_pct": null,
            "baseline_value": null,
            "change_from_baseline": null,
            "change_pct": null,
            "p_value": null,
            "confidence_interval": null,
            "statistical_significance": null,
            "notes": "Negative pull test after 10 months of dupilumab therapy"
          }
        ],
        "detailed_safety_endpoints": [
          {
            "event_name": "Treatment discontinuation due to lack of efficacy",
            "event_category": "Discontinuation",
            "severity_grade": null,
            "patients_affected_n": 1,
            "patients_affected_pct": null,
            "events_total": 1,
            "relatedness": null,
            "outcome": null,
            "action_taken": "Discontinued",
            "notes": "Baricitinib was discontinued after 6 months due to lack of improvement in alopecia universalis; patient's condition did not improve and SALT score remained 0"
          }
        ],
        "extraction_timestamp": "2025-12-07T18:06:23.145279",
        "extraction_confidence": 0.6,
        "extraction_method": "multi_stage",
        "extraction_stages_completed": [
          "section_identification",
          "efficacy_extraction",
          "safety_extraction"
        ],
        "data_sections_identified": {
          "baseline_tables": [],
          "efficacy_tables": [],
          "safety_tables": [],
          "efficacy_figures": [
            "Figure 1: Before dupilumab therapy",
            "Figure 2: After 3 months of dupilumab therapy",
            "Figure 3: After 10 months of dupilumab therapy"
          ],
          "results_sections": [
            "Case presentation section with treatment outcomes and SALT score improvements"
          ],
          "patient_count": 1,
          "study_type": "Case Report",
          "has_quantitative_outcomes": true,
          "notes": "Single case report with no formal tables. Efficacy data presented narratively with SALT scores: baseline 0, 3 months 58% improvement, 10 months 85% improvement. Patient was baricitinib-resistant but responded to dupilumab. Safety data mentioned briefly with no adverse events reported."
        }
      },
      "market_intelligence": {
        "disease": "pediatric alopecia universalis",
        "epidemiology": {
          "us_prevalence_estimate": null,
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": null,
          "prevalence_source": null,
          "prevalence_source_url": null,
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Litfulo (ritlecitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": "severe alopecia areata in adults and adolescents 12 years and older",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved for severe alopecia areata (includes universalis) in ages 12+ but not specifically for pediatric alopecia universalis as distinct indication"
            },
            {
              "drug_name": "Olumiant (baricitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": "alopecia areata",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved for alopecia areata in adults, not specifically for pediatric alopecia universalis"
            },
            {
              "drug_name": "Dupixent (dupilumab)",
              "drug_class": "IL-4/IL-13 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": false,
              "fda_approved_indication": null,
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "Used off-label for pediatric alopecia areata, not FDA approved for this indication"
            }
          ],
          "approved_drug_names": [],
          "num_approved_drugs": 0,
          "num_pipeline_therapies": 0,
          "pipeline_therapies": [],
          "pipeline_details": "No active clinical trials specifically for pediatric alopecia universalis were identified in the provided search results, which contained unrelated Phase 3 trials for other medical conditions.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "No FDA-approved branded innovative drugs exist specifically for pediatric alopecia universalis. Treatment relies on off-label use of topical corticosteroids, contact immunotherapy, and systemic JAK inhibitors approved for broader alopecia areata indications.",
          "unmet_need": true,
          "unmet_need_description": "Significant unmet need exists as no branded innovative drugs are FDA-approved specifically for pediatric alopecia universalis, requiring off-label use of treatments approved for general alopecia areata or other indications",
          "competitive_landscape": "The pediatric alopecia universalis market lacks FDA-approved branded innovative treatments, creating opportunity for drug developers. Current JAK inhibitors like Litfulo and Olumiant have approvals for broader alopecia areata populations but not pediatric universalis specifically.",
          "soc_source": "PMC article on pediatric alopecia areata treatment and FDA drug labels - https://pmc.ncbi.nlm.nih.gov/articles/PMC8556406/"
        },
        "market_size_estimate": null,
        "market_size_usd": null,
        "growth_rate": "5-8% CAGR (high unmet need)",
        "tam_usd": 140000000.0,
        "tam_estimate": "$140M",
        "tam_rationale": "Of ~8,000 US pediatric alopecia universalis patients, ~60% are diagnosed (4,800), ~70% seek treatment (3,360), ~80% fail first-line topical therapies and become candidates for systemic therapy (2,688). With no FDA-approved pediatric drugs, a new targeted therapy could capture 40-50% market share (~1,400 patients) given high unmet need. At $100K/yr orphan drug pricing for this severe rare pediatric condition, TAM = $140M.",
        "tam_sources": [
          "https://en.wikipedia.org/wiki/Pediatrics",
          "https://www.pecosvalleydocs.com/pediatric-care",
          "https://doctor.webmd.com/providers/specialty/pediatrics/new-mexico/artesia"
        ],
        "pipeline_sources": [
          "https://cdn.clinicaltrials.gov/large-docs/65/NCT04248465/SAP_001.pdf",
          "https://cdn.clinicaltrials.gov/large-docs/70/NCT04963270/Prot_000.pdf",
          "https://register.clinicaltrials.gov/"
        ],
        "attributed_sources": [
          {
            "url": "https://www.hcplive.com/view/prevalence-of-pediatric-alopecia-areata-doubled-in-last-decade",
            "title": "Prevalence of Pediatric Alopecia Areata Doubled in Last Decade",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.jaad.org/article/S0190-9622(17)31937-0/fulltext",
            "title": "Prevalence of pediatric alopecia areata among 572617 dermatology ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.drugs.com/clinical_trials/nektar-therapeutics-receives-fast-track-designation-rezpegaldesleukin-severe-very-severe-alopecia-22125.html",
            "title": "Nektar Therapeutics Receives Fast Track Designation for ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/215830Orig1s000RiskR.pdf",
            "title": "215830Orig1s000 - accessdata.fda.gov",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3519253/",
            "title": "Current Treatment Strategies in Pediatric Alopecia Areata - PMC - NIH",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/65/NCT04248465/SAP_001.pdf",
            "title": "A Phase 3, Double-Blind, Randomized, Placebo-Controlled ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://cdn.clinicaltrials.gov/large-docs/70/NCT04963270/Prot_000.pdf",
            "title": "Official Title: A Phase III, Randomized, Double-Blind ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://en.wikipedia.org/wiki/Pediatrics",
            "title": "Pediatrics - Wikipedia",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.pecosvalleydocs.com/pediatric-care",
            "title": "Pediatrics | Pecos Valley Physician Group | Carlsbad, Artesia , New Mexico",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 4.6,
        "evidence_quality": 4.0,
        "market_opportunity": 8.3,
        "overall_priority": 5.4,
        "clinical_breakdown": {
          "response_rate": 2.0,
          "safety_profile": 7.0,
          "endpoint_quality": 1.8,
          "organ_domain_breadth": 10.0,
          "safety_categories": [
            "discontinuation"
          ],
          "regulatory_flags": []
        },
        "response_rate_score": 2.0,
        "safety_profile_score": 7.0,
        "endpoint_quality_score": 1.8,
        "organ_domain_score": 10.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 2.0,
          "response_durability": 7.0,
          "extraction_completeness": 7.2
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 7.0,
        "extraction_completeness_score": 7.2,
        "market_breakdown": {
          "competitors": 10.0,
          "market_size": 5.0,
          "unmet_need": 10.0
        },
        "competitors_score": 10.0,
        "market_size_score": 5.0,
        "unmet_need_score": 10.0
      },
      "rank": 54
    },
    {
      "extraction": {
        "source": {
          "pmid": "39672377",
          "doi": "10.1016/j.jaip.2024.12.001",
          "url": "https://pubmed.ncbi.nlm.nih.gov/39672377/",
          "title": "Switching From Dupilumab to Tralokinumab or Janus Kinase Inhibitors in Cases of Ocular and/or Facial Adverse Events in Patients With Atopic Dermatitis: A Multicenter Retrospective Study.",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Peer-reviewed journal",
          "is_open_access": false
        },
        "disease": "atopic dermatitis",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Retrospective Study",
        "patient_population": {
          "n_patients": null,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "dupilumab"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "patients with atopic dermatitis who experienced dupilumab-induced ocular adverse events or dupilumab-induced facial redness"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": null,
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": null,
          "responders_pct": null,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": null,
          "primary_endpoint": null,
          "endpoint_result": null,
          "durability_signal": null,
          "efficacy_summary": "Abstract does not provide specific efficacy outcomes for JAK inhibitor treatment in atopic dermatitis patients switched from dupilumab."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No safety data provided in the abstract for JAK inhibitor treatment in this patient population.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Unknown",
        "efficacy_signal": "Unknown",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "Study examined switching from dupilumab to JAK inhibitors in atopic dermatitis patients with ocular or facial adverse events.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-07T17:49:19.070736",
        "extraction_confidence": 0.5,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "atopic dermatitis",
        "epidemiology": {
          "us_prevalence_estimate": "7.3% of US adults",
          "us_incidence_estimate": "889.90 per 100,000 in 2022",
          "global_prevalence": null,
          "patient_population_size": 25844871,
          "prevalence_source": "Journal of Allergy and Clinical Immunology: In Practice",
          "prevalence_source_url": "https://www.jaci-inpractice.org/article/S2213-2198(19)30055-8/pdf",
          "trend": "increasing"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Dupixent (dupilumab)",
              "drug_class": "IL-4/IL-13 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "atopic dermatitis",
              "efficacy_range": "60-70%",
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved for moderate-to-severe atopic dermatitis in adults, adolescents, and children as young as 6 months"
            },
            {
              "drug_name": "Cibinqo (abrocitinib)",
              "drug_class": "JAK1 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "atopic dermatitis",
              "efficacy_range": "50-60%",
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "FDA approved January 2022 for adults with refractory moderate-to-severe atopic dermatitis not adequately controlled with other systemic therapies"
            },
            {
              "drug_name": "Rinvoq (upadacitinib)",
              "drug_class": "JAK1 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "atopic dermatitis",
              "efficacy_range": "50-60%",
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "FDA approved for refractory moderate-to-severe atopic dermatitis in patients 12 years and older not adequately controlled with other systemic therapies"
            },
            {
              "drug_name": "Adbry (tralokinumab)",
              "drug_class": "IL-13 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "atopic dermatitis",
              "efficacy_range": "50-60%",
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved for moderate-to-severe atopic dermatitis in adults and children 12-17 years inadequately controlled with topical therapies"
            },
            {
              "drug_name": "Olumiant (baricitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "atopic dermatitis",
              "efficacy_range": "50-60%",
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "FDA approved for atopic dermatitis as strongly recommended by clinical guidelines"
            },
            {
              "drug_name": "Nemluvio (nemolizumab)",
              "drug_class": "IL-31 receptor antagonist",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "atopic dermatitis",
              "efficacy_range": "50-60%",
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved for moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years and older"
            },
            {
              "drug_name": "Opzelura (ruxolitinib cream)",
              "drug_class": "Topical JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "atopic dermatitis",
              "efficacy_range": "40-50%",
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved topical JAK inhibitor for mild to moderate atopic dermatitis with 1.5% and 0.75% formulations"
            }
          ],
          "approved_drug_names": [
            "Dupixent (dupilumab)",
            "Cibinqo (abrocitinib)",
            "Rinvoq (upadacitinib)",
            "Adbry (tralokinumab)",
            "Olumiant (baricitinib)",
            "Nemluvio (nemolizumab)",
            "Opzelura (ruxolitinib cream)"
          ],
          "num_approved_drugs": 7,
          "num_pipeline_therapies": 5,
          "pipeline_therapies": [
            {
              "drug_name": "Tapinarof",
              "company": "Not specified",
              "mechanism": "Not specified",
              "phase": "Phase 3",
              "trial_id": "NCT05014568",
              "expected_completion": null
            },
            {
              "drug_name": "Ivarmacitinib",
              "company": "Not specified",
              "mechanism": "Not specified",
              "phase": "Phase 3",
              "trial_id": "NCT04875169",
              "expected_completion": null
            },
            {
              "drug_name": "Dupilumab",
              "company": "Not specified",
              "mechanism": "Not specified",
              "phase": "Phase 3",
              "trial_id": null,
              "expected_completion": null
            },
            {
              "drug_name": "Upadacitinib",
              "company": "Not specified",
              "mechanism": "Not specified",
              "phase": "Phase 3",
              "trial_id": null,
              "expected_completion": null
            },
            {
              "drug_name": "Amlitelimab",
              "company": "Sanofi",
              "mechanism": "OX40-ligand antagonist",
              "phase": "Phase 3",
              "trial_id": null,
              "expected_completion": null
            }
          ],
          "pipeline_details": "The atopic dermatitis pipeline shows robust Phase 3 activity with multiple novel mechanisms including JAK inhibitors, IL-4/IL-13 pathway targeting, and OX40-ligand antagonism. Several therapies have demonstrated positive results in recent trials, indicating strong potential for new treatment options.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "First-line treatment typically includes topical therapies and biologics like dupilumab for moderate-to-severe disease. JAK inhibitors are used as second-line systemic therapies when biologics fail or are inadvisable.",
          "unmet_need": false,
          "unmet_need_description": null,
          "competitive_landscape": "The atopic dermatitis market has multiple FDA-approved branded innovative treatments including biologics targeting IL-4/IL-13 and IL-31 pathways, and JAK inhibitors for systemic use. The recent approvals of nemolizumab and multiple JAK inhibitors provide physicians with diverse therapeutic options across different mechanisms of action.",
          "soc_source": "FDA Multi-Disciplinary Review and AAD Clinical Guidelines"
        },
        "market_size_estimate": "$646.1B",
        "market_size_usd": 646121775000.0,
        "growth_rate": "5-10% CAGR (increasing prevalence)",
        "tam_usd": 2100000000.0,
        "tam_estimate": "$2.1B",
        "tam_rationale": "Of ~25.8M US adults with atopic dermatitis, ~80% are diagnosed (20.7M), ~60% receive treatment beyond topicals (12.4M), ~25% have moderate-to-severe disease requiring systemic therapy (3.1M). A new systemic drug could capture 15-20% market share in this crowded market with 7 approved competitors (~550K patients). At $40K/yr average pricing for chronic systemic AD therapy, TAM = $2.1B.",
        "tam_sources": [
          "https://www.datamintelligence.com/strategic-insights/atopic-dermatitis-ad",
          "https://www.marketdataforecast.com/market-reports/atopic-dermatitis-treatment-market",
          "https://straitsresearch.com/report/atopic-dermatitis-market"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov/study/NCT05014568",
          "https://jamanetwork.com/journals/jamadermatology/fullarticle/2833318",
          "https://pubmed.ncbi.nlm.nih.gov/27690741/"
        ],
        "attributed_sources": [
          {
            "url": "https://pubmed.ncbi.nlm.nih.gov/30389491/",
            "title": "Atopic Dermatitis in America Study: A Cross-Sectional ... - PubMed",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://aafa.org/wp-content/uploads/2022/08/Atopic-Dermatitis-in-America-Study-Overview.pdf",
            "title": "Atopic Dermatitis in America Study Overview",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.fda.gov/media/189437/download",
            "title": "NDA/BLA Multi-Disciplinary Review and Evaluation",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/1049085-treatment",
            "title": "Atopic Dermatitis Treatment & Management",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.aad.org/member/clinical-quality/guidelines/atopic-dermatitis",
            "title": "Atopic dermatitis clinical guideline",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT05014568",
            "title": "Tapinarof for the Treatment of Atopic Dermatitis in Children ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://jamanetwork.com/journals/jamadermatology/fullarticle/2833318",
            "title": "Ivarmacitinib for Moderate to Severe Atopic Dermatitis in ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.datamintelligence.com/strategic-insights/atopic-dermatitis-ad",
            "title": "Atopic Dermatitis (AD) - Strategic Pharma CI Insights",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.marketdataforecast.com/market-reports/atopic-dermatitis-treatment-market",
            "title": "Atopic Dermatitis Market Size, Share& Growth Report, 2033",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 5.2,
        "evidence_quality": 5.0,
        "market_opportunity": 6.0,
        "overall_priority": 5.3,
        "clinical_breakdown": {
          "response_rate": 5.0,
          "safety_profile": 5.0,
          "endpoint_quality": 5.0,
          "organ_domain_breadth": 6.0,
          "safety_categories": [],
          "regulatory_flags": []
        },
        "response_rate_score": 5.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": 5.0,
        "organ_domain_score": 6.0,
        "evidence_breakdown": {
          "sample_size": 3.0,
          "publication_venue": 10.0,
          "response_durability": 4.0,
          "extraction_completeness": 3.2
        },
        "sample_size_score": 3.0,
        "publication_venue_score": 10.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 3.2,
        "market_breakdown": {
          "competitors": 3.0,
          "market_size": 10.0,
          "unmet_need": 5.0
        },
        "competitors_score": 3.0,
        "market_size_score": 10.0,
        "unmet_need_score": 5.0
      },
      "rank": 55
    },
    {
      "extraction": {
        "source": {
          "pmid": null,
          "doi": null,
          "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10937442/",
          "title": "Off-label use of Baricitinib improves moderate and severe atopic ...",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "moderate and severe atopic dermatitis",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Retrospective Study",
        "patient_population": {
          "n_patients": null,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [],
          "disease_severity": null,
          "comorbidities": null,
          "description": "patients with moderate and severe atopic dermatitis with hyperactive immune status"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": null,
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": null,
          "responders_pct": null,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": "improvement in moderate and severe AD symptoms",
          "primary_endpoint": "clinical symptom improvement and immune hyperresponsiveness",
          "endpoint_result": "improved immune hyperresponsiveness and clinical symptoms",
          "durability_signal": null,
          "efficacy_summary": "Baricitinib improved immune hyperresponsiveness and clinical symptoms in moderate and severe atopic dermatitis patients. The mechanism involved inhibiting Th2 cell activation and cytokine secretion through MAPK, mTOR and PI3K-Akt pathways."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": null,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [],
          "safety_summary": "No safety outcomes were reported in the available abstract.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Success",
        "efficacy_signal": "Moderate",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "JAK1 and JAK2 genes were significantly upregulated in AD patients and correlated with symptom severity, providing mechanistic rationale for baricitinib use.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-07T17:21:17.761649",
        "extraction_confidence": 0.5,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "moderate and severe atopic dermatitis",
        "epidemiology": {
          "us_prevalence_estimate": "28.9% moderate AD, 11% severe AD among adults with atopic dermatitis",
          "us_incidence_estimate": null,
          "global_prevalence": null,
          "patient_population_size": 6600000,
          "prevalence_source": "Journal of Investigative Dermatology",
          "prevalence_source_url": "https://www.jidonline.org/article/S0022-202X(18)32678-2/fulltext",
          "trend": null
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Dupixent (dupilumab)",
              "drug_class": "IL-4/IL-13 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "moderate-to-severe atopic dermatitis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved for moderate-to-severe atopic dermatitis in patients aged 6 months and older, first biologic approved for this indication"
            },
            {
              "drug_name": "Adbry (tralokinumab-ldrm)",
              "drug_class": "IL-13 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "moderate-to-severe atopic dermatitis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved for moderate-to-severe atopic dermatitis in patients aged 12 years and older, first FDA approved biologic that specifically binds to and inhibits IL-13"
            },
            {
              "drug_name": "Cibinqo (abrocitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "moderate-to-severe atopic dermatitis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "FDA approved for adults with refractory moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics"
            },
            {
              "drug_name": "Rinvoq (upadacitinib)",
              "drug_class": "JAK1 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "moderate-to-severe atopic dermatitis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "FDA approved for treatment of refractory moderate-to-severe atopic dermatitis in patients aged 12 years or older whose disease is not adequately controlled with other systemic drug products"
            },
            {
              "drug_name": "Olumiant (baricitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "moderate-to-severe atopic dermatitis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "FDA approved for moderate-to-severe atopic dermatitis, mentioned in guidelines as strongly recommended treatment"
            },
            {
              "drug_name": "Nemolizumab",
              "drug_class": "IL-31 receptor antagonist",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "moderate-to-severe atopic dermatitis",
              "efficacy_range": null,
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved for moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years and older, used with topical corticosteroids or calcineurin inhibitors"
            }
          ],
          "approved_drug_names": [
            "Dupixent (dupilumab)",
            "Adbry (tralokinumab-ldrm)",
            "Cibinqo (abrocitinib)",
            "Rinvoq (upadacitinib)",
            "Olumiant (baricitinib)",
            "Nemolizumab"
          ],
          "num_approved_drugs": 6,
          "num_pipeline_therapies": 5,
          "pipeline_therapies": [
            {
              "drug_name": "rademikibart",
              "company": "Not specified",
              "mechanism": "Biologic therapy",
              "phase": "Phase 2",
              "trial_id": null,
              "expected_completion": null
            },
            {
              "drug_name": "nemolizumab",
              "company": "Not specified",
              "mechanism": "Biologic therapy",
              "phase": "Phase 3",
              "trial_id": "NCT03985943, NCT03989349",
              "expected_completion": null
            },
            {
              "drug_name": "BFB759",
              "company": "Not specified",
              "mechanism": "Not specified",
              "phase": "Phase 3",
              "trial_id": "NCT07105488",
              "expected_completion": null
            },
            {
              "drug_name": "EDP1815",
              "company": "EVELO",
              "mechanism": "Microbiome-based therapy",
              "phase": "Phase 2",
              "trial_id": "NCT05121480",
              "expected_completion": null
            },
            {
              "drug_name": "tradipitant",
              "company": "Not specified",
              "mechanism": "Not specified",
              "phase": "Phase 3",
              "trial_id": "NCT03568331",
              "expected_completion": null
            }
          ],
          "pipeline_details": "The moderate and severe atopic dermatitis pipeline shows strong activity with multiple biologic therapies in Phase 2 and 3 trials, including nemolizumab which has completed large multinational Phase 3 studies. Novel approaches include microbiome-based therapy EDP1815 and various other mechanisms targeting treatment-resistant cases.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "First-line treatment typically includes biologics like Dupixent or Adbry targeting IL-4/IL-13 pathways. Second-line treatment includes JAK inhibitors like Cibinqo, Rinvoq, or Olumiant for refractory cases not controlled by biologics or topical therapies.",
          "unmet_need": false,
          "unmet_need_description": null,
          "competitive_landscape": "The moderate-to-severe atopic dermatitis market has multiple FDA-approved innovative treatments including biologics targeting different cytokine pathways (IL-4/IL-13, IL-31) and oral JAK inhibitors. Competition exists between first-line biologics and second-line JAK inhibitors for refractory disease.",
          "soc_source": "American Academy of Dermatology Guidelines and FDA Drug Approval Database"
        },
        "market_size_estimate": "$165.0B",
        "market_size_usd": 165000000000.0,
        "growth_rate": "4-7% CAGR (active pipeline)",
        "tam_usd": 3570000000.0,
        "tam_estimate": "$3.57B",
        "tam_rationale": "Of 6.6M US atopic dermatitis patients, ~2.63M have moderate-severe disease (39.9%). Assuming ~85% are diagnosed (2.24M), ~65% receive systemic treatment (1.46M patients). With 6 approved drugs creating a competitive landscape, a new entrant could realistically capture 15-20% market share (~250K patients). At estimated $60K/yr for biologics/JAK inhibitors in this chronic condition requiring long-term treatment, TAM = $15B total market \u00d7 24% new drug share = $3.57B.",
        "tam_sources": [
          "https://www.mordorintelligence.com/industry-reports/nasal-polyps-treatment-market",
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC9195338/",
          "https://escholarship.org/content/qt1bk078v9/qt1bk078v9.pdf"
        ],
        "pipeline_sources": [
          "https://pmc.ncbi.nlm.nih.gov/articles/PMC11602808/",
          "https://clinicaltrials.gov/study/NCT07105488",
          "https://cdn.clinicaltrials.gov/large-docs/80/NCT05121480/Prot_000.pdf"
        ],
        "attributed_sources": [
          {
            "url": "https://www.sciencedirect.com/science/article/pii/S0022202X25022365",
            "title": "The Epidemiology of Atopic Dermatitis among Adults and ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.jidonline.org/article/S0022-202X%2818%2932678-2/fulltext",
            "title": "Atopic Dermatitis in America Study: A Cross-Sectional Study ...",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.drugs.com/history/adbry.html",
            "title": "Adbry (tralokinumab-ldrm) FDA Approval History",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/1049085-treatment",
            "title": "Atopic Dermatitis Treatment & Management: Medical Care, Diet ...",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11627575/",
            "title": "Atopic Dermatitis: A Review of Diagnosis and Treatment - PMC",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11602808/",
            "title": "Emerging Biologic Therapies for the Treatment of Atopic ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT07105488",
            "title": "A Study Evaluating BFB759 in Moderate to Severe Atopic ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.mordorintelligence.com/industry-reports/nasal-polyps-treatment-market",
            "title": "Nasal Polyps Treatment Market Size & Share Analysis",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9195338/",
            "title": "Narrative review on the management of moderate-severe atopic ...",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 5.8,
        "evidence_quality": 3.0,
        "market_opportunity": 6.0,
        "overall_priority": 5.1,
        "clinical_breakdown": {
          "response_rate": 6.0,
          "safety_profile": 5.0,
          "endpoint_quality": 5.0,
          "organ_domain_breadth": 8.0,
          "safety_categories": [],
          "regulatory_flags": []
        },
        "response_rate_score": 6.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": 5.0,
        "organ_domain_score": 8.0,
        "evidence_breakdown": {
          "sample_size": 3.0,
          "publication_venue": 2.0,
          "response_durability": 4.0,
          "extraction_completeness": 3.2
        },
        "sample_size_score": 3.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 3.2,
        "market_breakdown": {
          "competitors": 3.0,
          "market_size": 10.0,
          "unmet_need": 5.0
        },
        "competitors_score": 3.0,
        "market_size_score": 10.0,
        "unmet_need_score": 5.0
      },
      "rank": 56
    },
    {
      "extraction": {
        "source": {
          "pmid": "37495552",
          "doi": "10.1111/pde.15386",
          "url": "https://www.semanticscholar.org/paper/0187d39cff481d15d4f42136ef12d54bac749742",
          "title": "Use of tofacitinib in baricitinib\u2010refractory atopic dermatitis: An example of JAK inhibitor switching",
          "authors": null,
          "journal": null,
          "year": null,
          "citation": null,
          "publication_venue": "Web source",
          "is_open_access": false
        },
        "disease": "atopic dermatitis",
        "disease_normalized": null,
        "is_off_label": true,
        "evidence_level": "Case Report",
        "patient_population": {
          "n_patients": 1,
          "age_description": null,
          "sex_distribution": null,
          "prior_treatments_failed": [
            "baricitinib"
          ],
          "disease_severity": null,
          "comorbidities": null,
          "description": "patient with recalcitrant atopic dermatitis"
        },
        "treatment": {
          "drug_name": "baricitinib",
          "generic_name": "baricitinib",
          "mechanism": "Janus Kinase Inhibitor",
          "target": null,
          "route_of_administration": null,
          "dose": null,
          "frequency": null,
          "duration": null,
          "concomitant_medications": null
        },
        "efficacy": {
          "response_rate": null,
          "responders_n": 0,
          "responders_pct": 0.0,
          "time_to_response": null,
          "duration_of_response": null,
          "effect_size_description": "treatment failure",
          "primary_endpoint": "response to treatment",
          "endpoint_result": "failed baricitinib treatment",
          "durability_signal": null,
          "efficacy_summary": "Patient with recalcitrant atopic dermatitis failed to respond to baricitinib treatment. Subsequently demonstrated excellent response to tofacitinib after baricitinib failure."
        },
        "safety": {
          "adverse_events": [],
          "serious_adverse_events": [],
          "sae_count": null,
          "sae_percentage": null,
          "discontinuations_n": 1,
          "discontinuations_due_to_ae": null,
          "discontinuation_reasons": [
            "lack of efficacy"
          ],
          "safety_summary": "No safety information provided for baricitinib treatment in this case report.",
          "safety_profile": "Unknown"
        },
        "outcome_result": "Fail",
        "efficacy_signal": "None",
        "comparator_baseline": null,
        "follow_up_duration": null,
        "key_findings": "Baricitinib was ineffective in this case of recalcitrant atopic dermatitis, requiring switch to tofacitinib.",
        "detailed_efficacy_endpoints": [],
        "detailed_safety_endpoints": [],
        "extraction_timestamp": "2025-12-07T18:02:10.423221",
        "extraction_confidence": 0.5,
        "extraction_method": "single_pass",
        "extraction_stages_completed": [],
        "data_sections_identified": null
      },
      "market_intelligence": {
        "disease": "atopic dermatitis",
        "epidemiology": {
          "us_prevalence_estimate": "7.3% of US adults",
          "us_incidence_estimate": "889.90 per 100,000 in 2022",
          "global_prevalence": null,
          "patient_population_size": 25844871,
          "prevalence_source": "Journal of Allergy and Clinical Immunology: In Practice",
          "prevalence_source_url": "https://www.jaci-inpractice.org/article/S2213-2198(19)30055-8/pdf",
          "trend": "increasing"
        },
        "standard_of_care": {
          "top_treatments": [
            {
              "drug_name": "Dupixent (dupilumab)",
              "drug_class": "IL-4/IL-13 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "atopic dermatitis",
              "efficacy_range": "60-70%",
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved for moderate-to-severe atopic dermatitis in adults, adolescents, and children as young as 6 months"
            },
            {
              "drug_name": "Cibinqo (abrocitinib)",
              "drug_class": "JAK1 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "atopic dermatitis",
              "efficacy_range": "50-60%",
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "FDA approved January 2022 for adults with refractory moderate-to-severe atopic dermatitis not adequately controlled with other systemic therapies"
            },
            {
              "drug_name": "Rinvoq (upadacitinib)",
              "drug_class": "JAK1 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "atopic dermatitis",
              "efficacy_range": "50-60%",
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "FDA approved for refractory moderate-to-severe atopic dermatitis in patients 12 years and older not adequately controlled with other systemic therapies"
            },
            {
              "drug_name": "Adbry (tralokinumab)",
              "drug_class": "IL-13 inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "atopic dermatitis",
              "efficacy_range": "50-60%",
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved for moderate-to-severe atopic dermatitis in adults and children 12-17 years inadequately controlled with topical therapies"
            },
            {
              "drug_name": "Olumiant (baricitinib)",
              "drug_class": "JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "atopic dermatitis",
              "efficacy_range": "50-60%",
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "2L",
              "notes": "FDA approved for atopic dermatitis as strongly recommended by clinical guidelines"
            },
            {
              "drug_name": "Nemluvio (nemolizumab)",
              "drug_class": "IL-31 receptor antagonist",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "atopic dermatitis",
              "efficacy_range": "50-60%",
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved for moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years and older"
            },
            {
              "drug_name": "Opzelura (ruxolitinib cream)",
              "drug_class": "Topical JAK inhibitor",
              "is_branded_innovative": true,
              "fda_approved": true,
              "fda_approved_indication": "atopic dermatitis",
              "efficacy_range": "40-50%",
              "efficacy_pct": null,
              "annual_cost_usd": null,
              "line_of_therapy": "1L",
              "notes": "FDA approved topical JAK inhibitor for mild to moderate atopic dermatitis with 1.5% and 0.75% formulations"
            }
          ],
          "approved_drug_names": [
            "Dupixent (dupilumab)",
            "Cibinqo (abrocitinib)",
            "Rinvoq (upadacitinib)",
            "Adbry (tralokinumab)",
            "Olumiant (baricitinib)",
            "Nemluvio (nemolizumab)",
            "Opzelura (ruxolitinib cream)"
          ],
          "num_approved_drugs": 7,
          "num_pipeline_therapies": 5,
          "pipeline_therapies": [
            {
              "drug_name": "Tapinarof",
              "company": "Not specified",
              "mechanism": "Not specified",
              "phase": "Phase 3",
              "trial_id": "NCT05014568",
              "expected_completion": null
            },
            {
              "drug_name": "Ivarmacitinib",
              "company": "Not specified",
              "mechanism": "Not specified",
              "phase": "Phase 3",
              "trial_id": "NCT04875169",
              "expected_completion": null
            },
            {
              "drug_name": "Dupilumab",
              "company": "Not specified",
              "mechanism": "Not specified",
              "phase": "Phase 3",
              "trial_id": null,
              "expected_completion": null
            },
            {
              "drug_name": "Upadacitinib",
              "company": "Not specified",
              "mechanism": "Not specified",
              "phase": "Phase 3",
              "trial_id": null,
              "expected_completion": null
            },
            {
              "drug_name": "Amlitelimab",
              "company": "Sanofi",
              "mechanism": "OX40-ligand antagonist",
              "phase": "Phase 3",
              "trial_id": null,
              "expected_completion": null
            }
          ],
          "pipeline_details": "The atopic dermatitis pipeline shows robust Phase 3 activity with multiple novel mechanisms including JAK inhibitors, IL-4/IL-13 pathway targeting, and OX40-ligand antagonism. Several therapies have demonstrated positive results in recent trials, indicating strong potential for new treatment options.",
          "avg_annual_cost_usd": null,
          "treatment_paradigm": "First-line treatment typically includes topical therapies and biologics like dupilumab for moderate-to-severe disease. JAK inhibitors are used as second-line systemic therapies when biologics fail or are inadvisable.",
          "unmet_need": false,
          "unmet_need_description": null,
          "competitive_landscape": "The atopic dermatitis market has multiple FDA-approved branded innovative treatments including biologics targeting IL-4/IL-13 and IL-31 pathways, and JAK inhibitors for systemic use. The recent approvals of nemolizumab and multiple JAK inhibitors provide physicians with diverse therapeutic options across different mechanisms of action.",
          "soc_source": "FDA Multi-Disciplinary Review and AAD Clinical Guidelines"
        },
        "market_size_estimate": "$646.1B",
        "market_size_usd": 646121775000.0,
        "growth_rate": "5-10% CAGR (increasing prevalence)",
        "tam_usd": 2100000000.0,
        "tam_estimate": "$2.1B",
        "tam_rationale": "Of ~25.8M US adults with atopic dermatitis, ~80% are diagnosed (20.7M), ~60% receive treatment beyond topicals (12.4M), ~25% have moderate-to-severe disease requiring systemic therapy (3.1M). A new systemic drug could capture 15-20% market share in this crowded market with 7 approved competitors (~550K patients). At $40K/yr average pricing for chronic systemic AD therapy, TAM = $2.1B.",
        "tam_sources": [
          "https://www.datamintelligence.com/strategic-insights/atopic-dermatitis-ad",
          "https://www.marketdataforecast.com/market-reports/atopic-dermatitis-treatment-market",
          "https://straitsresearch.com/report/atopic-dermatitis-market"
        ],
        "pipeline_sources": [
          "https://clinicaltrials.gov/study/NCT05014568",
          "https://jamanetwork.com/journals/jamadermatology/fullarticle/2833318",
          "https://pubmed.ncbi.nlm.nih.gov/27690741/"
        ],
        "attributed_sources": [
          {
            "url": "https://pubmed.ncbi.nlm.nih.gov/30389491/",
            "title": "Atopic Dermatitis in America Study: A Cross-Sectional ... - PubMed",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://aafa.org/wp-content/uploads/2022/08/Atopic-Dermatitis-in-America-Study-Overview.pdf",
            "title": "Atopic Dermatitis in America Study Overview",
            "attribution": "Epidemiology"
          },
          {
            "url": "https://www.fda.gov/media/189437/download",
            "title": "NDA/BLA Multi-Disciplinary Review and Evaluation",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://emedicine.medscape.com/article/1049085-treatment",
            "title": "Atopic Dermatitis Treatment & Management",
            "attribution": "Approved Treatments"
          },
          {
            "url": "https://www.aad.org/member/clinical-quality/guidelines/atopic-dermatitis",
            "title": "Atopic dermatitis clinical guideline",
            "attribution": "Treatment Paradigm"
          },
          {
            "url": "https://clinicaltrials.gov/study/NCT05014568",
            "title": "Tapinarof for the Treatment of Atopic Dermatitis in Children ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://jamanetwork.com/journals/jamadermatology/fullarticle/2833318",
            "title": "Ivarmacitinib for Moderate to Severe Atopic Dermatitis in ...",
            "attribution": "Pipeline/Clinical Trials"
          },
          {
            "url": "https://www.datamintelligence.com/strategic-insights/atopic-dermatitis-ad",
            "title": "Atopic Dermatitis (AD) - Strategic Pharma CI Insights",
            "attribution": "TAM/Market Analysis"
          },
          {
            "url": "https://www.marketdataforecast.com/market-reports/atopic-dermatitis-treatment-market",
            "title": "Atopic Dermatitis Market Size, Share& Growth Report, 2033",
            "attribution": "TAM/Market Analysis"
          }
        ]
      },
      "scores": {
        "clinical_signal": 4.5,
        "evidence_quality": 2.8,
        "market_opportunity": 6.0,
        "overall_priority": 4.5,
        "clinical_breakdown": {
          "response_rate": 2.0,
          "safety_profile": 5.0,
          "endpoint_quality": 5.0,
          "organ_domain_breadth": 8.0,
          "safety_categories": [],
          "regulatory_flags": []
        },
        "response_rate_score": 2.0,
        "safety_profile_score": 5.0,
        "endpoint_quality_score": 5.0,
        "organ_domain_score": 8.0,
        "evidence_breakdown": {
          "sample_size": 1.0,
          "publication_venue": 2.0,
          "response_durability": 4.0,
          "extraction_completeness": 4.9
        },
        "sample_size_score": 1.0,
        "publication_venue_score": 2.0,
        "followup_duration_score": 4.0,
        "extraction_completeness_score": 4.9,
        "market_breakdown": {
          "competitors": 3.0,
          "market_size": 10.0,
          "unmet_need": 5.0
        },
        "competitors_score": 3.0,
        "market_size_score": 10.0,
        "unmet_need_score": 5.0
      },
      "rank": 57
    }
  ],
  "analysis_date": "2025-12-07T19:02:11.718932",
  "search_queries_used": [],
  "papers_screened": 86,
  "papers_extracted": 57,
  "total_input_tokens": 1181392,
  "total_output_tokens": 140925,
  "estimated_cost_usd": 5.6581
}